-DOCSTART- -X- -X- O

9288106 NN NN O
Clustering NN NN O
of NN NN O
missense NN NN O
mutations NN NN O
in NN NN O
the NN NN O
ataxia-telangiectasia NN NN B-Modifier
gene NN NN O
in NN NN O
a NN NN O
sporadic NN NN B-SpecificDisease
T-cell NN NN I-SpecificDisease
leukaemia NN NN I-SpecificDisease
. NN NN O

Ataxia-telangiectasia NN NN B-SpecificDisease
( NN NN O
A-T NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
recessive NN NN B-DiseaseClass
multi-system NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
at NN NN O
11q22-q23 NN NN O
( NN NN O
ref NN NN O
. NN NN O

3 NN NN O
) NN NN O
. NN NN O

The NN NN O
risk NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
, NN NN O
especially NN NN O
lymphoid NN NN B-DiseaseClass
neoplasias NN NN I-DiseaseClass
, NN NN O
is NN NN O
substantially NN NN O
elevated NN NN O
in NN NN O
A-T NN NN B-Modifier
patients NN NN O
and NN NN O
has NN NN O
long NN NN O
been NN NN O
associated NN NN O
with NN NN O
chromosomal NN NN O
instability NN NN O
. NN NN O

By NN NN O
analysing NN NN O
tumour NN NN B-Modifier
DNA NN NN O
from NN NN O
patients NN NN O
with NN NN O
sporadic NN NN B-SpecificDisease
T-cell NN NN I-SpecificDisease
prolymphocytic NN NN I-SpecificDisease
leukaemia NN NN I-SpecificDisease
( NN NN O
T-PLL NN NN B-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
rare NN NN O
clonal NN NN B-DiseaseClass
malignancy NN NN I-DiseaseClass
with NN NN O
similarities NN NN O
to NN NN O
a NN NN O
mature NN NN B-SpecificDisease
T-cell NN NN I-SpecificDisease
leukaemia NN NN I-SpecificDisease
seen NN NN O
in NN NN O
A-T NN NN B-SpecificDisease
, NN NN O
we NN NN O
demonstrate NN NN O
a NN NN O
high NN NN O
frequency NN NN O
of NN NN O
ATM NN NN O
mutations NN NN O
in NN NN O
T-PLL NN NN B-SpecificDisease
. NN NN O

In NN NN O
marked NN NN O
contrast NN NN O
to NN NN O
the NN NN O
ATM NN NN O
mutation NN NN O
pattern NN NN O
in NN NN O
A-T NN NN B-SpecificDisease
, NN NN O
the NN NN O
most NN NN O
frequent NN NN O
nucleotide NN NN O
changes NN NN O
in NN NN O
this NN NN O
leukaemia NN NN B-DiseaseClass
were NN NN O
missense NN NN O
mutations NN NN O
. NN NN O

These NN NN O
clustered NN NN O
in NN NN O
the NN NN O
region NN NN O
corresponding NN NN O
to NN NN O
the NN NN O
kinase NN NN O
domain NN NN O
, NN NN O
which NN NN O
is NN NN O
highly NN NN O
conserved NN NN O
in NN NN O
ATM-related NN NN O
proteins NN NN O
in NN NN O
mouse NN NN O
, NN NN O
yeast NN NN O
and NN NN O
Drosophila NN NN O
. NN NN O

The NN NN O
resulting NN NN O
amino-acid NN NN O
substitutions NN NN O
are NN NN O
predicted NN NN O
to NN NN O
interfere NN NN O
with NN NN O
ATP NN NN O
binding NN NN O
or NN NN O
substrate NN NN O
recognition NN NN O
. NN NN O

Two NN NN O
of NN NN O
seventeen NN NN O
mutated NN NN O
T-PLL NN NN B-SpecificDisease
samples NN NN O
had NN NN O
a NN NN O
previously NN NN O
reported NN NN O
A-T NN NN B-Modifier
allele NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
no NN NN O
mutations NN NN O
were NN NN O
detected NN NN O
in NN NN O
the NN NN O
p53 NN NN O
gene NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
this NN NN O
tumour NN NN B-Modifier
suppressor NN NN O
is NN NN O
not NN NN O
frequently NN NN O
altered NN NN O
in NN NN O
this NN NN O
leukaemia NN NN B-DiseaseClass
. NN NN O

Occasional NN NN O
missense NN NN O
mutations NN NN O
in NN NN O
ATM NN NN O
were NN NN O
also NN NN O
found NN NN O
in NN NN O
tumour NN NN B-Modifier
DNA NN NN O
from NN NN O
patients NN NN O
with NN NN O
B-cell NN NN B-SpecificDisease
non-Hodgkins NN NN I-SpecificDisease
lymphomas NN NN I-SpecificDisease
( NN NN O
B-NHL NN NN B-SpecificDisease
) NN NN O
and NN NN O
a NN NN O
B-NHL NN NN B-Modifier
cell NN NN O
line NN NN O
. NN NN O

The NN NN O
evidence NN NN O
of NN NN O
a NN NN O
significant NN NN O
proportion NN NN O
of NN NN O
loss-of-function NN NN O
mutations NN NN O
and NN NN O
a NN NN O
complete NN NN O
absence NN NN O
of NN NN O
the NN NN O
normal NN NN O
copy NN NN O
of NN NN O
ATM NN NN O
in NN NN O
the NN NN O
majority NN NN O
of NN NN O
mutated NN NN O
tumours NN NN B-DiseaseClass
establishes NN NN O
somatic NN NN O
inactivation NN NN O
of NN NN O
this NN NN O
gene NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
sporadic NN NN B-SpecificDisease
T-PLL NN NN I-SpecificDisease
and NN NN O
suggests NN NN O
that NN NN O
ATM NN NN O
acts NN NN O
as NN NN O
a NN NN O
tumour NN NN B-Modifier
suppressor NN NN O
. NN NN O

As NN NN O
constitutional NN NN O
DNA NN NN O
was NN NN O
not NN NN O
available NN NN O
, NN NN O
a NN NN O
putative NN NN O
hereditary NN NN O
predisposition NN NN O
to NN NN O
T-PLL NN NN B-SpecificDisease
will NN NN O
require NN NN O
further NN NN O
investigation NN NN O
. NN NN O

. NN NN O

9294109 NN NN O
Myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
protein NN NN O
kinase NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
modulation NN NN O
of NN NN O
the NN NN O
Ca2+ NN NN O
homeostasis NN NN O
in NN NN O
skeletal NN NN O
muscle NN NN O
cells NN NN O
. NN NN O

Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
, NN NN O
the NN NN O
most NN NN O
prevalent NN NN O
muscular NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
in NN NN O
adults NN NN O
, NN NN O
is NN NN O
caused NN NN O
by NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n-repeat NN NN O
expansion NN NN O
in NN NN O
a NN NN O
gene NN NN O
encoding NN NN O
a NN NN O
protein NN NN O
kinase NN NN O
( NN NN O
DM NN NN B-Modifier
protein NN NN O
kinase NN NN O
; NN NN O
DMPK NN NN O
) NN NN O
and NN NN O
involves NN NN O
changes NN NN O
in NN NN O
cytoarchitecture NN NN O
and NN NN O
ion NN NN O
homeostasis NN NN O
. NN NN O

To NN NN O
obtain NN NN O
clues NN NN O
to NN NN O
the NN NN O
normal NN NN O
biological NN NN O
role NN NN O
of NN NN O
DMPK NN NN O
in NN NN O
cellular NN NN O
ion NN NN O
homeostasis NN NN O
, NN NN O
we NN NN O
have NN NN O
compared NN NN O
the NN NN O
resting NN NN O
[ NN NN O
Ca2 NN NN O
+ NN NN O
] NN NN O
i NN NN O
, NN NN O
the NN NN O
amplitude NN NN O
and NN NN O
shape NN NN O
of NN NN O
depolarization-induced NN NN O
Ca2 NN NN O
+ NN NN O
transients NN NN O
, NN NN O
and NN NN O
the NN NN O
content NN NN O
of NN NN O
ATP-driven NN NN O
ion NN NN O
pumps NN NN O
in NN NN O
cultured NN NN O
skeletal NN NN O
muscle NN NN O
cells NN NN O
of NN NN O
wild-type NN NN O
and NN NN O
DMPK NN NN O
[ NN NN O
- NN NN O
/ NN NN O
- NN NN O
] NN NN O
knockout NN NN O
mice NN NN O
. NN NN O

In NN NN O
vitro-differentiated NN NN O
DMPK NN NN O
[ NN NN O
- NN NN O
/ NN NN O
- NN NN O
] NN NN O
myotubes NN NN O
exhibit NN NN O
a NN NN O
higher NN NN O
resting NN NN O
[ NN NN O
Ca2 NN NN O
+ NN NN O
] NN NN O
i NN NN O
than NN NN O
do NN NN O
wild-type NN NN O
myotubes NN NN O
because NN NN O
of NN NN O
an NN NN O
altered NN NN O
open NN NN O
probability NN NN O
of NN NN O
voltage-dependent NN NN O
l-type NN NN O
Ca2 NN NN O
+ NN NN O
and NN NN O
Na NN NN O
+ NN NN O
channels NN NN O
. NN NN O

The NN NN O
mutant NN NN O
myotubes NN NN O
exhibit NN NN O
smaller NN NN O
and NN NN O
slower NN NN O
Ca2 NN NN O
+ NN NN O
responses NN NN O
upon NN NN O
triggering NN NN O
by NN NN O
acetylcholine NN NN O
or NN NN O
high NN NN O
external NN NN O
K NN NN O
+ NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
we NN NN O
observed NN NN O
that NN NN O
these NN NN O
Ca2 NN NN O
+ NN NN O
transients NN NN O
partially NN NN O
result NN NN O
from NN NN O
an NN NN O
influx NN NN O
of NN NN O
extracellular NN NN O
Ca2 NN NN O
+ NN NN O
through NN NN O
the NN NN O
l-type NN NN O
Ca2 NN NN O
+ NN NN O
channel NN NN O
. NN NN O

Neither NN NN O
the NN NN O
content NN NN O
nor NN NN O
the NN NN O
activity NN NN O
of NN NN O
Na NN NN O
+ NN NN O
/ NN NN O
K NN NN O
+ NN NN O
ATPase NN NN O
and NN NN O
sarcoplasmic NN NN O
reticulum NN NN O
Ca2 NN NN O
+ NN NN O
-ATPase NN NN O
are NN NN O
affected NN NN O
by NN NN O
DMPK NN NN O
absence NN NN O
. NN NN O

In NN NN O
conclusion NN NN O
, NN NN O
our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
DMPK NN NN O
is NN NN O
involved NN NN O
in NN NN O
modulating NN NN O
the NN NN O
initial NN NN O
events NN NN O
of NN NN O
excitation-contraction NN NN O
coupling NN NN O
in NN NN O
skeletal NN NN O
muscle NN NN O
. NN NN O

. NN NN O

9311732 NN NN O
Constitutional NN NN O
RB1-gene NN NN O
mutations NN NN O
in NN NN O
patients NN NN O
with NN NN O
isolated NN NN O
unilateral NN NN B-SpecificDisease
retinoblastoma NN NN I-SpecificDisease
. NN NN O

In NN NN O
most NN NN O
patients NN NN O
with NN NN O
isolated NN NN O
unilateral NN NN B-SpecificDisease
retinoblastoma NN NN I-SpecificDisease
, NN NN O
tumor NN NN B-Modifier
development NN NN O
is NN NN O
initiated NN NN O
by NN NN O
somatic NN NN O
inactivation NN NN O
of NN NN O
both NN NN O
alleles NN NN O
of NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
. NN NN O

However NN NN O
, NN NN O
some NN NN O
of NN NN O
these NN NN O
patients NN NN O
can NN NN O
transmit NN NN O
retinoblastoma NN NN B-Modifier
predisposition NN NN O
to NN NN O
their NN NN O
offspring NN NN O
. NN NN O

To NN NN O
determine NN NN O
the NN NN O
frequency NN NN O
and NN NN O
nature NN NN O
of NN NN O
constitutional NN NN O
RB1-gene NN NN O
mutations NN NN O
in NN NN O
patients NN NN O
with NN NN O
isolated NN NN O
unilateral NN NN B-SpecificDisease
retinoblastoma NN NN I-SpecificDisease
, NN NN O
we NN NN O
analyzed NN NN O
DNA NN NN O
from NN NN O
peripheral NN NN O
blood NN NN O
and NN NN O
from NN NN O
tumor NN NN B-Modifier
tissue NN NN O
. NN NN O

The NN NN O
analysis NN NN O
of NN NN O
tumors NN NN B-DiseaseClass
from NN NN O
54 NN NN O
( NN NN O
71 NN NN O
% NN NN O
) NN NN O
of NN NN O
76 NN NN O
informative NN NN O
patients NN NN O
showed NN NN O
loss NN NN O
of NN NN O
constitutional NN NN O
heterozygosity NN NN O
( NN NN O
LOH NN NN O
) NN NN O
at NN NN O
intragenic NN NN O
loci NN NN O
. NN NN O

Three NN NN O
of NN NN O
13 NN NN O
uninformative NN NN O
patients NN NN O
had NN NN O
constitutional NN NN O
deletions NN NN O
. NN NN O

For NN NN O
39 NN NN O
randomly NN NN O
selected NN NN O
tumors NN NN B-DiseaseClass
, NN NN O
SSCP NN NN O
, NN NN O
hetero-duplex NN NN O
analysis NN NN O
, NN NN O
sequencing NN NN O
, NN NN O
and NN NN O
Southern NN NN O
blot NN NN O
analysis NN NN O
were NN NN O
used NN NN O
to NN NN O
identify NN NN O
mutations NN NN O
. NN NN O

Mutations NN NN O
were NN NN O
detected NN NN O
in NN NN O
21 NN NN O
( NN NN O
91 NN NN O
% NN NN O
) NN NN O
of NN NN O
23 NN NN O
tumors NN NN B-DiseaseClass
with NN NN O
LOH NN NN O
. NN NN O

In NN NN O
6 NN NN O
( NN NN O
38 NN NN O
% NN NN O
) NN NN O
of NN NN O
16 NN NN O
tumors NN NN B-DiseaseClass
without NN NN O
LOH NN NN O
, NN NN O
one NN NN O
mutation NN NN O
was NN NN O
detected NN NN O
, NN NN O
and NN NN O
in NN NN O
9 NN NN O
( NN NN O
56 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
tumors NN NN B-DiseaseClass
without NN NN O
LOH NN NN O
, NN NN O
both NN NN O
mutations NN NN O
were NN NN O
found NN NN O
. NN NN O

Thus NN NN O
, NN NN O
a NN NN O
total NN NN O
of NN NN O
45 NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
in NN NN O
tumors NN NN B-DiseaseClass
of NN NN O
36 NN NN O
patients NN NN O
. NN NN O

Thirty-nine NN NN O
of NN NN O
the NN NN O
mutations-including NN NN O
34 NN NN O
small NN NN O
mutations NN NN O
, NN NN O
2 NN NN O
large NN NN O
structural NN NN O
alterations NN NN O
, NN NN O
and NN NN O
hypermethylation NN NN O
in NN NN O
3 NN NN O
tumors-were NN NN O
not NN NN O
detected NN NN O
in NN NN O
the NN NN O
corresponding NN NN O
peripheral NN NN O
blood NN NN O
DNA NN NN O
. NN NN O

In NN NN O
6 NN NN O
( NN NN O
17 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
36 NN NN O
patients NN NN O
, NN NN O
a NN NN O
mutation NN NN O
was NN NN O
detected NN NN O
in NN NN O
constitutional NN NN O
DNA NN NN O
, NN NN O
and NN NN O
1 NN NN O
of NN NN O
these NN NN O
mutations NN NN O
is NN NN O
known NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
reduced NN NN O
expressivity NN NN O
. NN NN O

The NN NN O
presence NN NN O
of NN NN O
a NN NN O
constitutional NN NN O
mutation NN NN O
was NN NN O
not NN NN O
associated NN NN O
with NN NN O
an NN NN O
early NN NN O
age NN NN O
at NN NN O
treatment NN NN O
. NN NN O

In NN NN O
1 NN NN O
patient NN NN O
, NN NN O
somatic NN NN O
mosaicism NN NN O
was NN NN O
demonstrated NN NN O
by NN NN O
molecular NN NN O
analysis NN NN O
of NN NN O
DNA NN NN O
and NN NN O
RNA NN NN O
from NN NN O
peripheral NN NN O
blood NN NN O
. NN NN O

In NN NN O
2 NN NN O
patients NN NN O
without NN NN O
a NN NN O
detectable NN NN O
mutation NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
, NN NN O
mosaicism NN NN O
was NN NN O
suggested NN NN O
because NN NN O
1 NN NN O
of NN NN O
the NN NN O
patients NN NN O
showed NN NN O
multifocal NN NN O
tumors NN NN B-DiseaseClass
and NN NN O
the NN NN O
other NN NN O
later NN NN O
developed NN NN O
bilateral NN NN B-SpecificDisease
retinoblastoma NN NN I-SpecificDisease
. NN NN O

In NN NN O
conclusion NN NN O
, NN NN O
our NN NN O
results NN NN O
emphasize NN NN O
that NN NN O
the NN NN O
manifestation NN NN O
and NN NN O
transmissibility NN NN O
of NN NN O
retinoblastoma NN NN B-SpecificDisease
depend NN NN O
on NN NN O
the NN NN O
nature NN NN O
of NN NN O
the NN NN O
first NN NN O
mutation NN NN O
, NN NN O
its NN NN O
time NN NN O
in NN NN O
development NN NN O
, NN NN O
and NN NN O
the NN NN O
number NN NN O
and NN NN O
types NN NN O
of NN NN O
cells NN NN O
that NN NN O
are NN NN O
affected NN NN O
. NN NN O

. NN NN O

932197 NN NN O
Hereditary NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
fifth NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
in NN NN O
man NN NN O
. NN NN O

I NN NN O
. NN NN O

Clinical NN NN O
, NN NN O
immunochemical NN NN O
, NN NN O
and NN NN O
family NN NN O
studies NN NN O
. NN NN O

The NN NN O
first NN NN O
recognized NN NN O
human NN NN O
kindred NN NN O
with NN NN O
hereditary NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
fifth NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
( NN NN O
C5 NN NN O
) NN NN O
is NN NN O
described NN NN O
. NN NN O

The NN NN O
proband NN NN O
, NN NN O
a NN NN O
20-year-old NN NN O
black NN NN O
female NN NN O
with NN NN O
systemic NN NN B-SpecificDisease
lupus NN NN I-SpecificDisease
erythematosus NN NN I-SpecificDisease
since NN NN O
age NN NN O
11 NN NN O
, NN NN O
lacked NN NN O
serum NN NN O
hemolytic NN NN O
complement NN NN O
activity NN NN O
, NN NN O
even NN NN O
during NN NN O
remission NN NN O
. NN NN O

C5 NN NN O
was NN NN O
undetectable NN NN O
in NN NN O
her NN NN O
serum NN NN O
by NN NN O
both NN NN O
immunodiffusion NN NN O
and NN NN O
hemolytic NN NN O
assays NN NN O
. NN NN O

Other NN NN O
complement NN NN O
components NN NN O
were NN NN O
normal NN NN O
during NN NN O
remission NN NN O
of NN NN O
lupus NN NN O
, NN NN O
but NN NN O
C1 NN NN O
, NN NN O
C4 NN NN O
, NN NN O
C2 NN NN O
, NN NN O
and NN NN O
C3 NN NN O
levels NN NN O
fell NN NN O
during NN NN O
exacerbations NN NN O
. NN NN O

A NN NN O
younger NN NN O
half-sister NN NN O
, NN NN O
who NN NN O
had NN NN O
no NN NN O
underlying NN NN O
disease NN NN O
, NN NN O
was NN NN O
also NN NN O
found NN NN O
to NN NN O
lack NN NN O
immunochemically NN NN O
detectable NN NN O
C5 NN NN O
. NN NN O

By NN NN O
hemolytic NN NN O
assay NN NN O
, NN NN O
she NN NN O
exhibited NN NN O
1-2 NN NN O
% NN NN O
of NN NN O
the NN NN O
normal NN NN O
serum NN NN O
C5 NN NN O
level NN NN O
and NN NN O
normal NN NN O
concentrations NN NN O
of NN NN O
other NN NN O
complement NN NN O
components NN NN O
. NN NN O

C5 NN NN O
levels NN NN O
of NN NN O
other NN NN O
family NN NN O
members NN NN O
were NN NN O
either NN NN O
normal NN NN O
or NN NN O
approximately NN NN O
half-normal NN NN O
, NN NN O
consistent NN NN O
with NN NN O
autosomal NN NN O
codominant NN NN O
inheritance NN NN O
of NN NN O
the NN NN O
gene NN NN O
determining NN NN O
C5 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Normal NN NN O
hemolytic NN NN O
titers NN NN O
were NN NN O
restored NN NN O
to NN NN O
both NN NN O
homozygous NN NN O
C5-deficient NN NN B-Modifier
( NN NN O
C5D NN NN B-Modifier
) NN NN O
sera NN NN O
by NN NN O
addition NN NN O
of NN NN O
highly NN NN O
purified NN NN O
human NN NN O
C5 NN NN O
. NN NN O

In NN NN O
specific NN NN O
C5 NN NN O
titrations NN NN O
, NN NN O
however NN NN O
, NN NN O
it NN NN O
was NN NN O
noted NN NN O
that NN NN O
when NN NN O
limited NN NN O
amounts NN NN O
of NN NN O
C5 NN NN O
were NN NN O
assayed NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
low NN NN O
dilutions NN NN O
of NN NN O
either NN NN O
C5D NN NN B-Modifier
serum NN NN O
, NN NN O
curving NN NN O
rather NN NN O
than NN NN O
linear NN NN O
dose-response NN NN O
plots NN NN O
were NN NN O
consistently NN NN O
obtained NN NN O
, NN NN O
suggesting NN NN O
some NN NN O
inhibitory NN NN O
effect NN NN O
. NN NN O

Further NN NN O
studies NN NN O
suggested NN NN O
that NN NN O
low NN NN O
dilutions NN NN O
of NN NN O
C5D NN NN B-Modifier
serum NN NN O
contain NN NN O
a NN NN O
factor NN NN O
( NN NN O
or NN NN O
factors NN NN O
) NN NN O
interfering NN NN O
at NN NN O
some NN NN O
step NN NN O
in NN NN O
the NN NN O
hemolytic NN NN O
assay NN NN O
of NN NN O
C5 NN NN O
, NN NN O
rather NN NN O
than NN NN O
a NN NN O
true NN NN O
C5 NN NN O
inhibitor NN NN O
or NN NN O
inactivator NN NN O
. NN NN O

Of NN NN O
clinical NN NN O
interest NN NN O
are NN NN O
( NN NN O
a NN NN O
) NN NN O
the NN NN O
documentation NN NN O
of NN NN O
membranous NN NN O
glomerulonephritis NN NN B-SpecificDisease
, NN NN O
vasculitis NN NN B-SpecificDisease
, NN NN O
and NN NN O
arthritis NN NN B-DiseaseClass
in NN NN O
an NN NN O
individual NN NN O
lacking NN NN O
C5 NN NN O
( NN NN O
and NN NN O
its NN NN O
biologic NN NN O
functions NN NN O
) NN NN O
, NN NN O
and NN NN O
( NN NN O
b NN NN O
) NN NN O
a NN NN O
remarkable NN NN O
propensity NN NN O
to NN NN O
bacterial NN NN B-DiseaseClass
infections NN NN I-DiseaseClass
in NN NN O
the NN NN O
proband NN NN O
, NN NN O
even NN NN O
during NN NN O
periods NN NN O
of NN NN O
low-dose NN NN O
or NN NN O
alternate-day NN NN O
corticosteroid NN NN O
therapy NN NN O
. NN NN O

Other NN NN O
observations NN NN O
indicate NN NN O
that NN NN O
the NN NN O
C5D NN NN B-Modifier
state NN NN O
is NN NN O
compatible NN NN O
with NN NN O
normal NN NN O
coagulation NN NN O
function NN NN O
and NN NN O
the NN NN O
capacity NN NN O
to NN NN O
mount NN NN O
a NN NN O
neutrophilic NN NN O
leukocytosis NN NN O
during NN NN O
pyogenic NN NN B-DiseaseClass
infection NN NN I-DiseaseClass
. NN NN O

. NN NN O

9336417 NN NN O
Susceptibility NN NN O
to NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
in NN NN O
twins NN NN O
: NN NN O
the NN NN O
role NN NN O
of NN NN O
genes NN NN O
, NN NN O
HLA NN NN O
, NN NN O
and NN NN O
the NN NN O
environment NN NN O
. NN NN O

OBJECTIVE NN NN O
To NN NN O
determine NN NN O
the NN NN O
relative NN NN O
effects NN NN O
of NN NN O
genetic NN NN O
and NN NN O
environmental NN NN O
factors NN NN O
in NN NN O
susceptibility NN NN O
to NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
( NN NN O
AS NN NN B-SpecificDisease
) NN NN O
. NN NN O

METHODS NN NN O
Twins NN NN O
with NN NN O
AS NN NN B-SpecificDisease
were NN NN O
identified NN NN O
from NN NN O
the NN NN O
Royal NN NN O
National NN NN O
Hospital NN NN O
for NN NN O
Rheumatic NN NN B-DiseaseClass
Diseases NN NN I-DiseaseClass
database NN NN O
. NN NN O

Clinical NN NN O
and NN NN O
radiographic NN NN O
examinations NN NN O
were NN NN O
performed NN NN O
to NN NN O
establish NN NN O
diagnoses NN NN O
, NN NN O
and NN NN O
disease NN NN O
severity NN NN O
was NN NN O
assessed NN NN O
using NN NN O
a NN NN O
combination NN NN O
of NN NN O
validated NN NN O
scoring NN NN O
systems NN NN O
. NN NN O

HLA NN NN O
typing NN NN O
for NN NN O
HLA-B27 NN NN O
, NN NN O
HLA-B60 NN NN O
, NN NN O
and NN NN O
HLA-DR1 NN NN O
was NN NN O
performed NN NN O
by NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
with NN NN O
sequence-specific NN NN O
primers NN NN O
, NN NN O
and NN NN O
zygosity NN NN O
was NN NN O
assessed NN NN O
using NN NN O
microsatellite NN NN O
markers NN NN O
. NN NN O

Genetic NN NN O
and NN NN O
environmental NN NN O
variance NN NN O
components NN NN O
were NN NN O
assessed NN NN O
with NN NN O
the NN NN O
program NN NN O
Mx NN NN O
, NN NN O
using NN NN O
data NN NN O
from NN NN O
this NN NN O
and NN NN O
previous NN NN O
studies NN NN O
of NN NN O
twins NN NN O
with NN NN O
AS NN NN B-SpecificDisease
. NN NN O

RESULTS NN NN O
Six NN NN O
of NN NN O
8 NN NN O
monozygotic NN NN O
( NN NN O
MZ NN NN O
) NN NN O
twin NN NN O
pairs NN NN O
were NN NN O
disease NN NN O
concordant NN NN O
, NN NN O
compared NN NN O
with NN NN O
4 NN NN O
of NN NN O
15 NN NN O
B27-positive NN NN O
dizygotic NN NN O
( NN NN O
DZ NN NN O
) NN NN O
twin NN NN O
pairs NN NN O
( NN NN O
27 NN NN O
% NN NN O
) NN NN O
and NN NN O
4 NN NN O
of NN NN O
32 NN NN O
DZ NN NN O
twin NN NN O
pairs NN NN O
overall NN NN O
( NN NN O
12 NN NN O
. NN NN O

5 NN NN O
% NN NN O
) NN NN O
. NN NN O

Nonsignificant NN NN O
increases NN NN O
in NN NN O
similarity NN NN O
with NN NN O
regard NN NN O
to NN NN O
age NN NN O
at NN NN O
disease NN NN O
onset NN NN O
and NN NN O
all NN NN O
of NN NN O
the NN NN O
disease NN NN O
severity NN NN O
scores NN NN O
assessed NN NN O
were NN NN O
noted NN NN O
in NN NN O
disease-concordant NN NN O
MZ NN NN O
twins NN NN O
compared NN NN O
with NN NN O
concordant NN NN O
DZ NN NN O
twins NN NN O
. NN NN O

HLA-B27 NN NN O
and NN NN O
B60 NN NN O
were NN NN O
associated NN NN O
with NN NN O
the NN NN O
disease NN NN O
in NN NN O
probands NN NN O
, NN NN O
and NN NN O
the NN NN O
rate NN NN O
of NN NN O
disease NN NN O
concordance NN NN O
was NN NN O
significantly NN NN O
increased NN NN O
among NN NN O
DZ NN NN O
twin NN NN O
pairs NN NN O
in NN NN O
which NN NN O
the NN NN O
co-twin NN NN O
was NN NN O
positive NN NN O
for NN NN O
both NN NN O
B27 NN NN O
and NN NN O
DR1 NN NN O
. NN NN O

Additive NN NN O
genetic NN NN O
effects NN NN O
were NN NN O
estimated NN NN O
to NN NN O
contribute NN NN O
97 NN NN O
% NN NN O
of NN NN O
the NN NN O
population NN NN O
variance NN NN O
. NN NN O

CONCLUSION NN NN O
Susceptibility NN NN O
to NN NN O
AS NN NN B-SpecificDisease
is NN NN O
largely NN NN O
genetically NN NN O
determined NN NN O
, NN NN O
and NN NN O
the NN NN O
environmental NN NN O
trigger NN NN O
for NN NN O
the NN NN O
disease NN NN O
is NN NN O
probably NN NN O
ubiquitous NN NN O
. NN NN O

HLA-B27 NN NN O
accounts NN NN O
for NN NN O
a NN NN O
minority NN NN O
of NN NN O
the NN NN O
overall NN NN O
genetic NN NN O
susceptibility NN NN O
to NN NN O
AS NN NN B-SpecificDisease
. NN NN O

9342365 NN NN O
Cell NN NN O
cycle-dependent NN NN O
colocalization NN NN O
of NN NN O
BARD1 NN NN O
and NN NN O
BRCA1 NN NN O
proteins NN NN O
in NN NN O
discrete NN NN O
nuclear NN NN O
domains NN NN O
. NN NN O

Germ-line NN NN O
mutations NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
predispose NN NN O
women NN NN O
to NN NN O
early-onset NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
by NN NN O
compromising NN NN O
the NN NN O
genes NN NN O
presumptive NN NN O
function NN NN O
as NN NN O
a NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
. NN NN O

Although NN NN O
the NN NN O
biochemical NN NN O
properties NN NN O
of NN NN O
BRCA1 NN NN O
polypeptides NN NN O
are NN NN O
not NN NN O
understood NN NN O
, NN NN O
their NN NN O
expression NN NN O
pattern NN NN O
and NN NN O
subcellular NN NN O
localization NN NN O
suggest NN NN O
a NN NN O
role NN NN O
in NN NN O
cell-cycle NN NN O
regulation NN NN O
. NN NN O

When NN NN O
resting NN NN O
cells NN NN O
are NN NN O
induced NN NN O
to NN NN O
proliferate NN NN O
, NN NN O
the NN NN O
steady-state NN NN O
levels NN NN O
of NN NN O
BRCA1 NN NN O
increase NN NN O
in NN NN O
late NN NN O
G1 NN NN O
and NN NN O
reach NN NN O
a NN NN O
maximum NN NN O
during NN NN O
S NN NN O
phase NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
in NN NN O
S NN NN O
phase NN NN O
cells NN NN O
, NN NN O
BRCA1 NN NN O
polypeptides NN NN O
are NN NN O
hyperphosphorylated NN NN O
and NN NN O
accumulate NN NN O
into NN NN O
discrete NN NN O
subnuclear NN NN O
foci NN NN O
termed NN NN O
`` NN NN O
BRCA1 NN NN O
nuclear NN NN O
dots NN NN O
. NN NN O
`` NN NN O

BRCA1 NN NN O
associates NN NN O
in NN NN O
vivo NN NN O
with NN NN O
a NN NN O
structurally NN NN O
related NN NN O
protein NN NN O
termed NN NN O
BARD1 NN NN O
. NN NN O

Here NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
steady-state NN NN O
levels NN NN O
of NN NN O
BARD1 NN NN O
, NN NN O
unlike NN NN O
those NN NN O
of NN NN O
BRCA1 NN NN O
, NN NN O
remain NN NN O
relatively NN NN O
constant NN NN O
during NN NN O
cell NN NN O
cycle NN NN O
progression NN NN O
. NN NN O

However NN NN O
, NN NN O
immunostaining NN NN O
revealed NN NN O
that NN NN O
BARD1 NN NN O
resides NN NN O
within NN NN O
BRCA1 NN NN O
nuclear NN NN O
dots NN NN O
during NN NN O
S NN NN O
phase NN NN O
of NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
, NN NN O
but NN NN O
not NN NN O
during NN NN O
the NN NN O
G1 NN NN O
phase NN NN O
. NN NN O

Nevertheless NN NN O
, NN NN O
BARD1 NN NN O
polypeptides NN NN O
are NN NN O
found NN NN O
exclusively NN NN O
in NN NN O
the NN NN O
nuclear NN NN O
fractions NN NN O
of NN NN O
both NN NN O
G1- NN NN O
and NN NN O
S-phase NN NN O
cells NN NN O
. NN NN O

Therefore NN NN O
, NN NN O
progression NN NN O
to NN NN O
S NN NN O
phase NN NN O
is NN NN O
accompanied NN NN O
by NN NN O
the NN NN O
aggregation NN NN O
of NN NN O
nuclear NN NN O
BARD1 NN NN O
polypeptides NN NN O
into NN NN O
BRCA1 NN NN O
nuclear NN NN O
dots NN NN O
. NN NN O

This NN NN O
cell NN NN O
cycle-dependent NN NN O
colocalization NN NN O
of NN NN O
BARD1 NN NN O
and NN NN O
BRCA1 NN NN O
indicates NN NN O
a NN NN O
role NN NN O
for NN NN O
BARD1 NN NN O
in NN NN O
BRCA1-mediated NN NN O
tumor NN NN B-Modifier
suppression NN NN O
. NN NN O

9358014 NN NN O
Ethnic NN NN O
differences NN NN O
in NN NN O
the NN NN O
HFE NN NN O
codon NN NN O
282 NN NN O
( NN NN O
Cys/Tyr NN NN O
) NN NN O
polymorphism NN NN O
. NN NN O

Recent NN NN O
studies NN NN O
have NN NN O
shown NN NN O
that NN NN O
hereditary NN NN B-SpecificDisease
hemochromatosis NN NN I-SpecificDisease
( NN NN O
HH NN NN B-SpecificDisease
) NN NN O
is NN NN O
likely NN NN O
to NN NN O
be NN NN O
caused NN NN O
by NN NN O
homozygosity NN NN O
for NN NN O
a NN NN O
Cys282Tyr NN NN O
mutation NN NN O
in NN NN O
the NN NN O
HFE NN NN O
gene NN NN O
located NN NN O
4 NN NN O
. NN NN O

5 NN NN O
Mb NN NN O
telomeric NN NN O
to NN NN O
HLA-A NN NN O
. NN NN O

Population NN NN O
studies NN NN O
of NN NN O
this NN NN O
polymorphism NN NN O
are NN NN O
facilitated NN NN O
by NN NN O
the NN NN O
fact NN NN O
that NN NN O
the NN NN O
Cys282Tyr NN NN O
mutation NN NN O
creates NN NN O
a NN NN O
Rsal NN NN O
restriction NN NN O
site NN NN O
. NN NN O

We NN NN O
have NN NN O
studied NN NN O
the NN NN O
codon NN NN O
282 NN NN O
( NN NN O
Cys NN NN O
/ NN NN O
Tyr NN NN O
) NN NN O
polymorphism NN NN O
in NN NN O
different NN NN O
ethnic NN NN O
groups NN NN O
. NN NN O

In NN NN O
agreement NN NN O
with NN NN O
previous NN NN O
observations NN NN O
the NN NN O
Tyr NN NN O
allele NN NN O
appeared NN NN O
to NN NN O
be NN NN O
rare NN NN O
or NN NN O
absent NN NN O
in NN NN O
Asiatic NN NN O
( NN NN O
Indian NN NN O
, NN NN O
Chinese NN NN O
) NN NN O
populations NN NN O
. NN NN O

The NN NN O
highest NN NN O
allele NN NN O
frequency NN NN O
( NN NN O
7 NN NN O
. NN NN O

5 NN NN O
% NN NN O
) NN NN O
was NN NN O
found NN NN O
in NN NN O
Swedes NN NN O
. NN NN O

Saamis NN NN O
( NN NN O
2 NN NN O
% NN NN O
) NN NN O
and NN NN O
Mordvinians NN NN O
( NN NN O
1 NN NN O
. NN NN O

8 NN NN O
% NN NN O
) NN NN O
had NN NN O
significantly NN NN O
lower NN NN O
frequencies NN NN O
of NN NN O
the NN NN O
Tyr NN NN O
allele NN NN O
. NN NN O

Comparisons NN NN O
with NN NN O
allele NN NN O
frequencies NN NN O
based NN NN O
on NN NN O
prevalence NN NN O
estimates NN NN O
of NN NN O
HH NN NN B-SpecificDisease
showed NN NN O
some NN NN O
disagreements NN NN O
with NN NN O
the NN NN O
RFLP NN NN O
data NN NN O
, NN NN O
particularly NN NN O
in NN NN O
Finns NN NN O
. NN NN O

The NN NN O
newly NN NN O
described NN NN O
HFE NN NN O
marker NN NN O
provides NN NN O
a NN NN O
new NN NN O
approach NN NN O
to NN NN O
the NN NN O
screening NN NN O
of NN NN O
HH NN NN B-SpecificDisease
as NN NN O
well NN NN O
as NN NN O
studies NN NN O
of NN NN O
the NN NN O
relationship NN NN O
between NN NN O
the NN NN O
HFE NN NN O
Tyr NN NN O
allele NN NN O
and NN NN O
different NN NN O
disorders NN NN O
including NN NN O
cancer NN NN B-DiseaseClass

9360520 NN NN O
Autosomal NN NN B-SpecificDisease
dominant NN NN I-SpecificDisease
neurohypophyseal NN NN I-SpecificDisease
diabetes NN NN I-SpecificDisease
insipidus NN NN I-SpecificDisease
associated NN NN O
with NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
encoding NN NN O
Gly23 NN NN O
-- NN NN O
Val NN NN O
in NN NN O
neurophysin NN NN O
II NN NN O
. NN NN O

Autosomal NN NN B-SpecificDisease
dominant NN NN I-SpecificDisease
neurohypophyseal NN NN I-SpecificDisease
diabetes NN NN I-SpecificDisease
insipidus NN NN I-SpecificDisease
( NN NN O
ADNDI NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
inherited NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
caused NN NN O
by NN NN O
progressive NN NN O
degeneration NN NN O
of NN NN O
the NN NN O
magnocellular NN NN O
neurons NN NN O
of NN NN O
the NN NN O
hypothalamus NN NN O
leading NN NN O
to NN NN O
decreased NN NN O
ability NN NN O
to NN NN O
produce NN NN O
the NN NN O
hormone NN NN O
arginine NN NN O
vasopressin NN NN O
( NN NN O
AVP NN NN O
) NN NN O
. NN NN O

Affected NN NN O
individuals NN NN O
are NN NN O
not NN NN O
symptomatic NN NN O
at NN NN O
birth NN NN O
, NN NN O
but NN NN O
usually NN NN O
develop NN NN O
diabetes NN NN B-SpecificDisease
insipidus NN NN I-SpecificDisease
at NN NN O
1-6 NN NN O
yr NN NN O
of NN NN O
age NN NN O
. NN NN O

The NN NN O
genetic NN NN O
locus NN NN O
of NN NN O
the NN NN O
disease NN NN O
is NN NN O
the NN NN O
AVP-neurophysin NN NN O
II NN NN O
( NN NN O
NPII NN NN O
) NN NN O
gene NN NN O
, NN NN O
and NN NN O
mutations NN NN O
that NN NN O
cause NN NN O
ADNDI NN NN B-SpecificDisease
have NN NN O
been NN NN O
found NN NN O
in NN NN O
both NN NN O
the NN NN O
signal NN NN O
peptide NN NN O
of NN NN O
the NN NN O
prepro-AVP-NPII NN NN O
precursor NN NN O
and NN NN O
within NN NN O
NPII NN NN O
itself NN NN O
. NN NN O

An NN NN O
affected NN NN O
girl NN NN O
who NN NN O
presented NN NN O
at NN NN O
9 NN NN O
months NN NN O
of NN NN O
age NN NN O
and NN NN O
her NN NN O
similarly NN NN O
affected NN NN O
younger NN NN O
brother NN NN O
and NN NN O
father NN NN O
were NN NN O
all NN NN O
found NN NN O
to NN NN O
have NN NN O
a NN NN O
novel NN NN O
missense NN NN O
mutation NN NN O
( NN NN O
G1758 NN NN O
-- NN NN O
T NN NN O
) NN NN O
encoding NN NN O
the NN NN O
amino NN NN O
acid NN NN O
substitution NN NN O
Gly23 NN NN O
-- NN NN O
Val NN NN O
within NN NN O
NPII NN NN O
. NN NN O

The NN NN O
mutation NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
restriction NN NN O
endonuclease NN NN O
analysis NN NN O
. NN NN O

A NN NN O
T1-weighted NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
of NN NN O
the NN NN O
fathers NN NN O
pituitary NN NN O
gland NN NN O
demonstrates NN NN O
an NN NN O
attenuated NN NN O
posterior NN NN O
pituitary NN NN O
bright NN NN O
spot NN NN O
. NN NN O

This NN NN O
mutation NN NN O
may NN NN O
be NN NN O
valuable NN NN O
for NN NN O
developing NN NN O
models NN NN O
of NN NN O
dominantly NN NN B-DiseaseClass
inherited NN NN I-DiseaseClass
neurodegeneration NN NN I-DiseaseClass
, NN NN O
as NN NN O
the NN NN O
early NN NN O
age NN NN O
of NN NN O
onset NN NN O
of NN NN O
symptoms NN NN O
suggests NN NN O
that NN NN O
this NN NN O
mutation NN NN O
may NN NN O
be NN NN O
particularly NN NN O
deleterious NN NN O
to NN NN O
the NN NN O
magnocellular NN NN O
neuron NN NN O
. NN NN O

. NN NN O

9371490 NN NN O
Frequent NN NN O
inactivation NN NN O
of NN NN O
PTEN/MMAC1 NN NN O
in NN NN O
primary NN NN O
prostate NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Sporadic NN NN B-SpecificDisease
prostate NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
is NN NN O
the NN NN O
most NN NN O
common NN NN O
male NN NN B-DiseaseClass
cancer NN NN I-DiseaseClass
in NN NN O
the NN NN O
Western NN NN O
world NN NN O
, NN NN O
yet NN NN O
many NN NN O
of NN NN O
the NN NN O
major NN NN O
genetic NN NN O
events NN NN O
involved NN NN O
in NN NN O
the NN NN O
progression NN NN O
of NN NN O
this NN NN O
often NN NN O
fatal NN NN O
cancer NN NN B-DiseaseClass
remain NN NN O
to NN NN O
be NN NN O
elucidated NN NN O
. NN NN O

Numerous NN NN O
cytogenetic NN NN O
and NN NN O
allelotype NN NN O
studies NN NN O
have NN NN O
reported NN NN O
frequent NN NN O
loss NN NN O
of NN NN O
heterozygosity NN NN O
on NN NN O
chromosomal NN NN O
arm NN NN O
10q NN NN O
in NN NN O
sporadic NN NN B-SpecificDisease
prostate NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Deletion NN NN O
mapping NN NN O
studies NN NN O
have NN NN O
unambiguously NN NN O
identified NN NN O
a NN NN O
region NN NN O
of NN NN O
chromosome NN NN O
10q23 NN NN O
to NN NN O
be NN NN O
the NN NN O
minimal NN NN O
area NN NN O
of NN NN O
loss NN NN O
. NN NN O

A NN NN O
new NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
gene NN NN O
, NN NN O
PTEN NN NN O
/ NN NN O
MMAC1 NN NN O
, NN NN O
was NN NN O
isolated NN NN O
recently NN NN O
at NN NN O
this NN NN O
region NN NN O
of NN NN O
chromosome NN NN O
10q23 NN NN O
and NN NN O
found NN NN O
to NN NN O
be NN NN O
inactivated NN NN O
by NN NN O
mutation NN NN O
in NN NN O
three NN NN O
prostate NN NN B-Modifier
cancer NN NN I-Modifier
cell NN NN O
lines NN NN O
. NN NN O

We NN NN O
screened NN NN O
80 NN NN O
prostate NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
by NN NN O
microsatellite NN NN O
analysis NN NN O
and NN NN O
found NN NN O
chromosome NN NN O
10q23 NN NN O
to NN NN O
be NN NN O
deleted NN NN O
in NN NN O
23 NN NN O
cases NN NN O
. NN NN O

We NN NN O
then NN NN O
proceeded NN NN O
with NN NN O
sequence NN NN O
analysis NN NN O
of NN NN O
the NN NN O
entire NN NN O
PTEN NN NN O
/ NN NN O
MMAC1 NN NN O
coding NN NN O
region NN NN O
and NN NN O
tested NN NN O
for NN NN O
homozygous NN NN O
deletion NN NN O
with NN NN O
new NN NN O
intragenic NN NN O
markers NN NN O
in NN NN O
these NN NN O
23 NN NN O
cases NN NN O
with NN NN O
10q23 NN NN O
loss NN NN O
of NN NN O
heterozygosity NN NN O
. NN NN O

The NN NN O
identification NN NN O
of NN NN O
the NN NN O
second NN NN O
mutational NN NN O
event NN NN O
in NN NN O
10 NN NN O
( NN NN O
43 NN NN O
% NN NN O
) NN NN O
tumors NN NN B-DiseaseClass
establishes NN NN O
PTEN NN NN O
/ NN NN O
MMAC1 NN NN O
as NN NN O
a NN NN O
main NN NN O
inactivation NN NN O
target NN NN O
of NN NN O
10q NN NN O
loss NN NN O
in NN NN O
sporadic NN NN B-SpecificDisease
prostate NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

. NN NN O

9382108 NN NN O
Risk NN NN O
reversals NN NN O
in NN NN O
predictive NN NN O
testing NN NN O
for NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

The NN NN O
first NN NN O
predictive NN NN O
testing NN NN O
for NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
HD NN NN B-SpecificDisease
) NN NN O
was NN NN O
based NN NN O
on NN NN O
analysis NN NN O
of NN NN O
linked NN NN O
polymorphic NN NN O
DNA NN NN O
markers NN NN O
to NN NN O
estimate NN NN O
the NN NN O
likelihood NN NN O
of NN NN O
inheriting NN NN O
the NN NN O
mutation NN NN O
for NN NN O
HD NN NN B-SpecificDisease
. NN NN O

Limits NN NN O
to NN NN O
accuracy NN NN O
included NN NN O
recombination NN NN O
between NN NN O
the NN NN O
DNA NN NN O
markers NN NN O
and NN NN O
the NN NN O
mutation NN NN O
, NN NN O
pedigree NN NN O
structure NN NN O
, NN NN O
and NN NN O
whether NN NN O
DNA NN NN O
samples NN NN O
were NN NN O
available NN NN O
from NN NN O
family NN NN O
members NN NN O
. NN NN O

With NN NN O
direct NN NN O
tests NN NN O
for NN NN O
the NN NN O
HD NN NN B-Modifier
mutation NN NN O
, NN NN O
we NN NN O
have NN NN O
assessed NN NN O
the NN NN O
accuracy NN NN O
of NN NN O
results NN NN O
obtained NN NN O
by NN NN O
linkage NN NN O
approaches NN NN O
when NN NN O
requested NN NN O
to NN NN O
do NN NN O
so NN NN O
by NN NN O
the NN NN O
test NN NN O
individuals NN NN O
. NN NN O

For NN NN O
six NN NN O
such NN NN O
individuals NN NN O
, NN NN O
there NN NN O
was NN NN O
significant NN NN O
disparity NN NN O
between NN NN O
the NN NN O
tests NN NN O
. NN NN O

Three NN NN O
went NN NN O
from NN NN O
a NN NN O
decreased NN NN O
risk NN NN O
to NN NN O
an NN NN O
increased NN NN O
risk NN NN O
, NN NN O
while NN NN O
in NN NN O
another NN NN O
three NN NN O
the NN NN O
risk NN NN O
was NN NN O
decreased NN NN O
. NN NN O

Knowledge NN NN O
of NN NN O
the NN NN O
potential NN NN O
reasons NN NN O
for NN NN O
these NN NN O
changes NN NN O
in NN NN O
results NN NN O
and NN NN O
impact NN NN O
of NN NN O
these NN NN O
risk NN NN O
reversals NN NN O
on NN NN O
both NN NN O
patients NN NN O
and NN NN O
the NN NN O
counseling NN NN O
team NN NN O
can NN NN O
assist NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
strategies NN NN O
for NN NN O
the NN NN O
prevention NN NN O
and NN NN O
, NN NN O
where NN NN O
necessary NN NN O
, NN NN O
management NN NN O
of NN NN O
a NN NN O
risk NN NN O
reversal NN NN O
in NN NN O
any NN NN O
predictive NN NN O
testing NN NN O
program NN NN O
. NN NN O

. NN NN O

9385378 NN NN O
A NN NN O
novel NN NN O
common NN NN O
missense NN NN O
mutation NN NN O
G301C NN NN O
in NN NN O
the NN NN O
N-acetylgalactosamine-6-sulfate NN NN O
sulfatase NN NN O
gene NN NN O
in NN NN O
mucopolysaccharidosis NN NN B-SpecificDisease
IVA NN NN I-SpecificDisease
. NN NN O

Mucopolysaccharidosis NN NN B-SpecificDisease
IVA NN NN I-SpecificDisease
( NN NN O
MPS NN NN B-SpecificDisease
IVA NN NN I-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
lysosomal NN NN I-DiseaseClass
storage NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
a NN NN O
genetic NN NN B-DiseaseClass
defect NN NN I-DiseaseClass
in NN NN O
N-acetylgalactosamine-6-sulfate NN NN O
sulfatase NN NN O
( NN NN O
GALNS NN NN O
) NN NN O
. NN NN O

In NN NN O
previous NN NN O
studies NN NN O
, NN NN O
we NN NN O
have NN NN O
found NN NN O
two NN NN O
common NN NN O
mutations NN NN O
in NN NN O
Caucasians NN NN O
and NN NN O
Japanese NN NN O
, NN NN O
respectively NN NN O
. NN NN O

To NN NN O
characterize NN NN O
the NN NN O
mutational NN NN O
spectrum NN NN O
in NN NN O
various NN NN O
ethnic NN NN O
groups NN NN O
, NN NN O
mutations NN NN O
in NN NN O
the NN NN O
GALNS NN NN O
gene NN NN O
in NN NN O
Colombian NN NN O
MPS NN NN B-Modifier
IVA NN NN I-Modifier
patients NN NN O
were NN NN O
investigated NN NN O
, NN NN O
and NN NN O
genetic NN NN O
backgrounds NN NN O
were NN NN O
extensively NN NN O
analyzed NN NN O
to NN NN O
identify NN NN O
racial NN NN O
origin NN NN O
, NN NN O
based NN NN O
on NN NN O
mitochondrial NN NN O
DNA NN NN O
( NN NN O
mtDNA NN NN O
) NN NN O
lineages NN NN O
. NN NN O

Three NN NN O
novel NN NN O
missense NN NN O
mutations NN NN O
never NN NN O
identified NN NN O
previously NN NN O
in NN NN O
other NN NN O
populations NN NN O
and NN NN O
found NN NN O
in NN NN O
16 NN NN O
out NN NN O
of NN NN O
19 NN NN O
Colombian NN NN O
MPS NN NN B-Modifier
IVA NN NN I-Modifier
unrelated NN NN O
alleles NN NN O
account NN NN O
for NN NN O
84 NN NN O
. NN NN O

2 NN NN O
% NN NN O
of NN NN O
the NN NN O
alleles NN NN O
in NN NN O
this NN NN O
study NN NN O
. NN NN O

The NN NN O
G301C NN NN O
and NN NN O
S162F NN NN O
mutations NN NN O
account NN NN O
for NN NN O
68 NN NN O
. NN NN O

4 NN NN O
% NN NN O
and NN NN O
10 NN NN O
. NN NN O

5 NN NN O
% NN NN O
of NN NN O
mutations NN NN O
, NN NN O
respectively NN NN O
, NN NN O
whereas NN NN O
the NN NN O
remaining NN NN O
F69V NN NN O
is NN NN O
limited NN NN O
to NN NN O
a NN NN O
single NN NN O
allele NN NN O
. NN NN O

The NN NN O
skewed NN NN O
prevalence NN NN O
of NN NN O
G301C NN NN O
in NN NN O
only NN NN O
Colombian NN NN O
patients NN NN O
and NN NN O
haplotype NN NN O
analysis NN NN O
by NN NN O
restriction NN NN O
fragment NN NN O
length NN NN O
polymorphisms NN NN O
in NN NN O
the NN NN O
GALNS NN NN O
gene NN NN O
suggest NN NN O
that NN NN O
G301C NN NN O
originated NN NN O
from NN NN O
a NN NN O
common NN NN O
ancestor NN NN O
. NN NN O

Investigation NN NN O
of NN NN O
the NN NN O
genetic NN NN O
background NN NN O
by NN NN O
means NN NN O
of NN NN O
mtDNA NN NN O
lineages NN NN O
indicate NN NN O
that NN NN O
all NN NN O
our NN NN O
patients NN NN O
are NN NN O
probably NN NN O
of NN NN O
native NN NN O
American NN NN O
descent NN NN O

9391879 NN NN O
Low NN NN O
frequency NN NN O
of NN NN O
BRCA1 NN NN O
germline NN NN O
mutations NN NN O
in NN NN O
45 NN NN O
German NN NN O
breast/ovarian NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
. NN NN O

In NN NN O
this NN NN O
study NN NN O
we NN NN O
investigated NN NN O
45 NN NN O
German NN NN O
breast NN NN B-Modifier
/ NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
families NN NN O
for NN NN O
germline NN NN O
mutations NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
. NN NN O

We NN NN O
identified NN NN O
four NN NN O
germline NN NN O
mutations NN NN O
in NN NN O
three NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
and NN NN O
in NN NN O
one NN NN O
breast-ovarian NN NN B-Modifier
cancer NN NN I-Modifier
family NN NN O
. NN NN O

among NN NN O
these NN NN O
were NN NN O
one NN NN O
frameshift NN NN O
mutation NN NN O
, NN NN O
one NN NN O
nonsense NN NN O
mutation NN NN O
, NN NN O
one NN NN O
novel NN NN O
splice NN NN O
site NN NN O
mutation NN NN O
, NN NN O
and NN NN O
one NN NN O
missense NN NN O
mutation NN NN O
. NN NN O

The NN NN O
missense NN NN O
mutation NN NN O
was NN NN O
also NN NN O
found NN NN O
in NN NN O
2 NN NN O
. NN NN O

8 NN NN O
% NN NN O
of NN NN O
the NN NN O
general NN NN O
population NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
it NN NN O
is NN NN O
not NN NN O
disease NN NN O
associated NN NN O
. NN NN O

The NN NN O
average NN NN O
age NN NN O
of NN NN O
disease NN NN O
onset NN NN O
in NN NN O
those NN NN O
families NN NN O
harbouring NN NN O
causative NN NN O
mutations NN NN O
was NN NN O
between NN NN O
32 NN NN O
. NN NN O

3 NN NN O
and NN NN O
37 NN NN O
. NN NN O

4 NN NN O
years NN NN O
, NN NN O
whereas NN NN O
the NN NN O
family NN NN O
harbouring NN NN O
the NN NN O
missense NN NN O
mutation NN NN O
had NN NN O
an NN NN O
average NN NN O
age NN NN O
of NN NN O
onset NN NN O
of NN NN O
51 NN NN O
. NN NN O

2 NN NN O
years NN NN O
. NN NN O

These NN NN O
findings NN NN O
show NN NN O
that NN NN O
BRCA1 NN NN O
is NN NN O
implicated NN NN O
in NN NN O
a NN NN O
small NN NN O
fraction NN NN O
of NN NN O
breast NN NN B-Modifier
/ NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
families NN NN O
suggesting NN NN O
the NN NN O
involvement NN NN O
of NN NN O
another NN NN O
susceptibility NN NN O
gene NN NN O
( NN NN O
s NN NN O
) NN NN O

9391889 NN NN O
Paternal NN NN O
transmission NN NN O
of NN NN O
congenital NN NN B-SpecificDisease
myotonic NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

We NN NN O
report NN NN O
a NN NN O
rare NN NN O
case NN NN O
of NN NN O
paternally NN NN O
transmitted NN NN O
congenital NN NN B-SpecificDisease
myotonic NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
proband NN NN O
is NN NN O
a NN NN O
23 NN NN O
year NN NN O
old NN NN O
, NN NN O
mentally NN NN B-Modifier
retarded NN NN I-Modifier
male NN NN O
who NN NN O
suffers NN NN O
severe NN NN O
muscular NN NN B-DiseaseClass
weakness NN NN I-DiseaseClass
. NN NN O

He NN NN O
presented NN NN O
with NN NN O
respiratory NN NN O
and NN NN O
feeding NN NN O
difficulties NN NN O
at NN NN O
birth NN NN O
. NN NN O

His NN NN O
two NN NN O
sibs NN NN O
suffer NN NN O
from NN NN O
childhood NN NN O
onset NN NN O
DM NN NN B-SpecificDisease
. NN NN O

Their NN NN O
late NN NN O
father NN NN O
had NN NN O
the NN NN O
adult NN NN O
type NN NN O
of NN NN O
DM NN NN B-SpecificDisease
, NN NN O
with NN NN O
onset NN NN O
around NN NN O
30 NN NN O
years NN NN O
. NN NN O

Only NN NN O
six NN NN O
other NN NN O
cases NN NN O
of NN NN O
paternal NN NN O
transmission NN NN O
of NN NN O
congenital NN NN B-SpecificDisease
DM NN NN I-SpecificDisease
have NN NN O
been NN NN O
reported NN NN O
recently NN NN O
. NN NN O

We NN NN O
review NN NN O
the NN NN O
sex NN NN O
related NN NN O
effects NN NN O
on NN NN O
transmission NN NN O
of NN NN O
congenital NN NN B-SpecificDisease
DM NN NN I-SpecificDisease
. NN NN O

Decreased NN NN O
fertility NN NN O
of NN NN O
males NN NN O
with NN NN O
adult NN NN O
onset NN NN O
DM NN NN B-SpecificDisease
and NN NN O
contraction NN NN O
of NN NN O
the NN NN O
repeat NN NN O
upon NN NN O
male NN NN O
transmission NN NN O
contribute NN NN O
to NN NN O
the NN NN O
almost NN NN O
absent NN NN O
occurrence NN NN O
of NN NN O
paternal NN NN O
transmission NN NN O
of NN NN O
congenital NN NN B-SpecificDisease
DM NN NN I-SpecificDisease
. NN NN O

Also NN NN O
the NN NN O
fathers NN NN O
of NN NN O
the NN NN O
reported NN NN O
congenitally NN NN O
affected NN NN O
children NN NN O
showed NN NN O
, NN NN O
on NN NN O
average NN NN O
, NN NN O
shorter NN NN O
CTG NN NN O
repeat NN NN O
lengths NN NN O
and NN NN O
hence NN NN O
less NN NN O
severe NN NN O
clinical NN NN O
symptoms NN NN O
than NN NN O
the NN NN O
mothers NN NN O
of NN NN O
children NN NN O
with NN NN O
congenital NN NN B-SpecificDisease
DM NN NN I-SpecificDisease
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
paternal NN NN O
transmission NN NN O
of NN NN O
congenital NN NN B-SpecificDisease
DM NN NN I-SpecificDisease
is NN NN O
rare NN NN O
and NN NN O
preferentially NN NN O
occurs NN NN O
with NN NN O
onset NN NN O
of NN NN O
DM NN NN B-SpecificDisease
past NN NN O
30 NN NN O
years NN NN O
in NN NN O
the NN NN O
father NN NN O
. NN NN O

. NN NN O

9400934 NN NN O
The NN NN O
RB1 NN NN O
gene NN NN O
mutation NN NN O
in NN NN O
a NN NN O
child NN NN O
with NN NN O
ectopic NN NN B-SpecificDisease
intracranial NN NN I-SpecificDisease
retinoblastoma NN NN I-SpecificDisease
. NN NN O

The NN NN O
RB1 NN NN O
gene NN NN O
mutation NN NN O
was NN NN O
investigated NN NN O
in NN NN O
a NN NN O
child NN NN O
with NN NN O
ectopic NN NN B-SpecificDisease
intracranial NN NN I-SpecificDisease
retinoblastoma NN NN I-SpecificDisease
using NN NN O
DNA NN NN O
obtained NN NN O
from NN NN O
both NN NN O
the NN NN O
pineal NN NN B-CompositeMention
and NN NN I-CompositeMention
retinal NN NN I-CompositeMention
tumours NN NN I-CompositeMention
of NN NN O
the NN NN O
patient NN NN O
. NN NN O

A NN NN O
nonsense NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
17 NN NN O
( NN NN O
codon NN NN O
556 NN NN O
) NN NN O
of NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
present NN NN O
homozygously NN NN O
in NN NN O
both NN NN O
the NN NN O
retinal NN NN B-CompositeMention
and NN NN I-CompositeMention
the NN NN I-CompositeMention
pineal NN NN I-CompositeMention
tumours NN NN I-CompositeMention
. NN NN O

The NN NN O
same NN NN O
mutation NN NN O
was NN NN O
present NN NN O
heterozygously NN NN O
in NN NN O
the NN NN O
DNA NN NN O
from NN NN O
the NN NN O
constitutional NN NN O
cells NN NN O
of NN NN O
the NN NN O
patient NN NN O
, NN NN O
proving NN NN O
it NN NN O
to NN NN O
be NN NN O
of NN NN O
germline NN NN O
origin NN NN O
. NN NN O

The NN NN O
initial NN NN O
mutation NN NN O
was NN NN O
shown NN NN O
to NN NN O
have NN NN O
occurred NN NN O
in NN NN O
the NN NN O
paternally NN NN O
derived NN NN O
RB1 NN NN O
allele NN NN O
. NN NN O

The NN NN O
mutation NN NN O
is NN NN O
in NN NN O
an NN NN O
area NN NN O
of NN NN O
the NN NN O
gene NN NN O
that NN NN O
encodes NN NN O
the NN NN O
protein-binding NN NN O
region NN NN O
known NN NN O
as NN NN O
the NN NN O
pocket NN NN O
region NN NN O
and NN NN O
has NN NN O
been NN NN O
detected NN NN O
in NN NN O
other NN NN O
cases NN NN O
of NN NN O
retinoblastoma NN NN B-SpecificDisease
. NN NN O

. NN NN O

941901 NN NN O
Low NN NN O
levels NN NN O
of NN NN O
beta NN NN O
hexosaminidase NN NN O
A NN NN O
in NN NN O
healthy NN NN O
individuals NN NN O
with NN NN O
apparent NN NN O
deficiency NN NN O
of NN NN O
this NN NN O
enzyme NN NN O
. NN NN O

Appreciable NN NN O
beta NN NN O
hexosaminidase NN NN O
A NN NN O
( NN NN O
hex NN NN O
A NN NN O
) NN NN O
activity NN NN O
has NN NN O
been NN NN O
detected NN NN O
in NN NN O
cultured NN NN O
skin NN NN O
fibroblasts NN NN O
and NN NN O
melanoma NN NN B-Modifier
tissue NN NN O
from NN NN O
healthy NN NN O
individuals NN NN O
previously NN NN O
reported NN NN O
as NN NN O
having NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
hex NN NN I-SpecificDisease
A NN NN I-SpecificDisease
activity NN NN O
indistinguishable NN NN O
from NN NN O
that NN NN O
of NN NN O
patients NN NN O
with NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
TSD NN NN B-SpecificDisease
) NN NN O
. NN NN O

Identification NN NN O
and NN NN O
quantitation NN NN O
of NN NN O
hex NN NN O
A NN NN O
, NN NN O
amounting NN NN O
to NN NN O
3 NN NN O
. NN NN O

5 NN NN O
% NN NN O
-6 NN NN O
. NN NN O

9 NN NN O
% NN NN O
of NN NN O
total NN NN O
beta NN NN O
hexosaminidase NN NN O
activity NN NN O
, NN NN O
has NN NN O
been NN NN O
obtained NN NN O
by NN NN O
cellulose NN NN O
acetate NN NN O
gel NN NN O
electrophoresis NN NN O
, NN NN O
DEAE-cellulose NN NN O
ion-exchange NN NN O
chromatography NN NN O
, NN NN O
radial NN NN O
immunodiffusion NN NN O
, NN NN O
and NN NN O
radioimmunoassay NN NN O
. NN NN O

Previous NN NN O
family NN NN O
studies NN NN O
suggested NN NN O
that NN NN O
these NN NN O
individuals NN NN O
may NN NN O
be NN NN O
compound NN NN O
heterozygotes NN NN O
for NN NN O
the NN NN O
common NN NN O
mutant NN NN O
TSD NN NN B-Modifier
gene NN NN O
and NN NN O
a NN NN O
rare NN NN O
( NN NN O
allelic NN NN O
) NN NN O
mutant NN NN O
gene NN NN O
. NN NN O

Thus NN NN O
, NN NN O
the NN NN O
postulated NN NN O
rate NN NN O
mutant NN NN O
gene NN NN O
appears NN NN O
to NN NN O
code NN NN O
for NN NN O
the NN NN O
expression NN NN O
of NN NN O
low NN NN O
amounts NN NN O
of NN NN O
hex NN NN O
A NN NN O
. NN NN O

Heterozygotes NN NN O
for NN NN O
the NN NN O
rare NN NN O
mutant NN NN O
may NN NN O
be NN NN O
indistinguishable NN NN O
from NN NN O
heterozygotes NN NN O
for NN NN O
the NN NN O
common NN NN O
TSD NN NN B-Modifier
mutant NN NN O
. NN NN O

However NN NN O
, NN NN O
direct NN NN O
visualization NN NN O
and NN NN O
quantitation NN NN O
of NN NN O
hex NN NN O
A NN NN O
by NN NN O
the NN NN O
methods NN NN O
described NN NN O
may NN NN O
prevent NN NN O
false-positive NN NN O
prenatal NN NN O
diagnosis NN NN O
of NN NN O
TSD NN NN B-SpecificDisease
in NN NN O
fetuses NN NN O
having NN NN O
the NN NN O
incomplete NN NN O
hex NN NN B-SpecificDisease
A NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
of NN NN O
the NN NN O
type NN NN O
described NN NN O
in NN NN O
the NN NN O
four NN NN O
healthy NN NN O
individuals NN NN O

9420335 NN NN O
The NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
gene NN NN O
Smad4/Dpc4 NN NN O
is NN NN O
required NN NN O
for NN NN O
gastrulation NN NN O
and NN NN O
later NN NN O
for NN NN O
anterior NN NN O
development NN NN O
of NN NN O
the NN NN O
mouse NN NN O
embryo NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
SMAD4 NN NN O
/ NN NN O
DPC4 NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
gene NN NN O
, NN NN O
a NN NN O
key NN NN O
signal NN NN O
transducer NN NN O
in NN NN O
most NN NN O
TGFbeta-related NN NN O
pathways NN NN O
, NN NN O
are NN NN O
involved NN NN O
in NN NN O
50 NN NN O
% NN NN O
of NN NN O
pancreatic NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
. NN NN O

Homozygous NN NN O
Smad4 NN NN O
mutant NN NN O
mice NN NN O
die NN NN O
before NN NN O
day NN NN O
7 NN NN O
. NN NN O

5 NN NN O
of NN NN O
embryogenesis NN NN O
. NN NN O

Mutant NN NN O
embryos NN NN O
have NN NN O
reduced NN NN O
size NN NN O
, NN NN O
fail NN NN O
to NN NN O
gastrulate NN NN O
or NN NN O
express NN NN O
a NN NN O
mesodermal NN NN O
marker NN NN O
, NN NN O
and NN NN O
show NN NN O
abnormal NN NN O
visceral NN NN O
endoderm NN NN O
development NN NN O
. NN NN O

Growth NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
of NN NN O
the NN NN O
Smad4-deficient NN NN O
embryos NN NN O
results NN NN O
from NN NN O
reduced NN NN O
cell NN NN O
proliferation NN NN O
rather NN NN O
than NN NN O
increased NN NN O
apoptosis NN NN O
. NN NN O

Aggregation NN NN O
of NN NN O
mutant NN NN O
Smad4 NN NN O
ES NN NN O
cells NN NN O
with NN NN O
wild-type NN NN O
tetraploid NN NN O
morulae NN NN O
rescues NN NN O
the NN NN O
gastrulation NN NN B-SpecificDisease
defect NN NN I-SpecificDisease
. NN NN O

These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
Smad4 NN NN O
is NN NN O
initially NN NN O
required NN NN O
for NN NN O
the NN NN O
differentiation NN NN O
of NN NN O
the NN NN O
visceral NN NN O
endoderm NN NN O
and NN NN O
that NN NN O
the NN NN O
gastrulation NN NN B-SpecificDisease
defect NN NN I-SpecificDisease
in NN NN O
the NN NN O
epiblast NN NN O
is NN NN O
secondary NN NN O
and NN NN O
non-cell NN NN O
autonomous NN NN O
. NN NN O

Rescued NN NN O
embryos NN NN O
show NN NN O
severe NN NN O
anterior NN NN O
truncations NN NN O
, NN NN O
indicating NN NN O
a NN NN O
second NN NN O
important NN NN O
role NN NN O
for NN NN O
Smad4 NN NN O
in NN NN O
anterior NN NN O
patterning NN NN O
during NN NN O
embryogenesis NN NN O
. NN NN O

9425228 NN NN O
Prevalence NN NN O
of NN NN O
p16 NN NN O
and NN NN O
CDK4 NN NN O
germline NN NN O
mutations NN NN O
in NN NN O
48 NN NN O
melanoma NN NN B-Modifier
-prone NN NN O
families NN NN O
in NN NN O
France NN NN O
. NN NN O

The NN NN O
French NN NN O
Familial NN NN B-Modifier
Melanoma NN NN I-Modifier
Study NN NN O
Group NN NN O
. NN NN O

Germline NN NN O
mutations NN NN O
in NN NN O
the NN NN O
p16 NN NN O
and NN NN O
CDK4 NN NN O
genes NN NN O
have NN NN O
been NN NN O
reported NN NN O
in NN NN O
a NN NN O
subset NN NN O
of NN NN O
melanoma NN NN B-Modifier
pedigrees NN NN O
, NN NN O
but NN NN O
their NN NN O
prevalence NN NN O
is NN NN O
not NN NN O
well NN NN O
known NN NN O
. NN NN O

We NN NN O
searched NN NN O
for NN NN O
such NN NN O
germline NN NN O
mutations NN NN O
in NN NN O
48 NN NN O
French NN NN O
melanoma NN NN B-Modifier
-prone NN NN O
families NN NN O
selected NN NN O
according NN NN O
to NN NN O
two NN NN O
major NN NN O
criteria NN NN O
families NN NN O
with NN NN O
at NN NN O
least NN NN O
three NN NN O
affected NN NN O
members NN NN O
( NN NN O
n NN NN O
= NN NN O
20 NN NN O
) NN NN O
or NN NN O
families NN NN O
with NN NN O
two NN NN O
affected NN NN O
members NN NN O
, NN NN O
one NN NN O
of NN NN O
them NN NN O
affected NN NN O
before NN NN O
the NN NN O
age NN NN O
of NN NN O
50 NN NN O
( NN NN O
n NN NN O
= NN NN O
28 NN NN O
) NN NN O
, NN NN O
and NN NN O
one NN NN O
additional NN NN O
minor NN NN O
criterion NN NN O
. NN NN O

Sixteen NN NN O
different NN NN O
p16 NN NN O
germline NN NN O
mutations NN NN O
were NN NN O
found NN NN O
in NN NN O
21 NN NN O
families NN NN O
, NN NN O
while NN NN O
one NN NN O
germline NN NN O
mutation NN NN O
, NN NN O
Arg24His NN NN O
, NN NN O
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
CDK4 NN NN O
gene NN NN O
. NN NN O

The NN NN O
frequency NN NN O
of NN NN O
p16 NN NN O
gene NN NN O
mutation NN NN O
in NN NN O
our NN NN O
sample NN NN O
( NN NN O
44 NN NN O
% NN NN O
) NN NN O
is NN NN O
among NN NN O
the NN NN O
highest NN NN O
rates NN NN O
yet NN NN O
reported NN NN O
and NN NN O
the NN NN O
CDK4 NN NN O
mutation NN NN O
is NN NN O
the NN NN O
second NN NN O
mutation NN NN O
detected NN NN O
in NN NN O
this NN NN O
gene NN NN O
worldwide NN NN O
. NN NN O

In NN NN O
summary NN NN O
, NN NN O
our NN NN O
results NN NN O
show NN NN O
frequent NN NN O
involvement NN NN O
of NN NN O
the NN NN O
p16 NN NN O
gene NN NN O
in NN NN O
familial NN NN B-SpecificDisease
melanoma NN NN I-SpecificDisease
and NN NN O
confirm NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
CDK4 NN NN O
gene NN NN O
as NN NN O
a NN NN O
melanoma NN NN B-Modifier
-predisposing NN NN O
gene NN NN O
. NN NN O

. NN NN O

9425239 NN NN O
Progression NN NN O
of NN NN O
somatic NN NN O
CTG NN NN O
repeat NN NN O
length NN NN O
heterogeneity NN NN O
in NN NN O
the NN NN O
blood NN NN O
cells NN NN O
of NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
patients NN NN O
. NN NN O

The NN NN O
genetic NN NN O
basis NN NN O
of NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
is NN NN O
the NN NN O
expansion NN NN O
of NN NN O
an NN NN O
unstable NN NN O
CTG NN NN O
repeat NN NN O
in NN NN O
the NN NN O
34 NN NN O
UTR NN NN O
of NN NN O
the NN NN O
DM NN NN B-Modifier
protein NN NN O
kinase NN NN O
gene NN NN O
on NN NN O
chromosome NN NN O
19 NN NN O
. NN NN O

One NN NN O
of NN NN O
the NN NN O
principal NN NN O
features NN NN O
of NN NN O
the NN NN O
DM NN NN B-Modifier
mutation NN NN O
is NN NN O
an NN NN O
extraordinarily NN NN O
high NN NN O
level NN NN O
of NN NN O
somatic NN NN O
mosaicism NN NN O
, NN NN O
due NN NN O
to NN NN O
an NN NN O
extremely NN NN O
high NN NN O
degree NN NN O
of NN NN O
somatic NN NN O
instability NN NN O
both NN NN O
within NN NN O
and NN NN O
between NN NN O
different NN NN O
tissues NN NN O
. NN NN O

This NN NN O
instability NN NN O
appears NN NN O
to NN NN O
be NN NN O
biased NN NN O
towards NN NN O
further NN NN O
expansion NN NN O
and NN NN O
continuous NN NN O
throughout NN NN O
the NN NN O
life NN NN O
of NN NN O
an NN NN O
individual NN NN O
, NN NN O
features NN NN O
that NN NN O
could NN NN O
be NN NN O
associated NN NN O
with NN NN O
the NN NN O
progressive NN NN O
nature NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

Although NN NN O
increasing NN NN O
measured NN NN O
allele NN NN O
size NN NN O
between NN NN O
patients NN NN O
clearly NN NN O
correlates NN NN O
with NN NN O
an NN NN O
increased NN NN O
severity NN NN O
of NN NN O
symptoms NN NN O
and NN NN O
an NN NN O
earlier NN NN O
age NN NN O
of NN NN O
onset NN NN O
, NN NN O
this NN NN O
correlation NN NN O
is NN NN O
not NN NN O
precise NN NN O
and NN NN O
measured NN NN O
allele NN NN O
length NN NN O
can NN NN O
not NN NN O
be NN NN O
used NN NN O
as NN NN O
an NN NN O
accurate NN NN O
predictor NN NN O
of NN NN O
age NN NN O
of NN NN O
onset NN NN O
. NN NN O

In NN NN O
order NN NN O
to NN NN O
further NN NN O
characterize NN NN O
the NN NN O
dynamics NN NN O
of NN NN O
DM NN NN B-Modifier
CTG NN NN O
repeat NN NN O
somatic NN NN O
instability NN NN O
, NN NN O
we NN NN O
have NN NN O
studied NN NN O
repeat NN NN O
length NN NN O
changes NN NN O
over NN NN O
time NN NN O
in NN NN O
111 NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
patients NN NN O
with NN NN O
varying NN NN O
clinical NN NN O
severity NN NN O
and NN NN O
CTG NN NN O
repeat NN NN O
size NN NN O
over NN NN O
time NN NN O
intervals NN NN O
of NN NN O
1-7 NN NN O
years NN NN O
. NN NN O

We NN NN O
have NN NN O
found NN NN O
a NN NN O
direct NN NN O
progression NN NN O
of NN NN O
the NN NN O
size NN NN O
heterogeneity NN NN O
over NN NN O
time NN NN O
related NN NN O
to NN NN O
initial NN NN O
CTG NN NN O
repeat NN NN O
size NN NN O
and NN NN O
the NN NN O
time NN NN O
interval NN NN O
and NN NN O
always NN NN O
biased NN NN O
towards NN NN O
further NN NN O
expansion NN NN O
. NN NN O

Attempts NN NN O
to NN NN O
mathematically NN NN O
model NN NN O
the NN NN O
dynamics NN NN O
have NN NN O
proved NN NN O
only NN NN O
partially NN NN O
successful NN NN O
suggesting NN NN O
that NN NN O
individual NN NN O
specific NN NN O
genetic NN NN O
and NN NN O
/ NN NN O
or NN NN O
environmental NN NN O
factors NN NN O
also NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
somatic NN NN O
mosaicism NN NN O
. NN NN O

. NN NN O

9427148 NN NN O
Aspartylglucosaminuria NN NN B-SpecificDisease
among NN NN O
Palestinian NN NN O
Arabs NN NN O
. NN NN O

Aspartylglucosaminuria NN NN B-SpecificDisease
( NN NN O
AGU NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
rare NN NN O
disorder NN NN B-DiseaseClass
of NN NN I-DiseaseClass
glycoprotein NN NN I-DiseaseClass
metabolism NN NN I-DiseaseClass
caused NN NN O
by NN NN O
the NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
lysosomal NN NN I-SpecificDisease
enzyme NN NN I-SpecificDisease
aspartylglucosaminidase NN NN I-SpecificDisease
( NN NN O
AGA NN NN O
) NN NN O
. NN NN O

AGU NN NN B-SpecificDisease
is NN NN O
inherited NN NN O
as NN NN O
an NN NN O
autosomal NN NN O
recessive NN NN O
trait NN NN O
and NN NN O
occurs NN NN O
with NN NN O
a NN NN O
high NN NN O
frequency NN NN O
in NN NN O
Finland NN NN O
because NN NN O
of NN NN O
a NN NN O
founder NN NN O
effect NN NN O
. NN NN O

While NN NN O
very NN NN O
few NN NN O
patients NN NN O
with NN NN O
AGU NN NN B-SpecificDisease
have NN NN O
been NN NN O
reported NN NN O
from NN NN O
non-Finnish NN NN O
origin NN NN O
, NN NN O
we NN NN O
diagnosed NN NN O
the NN NN O
disorder NN NN O
in NN NN O
8 NN NN O
patients NN NN O
originating NN NN O
from NN NN O
3 NN NN O
unrelated NN NN O
families NN NN O
, NN NN O
all NN NN O
Palestinian NN NN O
Arabs NN NN O
from NN NN O
the NN NN O
region NN NN O
of NN NN O
Jerusalem NN NN O
. NN NN O

The NN NN O
clinical NN NN O
diagnosis NN NN O
of NN NN O
AGU NN NN B-SpecificDisease
is NN NN O
often NN NN O
difficult NN NN O
, NN NN O
in NN NN O
particular NN NN O
early NN NN O
in NN NN O
the NN NN O
course NN NN O
of NN NN O
the NN NN O
disease NN NN O
, NN NN O
and NN NN O
most NN NN O
of NN NN O
the NN NN O
patients NN NN O
are NN NN O
diagnosed NN NN O
after NN NN O
the NN NN O
age NN NN O
of NN NN O
5 NN NN O
years NN NN O
. NN NN O

However NN NN O
, NN NN O
since NN NN O
these NN NN O
patients NN NN O
excrete NN NN O
early NN NN O
large NN NN O
amounts NN NN O
of NN NN O
aspartylglucosamine NN NN O
in NN NN O
urine NN NN O
, NN NN O
biochemical NN NN O
screening NN NN O
is NN NN O
easy NN NN O
by NN NN O
urine NN NN O
chromatography NN NN O
. NN NN O

. NN NN O

9439660 NN NN O
Detection NN NN O
of NN NN O
heterozygous NN NN O
carriers NN NN O
of NN NN O
the NN NN O
ataxia-telangiectasia NN NN B-Modifier
( NN NN O
ATM NN NN O
) NN NN O
gene NN NN O
by NN NN O
G2 NN NN O
phase NN NN O
chromosomal NN NN O
radiosensitivity NN NN O
of NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
. NN NN O

In NN NN O
ataxia-telangiectasia NN NN B-Modifier
( NN NN O
A-T NN NN B-Modifier
) NN NN O
patients NN NN O
, NN NN O
mutations NN NN O
in NN NN O
a NN NN O
single NN NN O
gene NN NN O
, NN NN O
ATM NN NN O
, NN NN O
result NN NN O
in NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
syndrome NN NN I-DiseaseClass
that NN NN O
embraces NN NN O
a NN NN O
variety NN NN O
of NN NN O
clinical NN NN O
features NN NN O
and NN NN O
manifests NN NN O
extreme NN NN O
radiosensitivity NN NN O
and NN NN O
a NN NN O
strong NN NN O
pre-disposition NN NN O
to NN NN O
malignancy NN NN B-DiseaseClass
. NN NN O

Heterozygotes NN NN O
for NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
have NN NN O
no NN NN O
clinical NN NN O
expression NN NN O
of NN NN O
A-T NN NN B-SpecificDisease
but NN NN O
may NN NN O
be NN NN O
cancer NN NN B-Modifier
prone NN NN O
with NN NN O
a NN NN O
moderate NN NN O
increase NN NN O
in NN NN O
in NN NN O
vitro NN NN O
radiosensitivity NN NN O
. NN NN O

We NN NN O
performed NN NN O
a NN NN O
blind NN NN O
chromosomal NN NN O
analysis NN NN O
on NN NN O
G2-phase NN NN O
lymphocytes NN NN O
from NN NN O
7 NN NN O
unrelated NN NN O
A-T NN NN B-Modifier
patients NN NN O
, NN NN O
13 NN NN O
obligate NN NN O
A-T NN NN B-Modifier
heterozygotes NN NN O
( NN NN O
parents NN NN O
of NN NN O
the NN NN O
patients NN NN O
) NN NN O
, NN NN O
and NN NN O
14 NN NN O
normal NN NN O
controls NN NN O
following NN NN O
X-irradiation NN NN O
with NN NN O
1 NN NN O
Gy NN NN O
in NN NN O
order NN NN O
to NN NN O
evaluate NN NN O
this NN NN O
cytogenetic NN NN O
method NN NN O
as NN NN O
a NN NN O
tool NN NN O
for NN NN O
detection NN NN O
of NN NN O
ATM NN NN O
carriers NN NN O
. NN NN O

Both NN NN O
A-T NN NN B-Modifier
homozygotes NN NN O
and NN NN O
heterozygotes NN NN O
showed NN NN O
significantly NN NN O
increased NN NN O
levels NN NN O
of NN NN O
radiation-induced NN NN O
chromatid NN NN O
damage NN NN O
relative NN NN O
to NN NN O
that NN NN O
of NN NN O
normal NN NN O
controls NN NN O
. NN NN O

These NN NN O
results NN NN O
show NN NN O
that NN NN O
the NN NN O
G2-phase NN NN O
chromosomal NN NN O
radiosensitivity NN NN O
assay NN NN O
can NN NN O
be NN NN O
used NN NN O
for NN NN O
the NN NN O
detection NN NN O
of NN NN O
A-T NN NN B-Modifier
heterozygotes NN NN O
. NN NN O

In NN NN O
combination NN NN O
with NN NN O
molecular NN NN O
genetic NN NN O
analyses NN NN O
, NN NN O
this NN NN O
test NN NN O
may NN NN O
be NN NN O
of NN NN O
value NN NN O
in NN NN O
studies NN NN O
of NN NN O
familial NN NN B-CompositeMention
and NN NN I-CompositeMention
sporadic NN NN I-CompositeMention
cancers NN NN I-CompositeMention
aimed NN NN O
at NN NN O
determination NN NN O
of NN NN O
the NN NN O
potential NN NN O
involvement NN NN O
of NN NN O
ATM NN NN O
mutations NN NN O
in NN NN O
tumor NN NN B-Modifier
risk NN NN O
or NN NN O
development NN NN O
. NN NN O

. NN NN O

9443866 NN NN O
Ataxia-telangiectasia NN NN B-SpecificDisease
: NN NN O
identification NN NN O
and NN NN O
detection NN NN O
of NN NN O
founder-effect NN NN O
mutations NN NN O
in NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
in NN NN O
ethnic NN NN O
populations NN NN O
. NN NN O

To NN NN O
facilitate NN NN O
the NN NN O
evaluation NN NN O
of NN NN O
ATM NN NN O
heterozygotes NN NN O
for NN NN O
susceptibility NN NN O
to NN NN O
other NN NN O
diseases NN NN O
, NN NN O
such NN NN O
as NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
we NN NN O
have NN NN O
attempted NN NN O
to NN NN O
define NN NN O
the NN NN O
most NN NN O
common NN NN O
mutations NN NN O
and NN NN O
their NN NN O
frequencies NN NN O
in NN NN O
ataxia-telangiectasia NN NN B-Modifier
( NN NN O
A-T NN NN B-Modifier
) NN NN O
homozygotes NN NN O
from NN NN O
10 NN NN O
ethnic NN NN O
populations NN NN O
. NN NN O

Both NN NN O
genomic NN NN O
mutations NN NN O
and NN NN O
their NN NN O
effects NN NN O
on NN NN O
cDNA NN NN O
were NN NN O
characterized NN NN O
. NN NN O

Protein-truncation NN NN O
testing NN NN O
of NN NN O
the NN NN O
entire NN NN O
ATM NN NN O
cDNA NN NN O
detected NN NN O
92 NN NN O
( NN NN O
66 NN NN O
% NN NN O
) NN NN O
truncating NN NN O
mutations NN NN O
in NN NN O
140 NN NN O
mutant NN NN O
alleles NN NN O
screened NN NN O
. NN NN O

The NN NN O
haplotyping NN NN O
of NN NN O
patients NN NN O
with NN NN O
identical NN NN O
mutations NN NN O
indicates NN NN O
that NN NN O
almost NN NN O
all NN NN O
of NN NN O
these NN NN O
represent NN NN O
common NN NN O
ancestry NN NN O
and NN NN O
that NN NN O
very NN NN O
few NN NN O
spontaneously NN NN O
recurring NN NN O
ATM NN NN O
mutations NN NN O
exist NN NN O
. NN NN O

Assays NN NN O
requiring NN NN O
minimal NN NN O
amounts NN NN O
of NN NN O
genomic NN NN O
DNA NN NN O
were NN NN O
designed NN NN O
to NN NN O
allow NN NN O
rapid NN NN O
screening NN NN O
for NN NN O
common NN NN O
ethnic NN NN O
mutations NN NN O
. NN NN O

These NN NN O
rapid NN NN O
assays NN NN O
detected NN NN O
mutations NN NN O
in NN NN O
76 NN NN O
% NN NN O
of NN NN O
Costa NN NN O
Rican NN NN O
patients NN NN O
( NN NN O
3 NN NN O
) NN NN O
, NN NN O
50 NN NN O
% NN NN O
of NN NN O
Norwegian NN NN O
patients NN NN O
( NN NN O
1 NN NN O
) NN NN O
, NN NN O
25 NN NN O
% NN NN O
of NN NN O
Polish NN NN O
patients NN NN O
( NN NN O
4 NN NN O
) NN NN O
, NN NN O
and NN NN O
14 NN NN O
% NN NN O
of NN NN O
Italian NN NN O
patients NN NN O
( NN NN O
1 NN NN O
) NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
patients NN NN O
of NN NN O
Amish NN NN O
/ NN NN O
Mennonite NN NN O
and NN NN O
Irish NN NN O
English NN NN O
backgrounds NN NN O
. NN NN O

Additional NN NN O
mutations NN NN O
were NN NN O
observed NN NN O
in NN NN O
Japanese NN NN O
, NN NN O
Utah NN NN O
Mormon NN NN O
, NN NN O
and NN NN O
African NN NN O
American NN NN O
patients NN NN O
. NN NN O

These NN NN O
assays NN NN O
should NN NN O
facilitate NN NN O
screening NN NN O
for NN NN O
A-T NN NN B-Modifier
heterozygotes NN NN O
in NN NN O
the NN NN O
populations NN NN O
studied NN NN O
. NN NN O

. NN NN O

9448273 NN NN O
The NN NN O
von NN NN B-Modifier
Hippel-Lindau NN NN I-Modifier
tumor NN NN I-Modifier
suppressor NN NN O
gene NN NN O
is NN NN O
required NN NN O
for NN NN O
cell NN NN O
cycle NN NN O
exit NN NN O
upon NN NN O
serum NN NN O
withdrawal NN NN O
. NN NN O

The NN NN O
inactivation NN NN O
of NN NN O
the NN NN O
von NN NN B-Modifier
Hippel-Lindau NN NN I-Modifier
( NN NN I-Modifier
VHL NN NN I-Modifier
) NN NN I-Modifier
tumor NN NN I-Modifier
suppressor NN NN O
gene NN NN O
predisposes NN NN O
affected NN NN O
individuals NN NN O
to NN NN O
the NN NN O
human NN NN O
VHL NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
is NN NN O
associated NN NN O
with NN NN O
sporadic NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
( NN NN O
RCC NN NN B-SpecificDisease
) NN NN O
and NN NN O
brain NN NN B-SpecificDisease
hemangioblastomas NN NN I-SpecificDisease
. NN NN O

VHL-negative NN NN O
786-0 NN NN O
RCC NN NN B-Modifier
cells NN NN O
are NN NN O
tumorigenic NN NN O
in NN NN O
nude NN NN O
mice NN NN O
which NN NN O
is NN NN O
suppressed NN NN O
by NN NN O
the NN NN O
reintroduction NN NN O
of NN NN O
VHL NN NN B-SpecificDisease
. NN NN O

Remarkably NN NN O
, NN NN O
this NN NN O
occurs NN NN O
without NN NN O
affecting NN NN O
the NN NN O
growth NN NN O
rate NN NN O
and NN NN O
cell NN NN O
cycle NN NN O
profile NN NN O
of NN NN O
these NN NN O
cells NN NN O
in NN NN O
culture NN NN O
. NN NN O

The NN NN O
786-0 NN NN O
cell NN NN O
line NN NN O
, NN NN O
like NN NN O
many NN NN O
cancer NN NN B-Modifier
cells NN NN O
, NN NN O
fails NN NN O
to NN NN O
exit NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
upon NN NN O
serum NN NN O
withdrawal NN NN O
. NN NN O

Here NN NN O
, NN NN O
it NN NN O
is NN NN O
shown NN NN O
that NN NN O
reintroduction NN NN O
of NN NN O
the NN NN O
wild-type NN NN O
VHL NN NN B-Modifier
gene NN NN O
restores NN NN O
the NN NN O
ability NN NN O
of NN NN O
VHL-negative NN NN O
RCC NN NN B-Modifier
cancer NN NN I-Modifier
cells NN NN O
to NN NN O
exit NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
and NN NN O
enter NN NN O
G0 NN NN O
/ NN NN O
quiescence NN NN O
in NN NN O
low NN NN O
serum NN NN O
. NN NN O

Both NN NN O
VHL-positive NN NN O
and NN NN O
VHL-negative NN NN O
RCC NN NN B-Modifier
cells NN NN O
exit NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
by NN NN O
contact NN NN O
inhibition NN NN O
. NN NN O

The NN NN O
cyclin-dependent NN NN O
kinase NN NN O
inhibitor NN NN O
, NN NN O
p27 NN NN O
, NN NN O
accumulates NN NN O
upon NN NN O
serum NN NN O
withdrawal NN NN O
, NN NN O
only NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
VHL NN NN B-SpecificDisease
, NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
the NN NN O
stabilization NN NN O
of NN NN O
the NN NN O
protein NN NN O
. NN NN O

We NN NN O
propose NN NN O
that NN NN O
the NN NN O
loss NN NN O
of NN NN O
wild-type NN NN O
VHL NN NN B-Modifier
gene NN NN O
results NN NN O
in NN NN O
a NN NN O
specific NN NN O
cellular NN NN O
defect NN NN O
in NN NN O
serum-dependent NN NN O
growth NN NN O
control NN NN O
, NN NN O
which NN NN O
may NN NN O
initiate NN NN O
tumor NN NN B-Modifier
formation NN NN O
. NN NN O

This NN NN O
is NN NN O
corrected NN NN O
by NN NN O
the NN NN O
reintroduction NN NN O
of NN NN O
wild-type NN NN O
VHL NN NN B-SpecificDisease
, NN NN O
implicating NN NN O
VHL NN NN B-SpecificDisease
as NN NN O
the NN NN O
first NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
involved NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
cell NN NN O
cycle NN NN O
exit NN NN O
, NN NN O
which NN NN O
is NN NN O
consistent NN NN O
with NN NN O
its NN NN O
gatekeeper NN NN O
function NN NN O
in NN NN O
the NN NN O
kidney NN NN O
. NN NN O

. NN NN O

9450866 NN NN O
Piebaldism NN NN B-SpecificDisease
with NN NN O
deafness NN NN B-SpecificDisease
: NN NN O
molecular NN NN O
evidence NN NN O
for NN NN O
an NN NN O
expanded NN NN O
syndrome NN NN O
. NN NN O

In NN NN O
a NN NN O
South NN NN O
African NN NN O
girl NN NN O
of NN NN O
Xhosa NN NN O
stock NN NN O
with NN NN O
severe NN NN O
piebaldism NN NN B-SpecificDisease
and NN NN O
profound NN NN O
congenital NN NN O
sensorineural NN NN B-SpecificDisease
deafness NN NN I-SpecificDisease
we NN NN O
identified NN NN O
a NN NN O
novel NN NN O
missense NN NN O
substitution NN NN O
at NN NN O
a NN NN O
highly NN NN O
conserved NN NN O
residue NN NN O
in NN NN O
the NN NN O
intracellular NN NN O
kinase NN NN O
domain NN NN O
of NN NN O
the NN NN O
KIT NN NN O
proto-oncogene NN NN O
, NN NN O
R796G NN NN O
. NN NN O

Though NN NN O
auditory NN NN B-DiseaseClass
anomalies NN NN I-DiseaseClass
have NN NN O
been NN NN O
observed NN NN O
in NN NN O
mice NN NN O
with NN NN O
dominant NN NN O
white NN NN O
spotting NN NN O
( NN NN O
W NN NN O
) NN NN O
due NN NN O
to NN NN O
KIT NN NN O
mutations NN NN O
, NN NN O
deafness NN NN B-SpecificDisease
is NN NN O
not NN NN O
typical NN NN O
in NN NN O
human NN NN O
piebaldism NN NN B-SpecificDisease
. NN NN O

Thus NN NN O
, NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
sensorineural NN NN B-SpecificDisease
deafness NN NN I-SpecificDisease
in NN NN O
this NN NN O
patient NN NN O
extends NN NN O
considerably NN NN O
the NN NN O
phenotypic NN NN O
range NN NN O
of NN NN O
piebaldism NN NN B-SpecificDisease
due NN NN O
to NN NN O
KIT NN NN O
gene NN NN O
mutation NN NN O
in NN NN O
humans NN NN O
and NN NN O
tightens NN NN O
the NN NN O
clinical NN NN O
similarity NN NN O
between NN NN O
piebaldism NN NN B-SpecificDisease
and NN NN O
the NN NN O
various NN NN O
forms NN NN O
of NN NN O
Waardenburg NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

. NN NN O

9457913 NN NN O
Cycloheximide NN NN O
facilitates NN NN O
the NN NN O
identification NN NN O
of NN NN O
aberrant NN NN O
transcripts NN NN O
resulting NN NN O
from NN NN O
a NN NN O
novel NN NN O
splice-site NN NN O
mutation NN NN O
in NN NN O
COL17A1 NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
generalized NN NN O
atrophic NN NN B-SpecificDisease
benign NN NN I-SpecificDisease
epidermolysis NN NN I-SpecificDisease
bullosa NN NN I-SpecificDisease
. NN NN O

Patients NN NN O
with NN NN O
generalized NN NN O
atrophic NN NN B-SpecificDisease
benign NN NN I-SpecificDisease
epidermolysis NN NN I-SpecificDisease
bullosa NN NN I-SpecificDisease
often NN NN O
show NN NN O
decreased NN NN O
expression NN NN O
of NN NN O
type NN NN O
XVII NN NN O
collagen NN NN O
, NN NN O
a NN NN O
transmembrane NN NN O
hemidesmosomal NN NN O
protein NN NN O
encoded NN NN O
by NN NN O
COL17A1 NN NN O
. NN NN O

This NN NN O
report NN NN O
documents NN NN O
a NN NN O
novel NN NN O
splice-site NN NN O
mutation NN NN O
in NN NN O
COL17A1 NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
generalized NN NN O
atrophic NN NN B-SpecificDisease
benign NN NN I-SpecificDisease
epidermolysis NN NN I-SpecificDisease
bullosa NN NN I-SpecificDisease
, NN NN O
and NN NN O
applies NN NN O
a NN NN O
new NN NN O
methodology NN NN O
to NN NN O
define NN NN O
and NN NN O
characterize NN NN O
the NN NN O
resulting NN NN O
mRNA NN NN O
splice NN NN O
variants NN NN O
. NN NN O

Mutational NN NN O
analysis NN NN O
of NN NN O
COL17A1 NN NN O
identified NN NN O
a NN NN O
maternally NN NN O
inherited NN NN O
G-to-T NN NN O
transversion NN NN O
at NN NN O
the NN NN O
-1 NN NN O
position NN NN O
of NN NN O
exon NN NN O
32 NN NN O
. NN NN O

This NN NN O
acceptor NN NN O
splice-site NN NN O
mutation NN NN O
led NN NN O
to NN NN O
the NN NN O
formation NN NN O
of NN NN O
aberrant NN NN O
transcripts NN NN O
present NN NN O
at NN NN O
extremely NN NN O
low NN NN O
levels NN NN O
. NN NN O

Based NN NN O
on NN NN O
our NN NN O
recent NN NN O
finding NN NN O
that NN NN O
cycloheximide NN NN O
stabilized NN NN O
mutant NN NN O
COL17A1 NN NN O
transcripts NN NN O
in NN NN O
keratinocytes NN NN O
homozygous NN NN O
for NN NN O
a NN NN O
frameshift NN NN O
mutation NN NN O
, NN NN O
the NN NN O
effects NN NN O
of NN NN O
the NN NN O
splice-site NN NN O
mutation NN NN O
on NN NN O
splicing NN NN O
of NN NN O
COL17A1 NN NN O
transcripts NN NN O
were NN NN O
determined NN NN O
using NN NN O
reverse NN NN O
transcriptase NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
of NN NN O
total NN NN O
RNA NN NN O
from NN NN O
keratinocytes NN NN O
incubated NN NN O
for NN NN O
2 NN NN O
. NN NN O

5 NN NN O
h NN NN O
in NN NN O
the NN NN O
presence NN NN O
or NN NN O
absence NN NN O
of NN NN O
10 NN NN O
microg NN NN O
cycloheximide NN NN O
per NN NN O
ml NN NN O
. NN NN O

Using NN NN O
this NN NN O
approach NN NN O
, NN NN O
an NN NN O
abnormally NN NN O
spliced NN NN O
transcript NN NN O
was NN NN O
identified NN NN O
that NN NN O
contains NN NN O
an NN NN O
extra NN NN O
264 NN NN O
bases NN NN O
upstream NN NN O
from NN NN O
exon NN NN O
32 NN NN O
, NN NN O
resulting NN NN O
in NN NN O
a NN NN O
premature NN NN O
termination NN NN O
codon NN NN O
27 NN NN O
bp NN NN O
downstream NN NN O
from NN NN O
the NN NN O
cryptic NN NN O
splice NN NN O
site NN NN O
. NN NN O

Three NN NN O
other NN NN O
splice NN NN O
variants NN NN O
, NN NN O
including NN NN O
one NN NN O
derived NN NN O
from NN NN O
the NN NN O
skipping NN NN O
of NN NN O
exon NN NN O
32 NN NN O
, NN NN O
were NN NN O
also NN NN O
identified NN NN O
. NN NN O

These NN NN O
results NN NN O
indicate NN NN O
the NN NN O
usefulness NN NN O
of NN NN O
cycloheximide NN NN O
treatment NN NN O
in NN NN O
evaluating NN NN O
the NN NN O
abnormal NN NN O
processing NN NN O
of NN NN O
mRNA NN NN O
due NN NN O
to NN NN O
splice-site NN NN O
mutations NN NN O
, NN NN O
because NN NN O
( NN NN O
i NN NN O
) NN NN O
aberrant NN NN O
splicing NN NN O
often NN NN O
generates NN NN O
a NN NN O
premature NN NN O
termination NN NN O
codon NN NN O
, NN NN O
( NN NN O
ii NN NN O
) NN NN O
transcripts NN NN O
with NN NN O
premature NN NN O
termination NN NN O
codons NN NN O
can NN NN O
occur NN NN O
at NN NN O
low NN NN O
or NN NN O
undetectable NN NN O
levels NN NN O
due NN NN O
to NN NN O
nonsense-mediated NN NN O
mRNA NN NN O
decay NN NN O
, NN NN O
and NN NN O
( NN NN O
iii NN NN O
) NN NN O
the NN NN O
levels NN NN O
of NN NN O
these NN NN O
transcripts NN NN O
can NN NN O
be NN NN O
increased NN NN O
by NN NN O
cycloheximide NN NN O
. NN NN O

9457914 NN NN O
A NN NN O
deletion NN NN O
mutation NN NN O
in NN NN O
COL17A1 NN NN O
in NN NN O
five NN NN O
Austrian NN NN O
families NN NN O
with NN NN O
generalized NN NN O
atrophic NN NN B-SpecificDisease
benign NN NN I-SpecificDisease
epidermolysis NN NN I-SpecificDisease
bullosa NN NN I-SpecificDisease
represents NN NN O
propagation NN NN O
of NN NN O
an NN NN O
ancestral NN NN O
allele NN NN O
. NN NN O

Patients NN NN O
with NN NN O
generalized NN NN O
atrophic NN NN B-SpecificDisease
benign NN NN I-SpecificDisease
epidermolysis NN NN I-SpecificDisease
bullosa NN NN I-SpecificDisease
, NN NN O
a NN NN O
usually NN NN O
nonlethal NN NN O
form NN NN O
of NN NN O
junctional NN NN B-SpecificDisease
epidermolysis NN NN I-SpecificDisease
bullosa NN NN I-SpecificDisease
, NN NN O
have NN NN O
generalized NN NN O
blistering NN NN B-SpecificDisease
, NN NN O
nail NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
patchy NN NN B-SpecificDisease
alopecia NN NN I-SpecificDisease
, NN NN O
and NN NN O
dental NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
. NN NN O

Skin NN NN B-DiseaseClass
fragility NN NN I-DiseaseClass
in NN NN O
most NN NN O
cases NN NN O
is NN NN O
due NN NN O
to NN NN O
mutations NN NN O
in NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
type NN NN O
XVII NN NN O
collagen NN NN O
( NN NN O
COL17A1 NN NN O
) NN NN O
. NN NN O

Recently NN NN O
, NN NN O
we NN NN O
reported NN NN O
five NN NN O
Austrian NN NN O
families NN NN O
with NN NN O
generalized NN NN O
atrophic NN NN B-SpecificDisease
benign NN NN I-SpecificDisease
epidermolysis NN NN I-SpecificDisease
bullosa NN NN I-SpecificDisease
who NN NN O
share NN NN O
the NN NN O
same NN NN O
COL17A1 NN NN O
mutation NN NN O
. NN NN O

Affected NN NN O
individuals NN NN O
in NN NN O
three NN NN O
families NN NN O
are NN NN O
homozygous NN NN O
for NN NN O
4003delTC NN NN O
, NN NN O
whereas NN NN O
those NN NN O
in NN NN O
two NN NN O
others NN NN O
are NN NN O
compound NN NN O
heterozygotes NN NN O
. NN NN O

To NN NN O
determine NN NN O
if NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
4003delTC NN NN O
in NN NN O
these NN NN O
unrelated NN NN O
families NN NN O
signifies NN NN O
propagation NN NN O
of NN NN O
an NN NN O
ancestral NN NN O
allele NN NN O
or NN NN O
a NN NN O
mutational NN NN O
hot NN NN O
spot NN NN O
, NN NN O
haplotypes NN NN O
were NN NN O
determined NN NN O
for NN NN O
polymorphisms NN NN O
both NN NN O
within NN NN O
and NN NN O
flanking NN NN O
COL17A1 NN NN O
. NN NN O

Five NN NN O
intragenic NN NN O
polymorphisms NN NN O
were NN NN O
chosen NN NN O
based NN NN O
on NN NN O
their NN NN O
informativeness NN NN O
. NN NN O

One NN NN O
of NN NN O
these NN NN O
, NN NN O
not NN NN O
previously NN NN O
reported NN NN O
, NN NN O
was NN NN O
2988 NN NN O
A NN NN O
or NN NN O
C NN NN O
that NN NN O
introduces NN NN O
a NN NN O
new NN NN O
restriction NN NN O
site NN NN O
for NN NN O
Eco0109 NN NN O
I NN NN O
. NN NN O

All NN NN O
the NN NN O
4003delTC NN NN O
alleles NN NN O
showed NN NN O
the NN NN O
same NN NN O
haplotype NN NN O
for NN NN O
these NN NN O
five NN NN O
polymorphic NN NN O
markers NN NN O
. NN NN O

Fourteen NN NN O
microsatellite NN NN O
polymorphisms NN NN O
were NN NN O
selected NN NN O
based NN NN O
on NN NN O
their NN NN O
high NN NN O
heterozygosity NN NN O
and NN NN O
their NN NN O
location NN NN O
within NN NN O
10q23-q25 NN NN O
near NN NN O
COL17A1 NN NN O
. NN NN O

Three NN NN O
families NN NN O
shared NN NN O
microsatellite NN NN O
polymorphisms NN NN O
covering NN NN O
at NN NN O
most NN NN O
19 NN NN O
cM NN NN O
, NN NN O
whereas NN NN O
the NN NN O
others NN NN O
shared NN NN O
smaller NN NN O
regions NN NN O
consistent NN NN O
with NN NN O
cross-over NN NN O
events NN NN O
during NN NN O
passage NN NN O
of NN NN O
this NN NN O
mutation NN NN O
through NN NN O
several NN NN O
generations NN NN O
. NN NN O

These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
4003delTC NN NN O
occurs NN NN O
on NN NN O
a NN NN O
single NN NN O
ancestral NN NN O
allele NN NN O
. NN NN O

. NN NN O

9463309 NN NN O
The NN NN O
haptoglobin-gene NN NN O
deletion NN NN O
responsible NN NN O
for NN NN O
anhaptoglobinemia NN NN B-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
found NN NN O
an NN NN O
allelic NN NN O
deletion NN NN O
of NN NN O
the NN NN O
haptoglobin NN NN O
( NN NN O
Hp NN NN O
) NN NN O
gene NN NN O
from NN NN O
an NN NN O
individual NN NN O
with NN NN O
anhaptoglobinemia NN NN B-SpecificDisease
. NN NN O

The NN NN O
Hp NN NN O
gene NN NN O
cluster NN NN O
consists NN NN O
of NN NN O
coding NN NN O
regions NN NN O
of NN NN O
the NN NN O
alpha NN NN O
chain NN NN O
and NN NN O
beta NN NN O
chain NN NN O
of NN NN O
the NN NN O
haptoglobin NN NN O
gene NN NN O
( NN NN O
Hp NN NN O
) NN NN O
and NN NN O
of NN NN O
the NN NN O
alpha NN NN O
chain NN NN O
and NN NN O
beta NN NN O
chain NN NN O
of NN NN O
the NN NN O
haptoglobin-related NN NN O
gene NN NN O
( NN NN O
Hpr NN NN O
) NN NN O
, NN NN O
in NN NN O
tandem NN NN O
from NN NN O
the NN NN O
5 NN NN O
side NN NN O
. NN NN O

Southern NN NN O
blot NN NN O
and NN NN O
PCR NN NN O
analyses NN NN O
have NN NN O
indicated NN NN O
that NN NN O
the NN NN O
individual NN NN O
with NN NN O
anhaptoglobinemia NN NN B-SpecificDisease
was NN NN O
homozygous NN NN O
for NN NN O
the NN NN O
gene NN NN O
deletion NN NN O
and NN NN O
that NN NN O
the NN NN O
gene NN NN O
deletion NN NN O
was NN NN O
included NN NN O
at NN NN O
least NN NN O
from NN NN O
the NN NN O
promoter NN NN O
region NN NN O
of NN NN O
Hp NN NN O
to NN NN O
Hpr NN NN O
alpha NN NN O
but NN NN O
not NN NN O
to NN NN O
Hpr NN NN O
beta NN NN O
( NN NN O
Hpdel NN NN O
) NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
we NN NN O
found NN NN O
seven NN NN O
individuals NN NN O
with NN NN O
hypohaptoglobinemia NN NN B-SpecificDisease
in NN NN O
three NN NN O
families NN NN O
, NN NN O
and NN NN O
the NN NN O
genotypes NN NN O
of NN NN O
six NN NN O
of NN NN O
the NN NN O
seven NN NN O
individuals NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
Hp2 NN NN O
/ NN NN O
Hpdel NN NN O
. NN NN O

The NN NN O
phenotypes NN NN O
and NN NN O
genotypes NN NN O
in NN NN O
one NN NN O
of NN NN O
these NN NN O
three NN NN O
families NN NN O
showed NN NN O
the NN NN O
father NN NN O
to NN NN O
be NN NN O
hypohaptoglobinemic NN NN B-Modifier
( NN NN O
Hp2 NN NN O
) NN NN O
and NN NN O
Hp2 NN NN O
/ NN NN O
Hpdel NN NN O
, NN NN O
the NN NN O
mother NN NN O
to NN NN O
be NN NN O
Hp2-1 NN NN O
and NN NN O
Hp1 NN NN O
/ NN NN O
Hp2 NN NN O
, NN NN O
one NN NN O
of NN NN O
the NN NN O
two NN NN O
children NN NN O
to NN NN O
be NN NN O
hypohaptoglobinemic NN NN B-Modifier
( NN NN O
Hp2 NN NN O
) NN NN O
and NN NN O
Hp2 NN NN O
/ NN NN O
Hpdel NN NN O
, NN NN O
and NN NN O
the NN NN O
other NN NN O
child NN NN O
to NN NN O
be NN NN O
Hp1 NN NN O
and NN NN O
Hp1 NN NN O
/ NN NN O
Hpdel NN NN O
, NN NN O
showing NN NN O
an NN NN O
anomalous NN NN O
inheritance NN NN O
of NN NN O
Hp NN NN O
phenotypes NN NN O
in NN NN O
the NN NN O
child NN NN O
with NN NN O
Hp1 NN NN O
. NN NN O

The NN NN O
Hp2 NN NN O
/ NN NN O
Hpdel NN NN O
individuals NN NN O
had NN NN O
an NN NN O
extremely NN NN O
low NN NN O
level NN NN O
of NN NN O
Hp NN NN O
( NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
-SD NN NN O
= NN NN O
0 NN NN O
. NN NN O

049 NN NN O
+ NN NN O
/ NN NN O
-0 NN NN O
. NN NN O

043 NN NN O
mg NN NN O
/ NN NN O
ml NN NN O
; NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
, NN NN O
compared NN NN O
with NN NN O
the NN NN O
level NN NN O
( NN NN O
1 NN NN O
. NN NN O

64 NN NN O
+ NN NN O
/ NN NN O
-1 NN NN O
. NN NN O

07 NN NN O
mg NN NN O
/ NN NN O
ml NN NN O
) NN NN O
obtained NN NN O
from NN NN O
52 NN NN O
healthy NN NN O
volunteers NN NN O
having NN NN O
phenotype NN NN O
Hp2 NN NN O
, NN NN O
whereas NN NN O
the NN NN O
serum NN NN O
Hp NN NN O
level NN NN O
of NN NN O
an NN NN O
individual NN NN O
with NN NN O
Hp1 NN NN O
/ NN NN O
Hpdel NN NN O
was NN NN O
0 NN NN O
. NN NN O

50 NN NN O
mg NN NN O
/ NN NN O
ml NN NN O
, NN NN O
which NN NN O
was NN NN O
approximately NN NN O
half NN NN O
the NN NN O
level NN NN O
of NN NN O
Hp NN NN O
in NN NN O
control NN NN O
sera NN NN O
from NN NN O
the NN NN O
Hp1 NN NN O
phenotype NN NN O
( NN NN O
1 NN NN O
. NN NN O

26 NN NN O
+ NN NN O
/ NN NN O
-0 NN NN O
. NN NN O

33 NN NN O
mg NN NN O
/ NN NN O
ml NN NN O
; NN NN O
n NN NN O
= NN NN O
9 NN NN O
) NN NN O
, NN NN O
showing NN NN O
a NN NN O
gene-dosage NN NN O
effect NN NN O
. NN NN O

The NN NN O
other NN NN O
allele NN NN O
( NN NN O
Hp2 NN NN O
) NN NN O
of NN NN O
individuals NN NN O
with NN NN O
Hp2 NN NN O
/ NN NN O
Hpdel NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
, NN NN O
in NN NN O
all NN NN O
exons NN NN O
, NN NN O
no NN NN O
mutation NN NN O
, NN NN O
by NN NN O
DNA NN NN O
sequencing NN NN O
. NN NN O

On NN NN O
the NN NN O
basis NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
anhaptoglobinemia NN NN B-SpecificDisease
and NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
anomalous NN NN O
inheritance NN NN O
of NN NN O
Hp NN NN O
phenotypes NN NN O
were NN NN O
well NN NN O
explained NN NN O
. NN NN O

However NN NN O
, NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
hypohaptoglobinemia NN NN B-SpecificDisease
remains NN NN O
unknown NN NN O

9463314 NN NN O
ATM NN NN O
mutations NN NN O
and NN NN O
phenotypes NN NN O
in NN NN O
ataxia-telangiectasia NN NN B-Modifier
families NN NN O
in NN NN O
the NN NN O
British NN NN O
Isles NN NN O
: NN NN O
expression NN NN O
of NN NN O
mutant NN NN O
ATM NN NN O
and NN NN O
the NN NN O
risk NN NN O
of NN NN O
leukemia NN NN B-SpecificDisease
, NN NN O
lymphoma NN NN B-SpecificDisease
, NN NN O
and NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

We NN NN O
report NN NN O
the NN NN O
spectrum NN NN O
of NN NN O
59 NN NN O
ATM NN NN O
mutations NN NN O
observed NN NN O
in NN NN O
ataxia-telangiectasia NN NN B-Modifier
( NN NN O
A-T NN NN B-Modifier
) NN NN O
patients NN NN O
in NN NN O
the NN NN O
British NN NN O
Isles NN NN O
. NN NN O

Of NN NN O
51 NN NN O
ATM NN NN O
mutations NN NN O
identified NN NN O
in NN NN O
families NN NN O
native NN NN O
to NN NN O
the NN NN O
British NN NN O
Isles NN NN O
, NN NN O
11 NN NN O
were NN NN O
founder NN NN O
mutations NN NN O
, NN NN O
and NN NN O
2 NN NN O
of NN NN O
these NN NN O
11 NN NN O
conferred NN NN O
a NN NN O
milder NN NN O
clinical NN NN O
phenotype NN NN O
with NN NN O
respect NN NN O
to NN NN O
both NN NN O
cerebellar NN NN B-SpecificDisease
degeneration NN NN I-SpecificDisease
and NN NN O
cellular NN NN O
features NN NN O
. NN NN O

We NN NN O
report NN NN O
, NN NN O
in NN NN O
two NN NN O
A-T NN NN B-Modifier
families NN NN O
, NN NN O
an NN NN O
ATM NN NN O
mutation NN NN O
( NN NN O
7271T NN NN O
-- NN NN O
G NN NN O
) NN NN O
that NN NN O
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
in NN NN O
both NN NN O
homozygotes NN NN O
and NN NN O
heterozygotes NN NN O
( NN NN O
relative NN NN O
risk NN NN O
12 NN NN O
. NN NN O

7 NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O

0025 NN NN O
) NN NN O
, NN NN O
although NN NN O
there NN NN O
is NN NN O
a NN NN O
less NN NN O
severe NN NN O
A-T NN NN B-Modifier
phenotype NN NN O
in NN NN O
terms NN NN O
of NN NN O
the NN NN O
degree NN NN O
of NN NN O
cerebellar NN NN B-SpecificDisease
degeneration NN NN I-SpecificDisease
. NN NN O

This NN NN O
mutation NN NN O
( NN NN O
7271T NN NN O
-- NN NN O
G NN NN O
) NN NN O
also NN NN O
allows NN NN O
expression NN NN O
of NN NN O
full-length NN NN O
ATM NN NN O
protein NN NN O
at NN NN O
a NN NN O
level NN NN O
comparable NN NN O
with NN NN O
that NN NN O
in NN NN O
unaffected NN NN O
individuals NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
we NN NN O
have NN NN O
studied NN NN O
18 NN NN O
A-T NN NN B-Modifier
patients NN NN O
, NN NN O
in NN NN O
15 NN NN O
families NN NN O
, NN NN O
who NN NN O
developed NN NN O
leukemia NN NN B-SpecificDisease
, NN NN O
lymphoma NN NN B-SpecificDisease
, NN NN O
preleukemic NN NN O
T-cell NN NN O
proliferation NN NN O
, NN NN O
or NN NN O
Hodgkin NN NN B-SpecificDisease
lymphoma NN NN I-SpecificDisease
, NN NN O
mostly NN NN O
in NN NN O
childhood NN NN O
. NN NN O

A NN NN O
wide NN NN O
variety NN NN O
of NN NN O
ATM NN NN O
mutation NN NN O
types NN NN O
, NN NN O
including NN NN O
missense NN NN O
mutations NN NN O
and NN NN O
in-frame NN NN O
deletions NN NN O
, NN NN O
were NN NN O
seen NN NN O
in NN NN O
these NN NN O
patients NN NN O
. NN NN O

We NN NN O
also NN NN O
show NN NN O
that NN NN O
25 NN NN O
% NN NN O
of NN NN O
all NN NN O
A-T NN NN B-Modifier
patients NN NN O
carried NN NN O
in-frame NN NN O
deletions NN NN O
or NN NN O
missense NN NN O
mutations NN NN O
, NN NN O
many NN NN O
of NN NN O
which NN NN O
were NN NN O
also NN NN O
associated NN NN O
with NN NN O
expression NN NN O
of NN NN O
mutant NN NN O
ATM NN NN O
protein NN NN O
. NN NN O

9463318 NN NN O
The NN NN O
DMPK NN NN O
gene NN NN O
of NN NN O
severely NN NN O
affected NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
patients NN NN O
is NN NN O
hypermethylated NN NN O
proximal NN NN O
to NN NN O
the NN NN O
largely NN NN O
expanded NN NN O
CTG NN NN O
repeat NN NN O
. NN NN O

Using NN NN O
methylation-sensitive NN NN O
restriction NN NN O
enzymes NN NN O
, NN NN O
we NN NN O
characterized NN NN O
the NN NN O
methylation NN NN O
pattern NN NN O
on NN NN O
the NN NN O
5 NN NN O
side NN NN O
of NN NN O
the NN NN O
CTG NN NN O
repeat NN NN O
in NN NN O
the NN NN O
DMPK NN NN O
gene NN NN O
of NN NN O
normal NN NN O
individuals NN NN O
and NN NN O
of NN NN O
patients NN NN O
affected NN NN O
with NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
showing NN NN O
expansions NN NN O
of NN NN O
the NN NN O
repetitive NN NN O
sequence NN NN O
. NN NN O

The NN NN O
gene NN NN O
segment NN NN O
analyzed NN NN O
corresponds NN NN O
to NN NN O
the NN NN O
genomic NN NN O
SacI-HindIII NN NN O
fragment NN NN O
carrying NN NN O
exons NN NN O
11-15 NN NN O
. NN NN O

There NN NN O
is NN NN O
constitutive NN NN O
methylation NN NN O
in NN NN O
intron NN NN O
12 NN NN O
at NN NN O
restriction NN NN O
sites NN NN O
of NN NN O
SacII NN NN O
and NN NN O
HhaI NN NN O
, NN NN O
localized NN NN O
1 NN NN O
, NN NN O
159-1 NN NN O
, NN NN O
232 NN NN O
bp NN NN O
upstream NN NN O
of NN NN O
the NN NN O
CTG NN NN O
repeat NN NN O
, NN NN O
whereas NN NN O
most NN NN O
, NN NN O
if NN NN O
not NN NN O
all NN NN O
, NN NN O
of NN NN O
the NN NN O
other NN NN O
sites NN NN O
of NN NN O
SacII NN NN O
, NN NN O
HhaI NN NN O
, NN NN O
and NN NN O
HpaII NN NN O
in NN NN O
this NN NN O
region NN NN O
are NN NN O
unmethylated NN NN O
, NN NN O
in NN NN O
normal NN NN O
individuals NN NN O
and NN NN O
most NN NN O
of NN NN O
the NN NN O
patients NN NN O
. NN NN O

In NN NN O
a NN NN O
number NN NN O
of NN NN O
young NN NN O
and NN NN O
severely NN NN O
affected NN NN O
patients NN NN O
, NN NN O
however NN NN O
, NN NN O
complete NN NN O
methylation NN NN O
of NN NN O
these NN NN O
restriction NN NN O
sites NN NN O
was NN NN O
found NN NN O
in NN NN O
the NN NN O
mutated NN NN O
allele NN NN O
. NN NN O

In NN NN O
most NN NN O
of NN NN O
these NN NN O
patients NN NN O
, NN NN O
the NN NN O
onset NN NN O
of NN NN O
the NN NN O
disease NN NN O
was NN NN O
congenital NN NN O
. NN NN O

Preliminary NN NN O
in NN NN O
vivo NN NN O
footprinting NN NN O
data NN NN O
gave NN NN O
evidence NN NN O
for NN NN O
protein-DNA NN NN O
contact NN NN O
in NN NN O
normal NN NN O
genes NN NN O
at NN NN O
an NN NN O
Sp1 NN NN O
consensus NN NN O
binding NN NN O
site NN NN O
upstream NN NN O
of NN NN O
the NN NN O
CTG NN NN O
repeat NN NN O
and NN NN O
for NN NN O
a NN NN O
significant NN NN O
reduction NN NN O
of NN NN O
this NN NN O
interaction NN NN O
in NN NN O
cells NN NN O
with NN NN O
a NN NN O
hypermethylated NN NN O
DMPK NN NN O
gene NN NN O
. NN NN O

. NN NN O

9465039 NN NN O
The NN NN O
hemochromatosis NN NN B-Modifier
gene NN NN O
product NN NN O
complexes NN NN O
with NN NN O
the NN NN O
transferrin NN NN O
receptor NN NN O
and NN NN O
lowers NN NN O
its NN NN O
affinity NN NN O
for NN NN O
ligand NN NN O
binding NN NN O
. NN NN O

We NN NN O
recently NN NN O
reported NN NN O
the NN NN O
positional NN NN O
cloning NN NN O
of NN NN O
a NN NN O
candidate NN NN O
gene NN NN O
for NN NN O
hereditary NN NN B-SpecificDisease
hemochromatosis NN NN I-SpecificDisease
called NN NN O
HFE NN NN O
. NN NN O

The NN NN O
gene NN NN O
product NN NN O
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
class NN NN O
I-like NN NN O
family NN NN O
, NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
a NN NN O
mutation NN NN O
, NN NN O
Cys-282 NN NN O
-- NN NN O
Tyr NN NN O
( NN NN O
C282Y NN NN O
) NN NN O
, NN NN O
in NN NN O
85 NN NN O
% NN NN O
of NN NN O
patient NN NN O
chromosomes NN NN O
. NN NN O

This NN NN O
mutation NN NN O
eliminates NN NN O
the NN NN O
ability NN NN O
of NN NN O
HFE NN NN O
to NN NN O
associate NN NN O
with NN NN O
beta2-microglobulin NN NN O
( NN NN O
beta2m NN NN O
) NN NN O
and NN NN O
prevents NN NN O
cell-surface NN NN O
expression NN NN O
. NN NN O

A NN NN O
second NN NN O
mutation NN NN O
that NN NN O
has NN NN O
no NN NN O
effect NN NN O
on NN NN O
beta2m NN NN O
association NN NN O
, NN NN O
H63D NN NN O
, NN NN O
was NN NN O
found NN NN O
in NN NN O
eight NN NN O
out NN NN O
of NN NN O
nine NN NN O
patients NN NN O
heterozygous NN NN O
for NN NN O
the NN NN O
C282Y NN NN O
mutant NN NN O
. NN NN O

In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
in NN NN O
cultured NN NN O
293 NN NN O
cells NN NN O
overexpressing NN NN O
wild-type NN NN O
or NN NN O
mutant NN NN O
HFE NN NN O
proteins NN NN O
that NN NN O
both NN NN O
the NN NN O
wild-type NN NN O
and NN NN O
H63D NN NN O
HFE NN NN O
proteins NN NN O
form NN NN O
stable NN NN O
complexes NN NN O
with NN NN O
the NN NN O
transferrin NN NN O
receptor NN NN O
( NN NN O
TfR NN NN O
) NN NN O
. NN NN O

The NN NN O
C282Y NN NN O
mutation NN NN O
nearly NN NN O
completely NN NN O
prevents NN NN O
the NN NN O
association NN NN O
of NN NN O
the NN NN O
mutant NN NN O
HFE NN NN O
protein NN NN O
with NN NN O
the NN NN O
TfR NN NN O
. NN NN O

Studies NN NN O
on NN NN O
cell-associated NN NN O
transferrin NN NN O
at NN NN O
37 NN NN O
degrees NN NN O
C NN NN O
suggest NN NN O
that NN NN O
the NN NN O
overexpressed NN NN O
wild-type NN NN O
HFE NN NN O
protein NN NN O
decreases NN NN O
the NN NN O
affinity NN NN O
of NN NN O
the NN NN O
TfR NN NN O
for NN NN O
transferrin NN NN O
. NN NN O

The NN NN O
overexpressed NN NN O
H63D NN NN O
protein NN NN O
does NN NN O
not NN NN O
have NN NN O
this NN NN O
effect NN NN O
, NN NN O
providing NN NN O
the NN NN O
first NN NN O
direct NN NN O
evidence NN NN O
for NN NN O
a NN NN O
functional NN NN O
consequence NN NN O
of NN NN O
the NN NN O
H63D NN NN O
mutation NN NN O
. NN NN O

Addition NN NN O
of NN NN O
soluble NN NN O
wild-type NN NN O
HFE NN NN O
/ NN NN O
beta2m NN NN O
heterodimers NN NN O
to NN NN O
cultured NN NN O
cells NN NN O
also NN NN O
decreased NN NN O
the NN NN O
apparent NN NN O
affinity NN NN O
of NN NN O
the NN NN O
TfR NN NN O
for NN NN O
its NN NN O
ligand NN NN O
under NN NN O
steady-state NN NN O
conditions NN NN O
, NN NN O
both NN NN O
in NN NN O
293 NN NN O
cells NN NN O
and NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
at NN NN O
4 NN NN O
degrees NN NN O
C NN NN O
, NN NN O
the NN NN O
added NN NN O
soluble NN NN O
complex NN NN O
of NN NN O
HFE NN NN O
/ NN NN O
beta2m NN NN O
inhibited NN NN O
binding NN NN O
of NN NN O
transferrin NN NN O
to NN NN O
HeLa NN NN O
cell NN NN O
TfR NN NN O
in NN NN O
a NN NN O
concentration-dependent NN NN O
manner NN NN O
. NN NN O

Scatchard NN NN O
plots NN NN O
of NN NN O
these NN NN O
data NN NN O
indicate NN NN O
that NN NN O
the NN NN O
added NN NN O
heterodimer NN NN O
substantially NN NN O
reduced NN NN O
the NN NN O
affinity NN NN O
of NN NN O
TfR NN NN O
for NN NN O
transferrin NN NN O
. NN NN O

These NN NN O
results NN NN O
establish NN NN O
a NN NN O
molecular NN NN O
link NN NN O
between NN NN O
HFE NN NN O
and NN NN O
a NN NN O
key NN NN O
protein NN NN O
involved NN NN O
in NN NN O
iron NN NN O
transport NN NN O
, NN NN O
the NN NN O
TfR NN NN O
, NN NN O
and NN NN O
raise NN NN O
the NN NN O
possibility NN NN O
that NN NN O
alterations NN NN O
in NN NN O
this NN NN O
regulatory NN NN O
mechanism NN NN O
may NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
hereditary NN NN B-SpecificDisease
hemochromatosis NN NN I-SpecificDisease
. NN NN O

. NN NN O

9465301 NN NN O
Genomic NN NN O
organization NN NN O
of NN NN O
the NN NN O
UBE3A/E6-AP NN NN O
gene NN NN O
and NN NN O
related NN NN O
pseudogenes NN NN O
. NN NN O

The NN NN O
UBE3A NN NN O
gene NN NN O
encodes NN NN O
the NN NN O
E6-AP NN NN O
ubiquitin-protein NN NN O
ligase NN NN O
and NN NN O
has NN NN O
recently NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
mutated NN NN O
in NN NN O
Angelman NN NN B-Modifier
syndrome NN NN I-Modifier
patients NN NN O
who NN NN O
lack NN NN O
15q11-q13 NN NN O
deletions NN NN O
or NN NN O
chromosome NN NN O
15 NN NN O
paternal NN NN O
uniparental NN NN B-SpecificDisease
disomy NN NN I-SpecificDisease
. NN NN O

Previous NN NN O
UBE3A NN NN O
cDNA NN NN O
analysis NN NN O
has NN NN O
shown NN NN O
a NN NN O
coding NN NN O
region NN NN O
of NN NN O
approximately NN NN O
2 NN NN O
. NN NN O

6 NN NN O
kb NN NN O
and NN NN O
a NN NN O
3-untranslated NN NN O
region NN NN O
( NN NN O
UTR NN NN O
) NN NN O
of NN NN O
50 NN NN O
bp NN NN O
, NN NN O
whereas NN NN O
Northern NN NN O
analysis NN NN O
has NN NN O
indicated NN NN O
mRNA NN NN O
sizes NN NN O
of NN NN O
5-8 NN NN O
kb NN NN O
. NN NN O

We NN NN O
have NN NN O
analyzed NN NN O
additional NN NN O
cDNA NN NN O
clones NN NN O
and NN NN O
provide NN NN O
evidence NN NN O
for NN NN O
an NN NN O
additional NN NN O
0 NN NN O
. NN NN O

5 NN NN O
kb NN NN O
of NN NN O
5-UTR NN NN O
and NN NN O
2 NN NN O
kb NN NN O
of NN NN O
3-UTR NN NN O
. NN NN O

We NN NN O
have NN NN O
established NN NN O
the NN NN O
genomic NN NN O
organization NN NN O
of NN NN O
UBE3A NN NN O
and NN NN O
the NN NN O
sequence NN NN O
of NN NN O
intron-exon NN NN O
borders NN NN O
. NN NN O

We NN NN O
have NN NN O
also NN NN O
mapped NN NN O
two NN NN O
highly NN NN O
homologous NN NN O
processed NN NN O
pseudogenes NN NN O
, NN NN O
UBE3AP1 NN NN O
and NN NN O
UBE3AP2 NN NN O
, NN NN O
to NN NN O
chromosomes NN NN O
2 NN NN O
and NN NN O
21 NN NN O
, NN NN O
respectively NN NN O
, NN NN O
and NN NN O
determined NN NN O
their NN NN O
genomic NN NN O
organization NN NN O
. NN NN O

These NN NN O
results NN NN O
will NN NN O
form NN NN O
the NN NN O
basis NN NN O
for NN NN O
studies NN NN O
of NN NN O
mutation NN NN O
and NN NN O
imprinting NN NN O
of NN NN O
UBE3A NN NN O
. NN NN O

9467011 NN NN O
Mutation NN NN O
spectrum NN NN O
and NN NN O
genotype-phenotype NN NN O
analyses NN NN O
in NN NN O
Cowden NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
and NN NN O
Bannayan-Zonana NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
two NN NN O
hamartoma NN NN B-DiseaseClass
syndromes NN NN I-DiseaseClass
with NN NN O
germline NN NN O
PTEN NN NN O
mutation NN NN O
. NN NN O

The NN NN O
tumour NN NN B-Modifier
suppressor NN NN O
gene NN NN O
PTEN NN NN O
, NN NN O
which NN NN O
maps NN NN O
to NN NN O
10q23 NN NN O
. NN NN O

3 NN NN O
and NN NN O
encodes NN NN O
a NN NN O
403 NN NN O
amino NN NN O
acid NN NN O
dual NN NN O
specificity NN NN O
phosphatase NN NN O
( NN NN O
protein NN NN O
tyrosine NN NN O
phosphatase NN NN O
; NN NN O
PTPase NN NN O
) NN NN O
, NN NN O
was NN NN O
shown NN NN O
recently NN NN O
to NN NN O
play NN NN O
a NN NN O
broad NN NN O
role NN NN O
in NN NN O
human NN NN O
malignancy NN NN B-DiseaseClass
. NN NN O

Somatic NN NN O
PTEN NN NN O
deletions NN NN O
and NN NN O
mutations NN NN O
were NN NN O
observed NN NN O
in NN NN O
sporadic NN NN B-Modifier
breast NN NN I-Modifier
, NN NN I-Modifier
brain NN NN I-Modifier
, NN NN I-Modifier
prostate NN NN I-Modifier
and NN NN I-Modifier
kidney NN NN I-Modifier
cancer NN NN I-Modifier
cell NN NN O
lines NN NN O
and NN NN O
in NN NN O
several NN NN O
primary NN NN O
tumours NN NN B-DiseaseClass
such NN NN O
as NN NN O
endometrial NN NN B-SpecificDisease
carcinomas NN NN I-SpecificDisease
, NN NN O
malignant NN NN B-SpecificDisease
melanoma NN NN I-SpecificDisease
and NN NN O
thyroid NN NN B-SpecificDisease
tumours NN NN I-SpecificDisease
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
PTEN NN NN O
was NN NN O
identified NN NN O
as NN NN O
the NN NN O
susceptibility NN NN O
gene NN NN O
for NN NN O
two NN NN O
hamartoma NN NN B-DiseaseClass
syndromes NN NN I-DiseaseClass
Cowden NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
CD NN NN B-SpecificDisease
; NN NN O
MIM NN NN O
158350 NN NN O
) NN NN O
and NN NN O
Bannayan-Zonana NN NN B-CompositeMention
( NN NN I-CompositeMention
BZS NN NN I-CompositeMention
) NN NN I-CompositeMention
or NN NN I-CompositeMention
Ruvalcaba-Riley-Smith NN NN I-CompositeMention
syndrome NN NN I-CompositeMention
( NN NN O
MIM NN NN O
153480 NN NN O
) NN NN O
. NN NN O

Constitutive NN NN O
DNA NN NN O
from NN NN O
37 NN NN O
CD NN NN B-Modifier
families NN NN O
and NN NN O
seven NN NN O
BZS NN NN B-Modifier
families NN NN O
was NN NN O
screened NN NN O
for NN NN O
germline NN NN O
PTEN NN NN O
mutations NN NN O
. NN NN O

PTEN NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
in NN NN O
30 NN NN O
of NN NN O
37 NN NN O
( NN NN O
81 NN NN O
% NN NN O
) NN NN O
CD NN NN B-Modifier
families NN NN O
, NN NN O
including NN NN O
missense NN NN O
and NN NN O
nonsense NN NN O
point NN NN O
mutations NN NN O
, NN NN O
deletions NN NN O
, NN NN O
insertions NN NN O
, NN NN O
a NN NN O
deletion NN NN O
/ NN NN O
insertion NN NN O
and NN NN O
splice NN NN O
site NN NN O
mutations NN NN O
. NN NN O

These NN NN O
mutations NN NN O
were NN NN O
scattered NN NN O
over NN NN O
the NN NN O
entire NN NN O
length NN NN O
of NN NN O
PTEN NN NN O
, NN NN O
with NN NN O
the NN NN O
exception NN NN O
of NN NN O
the NN NN O
first NN NN O
, NN NN O
fourth NN NN O
and NN NN O
last NN NN O
exons NN NN O
. NN NN O

A NN NN O
hot NN NN O
spot NN NN O
for NN NN O
PTEN NN NN O
mutation NN NN O
in NN NN O
CD NN NN B-SpecificDisease
was NN NN O
identified NN NN O
in NN NN O
exon NN NN O
5 NN NN O
that NN NN O
contains NN NN O
the NN NN O
PTPase NN NN O
core NN NN O
motif NN NN O
, NN NN O
with NN NN O
13 NN NN O
of NN NN O
30 NN NN O
( NN NN O
43 NN NN O
% NN NN O
) NN NN O
CD NN NN B-Modifier
mutations NN NN O
identified NN NN O
in NN NN O
this NN NN O
exon NN NN O
. NN NN O

Seven NN NN O
of NN NN O
30 NN NN O
( NN NN O
23 NN NN O
% NN NN O
) NN NN O
were NN NN O
within NN NN O
the NN NN O
core NN NN O
motif NN NN O
, NN NN O
the NN NN O
majority NN NN O
( NN NN O
five NN NN O
of NN NN O
seven NN NN O
) NN NN O
of NN NN O
which NN NN O
were NN NN O
missense NN NN O
mutations NN NN O
, NN NN O
possibly NN NN O
pointing NN NN O
to NN NN O
the NN NN O
functional NN NN O
significance NN NN O
of NN NN O
this NN NN O
region NN NN O
. NN NN O

Germline NN NN O
PTEN NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
in NN NN O
four NN NN O
of NN NN O
seven NN NN O
( NN NN O
57 NN NN O
% NN NN O
) NN NN O
BZS NN NN B-Modifier
families NN NN O
studied NN NN O
. NN NN O

Interestingly NN NN O
, NN NN O
none NN NN O
of NN NN O
these NN NN O
mutations NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
PTPase NN NN O
core NN NN O
motif NN NN O
. NN NN O

It NN NN O
is NN NN O
also NN NN O
worthy NN NN O
of NN NN O
note NN NN O
that NN NN O
a NN NN O
single NN NN O
nonsense NN NN O
point NN NN O
mutation NN NN O
, NN NN O
R233X NN NN O
, NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
germline NN NN O
DNA NN NN O
from NN NN O
two NN NN O
unrelated NN NN O
CD NN NN B-Modifier
families NN NN O
and NN NN O
one NN NN O
BZS NN NN B-Modifier
family NN NN O
. NN NN O

Genotype-phenotype NN NN O
studies NN NN O
were NN NN O
not NN NN O
performed NN NN O
on NN NN O
this NN NN O
small NN NN O
group NN NN O
of NN NN O
BZS NN NN B-Modifier
families NN NN O
. NN NN O

However NN NN O
, NN NN O
genotype-phenotype NN NN O
analysis NN NN O
inthe NN NN O
group NN NN O
of NN NN O
CD NN NN B-Modifier
families NN NN O
revealed NN NN O
two NN NN O
possible NN NN O
associations NN NN O
worthy NN NN O
of NN NN O
follow-up NN NN O
in NN NN O
independent NN NN O
analyses NN NN O
. NN NN O

The NN NN O
first NN NN O
was NN NN O
an NN NN O
association NN NN O
noted NN NN O
in NN NN O
the NN NN O
group NN NN O
of NN NN O
CD NN NN B-Modifier
families NN NN O
with NN NN O
breast NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
. NN NN O

A NN NN O
correlation NN NN O
was NN NN O
observed NN NN O
between NN NN O
the NN NN O
presence NN NN O
/ NN NN O
absence NN NN O
of NN NN O
a NN NN O
PTEN NN NN O
mutation NN NN O
and NN NN O
the NN NN O
type NN NN O
of NN NN O
breast NN NN O
involvement NN NN O
( NN NN O
unaffected NN NN O
versus NN NN O
benign NN NN O
versus NN NN O
malignant NN NN O
) NN NN O
. NN NN O

Specifically NN NN O
and NN NN O
more NN NN O
directly NN NN O
, NN NN O
an NN NN O
association NN NN O
was NN NN O
also NN NN O
observed NN NN O
between NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
PTEN NN NN O
mutation NN NN O
and NN NN O
malignant NN NN B-DiseaseClass
breast NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
. NN NN O

Secondly NN NN O
, NN NN O
there NN NN O
appeared NN NN O
to NN NN O
be NN NN O
an NN NN O
interdependent NN NN O
association NN NN O
between NN NN O
mutations NN NN O
upstream NN NN O
and NN NN O
within NN NN O
the NN NN O
PTPase NN NN O
core NN NN O
motif NN NN O
, NN NN O
the NN NN O
core NN NN O
motif NN NN O
containing NN NN O
the NN NN O
majority NN NN O
of NN NN O
missense NN NN O
mutations NN NN O
, NN NN O
and NN NN O
the NN NN O
involvement NN NN O
of NN NN O
all NN NN O
major NN NN O
organ NN NN O
systems NN NN O
( NN NN O
central NN NN O
nervous NN NN O
system NN NN O
, NN NN O
thyroid NN NN O
, NN NN O
breast NN NN O
, NN NN O
skin NN NN O
and NN NN O
gastrointestinal NN NN O
tract NN NN O
) NN NN O
. NN NN O

However NN NN O
, NN NN O
these NN NN O
observations NN NN O
would NN NN O
need NN NN O
to NN NN O
be NN NN O
confirmed NN NN O
by NN NN O
studying NN NN O
a NN NN O
larger NN NN O
number NN NN O
of NN NN O
CD NN NN B-Modifier
families NN NN O
. NN NN O

9472666 NN NN O
Molecular NN NN O
defects NN NN O
leading NN NN O
to NN NN O
human NN NN O
complement NN NN B-SpecificDisease
component NN NN I-SpecificDisease
C6 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
an NN NN O
African-American NN NN O
family NN NN O
. NN NN O

Complement NN NN B-SpecificDisease
component NN NN I-SpecificDisease
C6 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
( NN NN O
C6D NN NN B-SpecificDisease
) NN NN O
was NN NN O
diagnosed NN NN O
in NN NN O
a NN NN O
16-year-old NN NN O
African-American NN NN O
male NN NN O
with NN NN O
meningococcal NN NN B-SpecificDisease
meningitis NN NN I-SpecificDisease
. NN NN O

The NN NN O
patients NN NN O
father NN NN O
and NN NN O
two NN NN O
brothers NN NN O
also NN NN O
had NN NN O
C6D NN NN B-SpecificDisease
, NN NN O
but NN NN O
gave NN NN O
no NN NN O
history NN NN O
of NN NN O
meningitis NN NN B-SpecificDisease
or NN NN O
other NN NN O
neisserial NN NN B-SpecificDisease
infection NN NN I-SpecificDisease
. NN NN O

By NN NN O
using NN NN O
exon-specific NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
/ NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
as NN NN O
a NN NN O
screening NN NN O
step NN NN O
and NN NN O
nucleotide NN NN O
sequencing NN NN O
of NN NN O
target NN NN O
exons NN NN O
, NN NN O
we NN NN O
determined NN NN O
that NN NN O
the NN NN O
proband NN NN O
was NN NN O
a NN NN O
compound NN NN O
heterozygote NN NN O
for NN NN O
two NN NN O
C6 NN NN O
gene NN NN O
mutations NN NN O
. NN NN O

The NN NN O
first NN NN O
, NN NN O
1195delC NN NN O
located NN NN O
in NN NN O
exon NN NN O
7 NN NN O
, NN NN O
is NN NN O
a NN NN O
novel NN NN O
mutation NN NN O
, NN NN O
while NN NN O
the NN NN O
second NN NN O
, NN NN O
1936delG NN NN O
in NN NN O
exon NN NN O
12 NN NN O
, NN NN O
has NN NN O
been NN NN O
described NN NN O
before NN NN O
to NN NN O
cause NN NN O
C6D NN NN B-SpecificDisease
in NN NN O
an NN NN O
unrelated NN NN O
African-American NN NN O
individual NN NN O
. NN NN O

Both NN NN O
mutations NN NN O
result NN NN O
in NN NN O
premature NN NN O
termination NN NN O
codons NN NN O
and NN NN O
C6 NN NN O
null NN NN O
alleles NN NN O
. NN NN O

Allele-specific NN NN O
PCR NN NN O
indicated NN NN O
that NN NN O
the NN NN O
probands NN NN O
two NN NN O
brothers NN NN O
also NN NN O
inherited NN NN O
the NN NN O
1195delC NN NN O
mutation NN NN O
from NN NN O
their NN NN O
heterozygous NN NN O
mother NN NN O
and NN NN O
the NN NN O
1936delG NN NN O
mutation NN NN O
from NN NN O
their NN NN O
homozygous NN NN O
father NN NN O
. NN NN O

. NN NN O

9482572 NN NN O
PAX6 NN NN O
mutations NN NN O
reviewed NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
PAX6 NN NN O
are NN NN O
responsible NN NN O
for NN NN O
human NN NN O
aniridia NN NN B-SpecificDisease
and NN NN O
have NN NN O
also NN NN O
been NN NN O
found NN NN O
in NN NN O
patients NN NN O
with NN NN O
Peters NN NN B-SpecificDisease
anomaly NN NN I-SpecificDisease
, NN NN O
with NN NN O
congenital NN NN B-SpecificDisease
cataracts NN NN I-SpecificDisease
, NN NN O
with NN NN O
autosomal NN NN B-SpecificDisease
dominant NN NN I-SpecificDisease
keratitis NN NN I-SpecificDisease
, NN NN O
and NN NN O
with NN NN O
isolated NN NN B-SpecificDisease
foveal NN NN I-SpecificDisease
hypoplasia NN NN I-SpecificDisease
. NN NN O

No NN NN O
locus NN NN O
other NN NN O
than NN NN O
chromosome NN NN O
11p13 NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
aniridia NN NN B-SpecificDisease
, NN NN O
and NN NN O
PAX6 NN NN O
is NN NN O
clearly NN NN O
the NN NN O
major NN NN O
, NN NN O
if NN NN O
not NN NN O
only NN NN O
, NN NN O
gene NN NN O
responsible NN NN O
. NN NN O

Twenty-eight NN NN O
percent NN NN O
of NN NN O
identified NN NN O
PAX6 NN NN O
mutations NN NN O
are NN NN O
C-T NN NN O
changes NN NN O
at NN NN O
CpG NN NN O
dinucleotides NN NN O
, NN NN O
20 NN NN O
% NN NN O
are NN NN O
splicing NN NN O
errors NN NN O
, NN NN O
and NN NN O
more NN NN O
than NN NN O
30 NN NN O
% NN NN O
are NN NN O
deletion NN NN O
or NN NN O
insertion NN NN O
events NN NN O
. NN NN O

There NN NN O
is NN NN O
a NN NN O
noticeably NN NN O
elevated NN NN O
level NN NN O
of NN NN O
mutation NN NN O
in NN NN O
the NN NN O
paired NN NN O
domain NN NN O
compared NN NN O
with NN NN O
the NN NN O
rest NN NN O
of NN NN O
the NN NN O
gene NN NN O
. NN NN O

Increased NN NN O
mutation NN NN O
in NN NN O
the NN NN O
homeodomain NN NN O
is NN NN O
accounted NN NN O
for NN NN O
by NN NN O
the NN NN O
hypermutable NN NN O
CpG NN NN O
dinucleotide NN NN O
in NN NN O
codon NN NN O
240 NN NN O
. NN NN O

Very NN NN O
nearly NN NN O
all NN NN O
mutations NN NN O
appear NN NN O
to NN NN O
cause NN NN O
loss NN NN O
of NN NN O
function NN NN O
of NN NN O
the NN NN O
mutant NN NN O
allele NN NN O
, NN NN O
and NN NN O
more NN NN O
than NN NN O
80 NN NN O
% NN NN O
of NN NN O
exonic NN NN O
substitutions NN NN O
result NN NN O
in NN NN O
nonsense NN NN O
codons NN NN O
. NN NN O

In NN NN O
a NN NN O
gene NN NN O
with NN NN O
such NN NN O
extraordinarily NN NN O
high NN NN O
sequence NN NN O
conservation NN NN O
throughout NN NN O
evolution NN NN O
, NN NN O
there NN NN O
are NN NN O
presumed NN NN O
undiscovered NN NN O
missense NN NN O
mutations NN NN O
, NN NN O
these NN NN O
are NN NN O
hypothesized NN NN O
to NN NN O
exist NN NN O
in NN NN O
as-yet NN NN O
unidentified NN NN O
phenotypes NN NN O
. NN NN O

. NN NN O

9497246 NN NN O
Genetic NN NN O
heterogeneity NN NN O
and NN NN O
penetrance NN NN O
analysis NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
genes NN NN O
in NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
. NN NN O

The NN NN O
Breast NN NN B-Modifier
Cancer NN NN I-Modifier
Linkage NN NN O
Consortium NN NN O
. NN NN O

The NN NN O
contribution NN NN O
of NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
to NN NN O
inherited NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
was NN NN O
assessed NN NN O
by NN NN O
linkage NN NN O
and NN NN O
mutation NN NN O
analysis NN NN O
in NN NN O
237 NN NN O
families NN NN O
, NN NN O
each NN NN O
with NN NN O
at NN NN O
least NN NN O
four NN NN O
cases NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
collected NN NN O
by NN NN O
the NN NN O
Breast NN NN B-Modifier
Cancer NN NN I-Modifier
Linkage NN NN O
Consortium NN NN O
. NN NN O

Families NN NN O
were NN NN O
included NN NN O
without NN NN O
regard NN NN O
to NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
ovarian NN NN B-CompositeMention
or NN NN I-CompositeMention
other NN NN I-CompositeMention
cancers NN NN I-CompositeMention
. NN NN O

Overall NN NN O
, NN NN O
disease NN NN O
was NN NN O
linked NN NN O
to NN NN O
BRCA1 NN NN O
in NN NN O
an NN NN O
estimated NN NN O
52 NN NN O
% NN NN O
of NN NN O
families NN NN O
, NN NN O
to NN NN O
BRCA2 NN NN O
in NN NN O
32 NN NN O
% NN NN O
of NN NN O
families NN NN O
, NN NN O
and NN NN O
to NN NN O
neither NN NN O
gene NN NN O
in NN NN O
16 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NN NN O
] NN NN O
6 NN NN O
% NN NN O
-28 NN NN O
% NN NN O
) NN NN O
, NN NN O
suggesting NN NN O
other NN NN O
predisposition NN NN O
genes NN NN O
. NN NN O

The NN NN O
majority NN NN O
( NN NN O
81 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
breast-ovarian NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
were NN NN O
due NN NN O
to NN NN O
BRCA1 NN NN O
, NN NN O
with NN NN O
most NN NN O
others NN NN O
( NN NN O
14 NN NN O
% NN NN O
) NN NN O
due NN NN O
to NN NN O
BRCA2 NN NN O
. NN NN O

Conversely NN NN O
, NN NN O
the NN NN O
majority NN NN O
of NN NN O
families NN NN O
with NN NN O
male NN NN B-CompositeMention
and NN NN I-CompositeMention
female NN NN I-CompositeMention
breast NN NN I-CompositeMention
cancer NN NN I-CompositeMention
were NN NN O
due NN NN O
to NN NN O
BRCA2 NN NN O
( NN NN O
76 NN NN O
% NN NN O
) NN NN O
. NN NN O

The NN NN O
largest NN NN O
proportion NN NN O
( NN NN O
67 NN NN O
% NN NN O
) NN NN O
of NN NN O
families NN NN O
due NN NN O
to NN NN O
other NN NN O
genes NN NN O
was NN NN O
found NN NN O
in NN NN O
families NN NN O
with NN NN O
four NN NN O
or NN NN O
five NN NN O
cases NN NN O
of NN NN O
female NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
only NN NN O
. NN NN O

These NN NN O
estimates NN NN O
were NN NN O
not NN NN O
substantially NN NN O
affected NN NN O
either NN NN O
by NN NN O
changing NN NN O
the NN NN O
assumed NN NN O
penetrance NN NN O
model NN NN O
for NN NN O
BRCA1 NN NN O
or NN NN O
by NN NN O
including NN NN O
or NN NN O
excluding NN NN O
BRCA1 NN NN O
mutation NN NN O
data NN NN O
. NN NN O

Among NN NN O
those NN NN O
families NN NN O
with NN NN O
disease NN NN O
due NN NN O
to NN NN O
BRCA1 NN NN O
that NN NN O
were NN NN O
tested NN NN O
by NN NN O
one NN NN O
of NN NN O
the NN NN O
standard NN NN O
screening NN NN O
methods NN NN O
, NN NN O
mutations NN NN O
were NN NN O
detected NN NN O
in NN NN O
the NN NN O
coding NN NN O
sequence NN NN O
or NN NN O
splice NN NN O
sites NN NN O
in NN NN O
an NN NN O
estimated NN NN O
63 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
51 NN NN O
% NN NN O
-77 NN NN O
% NN NN O
) NN NN O
. NN NN O

The NN NN O
estimated NN NN O
sensitivity NN NN O
was NN NN O
identical NN NN O
for NN NN O
direct NN NN O
sequencing NN NN O
and NN NN O
other NN NN O
techniques NN NN O
. NN NN O

The NN NN O
penetrance NN NN O
of NN NN O
BRCA2 NN NN O
was NN NN O
estimated NN NN O
by NN NN O
maximizing NN NN O
the NN NN O
LOD NN NN O
score NN NN O
in NN NN O
BRCA2-mutation NN NN O
families NN NN O
, NN NN O
over NN NN O
all NN NN O
possible NN NN O
penetrance NN NN O
functions NN NN O
. NN NN O

The NN NN O
estimated NN NN O
cumulative NN NN O
risk NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
reached NN NN O
28 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
9 NN NN O
% NN NN O
-44 NN NN O
% NN NN O
) NN NN O
by NN NN O
age NN NN O
50 NN NN O
years NN NN O
and NN NN O
84 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
43 NN NN O
% NN NN O
-95 NN NN O
% NN NN O
) NN NN O
by NN NN O
age NN NN O
70 NN NN O
years NN NN O
. NN NN O

The NN NN O
corresponding NN NN O
ovarian NN NN B-Modifier
cancer NN NN I-Modifier
risks NN NN O
were NN NN O
0 NN NN O
. NN NN O

4 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
% NN NN O
-1 NN NN O
% NN NN O
) NN NN O
by NN NN O
age NN NN O
50 NN NN O
years NN NN O
and NN NN O
27 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0 NN NN O
% NN NN O
-47 NN NN O
% NN NN O
) NN NN O
by NN NN O
age NN NN O
70 NN NN O
years NN NN O
. NN NN O

The NN NN O
lifetime NN NN O
risk NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
appears NN NN O
similar NN NN O
to NN NN O
the NN NN O
risk NN NN O
in NN NN O
BRCA1 NN NN O
carriers NN NN O
, NN NN O
but NN NN O
there NN NN O
was NN NN O
some NN NN O
suggestion NN NN O
of NN NN O
a NN NN O
lower NN NN O
risk NN NN O
in NN NN O
BRCA2 NN NN O
carriers NN NN O
50 NN NN O
years NN NN O
of NN NN O
age NN NN O
. NN NN O

9506545 NN NN O
Eye NN NN B-DiseaseClass
movement NN NN I-DiseaseClass
abnormalities NN NN I-DiseaseClass
correlate NN NN O
with NN NN O
genotype NN NN O
in NN NN O
autosomal NN NN O
dominant NN NN O
cerebellar NN NN B-DiseaseClass
ataxia NN NN I-DiseaseClass
type NN NN I-DiseaseClass
I NN NN I-DiseaseClass
. NN NN O

We NN NN O
compared NN NN O
horizontal NN NN O
eye NN NN O
movements NN NN O
( NN NN O
visually NN NN O
guided NN NN O
saccades NN NN O
, NN NN O
antisaccades NN NN O
, NN NN O
and NN NN O
smooth NN NN O
pursuit NN NN O
) NN NN O
in NN NN O
control NN NN O
subjects NN NN O
( NN NN O
n NN NN O
= NN NN O
14 NN NN O
) NN NN O
and NN NN O
patients NN NN O
with NN NN O
three NN NN O
forms NN NN O
of NN NN O
autosomal NN NN O
dominant NN NN O
cerebellar NN NN B-DiseaseClass
ataxias NN NN I-DiseaseClass
type NN NN I-DiseaseClass
I NN NN I-DiseaseClass
spinocerebellar NN NN B-CompositeMention
ataxias NN NN I-CompositeMention
1 NN NN I-CompositeMention
and NN NN I-CompositeMention
2 NN NN I-CompositeMention
( NN NN O
SCA1 NN NN B-SpecificDisease
, NN NN O
n NN NN O
= NN NN O
11 NN NN O
; NN NN O
SCA2 NN NN B-SpecificDisease
, NN NN O
n NN NN O
= NN NN O
10 NN NN O
) NN NN O
and NN NN O
SCA3 NN NN B-SpecificDisease
/ NN NN O
Machado-Joseph NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
MJD NN NN B-SpecificDisease
) NN NN O
( NN NN O
n NN NN O
= NN NN O
16 NN NN O
) NN NN O
. NN NN O

In NN NN O
SCA1 NN NN B-SpecificDisease
, NN NN O
saccade NN NN O
amplitude NN NN O
was NN NN O
significantly NN NN O
increased NN NN O
, NN NN O
resulting NN NN O
in NN NN O
hypermetria NN NN B-SpecificDisease
. NN NN O

The NN NN O
smooth NN NN O
pursuit NN NN O
gain NN NN O
was NN NN O
decreased NN NN O
. NN NN O

In NN NN O
SCA2 NN NN B-SpecificDisease
, NN NN O
saccade NN NN O
velocity NN NN O
was NN NN O
markedly NN NN O
decreased NN NN O
. NN NN O

The NN NN O
percentage NN NN O
of NN NN O
errors NN NN O
in NN NN O
antisaccades NN NN O
was NN NN O
greatly NN NN O
increased NN NN O
and NN NN O
was NN NN O
significantly NN NN O
correlated NN NN O
with NN NN O
age NN NN O
at NN NN O
disease NN NN O
onset NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
a NN NN O
correlation NN NN O
between NN NN O
smooth NN NN O
pursuit NN NN O
gain NN NN O
and NN NN O
the NN NN O
number NN NN O
of NN NN O
trinucleotide NN NN O
repeats NN NN O
was NN NN O
found NN NN O
. NN NN O

In NN NN O
SCA3 NN NN B-SpecificDisease
, NN NN O
gaze-evoked NN NN B-SpecificDisease
nystagmus NN NN I-SpecificDisease
was NN NN O
often NN NN O
present NN NN O
as NN NN O
was NN NN O
saccade NN NN O
hypometria NN NN B-SpecificDisease
and NN NN O
smooth NN NN O
pursuit NN NN O
gain NN NN O
was NN NN O
markedly NN NN O
decreased NN NN O
. NN NN O

Three NN NN O
major NN NN O
criteria NN NN O
, NN NN O
saccade NN NN O
amplitude NN NN O
, NN NN O
saccade NN NN O
velocity NN NN O
, NN NN O
and NN NN O
presence NN NN O
of NN NN O
gaze-evoked NN NN B-SpecificDisease
nystagmus NN NN I-SpecificDisease
, NN NN O
permitted NN NN O
the NN NN O
correct NN NN O
assignment NN NN O
of NN NN O
90 NN NN O
% NN NN O
of NN NN O
the NN NN O
SCA1 NN NN B-SpecificDisease
, NN NN O
90 NN NN O
% NN NN O
of NN NN O
the NN NN O
SCA2 NN NN B-SpecificDisease
, NN NN O
and NN NN O
93 NN NN O
% NN NN O
of NN NN O
the NN NN O
patients NN NN O
with NN NN O
SCA3 NN NN B-SpecificDisease
to NN NN O
their NN NN O
genetically NN NN O
confirmed NN NN O
patient NN NN O
group NN NN O
and NN NN O
, NN NN O
therefore NN NN O
, NN NN O
may NN NN O
help NN NN O
orient NN NN O
diagnoses NN NN O
of NN NN O
SCA1 NN NN B-SpecificDisease
, NN NN O
SCA2 NN NN B-SpecificDisease
, NN NN O
and NN NN O
SCA3 NN NN B-SpecificDisease
at NN NN O
early NN NN O
clinical NN NN O
stages NN NN O
of NN NN O
the NN NN O
diseases NN NN O
. NN NN O

. NN NN O

9521325 NN NN O
Genetic NN NN O
basis NN NN O
and NN NN O
molecular NN NN O
mechanism NN NN O
for NN NN O
idiopathic NN NN B-SpecificDisease
ventricular NN NN I-SpecificDisease
fibrillation NN NN I-SpecificDisease
. NN NN O

Ventricular NN NN B-SpecificDisease
fibrillation NN NN I-SpecificDisease
causes NN NN O
more NN NN O
than NN NN O
300 NN NN O
, NN NN O
000 NN NN O
sudden NN NN O
deaths NN NN O
each NN NN O
year NN NN O
in NN NN O
the NN NN O
USA NN NN O
alone NN NN O
. NN NN O

In NN NN O
approximately NN NN O
5-12 NN NN O
% NN NN O
of NN NN O
these NN NN O
cases NN NN O
, NN NN O
there NN NN O
are NN NN O
no NN NN O
demonstrable NN NN O
cardiac NN NN O
or NN NN O
non-cardiac NN NN O
causes NN NN O
to NN NN O
account NN NN O
for NN NN O
the NN NN O
episode NN NN O
, NN NN O
which NN NN O
is NN NN O
therefore NN NN O
classified NN NN O
as NN NN O
idiopathic NN NN B-SpecificDisease
ventricular NN NN I-SpecificDisease
fibrillation NN NN I-SpecificDisease
( NN NN O
IVF NN NN B-SpecificDisease
) NN NN O
. NN NN O

A NN NN O
distinct NN NN O
group NN NN O
of NN NN O
IVF NN NN B-Modifier
patients NN NN O
has NN NN O
been NN NN O
found NN NN O
to NN NN O
present NN NN O
with NN NN O
a NN NN O
characteristic NN NN O
electrocardiographic NN NN O
pattern NN NN O
. NN NN O

Because NN NN O
of NN NN O
the NN NN O
small NN NN O
size NN NN O
of NN NN O
most NN NN O
pedigrees NN NN O
and NN NN O
the NN NN O
high NN NN O
incidence NN NN O
of NN NN O
sudden NN NN B-SpecificDisease
death NN NN I-SpecificDisease
, NN NN O
however NN NN O
, NN NN O
molecular NN NN O
genetic NN NN O
studies NN NN O
of NN NN O
IVF NN NN B-SpecificDisease
have NN NN O
not NN NN O
yet NN NN O
been NN NN O
done NN NN O
. NN NN O

Because NN NN O
IVF NN NN B-SpecificDisease
causes NN NN O
cardiac NN NN O
rhythm NN NN O
disturbance NN NN O
, NN NN O
we NN NN O
investigated NN NN O
whether NN NN O
malfunction NN NN O
of NN NN O
ion NN NN O
channels NN NN O
could NN NN O
cause NN NN O
the NN NN O
disorder NN NN O
by NN NN O
studying NN NN O
mutations NN NN O
in NN NN O
the NN NN O
cardiac NN NN O
sodium NN NN O
channel NN NN O
gene NN NN O
SCN5A NN NN O
. NN NN O

We NN NN O
have NN NN O
now NN NN O
identified NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
, NN NN O
a NN NN O
splice-donor NN NN O
mutation NN NN O
, NN NN O
and NN NN O
a NN NN O
frameshift NN NN O
mutation NN NN O
in NN NN O
the NN NN O
coding NN NN O
region NN NN O
of NN NN O
SCN5A NN NN O
in NN NN O
three NN NN O
IVF NN NN B-Modifier
families NN NN O
. NN NN O

We NN NN O
show NN NN O
that NN NN O
sodium NN NN O
channels NN NN O
with NN NN O
the NN NN O
missense NN NN O
mutation NN NN O
recover NN NN O
from NN NN O
inactivation NN NN O
more NN NN O
rapidly NN NN O
than NN NN O
normal NN NN O
and NN NN O
that NN NN O
the NN NN O
frameshift NN NN O
mutation NN NN O
causes NN NN O
the NN NN O
sodium NN NN O
channel NN NN O
to NN NN O
be NN NN O
non-functional NN NN O
. NN NN O

Our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
mutations NN NN O
in NN NN O
cardiac NN NN O
ion-channel NN NN O
genes NN NN O
contribute NN NN O
to NN NN O
the NN NN O
risk NN NN O
of NN NN O
developing NN NN O
IVF NN NN B-SpecificDisease
. NN NN O

. NN NN O

9521421 NN NN O
Molecular NN NN O
heterogeneity NN NN O
in NN NN O
mucopolysaccharidosis NN NN B-SpecificDisease
IVA NN NN I-SpecificDisease
in NN NN O
Australia NN NN O
and NN NN O
Northern NN NN O
Ireland NN NN O
: NN NN O
nine NN NN O
novel NN NN O
mutations NN NN O
including NN NN O
T312S NN NN O
, NN NN O
a NN NN O
common NN NN O
allele NN NN O
that NN NN O
confers NN NN O
a NN NN O
mild NN NN O
phenotype NN NN O
. NN NN O

Mucopolysaccharidosis NN NN B-SpecificDisease
IVA NN NN I-SpecificDisease
( NN NN O
MPS NN NN B-SpecificDisease
IVA NN NN I-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
lysosomal NN NN I-DiseaseClass
storage NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
a NN NN O
genetic NN NN B-DiseaseClass
defect NN NN I-DiseaseClass
in NN NN O
N-acetylgalactosamine-6-sulfate NN NN O
sulfatase NN NN O
( NN NN O
GALNS NN NN O
) NN NN O
. NN NN O

Previous NN NN O
studies NN NN O
of NN NN O
patients NN NN O
from NN NN O
a NN NN O
British-Irish NN NN O
population NN NN O
showed NN NN O
that NN NN O
the NN NN O
I113F NN NN O
mutation NN NN O
is NN NN O
the NN NN O
most NN NN O
common NN NN O
single NN NN O
mutation NN NN O
among NN NN O
MPS NN NN B-Modifier
IVA NN NN I-Modifier
patients NN NN O
and NN NN O
produces NN NN O
a NN NN O
severe NN NN O
clinical NN NN O
phenotype NN NN O
. NN NN O

We NN NN O
studied NN NN O
mutations NN NN O
in NN NN O
the NN NN O
GALNS NN NN O
gene NN NN O
from NN NN O
23 NN NN O
additional NN NN O
MPS NN NN B-Modifier
IVA NN NN I-Modifier
patients NN NN O
( NN NN O
15 NN NN O
from NN NN O
Australia NN NN O
, NN NN O
8 NN NN O
from NN NN O
Northern NN NN O
Ireland NN NN O
) NN NN O
, NN NN O
with NN NN O
various NN NN O
clinical NN NN O
phenotypes NN NN O
( NN NN O
severe NN NN O
, NN NN O
16 NN NN O
cases NN NN O
; NN NN O
intermediate NN NN O
, NN NN O
4 NN NN O
cases NN NN O
; NN NN O
mild NN NN O
, NN NN O
3 NN NN O
cases NN NN O
) NN NN O
. NN NN O

We NN NN O
found NN NN O
two NN NN O
common NN NN O
mutations NN NN O
that NN NN O
together NN NN O
accounted NN NN O
for NN NN O
32 NN NN O
% NN NN O
of NN NN O
the NN NN O
44 NN NN O
unrelated NN NN O
alleles NN NN O
in NN NN O
these NN NN O
patients NN NN O
. NN NN O

One NN NN O
is NN NN O
the NN NN O
T312S NN NN O
mutation NN NN O
, NN NN O
a NN NN O
novel NN NN O
mutation NN NN O
found NN NN O
exclusively NN NN O
in NN NN O
milder NN NN O
patients NN NN O
. NN NN O

The NN NN O
other NN NN O
is NN NN O
the NN NN O
previously NN NN O
described NN NN O
I113F NN NN O
that NN NN O
produces NN NN O
a NN NN O
severe NN NN O
phenotype NN NN O
. NN NN O

The NN NN O
I113F NN NN O
and NN NN O
T312S NN NN O
mutations NN NN O
accounted NN NN O
for NN NN O
8 NN NN O
( NN NN O
18 NN NN O
% NN NN O
) NN NN O
and NN NN O
6 NN NN O
( NN NN O
14 NN NN O
% NN NN O
) NN NN O
of NN NN O
44 NN NN O
unrelated NN NN O
alleles NN NN O
, NN NN O
respectively NN NN O
. NN NN O

The NN NN O
relatively NN NN O
high NN NN O
residual NN NN O
GALNS NN NN O
activity NN NN O
seen NN NN O
when NN NN O
the NN NN O
T312S NN NN O
mutant NN NN O
cDNA NN NN O
is NN NN O
overexpressed NN NN O
in NN NN O
mutant NN NN O
cells NN NN O
provides NN NN O
an NN NN O
explanation NN NN O
for NN NN O
the NN NN O
mild NN NN O
phenotype NN NN O
in NN NN O
patients NN NN O
with NN NN O
this NN NN O
mutation NN NN O
. NN NN O

The NN NN O
distribution NN NN O
and NN NN O
relative NN NN O
frequencies NN NN O
of NN NN O
the NN NN O
I113F NN NN O
and NN NN O
T312S NN NN O
mutations NN NN O
in NN NN O
Australia NN NN O
corresponded NN NN O
to NN NN O
those NN NN O
observed NN NN O
in NN NN O
Northern NN NN O
Ireland NN NN O
and NN NN O
are NN NN O
unique NN NN O
to NN NN O
these NN NN O
two NN NN O
populations NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
both NN NN O
mutations NN NN O
were NN NN O
probably NN NN O
introduced NN NN O
to NN NN O
Australia NN NN O
by NN NN O
Irish NN NN O
migrants NN NN O
during NN NN O
the NN NN O
19th NN NN O
century NN NN O
. NN NN O

Haplotype NN NN O
analysis NN NN O
using NN NN O
6 NN NN O
RFLPs NN NN O
provides NN NN O
additional NN NN O
data NN NN O
that NN NN O
the NN NN O
I113F NN NN O
mutation NN NN O
originated NN NN O
from NN NN O
a NN NN O
common NN NN O
ancestor NN NN O
. NN NN O

The NN NN O
other NN NN O
9 NN NN O
novel NN NN O
mutations NN NN O
identified NN NN O
in NN NN O
these NN NN O
23 NN NN O
patients NN NN O
were NN NN O
each NN NN O
limited NN NN O
to NN NN O
a NN NN O
single NN NN O
family NN NN O
. NN NN O

These NN NN O
data NN NN O
provide NN NN O
further NN NN O
evidence NN NN O
for NN NN O
extensive NN NN O
allelic NN NN O
heterogeneity NN NN O
in NN NN O
MPS NN NN B-SpecificDisease
IVA NN NN I-SpecificDisease
in NN NN O
British-Irish NN NN O
patients NN NN O
and NN NN O
provide NN NN O
evidence NN NN O
for NN NN O
their NN NN O
transmission NN NN O
to NN NN O
Australia NN NN O
by NN NN O
British-Irish NN NN O
migrants NN NN O
. NN NN O

. NN NN O

9529364 NN NN O
Identification NN NN O
of NN NN O
constitutional NN NN O
WT1 NN NN O
mutations NN NN O
, NN NN O
in NN NN O
patients NN NN O
with NN NN O
isolated NN NN O
diffuse NN NN B-SpecificDisease
mesangial NN NN I-SpecificDisease
sclerosis NN NN I-SpecificDisease
, NN NN O
and NN NN O
analysis NN NN O
of NN NN O
genotype/phenotype NN NN O
correlations NN NN O
by NN NN O
use NN NN O
of NN NN O
a NN NN O
computerized NN NN O
mutation NN NN O
database NN NN O
. NN NN O

Constitutional NN NN O
mutations NN NN O
of NN NN O
the NN NN O
WT1 NN NN O
gene NN NN O
, NN NN O
encoding NN NN O
a NN NN O
zinc-finger NN NN O
transcription NN NN O
factor NN NN O
involved NN NN O
in NN NN O
renal NN NN O
and NN NN O
gonadal NN NN O
development NN NN O
, NN NN O
are NN NN O
found NN NN O
in NN NN O
most NN NN O
patients NN NN O
with NN NN O
Denys-Drash NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
DDS NN NN B-SpecificDisease
) NN NN O
, NN NN O
or NN NN O
diffuse NN NN B-SpecificDisease
mesangial NN NN I-SpecificDisease
sclerosis NN NN I-SpecificDisease
( NN NN O
DMS NN NN B-SpecificDisease
) NN NN O
associated NN NN O
with NN NN O
pseudohermaphroditism NN NN B-SpecificDisease
and NN NN O
/ NN NN O
or NN NN O
Wilms NN NN B-SpecificDisease
tumor NN NN I-SpecificDisease
( NN NN O
WT NN NN B-SpecificDisease
) NN NN O
. NN NN O

Most NN NN O
mutations NN NN O
in NN NN O
DDS NN NN B-Modifier
patients NN NN O
lie NN NN O
in NN NN O
exon NN NN O
8 NN NN O
or NN NN O
exon NN NN O
9 NN NN O
, NN NN O
encoding NN NN O
zinc NN NN O
finger NN NN O
2 NN NN O
or NN NN O
zinc NN NN O
finger NN NN O
3 NN NN O
, NN NN O
respectively NN NN O
, NN NN O
with NN NN O
a NN NN O
hot NN NN O
spot NN NN O
( NN NN O
R394W NN NN O
) NN NN O
in NN NN O
exon NN NN O
9 NN NN O
. NN NN O

We NN NN O
analyzed NN NN O
a NN NN O
series NN NN O
of NN NN O
24 NN NN O
patients NN NN O
, NN NN O
10 NN NN O
with NN NN O
isolated NN NN B-SpecificDisease
DMS NN NN I-SpecificDisease
( NN NN O
IDMS NN NN B-SpecificDisease
) NN NN O
, NN NN O
10 NN NN O
with NN NN O
DDS NN NN B-SpecificDisease
, NN NN O
and NN NN O
4 NN NN O
with NN NN O
urogenital NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
and NN NN O
/ NN NN O
or NN NN O
WT NN NN B-SpecificDisease
. NN NN O

We NN NN O
report NN NN O
WT1 NN NN O
heterozygous NN NN O
mutations NN NN O
in NN NN O
16 NN NN O
patients NN NN O
, NN NN O
4 NN NN O
of NN NN O
whom NN NN O
presented NN NN O
with NN NN O
IDMS NN NN B-SpecificDisease
. NN NN O

One NN NN O
male NN NN O
and NN NN O
two NN NN O
female NN NN O
IDMS NN NN B-Modifier
patients NN NN O
with NN NN O
WT1 NN NN O
mutations NN NN O
underwent NN NN O
normal NN NN O
puberty NN NN O
. NN NN O

Two NN NN O
mutations NN NN O
associated NN NN O
with NN NN O
IDMS NN NN B-SpecificDisease
are NN NN O
different NN NN O
from NN NN O
those NN NN O
described NN NN O
in NN NN O
DDS NN NN B-Modifier
patients NN NN O
. NN NN O

No NN NN O
WT1 NN NN O
mutations NN NN O
were NN NN O
detected NN NN O
in NN NN O
the NN NN O
six NN NN O
other NN NN O
IDMS NN NN B-Modifier
patients NN NN O
, NN NN O
suggesting NN NN O
genetic NN NN O
heterogeneity NN NN O
of NN NN O
this NN NN O
disease NN NN O
. NN NN O

We NN NN O
analyzed NN NN O
genotype NN NN O
/ NN NN O
phenotype NN NN O
correlations NN NN O
, NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
the NN NN O
constitution NN NN O
of NN NN O
a NN NN O
WT1 NN NN O
mutation NN NN O
database NN NN O
of NN NN O
84 NN NN O
germ-line NN NN O
mutations NN NN O
, NN NN O
to NN NN O
compare NN NN O
the NN NN O
distribution NN NN O
and NN NN O
type NN NN O
of NN NN O
mutations NN NN O
, NN NN O
according NN NN O
to NN NN O
the NN NN O
different NN NN O
symptoms NN NN O
. NN NN O

This NN NN O
demonstrated NN NN O
( NN NN O
1 NN NN O
) NN NN O
the NN NN O
association NN NN O
between NN NN O
mutations NN NN O
in NN NN O
exons NN NN O
8 NN NN O
and NN NN O
9 NN NN O
and NN NN O
DMS NN NN B-SpecificDisease
; NN NN O
( NN NN O
2 NN NN O
) NN NN O
among NN NN O
patients NN NN O
with NN NN O
DMS NN NN B-SpecificDisease
, NN NN O
a NN NN O
higher NN NN O
frequency NN NN O
of NN NN O
exon NN NN O
8 NN NN O
mutations NN NN O
among NN NN O
46 NN NN O
, NN NN O
XY NN NN O
patients NN NN O
with NN NN O
female NN NN O
phenotype NN NN O
than NN NN O
among NN NN O
46 NN NN O
, NN NN O
XY NN NN O
patients NN NN O
with NN NN O
sexual NN NN O
ambiguity NN NN O
or NN NN O
male NN NN O
phenotype NN NN O
; NN NN O
and NN NN O
( NN NN O
3 NN NN O
) NN NN O
statistically NN NN O
significant NN NN O
evidence NN NN O
that NN NN O
mutations NN NN O
in NN NN O
exons NN NN O
8 NN NN O
and NN NN O
9 NN NN O
preferentially NN NN O
affect NN NN O
amino NN NN O
acids NN NN O
with NN NN O
different NN NN O
functions NN NN O
. NN NN O

. NN NN O

9536083 NN NN O
The NN NN O
185delAG NN NN O
BRCA1 NN NN O
mutation NN NN O
originated NN NN O
before NN NN O
the NN NN O
dispersion NN NN O
of NN NN O
Jews NN NN O
in NN NN O
the NN NN O
diaspora NN NN O
and NN NN O
is NN NN O
not NN NN O
limited NN NN O
to NN NN O
Ashkenazim NN NN O
. NN NN O

The NN NN O
185delAG NN NN O
mutation NN NN O
in NN NN O
BRCA1 NN NN O
is NN NN O
detected NN NN O
in NN NN O
Ashkenazi NN NN O
Jews NN NN O
both NN NN O
in NN NN O
familial NN NN B-CompositeMention
breast NN NN I-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
and NN NN O
in NN NN O
the NN NN O
general NN NN O
population NN NN O
. NN NN O

All NN NN O
tested NN NN O
Ashkenazi NN NN O
mutation NN NN O
carriers NN NN O
share NN NN O
the NN NN O
same NN NN O
allelic NN NN O
pattern NN NN O
at NN NN O
the NN NN O
BRCA1 NN NN O
locus NN NN O
. NN NN O

Our NN NN O
previous NN NN O
study NN NN O
showed NN NN O
that NN NN O
this NN NN O
Ashkenazi NN NN O
mutation NN NN O
also NN NN O
occurs NN NN O
in NN NN O
Iraqi NN NN O
Jews NN NN O
with NN NN O
a NN NN O
similar NN NN O
allelic NN NN O
pattern NN NN O
. NN NN O

We NN NN O
extended NN NN O
our NN NN O
analysis NN NN O
to NN NN O
other NN NN O
non-Ashkenazi NN NN O
subsets NN NN O
354 NN NN O
of NN NN O
Moroccan NN NN O
origin NN NN O
, NN NN O
200 NN NN O
Yemenites NN NN O
and NN NN O
150 NN NN O
Iranian NN NN O
Jews NN NN O
. NN NN O

Heteroduplex NN NN O
analysis NN NN O
complemented NN NN O
by NN NN O
direct NN NN O
DNA NN NN O
sequencing NN NN O
of NN NN O
abnormally NN NN O
migrating NN NN O
bands NN NN O
were NN NN O
employed NN NN O
. NN NN O

Four NN NN O
of NN NN O
Moroccan NN NN O
origin NN NN O
( NN NN O
1 NN NN O
. NN NN O

1 NN NN O
% NN NN O
) NN NN O
and NN NN O
none NN NN O
of NN NN O
the NN NN O
Yemenites NN NN O
or NN NN O
Iranians NN NN O
was NN NN O
a NN NN O
carrier NN NN O
of NN NN O
the NN NN O
185delAG NN NN O
mutation NN NN O
. NN NN O

BRCA1 NN NN O
allelic NN NN O
patterns NN NN O
were NN NN O
determined NN NN O
for NN NN O
four NN NN O
of NN NN O
these NN NN O
individuals NN NN O
and NN NN O
for NN NN O
12 NN NN O
additional NN NN O
non-Ashkenazi NN NN O
185delAG NN NN O
mutation NN NN O
carriers NN NN O
who NN NN O
had NN NN O
breast NN NN B-CompositeMention
/ NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

Six NN NN O
non-Ashkenazi NN NN O
individuals NN NN O
shared NN NN O
the NN NN O
common NN NN O
Ashkenazi NN NN O
haplotype NN NN O
, NN NN O
four NN NN O
had NN NN O
a NN NN O
closely NN NN O
related NN NN O
pattern NN NN O
, NN NN O
and NN NN O
the NN NN O
rest NN NN O
( NN NN O
n NN NN O
= NN NN O
6 NN NN O
) NN NN O
displayed NN NN O
a NN NN O
distinct NN NN O
BRCA1 NN NN O
allelic NN NN O
pattern NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
185delAG NN NN O
BRCA1 NN NN O
mutation NN NN O
occurs NN NN O
in NN NN O
some NN NN O
non-Ashkenazi NN NN O
populations NN NN O
at NN NN O
rates NN NN O
comparable NN NN O
with NN NN O
that NN NN O
of NN NN O
Ashkenazim NN NN O
. NN NN O

The NN NN O
majority NN NN O
of NN NN O
Jewish NN NN O
185delAG NN NN O
mutation NN NN O
carriers NN NN O
have NN NN O
a NN NN O
common NN NN O
allelic NN NN O
pattern NN NN O
, NN NN O
supporting NN NN O
the NN NN O
founder NN NN O
effect NN NN O
notion NN NN O
, NN NN O
but NN NN O
dating NN NN O
the NN NN O
mutations NN NN O
origin NN NN O
to NN NN O
an NN NN O
earlier NN NN O
date NN NN O
than NN NN O
currently NN NN O
estimated NN NN O
. NN NN O

However NN NN O
, NN NN O
the NN NN O
different NN NN O
allelic NN NN O
pattern NN NN O
at NN NN O
the NN NN O
BRCA1 NN NN O
locus NN NN O
even NN NN O
in NN NN O
some NN NN O
Jewish NN NN O
mutation NN NN O
carriers NN NN O
, NN NN O
might NN NN O
suggest NN NN O
that NN NN O
the NN NN O
mutation NN NN O
arose NN NN O
independently NN NN O
. NN NN O

. NN NN O

9546397 NN NN O
Crystal NN NN O
structure NN NN O
of NN NN O
the NN NN O
hemochromatosis NN NN B-Modifier
protein NN NN O
HFE NN NN O
and NN NN O
characterization NN NN O
of NN NN O
its NN NN O
interaction NN NN O
with NN NN O
transferrin NN NN O
receptor NN NN O
. NN NN O

HFE NN NN O
is NN NN O
an NN NN O
MHC-related NN NN O
protein NN NN O
that NN NN O
is NN NN O
mutated NN NN O
in NN NN O
the NN NN O
iron-overload NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
hereditary NN NN B-SpecificDisease
hemochromatosis NN NN I-SpecificDisease
. NN NN O

HFE NN NN O
binds NN NN O
to NN NN O
transferrin NN NN O
receptor NN NN O
( NN NN O
TfR NN NN O
) NN NN O
and NN NN O
reduces NN NN O
its NN NN O
affinity NN NN O
for NN NN O
iron-loaded NN NN O
transferrin NN NN O
, NN NN O
implicating NN NN O
HFE NN NN O
in NN NN O
iron NN NN O
metabolism NN NN O
. NN NN O

The NN NN O
2 NN NN O
. NN NN O

6 NN NN O
A NN NN O
crystal NN NN O
structure NN NN O
of NN NN O
HFE NN NN O
reveals NN NN O
the NN NN O
locations NN NN O
of NN NN O
hemochromatosis NN NN B-Modifier
mutations NN NN O
and NN NN O
a NN NN O
patch NN NN O
of NN NN O
histidines NN NN O
that NN NN O
could NN NN O
be NN NN O
involved NN NN O
in NN NN O
pH-dependent NN NN O
interactions NN NN O
. NN NN O

We NN NN O
also NN NN O
demonstrate NN NN O
that NN NN O
soluble NN NN O
TfR NN NN O
and NN NN O
HFE NN NN O
bind NN NN O
tightly NN NN O
at NN NN O
the NN NN O
basic NN NN O
pH NN NN O
of NN NN O
the NN NN O
cell NN NN O
surface NN NN O
, NN NN O
but NN NN O
not NN NN O
at NN NN O
the NN NN O
acidic NN NN O
pH NN NN O
of NN NN O
intracellular NN NN O
vesicles NN NN O
. NN NN O

TfR NN NN O
HFE NN NN O
stoichiometry NN NN O
( NN NN O
2 NN NN O
1 NN NN O
) NN NN O
differs NN NN O
from NN NN O
TfR NN NN O
transferrin NN NN O
stoichiometry NN NN O
( NN NN O
2 NN NN O
2 NN NN O
) NN NN O
, NN NN O
implying NN NN O
a NN NN O
different NN NN O
mode NN NN O
of NN NN O
binding NN NN O
for NN NN O
HFE NN NN O
and NN NN O
transferrin NN NN O
to NN NN O
TfR NN NN O
, NN NN O
consistent NN NN O
with NN NN O
our NN NN O
demonstration NN NN O
that NN NN O
HFE NN NN O
, NN NN O
transferrin NN NN O
, NN NN O
and NN NN O
TfR NN NN O
form NN NN O
a NN NN O
ternary NN NN O
complex NN NN O
. NN NN O

9554743 NN NN O
Identification NN NN O
of NN NN O
three NN NN O
novel NN NN O
mutations NN NN O
and NN NN O
a NN NN O
high NN NN O
frequency NN NN O
of NN NN O
the NN NN O
Arg778Leu NN NN O
mutation NN NN O
in NN NN O
Korean NN NN O
patients NN NN O
with NN NN O
Wilson NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Four NN NN O
mutations NN NN O
-- NN NN O
R778L NN NN O
, NN NN O
A874V NN NN O
, NN NN O
L1083F NN NN O
, NN NN O
and NN NN O
2304delC NN NN O
-- NN NN O
in NN NN O
the NN NN O
copper-transporting NN NN O
enzyme NN NN O
, NN NN O
P-type NN NN O
ATPase NN NN O
( NN NN O
ATP7B NN NN O
) NN NN O
, NN NN O
were NN NN O
identified NN NN O
in NN NN O
Korean NN NN O
Patients NN NN O
with NN NN O
Wilson NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Arg778Leu NN NN O
, NN NN O
the NN NN O
most NN NN O
frequently NN NN O
reported NN NN O
mutation NN NN O
of NN NN O
this NN NN O
enzyme NN NN O
, NN NN O
was NN NN O
found NN NN O
in NN NN O
six NN NN O
of NN NN O
eight NN NN O
unrelated NN NN O
patients NN NN O
studied NN NN O
, NN NN O
an NN NN O
allele NN NN O
frequency NN NN O
of NN NN O
37 NN NN O
. NN NN O

5 NN NN O
% NN NN O
, NN NN O
which NN NN O
is NN NN O
considerably NN NN O
higher NN NN O
than NN NN O
those NN NN O
in NN NN O
other NN NN O
Asian NN NN O
populations NN NN O
. NN NN O

The NN NN O
novel NN NN O
single NN NN O
nucleotide NN NN O
deletion NN NN O
, NN NN O
2304delC NN NN O
, NN NN O
was NN NN O
found NN NN O
in NN NN O
one NN NN O
patient NN NN O
. NN NN O

Since NN NN O
a NN NN O
mutation NN NN O
at NN NN O
cDNA NN NN O
nucleotide NN NN O
2302 NN NN O
( NN NN O
2302insC NN NN O
) NN NN O
had NN NN O
been NN NN O
previously NN NN O
described NN NN O
, NN NN O
this NN NN O
region NN NN O
of NN NN O
the NN NN O
ATP7B NN NN O
gene NN NN O
may NN NN O
be NN NN O
susceptible NN NN O
to NN NN O
gene NN NN O
rearrangements NN NN O
causing NN NN O
Wilson NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

9563950 NN NN O
Disruption NN NN O
of NN NN O
splicing NN NN O
regulated NN NN O
by NN NN O
a NN NN O
CUG-binding NN NN O
protein NN NN O
in NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
is NN NN O
caused NN NN O
by NN NN O
a NN NN O
CTG NN NN O
expansion NN NN O
in NN NN O
the NN NN O
3 NN NN O
untranslated NN NN O
region NN NN O
of NN NN O
the NN NN O
DM NN NN B-Modifier
gene NN NN O
. NN NN O

One NN NN O
model NN NN O
of NN NN O
DM NN NN B-Modifier
pathogenesis NN NN O
suggests NN NN O
that NN NN O
RNAs NN NN O
from NN NN O
the NN NN O
expanded NN NN O
allele NN NN O
create NN NN O
a NN NN O
gain-of-function NN NN O
mutation NN NN O
by NN NN O
the NN NN O
inappropriate NN NN O
binding NN NN O
of NN NN O
proteins NN NN O
to NN NN O
the NN NN O
CUG NN NN O
repeats NN NN O
. NN NN O

Data NN NN O
presented NN NN O
here NN NN O
indicate NN NN O
that NN NN O
the NN NN O
conserved NN NN O
heterogeneous NN NN O
nuclear NN NN O
ribonucleoprotein NN NN O
, NN NN O
CUG-binding NN NN O
protein NN NN O
( NN NN O
CUG-BP NN NN O
) NN NN O
, NN NN O
may NN NN O
mediate NN NN O
the NN NN O
trans-dominant NN NN O
effect NN NN O
of NN NN O
the NN NN O
RNA NN NN O
. NN NN O

CUG-BP NN NN O
was NN NN O
found NN NN O
to NN NN O
bind NN NN O
to NN NN O
the NN NN O
human NN NN O
cardiac NN NN O
troponin NN NN O
T NN NN O
( NN NN O
cTNT NN NN O
) NN NN O
pre-messenger NN NN O
RNA NN NN O
and NN NN O
regulate NN NN O
its NN NN O
alternative NN NN O
splicing NN NN O
. NN NN O

Splicing NN NN O
of NN NN O
cTNT NN NN O
was NN NN O
disrupted NN NN O
in NN NN O
DM NN NN B-Modifier
striated NN NN O
muscle NN NN O
and NN NN O
in NN NN O
normal NN NN O
cells NN NN O
expressing NN NN O
transcripts NN NN O
that NN NN O
contain NN NN O
CUG NN NN O
repeats NN NN O
. NN NN O

Altered NN NN O
expression NN NN O
of NN NN O
genes NN NN O
regulated NN NN O
posttranscriptionally NN NN O
by NN NN O
CUG-BP NN NN O
therefore NN NN O
may NN NN O
contribute NN NN O
to NN NN O
DM NN NN B-Modifier
pathogenesis NN NN O
. NN NN O

. NN NN O

9580132 NN NN O
Identification NN NN O
of NN NN O
a NN NN O
novel NN NN O
nonsense NN NN O
mutation NN NN O
and NN NN O
a NN NN O
missense NN NN O
substitution NN NN O
in NN NN O
the NN NN O
vasopressin-neurophysin NN NN O
II NN NN O
gene NN NN O
in NN NN O
two NN NN O
Spanish NN NN O
kindreds NN NN O
with NN NN O
familial NN NN B-SpecificDisease
neurohypophyseal NN NN I-SpecificDisease
diabetes NN NN I-SpecificDisease
insipidus NN NN I-SpecificDisease
. NN NN O

Familial NN NN B-SpecificDisease
neurohypophyseal NN NN I-SpecificDisease
diabetes NN NN I-SpecificDisease
insipidus NN NN I-SpecificDisease
( NN NN O
FNDI NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
caused NN NN O
by NN NN O
deficiency NN NN O
in NN NN O
the NN NN O
antidiuretic NN NN O
hormone NN NN O
arginine NN NN O
vasopressin NN NN O
( NN NN O
AVP NN NN O
) NN NN O
encoded NN NN O
by NN NN O
the NN NN O
AVP-neurophysin NN NN O
II NN NN O
( NN NN O
AVP-NPII NN NN O
) NN NN O
gene NN NN O
on NN NN O
chromosome NN NN O
20p13 NN NN O
. NN NN O

In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
two NN NN O
families NN NN O
with NN NN O
FNDI NN NN B-SpecificDisease
using NN NN O
direct NN NN O
automated NN NN O
fluorescent NN NN O
, NN NN O
solid NN NN O
phase NN NN O
, NN NN O
single-stranded NN NN O
DNA NN NN O
sequencing NN NN O
of NN NN O
PCR-amplified NN NN O
AVP-NPII NN NN O
DNA NN NN O
. NN NN O

In NN NN O
one NN NN O
of NN NN O
the NN NN O
families NN NN O
, NN NN O
affected NN NN O
individuals NN NN O
presented NN NN O
a NN NN O
novel NN NN O
nonsense NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
3 NN NN O
of NN NN O
the NN NN O
gene NN NN O
, NN NN O
consisting NN NN O
in NN NN O
a NN NN O
G NN NN O
to NN NN O
T NN NN O
transition NN NN O
at NN NN O
nucleotide NN NN O
2101 NN NN O
, NN NN O
which NN NN O
produces NN NN O
a NN NN O
stop NN NN O
signal NN NN O
in NN NN O
codon NN NN O
82 NN NN O
( NN NN O
Glu NN NN O
) NN NN O
of NN NN O
NPII NN NN O
. NN NN O

The NN NN O
premature NN NN O
termination NN NN O
eliminates NN NN O
part NN NN O
of NN NN O
the NN NN O
C-terminal NN NN O
domain NN NN O
of NN NN O
NPII NN NN O
, NN NN O
including NN NN O
a NN NN O
cysteine NN NN O
residue NN NN O
in NN NN O
position NN NN O
85 NN NN O
, NN NN O
which NN NN O
could NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
correct NN NN O
folding NN NN O
of NN NN O
the NN NN O
prohormone NN NN O
. NN NN O

In NN NN O
the NN NN O
second NN NN O
family NN NN O
, NN NN O
a NN NN O
G279A NN NN O
substitution NN NN O
at NN NN O
position NN NN O
-1 NN NN O
of NN NN O
the NN NN O
signal NN NN O
peptide NN NN O
was NN NN O
observed NN NN O
in NN NN O
all NN NN O
affected NN NN O
individuals NN NN O
. NN NN O

This NN NN O
missense NN NN O
mutation NN NN O
, NN NN O
which NN NN O
replaces NN NN O
Ala NN NN O
with NN NN O
Thr NN NN O
, NN NN O
is NN NN O
frequent NN NN O
among NN NN O
FNDI NN NN B-Modifier
patients NN NN O
and NN NN O
is NN NN O
thought NN NN O
to NN NN O
reduce NN NN O
the NN NN O
efficiency NN NN O
of NN NN O
cleavage NN NN O
by NN NN O
signal NN NN O
peptidases NN NN O
. NN NN O

. NN NN O

9585583 NN NN O
Genetic NN NN O
heterogeneity NN NN O
of NN NN O
Saethre-Chotzen NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
due NN NN O
to NN NN O
TWIST NN NN O
and NN NN O
FGFR NN NN O
mutations NN NN O
. NN NN O

Thirty-two NN NN O
unrelated NN NN O
patients NN NN O
with NN NN O
features NN NN O
of NN NN O
Saethre-Chotzen NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
a NN NN O
common NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
condition NN NN I-DiseaseClass
of NN NN O
craniosynostosis NN NN B-SpecificDisease
and NN NN O
limb NN NN B-DiseaseClass
anomalies NN NN I-DiseaseClass
, NN NN O
were NN NN O
screened NN NN O
for NN NN O
mutations NN NN O
in NN NN O
TWIST NN NN O
, NN NN O
FGFR2 NN NN O
, NN NN O
and NN NN O
FGFR3 NN NN O
. NN NN O

Nine NN NN O
novel NN NN O
and NN NN O
three NN NN O
recurrent NN NN O
TWIST NN NN O
mutations NN NN O
were NN NN O
found NN NN O
in NN NN O
12 NN NN O
families NN NN O
. NN NN O

Seven NN NN O
families NN NN O
were NN NN O
found NN NN O
to NN NN O
have NN NN O
the NN NN O
FGFR3 NN NN O
P250R NN NN O
mutation NN NN O
, NN NN O
and NN NN O
one NN NN O
individual NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
an NN NN O
FGFR2 NN NN O
VV269-270 NN NN O
deletion NN NN O
. NN NN O

To NN NN O
date NN NN O
, NN NN O
our NN NN O
detection NN NN O
rate NN NN O
for NN NN O
TWIST NN NN O
or NN NN O
FGFR NN NN O
mutations NN NN O
is NN NN O
68 NN NN O
% NN NN O
in NN NN O
our NN NN O
Saethre-Chotzen NN NN B-Modifier
syndrome NN NN I-Modifier
patients NN NN O
, NN NN O
including NN NN O
our NN NN O
five NN NN O
patients NN NN O
elsewhere NN NN O
reported NN NN O
with NN NN O
TWIST NN NN O
mutations NN NN O
. NN NN O

More NN NN O
than NN NN O
35 NN NN O
different NN NN O
TWIST NN NN O
mutations NN NN O
are NN NN O
now NN NN O
known NN NN O
in NN NN O
the NN NN O
literature NN NN O
. NN NN O

The NN NN O
most NN NN O
common NN NN O
phenotypic NN NN O
features NN NN O
, NN NN O
present NN NN O
in NN NN O
more NN NN O
than NN NN O
a NN NN O
third NN NN O
of NN NN O
our NN NN O
patients NN NN O
with NN NN O
TWIST NN NN O
mutations NN NN O
, NN NN O
are NN NN O
coronal NN NN B-SpecificDisease
synostosis NN NN I-SpecificDisease
, NN NN O
brachycephaly NN NN B-SpecificDisease
, NN NN O
low NN NN B-SpecificDisease
frontal NN NN I-SpecificDisease
hairline NN NN I-SpecificDisease
, NN NN O
facial NN NN B-SpecificDisease
asymmetry NN NN I-SpecificDisease
, NN NN O
ptosis NN NN B-SpecificDisease
, NN NN O
hypertelorism NN NN B-SpecificDisease
, NN NN O
broad NN NN B-SpecificDisease
great NN NN I-SpecificDisease
toes NN NN I-SpecificDisease
, NN NN O
and NN NN O
clinodactyly NN NN B-SpecificDisease
. NN NN O

Significant NN NN O
intra- NN NN O
and NN NN O
interfamilial NN NN O
phenotypic NN NN O
variability NN NN O
is NN NN O
present NN NN O
for NN NN O
either NN NN O
TWIST NN NN O
mutations NN NN O
or NN NN O
FGFR NN NN O
mutations NN NN O
. NN NN O

The NN NN O
overlap NN NN O
in NN NN O
clinical NN NN O
features NN NN O
and NN NN O
the NN NN O
presence NN NN O
, NN NN O
in NN NN O
the NN NN O
same NN NN O
genes NN NN O
, NN NN O
of NN NN O
mutations NN NN O
for NN NN O
more NN NN O
than NN NN O
one NN NN O
craniosynostotic NN NN B-DiseaseClass
condition NN NN I-DiseaseClass
-such NN NN O
as NN NN O
Saethre-Chotzen NN NN B-CompositeMention
, NN NN I-CompositeMention
Crouzon NN NN I-CompositeMention
, NN NN I-CompositeMention
and NN NN I-CompositeMention
Pfeiffer NN NN I-CompositeMention
syndromes NN NN I-CompositeMention
-support NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
TWIST NN NN O
and NN NN O
FGFRs NN NN O
are NN NN O
components NN NN O
of NN NN O
the NN NN O
same NN NN O
molecular NN NN O
pathway NN NN O
involved NN NN O
in NN NN O
the NN NN O
modulation NN NN O
of NN NN O
craniofacial NN NN O
and NN NN O
limb NN NN O
development NN NN O
in NN NN O
humans NN NN O
. NN NN O

. NN NN O

9585605 NN NN O
Mutation NN NN O
analysis NN NN O
of NN NN O
UBE3A NN NN O
in NN NN O
Angelman NN NN B-Modifier
syndrome NN NN I-Modifier
patients NN NN O
. NN NN O

Angelman NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
AS NN NN B-SpecificDisease
) NN NN O
is NN NN O
caused NN NN O
by NN NN O
chromosome NN NN O
15q11-q13 NN NN O
deletions NN NN O
of NN NN O
maternal NN NN O
origin NN NN O
, NN NN O
by NN NN O
paternal NN NN O
uniparental NN NN B-SpecificDisease
disomy NN NN I-SpecificDisease
( NN NN O
UPD NN NN B-SpecificDisease
) NN NN O
15 NN NN O
, NN NN O
by NN NN O
imprinting NN NN O
defects NN NN O
, NN NN O
and NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
UBE3A NN NN O
gene NN NN O
. NN NN O

UBE3A NN NN O
encodes NN NN O
a NN NN O
ubiquitin-protein NN NN O
ligase NN NN O
and NN NN O
shows NN NN O
brain-specific NN NN O
imprinting NN NN O
. NN NN O

Here NN NN O
we NN NN O
describe NN NN O
UBE3A NN NN O
coding-region NN NN O
mutations NN NN O
detected NN NN O
by NN NN O
SSCP NN NN O
analysis NN NN O
in NN NN O
13 NN NN O
AS NN NN B-Modifier
individuals NN NN O
or NN NN O
families NN NN O
. NN NN O

Two NN NN O
identical NN NN O
de NN NN O
novo NN NN O
5-bp NN NN O
duplications NN NN O
in NN NN O
exon NN NN O
16 NN NN O
were NN NN O
found NN NN O
. NN NN O

Among NN NN O
the NN NN O
other NN NN O
11 NN NN O
unique NN NN O
mutations NN NN O
, NN NN O
8 NN NN O
were NN NN O
small NN NN O
deletions NN NN O
or NN NN O
insertions NN NN O
predicted NN NN O
to NN NN O
cause NN NN O
frameshifts NN NN O
, NN NN O
1 NN NN O
was NN NN O
a NN NN O
mutation NN NN O
to NN NN O
a NN NN O
stop NN NN O
codon NN NN O
, NN NN O
1 NN NN O
was NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
, NN NN O
and NN NN O
1 NN NN O
was NN NN O
predicted NN NN O
to NN NN O
cause NN NN O
insertion NN NN O
of NN NN O
an NN NN O
isoleucine NN NN O
in NN NN O
the NN NN O
hect NN NN O
domain NN NN O
of NN NN O
the NN NN O
UBE3A NN NN O
protein NN NN O
, NN NN O
which NN NN O
functions NN NN O
in NN NN O
E2 NN NN O
binding NN NN O
and NN NN O
ubiquitin NN NN O
transfer NN NN O
. NN NN O

Eight NN NN O
of NN NN O
the NN NN O
cases NN NN O
were NN NN O
familial NN NN O
, NN NN O
and NN NN O
five NN NN O
were NN NN O
sporadic NN NN O
. NN NN O

In NN NN O
two NN NN O
familial NN NN O
cases NN NN O
and NN NN O
one NN NN O
sporadic NN NN O
case NN NN O
, NN NN O
mosaicism NN NN O
for NN NN O
UBE3A NN NN O
mutations NN NN O
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
mother NN NN O
of NN NN O
three NN NN O
AS NN NN B-Modifier
sons NN NN O
, NN NN O
in NN NN O
the NN NN O
maternal NN NN O
grandfather NN NN O
of NN NN O
two NN NN O
AS NN NN B-Modifier
first NN NN O
cousins NN NN O
, NN NN O
and NN NN O
in NN NN O
the NN NN O
mother NN NN O
of NN NN O
an NN NN O
AS NN NN B-Modifier
daughter NN NN O
. NN NN O

The NN NN O
frequencies NN NN O
with NN NN O
which NN NN O
we NN NN O
detected NN NN O
mutations NN NN O
were NN NN O
5 NN NN O
( NN NN O
14 NN NN O
% NN NN O
) NN NN O
of NN NN O
35 NN NN O
in NN NN O
sporadic NN NN O
cases NN NN O
and NN NN O
8 NN NN O
( NN NN O
80 NN NN O
% NN NN O
) NN NN O
of NN NN O
10 NN NN O
in NN NN O
familial NN NN O
cases NN NN O
. NN NN O

. NN NN O

9585606 NN NN O
The NN NN O
hemochromatosis NN NN B-Modifier
845 NN NN O
G NN NN O
-- NN NN O
A NN NN O
and NN NN O
187 NN NN O
C NN NN O
-- NN NN O
G NN NN O
mutations NN NN O
: NN NN O
prevalence NN NN O
in NN NN O
non-Caucasian NN NN O
populations NN NN O
. NN NN O

Hemochromatosis NN NN B-SpecificDisease
, NN NN O
the NN NN O
inherited NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
of NN NN I-DiseaseClass
iron NN NN I-DiseaseClass
metabolism NN NN I-DiseaseClass
, NN NN O
leads NN NN O
, NN NN O
if NN NN O
untreated NN NN O
, NN NN O
to NN NN O
progressive NN NN O
iron NN NN B-SpecificDisease
overload NN NN I-SpecificDisease
and NN NN O
premature NN NN B-SpecificDisease
death NN NN I-SpecificDisease
. NN NN O

The NN NN O
hemochromatosis NN NN B-Modifier
gene NN NN O
, NN NN O
HFE NN NN O
, NN NN O
recently NN NN O
has NN NN O
been NN NN O
identified NN NN O
, NN NN O
and NN NN O
characterization NN NN O
of NN NN O
this NN NN O
gene NN NN O
has NN NN O
shown NN NN O
that NN NN O
it NN NN O
contains NN NN O
two NN NN O
mutations NN NN O
that NN NN O
result NN NN O
in NN NN O
amino NN NN O
acid NN NN O
substitutions-cDNA NN NN O
nucleotides NN NN O
845 NN NN O
G NN NN O
-- NN NN O
A NN NN O
( NN NN O
C282Y NN NN O
) NN NN O
and NN NN O
187 NN NN O
C NN NN O
-- NN NN O
G NN NN O
( NN NN O
H63D NN NN O
) NN NN O
. NN NN O

Although NN NN O
hemochromatosis NN NN B-SpecificDisease
is NN NN O
common NN NN O
in NN NN O
Caucasians NN NN O
, NN NN O
affecting NN NN O
= NN NN O
1 NN NN O
/ NN NN O
300 NN NN O
individuals NN NN O
of NN NN O
northern NN NN O
European NN NN O
origin NN NN O
, NN NN O
it NN NN O
has NN NN O
not NN NN O
been NN NN O
recognized NN NN O
in NN NN O
other NN NN O
populations NN NN O
. NN NN O

The NN NN O
present NN NN O
study NN NN O
used NN NN O
PCR NN NN O
and NN NN O
restriction-enzyme NN NN O
digestion NN NN O
to NN NN O
analyze NN NN O
the NN NN O
frequency NN NN O
of NN NN O
the NN NN O
845 NN NN O
G NN NN O
-- NN NN O
A NN NN O
and NN NN O
187 NN NN O
C NN NN O
-- NN NN O
G NN NN O
mutations NN NN O
in NN NN O
HLA-typed NN NN O
samples NN NN O
from NN NN O
non-Caucasian NN NN O
populations NN NN O
, NN NN O
comprising NN NN O
Australian NN NN O
Aboriginal NN NN O
, NN NN O
Chinese NN NN O
, NN NN O
and NN NN O
Pacific NN NN O
Islanders NN NN O
. NN NN O

Results NN NN O
showed NN NN O
that NN NN O
the NN NN O
845 NN NN O
G NN NN O
-- NN NN O
A NN NN O
mutation NN NN O
was NN NN O
present NN NN O
in NN NN O
these NN NN O
populations NN NN O
( NN NN O
allele NN NN O
frequency NN NN O
0 NN NN O
. NN NN O

32 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
, NN NN O
furthermore NN NN O
, NN NN O
it NN NN O
was NN NN O
always NN NN O
seen NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
HLA NN NN O
haplotypes NN NN O
common NN NN O
in NN NN O
Caucasians NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
845 NN NN O
G NN NN O
-- NN NN O
A NN NN O
may NN NN O
have NN NN O
been NN NN O
introduced NN NN O
into NN NN O
these NN NN O
populations NN NN O
by NN NN O
Caucasian NN NN O
admixture NN NN O
. NN NN O

187 NN NN O
C NN NN O
-- NN NN O
G NN NN O
was NN NN O
present NN NN O
at NN NN O
an NN NN O
allele NN NN O
frequency NN NN O
of NN NN O
2 NN NN O
. NN NN O

68 NN NN O
% NN NN O
in NN NN O
the NN NN O
two NN NN O
populations NN NN O
analyzed NN NN O
( NN NN O
Australian NN NN O
Aboriginal NN NN O
and NN NN O
Chinese NN NN O
) NN NN O
. NN NN O

In NN NN O
the NN NN O
Australian NN NN O
Aboriginal NN NN O
samples NN NN O
, NN NN O
187 NN NN O
C NN NN O
-- NN NN O
G NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
HLA NN NN O
haplotypes NN NN O
common NN NN O
in NN NN O
Caucasians NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
it NN NN O
was NN NN O
introduced NN NN O
by NN NN O
recent NN NN O
admixture NN NN O
. NN NN O

In NN NN O
the NN NN O
Chinese NN NN O
samples NN NN O
analyzed NN NN O
, NN NN O
187 NN NN O
C NN NN O
-- NN NN O
G NN NN O
was NN NN O
present NN NN O
in NN NN O
association NN NN O
with NN NN O
a NN NN O
wide NN NN O
variety NN NN O
of NN NN O
HLA NN NN O
haplotypes NN NN O
, NN NN O
showing NN NN O
this NN NN O
mutation NN NN O
to NN NN O
be NN NN O
widespread NN NN O
and NN NN O
likely NN NN O
to NN NN O
predate NN NN O
the NN NN O
more NN NN O
genetically NN NN O
restricted NN NN O
845 NN NN O
G NN NN O
-- NN NN O
A NN NN O
mutation NN NN O
. NN NN O

9585611 NN NN O
Genotype-phenotype NN NN O
correlations NN NN O
in NN NN O
attenuated NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
. NN NN O

Germ-line NN NN O
mutations NN NN O
of NN NN O
the NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
APC NN NN O
are NN NN O
implicated NN NN O
in NN NN O
attenuated NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
( NN NN O
AAPC NN NN B-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
variant NN NN O
of NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
( NN NN O
FAP NN NN B-SpecificDisease
) NN NN O
. NN NN O

AAPC NN NN B-SpecificDisease
is NN NN O
recognized NN NN O
by NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
100 NN NN O
colonic NN NN B-SpecificDisease
adenomas NN NN I-SpecificDisease
and NN NN O
a NN NN O
later NN NN O
onset NN NN O
of NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
( NN NN O
age NN NN O
40 NN NN O
years NN NN O
) NN NN O
. NN NN O

The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
assess NN NN O
genotype-phenotype NN NN O
correlations NN NN O
in NN NN O
AAPC NN NN B-Modifier
families NN NN O
. NN NN O

By NN NN O
protein-truncation NN NN O
test NN NN O
( NN NN O
PTT NN NN O
) NN NN O
assay NN NN O
, NN NN O
the NN NN O
entire NN NN O
coding NN NN O
region NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
was NN NN O
screened NN NN O
in NN NN O
affected NN NN O
individuals NN NN O
from NN NN O
11 NN NN O
AAPC NN NN B-Modifier
kindreds NN NN O
, NN NN O
and NN NN O
their NN NN O
phenotypic NN NN O
differences NN NN O
were NN NN O
examined NN NN O
. NN NN O

Five NN NN O
novel NN NN O
germ-line NN NN O
APC NN NN B-Modifier
mutations NN NN O
were NN NN O
identified NN NN O
in NN NN O
seven NN NN O
kindreds NN NN O
. NN NN O

Mutations NN NN O
were NN NN O
located NN NN O
in NN NN O
three NN NN O
different NN NN O
regions NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
( NN NN O
1 NN NN O
) NN NN O
at NN NN O
the NN NN O
5 NN NN O
end NN NN O
spanning NN NN O
exons NN NN O
4 NN NN O
and NN NN O
5 NN NN O
, NN NN O
( NN NN O
2 NN NN O
) NN NN O
within NN NN O
exon NN NN O
9 NN NN O
, NN NN O
and NN NN O
( NN NN O
3 NN NN O
) NN NN O
at NN NN O
the NN NN O
3 NN NN O
distal NN NN O
end NN NN O
of NN NN O
the NN NN O
gene NN NN O
. NN NN O

Variability NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
colorectal NN NN B-SpecificDisease
adenomas NN NN I-SpecificDisease
was NN NN O
most NN NN O
apparent NN NN O
in NN NN O
individuals NN NN O
with NN NN O
mutations NN NN O
in NN NN O
region NN NN O
1 NN NN O
, NN NN O
and NN NN O
upper-gastrointestinal NN NN O
manifestations NN NN O
were NN NN O
more NN NN O
severe NN NN O
in NN NN O
them NN NN O
. NN NN O

In NN NN O
individuals NN NN O
with NN NN O
mutations NN NN O
in NN NN O
either NN NN O
region NN NN O
2 NN NN O
or NN NN O
region NN NN O
3 NN NN O
, NN NN O
the NN NN O
average NN NN O
number NN NN O
of NN NN O
adenomas NN NN B-DiseaseClass
tended NN NN O
to NN NN O
be NN NN O
lower NN NN O
than NN NN O
those NN NN O
in NN NN O
individuals NN NN O
with NN NN O
mutations NN NN O
in NN NN O
region NN NN O
1 NN NN O
, NN NN O
although NN NN O
age NN NN O
at NN NN O
diagnosis NN NN O
was NN NN O
similar NN NN O
. NN NN O

In NN NN O
all NN NN O
AAPC NN NN B-Modifier
kindreds NN NN O
, NN NN O
a NN NN O
predominance NN NN O
of NN NN O
right-sided NN NN O
colorectal NN NN B-SpecificDisease
adenomas NN NN I-SpecificDisease
and NN NN O
rectal NN NN B-Modifier
polyp NN NN I-Modifier
sparing NN NN O
was NN NN O
observed NN NN O
. NN NN O

No NN NN O
desmoid NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
were NN NN O
found NN NN O
in NN NN O
these NN NN O
kindreds NN NN O
. NN NN O

Our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
, NN NN O
in NN NN O
AAPC NN NN B-Modifier
families NN NN O
, NN NN O
the NN NN O
location NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
mutation NN NN O
may NN NN O
partially NN NN O
predict NN NN O
specific NN NN O
phenotypic NN NN O
expression NN NN O
. NN NN O

This NN NN O
should NN NN O
help NN NN O
in NN NN O
the NN NN O
design NN NN O
of NN NN O
tailored NN NN O
clinical-management NN NN O
protocols NN NN O
in NN NN O
this NN NN O
subset NN NN O
of NN NN O
FAP NN NN B-Modifier
patients NN NN O
. NN NN O

. NN NN O

9590178 NN NN O
Wilms NN NN B-Modifier
' NN NN I-Modifier
tumor NN NN I-Modifier
1 NN NN O
and NN NN O
Dax-1 NN NN O
modulate NN NN O
the NN NN O
orphan NN NN O
nuclear NN NN O
receptor NN NN O
SF-1 NN NN O
in NN NN O
sex-specific NN NN O
gene NN NN O
expression NN NN O
. NN NN O

Products NN NN O
of NN NN O
steroidogenic NN NN O
factor NN NN O
1 NN NN O
( NN NN O
SF-1 NN NN O
) NN NN O
and NN NN O
Wilms NN NN B-Modifier
tumor NN NN I-Modifier
1 NN NN O
( NN NN O
WT1 NN NN O
) NN NN O
genes NN NN O
are NN NN O
essential NN NN O
for NN NN O
mammalian NN NN O
gonadogenesis NN NN O
prior NN NN O
to NN NN O
sexual NN NN O
differentiation NN NN O
. NN NN O

In NN NN O
males NN NN O
, NN NN O
SF-1 NN NN O
participates NN NN O
in NN NN O
sexual NN NN O
development NN NN O
by NN NN O
regulating NN NN O
expression NN NN O
of NN NN O
the NN NN O
polypeptide NN NN O
hormone NN NN O
Mullerian NN NN O
inhibiting NN NN O
substance NN NN O
( NN NN O
MIS NN NN O
) NN NN O
. NN NN O

Here NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
WT1 NN NN O
-KTS NN NN O
isoforms NN NN O
associate NN NN O
and NN NN O
synergize NN NN O
with NN NN O
SF-1 NN NN O
to NN NN O
promote NN NN O
MIS NN NN O
expression NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
WT1 NN NN O
missense NN NN O
mutations NN NN O
, NN NN O
associated NN NN O
with NN NN O
male NN NN B-SpecificDisease
pseudohermaphroditism NN NN I-SpecificDisease
in NN NN O
Denys-Drash NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
fail NN NN O
to NN NN O
synergize NN NN O
with NN NN O
SF-1 NN NN O
. NN NN O

Additionally NN NN O
, NN NN O
the NN NN O
X-linked NN NN O
, NN NN O
candidate NN NN O
dosage-sensitive NN NN O
sex-reversal NN NN O
gene NN NN O
, NN NN O
Dax-1 NN NN O
, NN NN O
antagonizes NN NN O
synergy NN NN O
between NN NN O
SF-1 NN NN O
and NN NN O
WT1 NN NN O
, NN NN O
most NN NN O
likely NN NN O
through NN NN O
a NN NN O
direct NN NN O
interaction NN NN O
with NN NN O
SF-1 NN NN O
. NN NN O

We NN NN O
propose NN NN O
that NN NN O
WT1 NN NN O
and NN NN O
Dax-1 NN NN O
functionally NN NN O
oppose NN NN O
each NN NN O
other NN NN O
in NN NN O
testis NN NN O
development NN NN O
by NN NN O
modulating NN NN O
SF-1-mediated NN NN O
transactivation NN NN O
. NN NN O

. NN NN O

9590284 NN NN O
A NN NN O
mouse NN NN O
model NN NN O
for NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
imprinting-centre NN NN O
mutations NN NN O
. NN NN O

Imprinting NN NN O
in NN NN O
the NN NN O
15q11-q13 NN NN O
region NN NN O
involves NN NN O
an NN NN O
imprinting NN NN O
centre NN NN O
( NN NN O
IC NN NN O
) NN NN O
, NN NN O
mapping NN NN O
in NN NN O
part NN NN O
to NN NN O
the NN NN O
promoter NN NN O
and NN NN O
first NN NN O
exon NN NN O
of NN NN O
SNRPN NN NN O
. NN NN O

Deletion NN NN O
of NN NN O
this NN NN O
IC NN NN O
abolishes NN NN O
local NN NN O
paternally NN NN O
derived NN NN O
gene NN NN O
expression NN NN O
and NN NN O
results NN NN O
in NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
. NN NN O

We NN NN O
have NN NN O
created NN NN O
two NN NN O
deletion NN NN O
mutations NN NN O
in NN NN O
mice NN NN O
to NN NN O
understand NN NN O
PWS NN NN B-SpecificDisease
and NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
this NN NN O
IC NN NN O
. NN NN O

Mice NN NN O
harbouring NN NN O
an NN NN O
intragenic NN NN O
deletion NN NN O
in NN NN O
Snrpn NN NN O
are NN NN O
phenotypically NN NN O
normal NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
mutations NN NN O
of NN NN O
SNRPN NN NN O
are NN NN O
not NN NN O
sufficient NN NN O
to NN NN O
induce NN NN O
PWS NN NN B-SpecificDisease
. NN NN O

Mice NN NN O
with NN NN O
a NN NN O
larger NN NN O
deletion NN NN O
involving NN NN O
both NN NN O
Snrpn NN NN O
and NN NN O
the NN NN O
putative NN NN O
PWS-IC NN NN O
lack NN NN O
expression NN NN O
of NN NN O
the NN NN O
imprinted NN NN O
genes NN NN O
Zfp127 NN NN O
( NN NN O
mouse NN NN O
homologue NN NN O
of NN NN O
ZNF127 NN NN O
) NN NN O
, NN NN O
Ndn NN NN O
and NN NN O
Ipw NN NN O
, NN NN O
and NN NN O
manifest NN NN O
several NN NN O
phenotypes NN NN O
common NN NN O
to NN NN O
PWS NN NN B-Modifier
infants NN NN O
. NN NN O

These NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
both NN NN O
the NN NN O
position NN NN O
of NN NN O
the NN NN O
IC NN NN O
and NN NN O
its NN NN O
role NN NN O
in NN NN O
the NN NN O
coordinate NN NN O
expression NN NN O
of NN NN O
genes NN NN O
is NN NN O
conserved NN NN O
between NN NN O
mouse NN NN O
and NN NN O
human NN NN O
, NN NN O
and NN NN O
indicate NN NN O
that NN NN O
the NN NN O
mouse NN NN O
is NN NN O
a NN NN O
suitable NN NN O
model NN NN O
system NN NN O
in NN NN O
which NN NN O
to NN NN O
investigate NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
of NN NN O
imprinting NN NN O
in NN NN O
this NN NN O
region NN NN O
of NN NN O
the NN NN O
genome NN NN O
. NN NN O

. NN NN O

9600235 NN NN O
Mutations NN NN O
of NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
detected NN NN O
in NN NN O
Japanese NN NN O
ataxia-telangiectasia NN NN B-Modifier
patients NN NN O
: NN NN O
possible NN NN O
preponderance NN NN O
of NN NN O
the NN NN O
two NN NN O
founder NN NN O
mutations NN NN O
4612del165 NN NN O
and NN NN O
7883del5 NN NN O
. NN NN O

The NN NN O
ATM NN NN O
( NN NN O
A-T NN NN O
, NN NN O
mutated NN NN O
) NN NN O
gene NN NN O
on NN NN O
human NN NN O
chromosome NN NN O
11q22 NN NN O
. NN NN O

3 NN NN O
has NN NN O
recently NN NN O
been NN NN O
identified NN NN O
as NN NN O
the NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
the NN NN O
human NN NN O
recessive NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
ataxia-telangiectasia NN NN B-SpecificDisease
( NN NN O
A-T NN NN B-SpecificDisease
) NN NN O
. NN NN O

In NN NN O
order NN NN O
to NN NN O
define NN NN O
the NN NN O
types NN NN O
of NN NN O
disease-causing NN NN O
ATM NN NN O
mutations NN NN O
in NN NN O
Japanese NN NN O
A-T NN NN B-Modifier
patients NN NN O
as NN NN O
well NN NN O
as NN NN O
to NN NN O
look NN NN O
for NN NN O
possible NN NN O
mutational NN NN O
hotspots NN NN O
, NN NN O
reverse-transcribed NN NN O
RNA NN NN O
derived NN NN O
from NN NN O
ten NN NN O
patients NN NN O
belonging NN NN O
to NN NN O
eight NN NN O
unrelated NN NN O
Japanese NN NN O
A-T NN NN B-Modifier
families NN NN O
was NN NN O
analyzed NN NN O
for NN NN O
mutations NN NN O
by NN NN O
the NN NN O
restriction NN NN O
endonuclease NN NN O
fingerprinting NN NN O
method NN NN O
. NN NN O

As NN NN O
has NN NN O
been NN NN O
reported NN NN O
by NN NN O
others NN NN O
, NN NN O
mutations NN NN O
that NN NN O
lead NN NN O
to NN NN O
exon NN NN O
skipping NN NN O
or NN NN O
premature NN NN O
protein NN NN O
truncation NN NN O
were NN NN O
also NN NN O
predominant NN NN O
in NN NN O
our NN NN O
mutants NN NN O
. NN NN O

Six NN NN O
different NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
on NN NN O
12 NN NN O
of NN NN O
the NN NN O
16 NN NN O
alleles NN NN O
examined NN NN O
. NN NN O

Four NN NN O
were NN NN O
deletions NN NN O
involving NN NN O
a NN NN O
loss NN NN O
of NN NN O
a NN NN O
single NN NN O
exon NN NN O
exon NN NN O
7 NN NN O
, NN NN O
exon NN NN O
16 NN NN O
, NN NN O
exon NN NN O
33 NN NN O
or NN NN O
exon NN NN O
35 NN NN O
. NN NN O

The NN NN O
others NN NN O
were NN NN O
minute NN NN O
deletions NN NN O
, NN NN O
4649delA NN NN O
in NN NN O
exon NN NN O
33 NN NN O
and NN NN O
7883del5 NN NN O
in NN NN O
exon NN NN O
55 NN NN O
. NN NN O

The NN NN O
mutations NN NN O
4612del165 NN NN O
and NN NN O
7883del5 NN NN O
were NN NN O
found NN NN O
in NN NN O
more NN NN O
than NN NN O
two NN NN O
unrelated NN NN O
families NN NN O
; NN NN O
44 NN NN O
% NN NN O
( NN NN O
7 NN NN O
of NN NN O
16 NN NN O
) NN NN O
of NN NN O
the NN NN O
mutant NN NN O
alleles NN NN O
had NN NN O
one NN NN O
of NN NN O
the NN NN O
two NN NN O
mutations NN NN O
. NN NN O

The NN NN O
4612del165 NN NN O
mutations NN NN O
in NN NN O
three NN NN O
different NN NN O
families NN NN O
were NN NN O
all NN NN O
ascribed NN NN O
to NN NN O
the NN NN O
same NN NN O
T NN NN O
-- NN NN O
A NN NN O
substitution NN NN O
at NN NN O
the NN NN O
splice NN NN O
donor NN NN O
site NN NN O
in NN NN O
intron NN NN O
33 NN NN O
. NN NN O

Microsatellite NN NN O
genotyping NN NN O
around NN NN O
the NN NN O
ATM NN NN O
locus NN NN O
also NN NN O
indicated NN NN O
that NN NN O
a NN NN O
common NN NN O
haplotype NN NN O
was NN NN O
shared NN NN O
by NN NN O
the NN NN O
mutant NN NN O
alleles NN NN O
in NN NN O
both NN NN O
mutations NN NN O
. NN NN O

This NN NN O
suggests NN NN O
that NN NN O
these NN NN O
two NN NN O
founder NN NN O
mutations NN NN O
may NN NN O
be NN NN O
predominant NN NN O
among NN NN O
Japanese NN NN O
ATM NN NN O
mutant NN NN O
alleles NN NN O
. NN NN O

9603435 NN NN O
W474C NN NN O
amino NN NN O
acid NN NN O
substitution NN NN O
affects NN NN O
early NN NN O
processing NN NN O
of NN NN O
the NN NN O
alpha-subunit NN NN O
of NN NN O
beta-hexosaminidase NN NN O
A NN NN O
and NN NN O
is NN NN O
associated NN NN O
with NN NN O
subacute NN NN O
G NN NN B-SpecificDisease
( NN NN I-SpecificDisease
M2 NN NN I-SpecificDisease
) NN NN I-SpecificDisease
gangliosidosis NN NN I-SpecificDisease
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
HEXA NN NN O
gene NN NN O
, NN NN O
encoding NN NN O
the NN NN O
alpha-subunit NN NN O
of NN NN O
beta-hexosaminidase NN NN O
A NN NN O
( NN NN O
Hex NN NN O
A NN NN O
) NN NN O
, NN NN O
that NN NN O
abolish NN NN O
Hex NN NN O
A NN NN O
enzyme NN NN O
activity NN NN O
cause NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
TSD NN NN B-SpecificDisease
) NN NN O
, NN NN O
the NN NN O
fatal NN NN O
infantile NN NN B-SpecificDisease
form NN NN I-SpecificDisease
of NN NN I-SpecificDisease
G NN NN I-SpecificDisease
( NN NN I-SpecificDisease
M2 NN NN I-SpecificDisease
) NN NN I-SpecificDisease
gangliosidosis NN NN I-SpecificDisease
, NN NN I-SpecificDisease
Type NN NN I-SpecificDisease
1 NN NN I-SpecificDisease
. NN NN O

Less NN NN O
severe NN NN O
, NN NN O
subacute NN NN O
( NN NN O
juvenile-onset NN NN O
) NN NN O
and NN NN O
chronic NN NN O
( NN NN O
adult-onset NN NN O
) NN NN O
variants NN NN O
are NN NN O
characterized NN NN O
by NN NN O
a NN NN O
broad NN NN O
spectrum NN NN O
of NN NN O
clinical NN NN O
manifestations NN NN O
and NN NN O
are NN NN O
associated NN NN O
with NN NN O
residual NN NN O
levels NN NN O
of NN NN O
Hex NN NN O
A NN NN O
enzyme NN NN O
activity NN NN O
. NN NN O

We NN NN O
identified NN NN O
a NN NN O
1422 NN NN O
G NN NN O
-- NN NN O
C NN NN O
( NN NN O
amino NN NN O
acid NN NN O
W474C NN NN O
) NN NN O
substitution NN NN O
in NN NN O
the NN NN O
first NN NN O
position NN NN O
of NN NN O
exon NN NN O
13 NN NN O
of NN NN O
HEXA NN NN O
of NN NN O
a NN NN O
non-Jewish NN NN O
proband NN NN O
who NN NN O
manifested NN NN O
a NN NN O
subacute NN NN O
variant NN NN O
of NN NN O
G NN NN B-SpecificDisease
( NN NN I-SpecificDisease
M2 NN NN I-SpecificDisease
) NN NN I-SpecificDisease
gangliosidosis NN NN I-SpecificDisease
. NN NN O

On NN NN O
the NN NN O
second NN NN O
maternally NN NN O
inherited NN NN O
allele NN NN O
, NN NN O
we NN NN O
identified NN NN O
the NN NN O
common NN NN O
infantile NN NN O
disease-causing NN NN O
4-bp NN NN O
insertion NN NN O
, NN NN O
+ NN NN O
TATC NN NN O
1278 NN NN O
, NN NN O
in NN NN O
exon NN NN O
11 NN NN O
. NN NN O

Pulse-chase NN NN O
analysis NN NN O
using NN NN O
proband NN NN O
fibroblasts NN NN O
revealed NN NN O
that NN NN O
the NN NN O
W474C-containing NN NN O
alpha-subunit NN NN O
precursor NN NN O
was NN NN O
normally NN NN O
synthesized NN NN O
, NN NN O
but NN NN O
not NN NN O
phosphorylated NN NN O
or NN NN O
secreted NN NN O
, NN NN O
and NN NN O
the NN NN O
mature NN NN O
lysosomal NN NN O
alpha-subunit NN NN O
was NN NN O
not NN NN O
detected NN NN O
. NN NN O

When NN NN O
the NN NN O
W474C-containing NN NN O
alpha-subunit NN NN O
was NN NN O
transiently NN NN O
co-expressed NN NN O
with NN NN O
the NN NN O
beta-subunit NN NN O
to NN NN O
produce NN NN O
Hex NN NN O
A NN NN O
( NN NN O
alphabeta NN NN O
) NN NN O
in NN NN O
COS-7 NN NN O
cells NN NN O
, NN NN O
the NN NN O
mature NN NN O
alpha-subunit NN NN O
was NN NN O
present NN NN O
, NN NN O
but NN NN O
its NN NN O
level NN NN O
was NN NN O
much NN NN O
lower NN NN O
than NN NN O
that NN NN O
from NN NN O
normal NN NN O
alpha-subunit NN NN O
transfections NN NN O
, NN NN O
although NN NN O
higher NN NN O
than NN NN O
in NN NN O
those NN NN O
cells NN NN O
transfected NN NN O
with NN NN O
an NN NN O
alpha-subunit NN NN O
associated NN NN O
with NN NN O
infantile NN NN O
TSD NN NN B-SpecificDisease
. NN NN O

Furthermore NN NN O
, NN NN O
the NN NN O
precursor NN NN O
level NN NN O
of NN NN O
the NN NN O
W474C NN NN O
alpha-subunit NN NN O
was NN NN O
found NN NN O
to NN NN O
accumulate NN NN O
in NN NN O
comparison NN NN O
to NN NN O
the NN NN O
normal NN NN O
alpha-subunit NN NN O
precursor NN NN O
levels NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
1422 NN NN O
G NN NN O
-- NN NN O
C NN NN O
mutation NN NN O
is NN NN O
the NN NN O
cause NN NN O
of NN NN O
Hex NN NN B-SpecificDisease
A NN NN I-SpecificDisease
enzyme NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
the NN NN O
proband NN NN O
. NN NN O

The NN NN O
resulting NN NN O
W474C NN NN O
substitution NN NN O
clearly NN NN O
interferes NN NN O
with NN NN O
alpha-subunit NN NN O
processing NN NN O
, NN NN O
but NN NN O
because NN NN O
the NN NN O
base NN NN O
substitution NN NN O
falls NN NN O
at NN NN O
the NN NN O
first NN NN O
position NN NN O
of NN NN O
exon NN NN O
13 NN NN O
, NN NN O
aberrant NN NN O
splicing NN NN O
may NN NN O
also NN NN O
contribute NN NN O
to NN NN O
Hex NN NN B-SpecificDisease
A NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
this NN NN O
proband NN NN O
. NN NN O

. NN NN O

9618166 NN NN O
Two NN NN O
frequent NN NN O
missense NN NN O
mutations NN NN O
in NN NN O
Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
early NN NN O
childhood NN NN O
deafness NN NN B-SpecificDisease
and NN NN O
goiter NN NN B-SpecificDisease
. NN NN O

A NN NN O
century NN NN O
after NN NN O
its NN NN O
recognition NN NN O
as NN NN O
a NN NN O
syndrome NN NN O
by NN NN O
Vaughan NN NN O
Pendred NN NN O
, NN NN O
the NN NN O
disease NN NN O
gene NN NN O
( NN NN O
PDS NN NN O
) NN NN O
was NN NN O
mapped NN NN O
to NN NN O
chromosome NN NN O
7q22-q31 NN NN O
. NN NN O

1 NN NN O
and NN NN O
, NN NN O
recently NN NN O
, NN NN O
found NN NN O
to NN NN O
encode NN NN O
a NN NN O
putative NN NN O
sulfate NN NN O
transporter NN NN O
. NN NN O

We NN NN O
performed NN NN O
mutation NN NN O
analysis NN NN O
of NN NN O
the NN NN O
PDS NN NN B-Modifier
gene NN NN O
in NN NN O
patients NN NN O
from NN NN O
14 NN NN O
Pendred NN NN B-Modifier
families NN NN O
originating NN NN O
from NN NN O
seven NN NN O
countries NN NN O
and NN NN O
identified NN NN O
all NN NN O
mutations NN NN O
. NN NN O

The NN NN O
mutations NN NN O
include NN NN O
three NN NN O
single NN NN O
base NN NN O
deletions NN NN O
, NN NN O
one NN NN O
splice NN NN O
site NN NN O
mutation NN NN O
and NN NN O
10 NN NN O
missense NN NN O
mutations NN NN O
. NN NN O

One NN NN O
missense NN NN O
mutation NN NN O
( NN NN O
L236P NN NN O
) NN NN O
was NN NN O
found NN NN O
in NN NN O
a NN NN O
homozygous NN NN O
state NN NN O
in NN NN O
two NN NN O
consanguineous NN NN O
families NN NN O
and NN NN O
in NN NN O
a NN NN O
heterozygous NN NN O
state NN NN O
in NN NN O
five NN NN O
additional NN NN O
non-consanguineous NN NN O
families NN NN O
. NN NN O

Another NN NN O
missense NN NN O
mutation NN NN O
( NN NN O
T416P NN NN O
) NN NN O
was NN NN O
found NN NN O
in NN NN O
a NN NN O
homozygous NN NN O
state NN NN O
in NN NN O
one NN NN O
family NN NN O
and NN NN O
in NN NN O
a NN NN O
heterozygous NN NN O
state NN NN O
in NN NN O
four NN NN O
families NN NN O
. NN NN O

Pendred NN NN B-Modifier
patients NN NN O
in NN NN O
three NN NN O
non-consanguineous NN NN O
families NN NN O
were NN NN O
shown NN NN O
to NN NN O
be NN NN O
compound NN NN O
heterozygotes NN NN O
for NN NN O
L236P NN NN O
and NN NN O
T416P NN NN O
. NN NN O

In NN NN O
total NN NN O
, NN NN O
one NN NN O
or NN NN O
both NN NN O
of NN NN O
these NN NN O
mutations NN NN O
were NN NN O
found NN NN O
in NN NN O
nine NN NN O
of NN NN O
the NN NN O
14 NN NN O
families NN NN O
analyzed NN NN O
. NN NN O

The NN NN O
identification NN NN O
of NN NN O
two NN NN O
frequent NN NN O
PDS NN NN B-Modifier
mutations NN NN O
will NN NN O
facilitate NN NN O
the NN NN O
molecular NN NN O
diagnosis NN NN O
of NN NN O
Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

9618170 NN NN O
Insertional NN NN O
mutation NN NN O
by NN NN O
transposable NN NN O
element NN NN O
, NN NN O
L1 NN NN O
, NN NN O
in NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
results NN NN O
in NN NN O
X-linked NN NN B-SpecificDisease
dilated NN NN I-SpecificDisease
cardiomyopathy NN NN I-SpecificDisease
. NN NN O

X-linked NN NN B-SpecificDisease
dilated NN NN I-SpecificDisease
cardiomyopathy NN NN I-SpecificDisease
( NN NN O
XLDCM NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
clinical NN NN O
phenotype NN NN O
of NN NN O
dystrophinopathy NN NN B-DiseaseClass
which NN NN O
is NN NN O
characterized NN NN O
by NN NN O
preferential NN NN O
myocardial NN NN B-DiseaseClass
involvement NN NN I-DiseaseClass
without NN NN O
any NN NN O
overt NN NN O
clinical NN NN O
signs NN NN O
of NN NN O
skeletal NN NN B-SpecificDisease
myopathy NN NN I-SpecificDisease
. NN NN O

To NN NN O
date NN NN O
, NN NN O
several NN NN O
mutations NN NN O
in NN NN O
the NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
gene NN NN O
, NN NN O
DMD NN NN O
, NN NN O
have NN NN O
been NN NN O
identified NN NN O
in NN NN O
patients NN NN O
with NN NN O
XLDCM NN NN B-SpecificDisease
, NN NN O
but NN NN O
a NN NN O
pathogenic NN NN O
correlation NN NN O
of NN NN O
these NN NN O
cardiospecific NN NN O
mutations NN NN O
in NN NN O
DMD NN NN O
with NN NN O
the NN NN O
XLDCM NN NN B-Modifier
phenotype NN NN O
has NN NN O
remained NN NN O
to NN NN O
be NN NN O
elucidated NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
the NN NN O
identification NN NN O
of NN NN O
a NN NN O
unique NN NN O
de NN NN O
novo NN NN O
L1 NN NN O
insertion NN NN O
in NN NN O
the NN NN O
muscle NN NN O
exon NN NN O
1 NN NN O
in NN NN O
DMD NN NN O
in NN NN O
three NN NN O
XLDCM NN NN B-Modifier
patients NN NN O
from NN NN O
two NN NN O
unrelated NN NN O
Japanese NN NN O
families NN NN O
. NN NN O

The NN NN O
insertion NN NN O
was NN NN O
a NN NN O
5-truncated NN NN O
form NN NN O
of NN NN O
human NN NN O
L1 NN NN O
inversely NN NN O
integrated NN NN O
in NN NN O
the NN NN O
5-untranslated NN NN O
region NN NN O
in NN NN O
the NN NN O
muscle NN NN O
exon NN NN O
1 NN NN O
, NN NN O
which NN NN O
affected NN NN O
the NN NN O
transcription NN NN O
or NN NN O
the NN NN O
stability NN NN O
of NN NN O
the NN NN O
muscle NN NN O
form NN NN O
of NN NN O
dystrophin NN NN O
transcripts NN NN O
but NN NN O
not NN NN O
that NN NN O
of NN NN O
the NN NN O
brain NN NN O
or NN NN O
Purkinje NN NN O
cell NN NN O
form NN NN O
, NN NN O
probably NN NN O
due NN NN O
to NN NN O
its NN NN O
unique NN NN O
site NN NN O
of NN NN O
integration NN NN O
. NN NN O

We NN NN O
speculate NN NN O
that NN NN O
this NN NN O
insertion NN NN O
of NN NN O
an NN NN O
L1 NN NN O
sequence NN NN O
in NN NN O
DMD NN NN O
is NN NN O
responsible NN NN O
for NN NN O
some NN NN O
of NN NN O
the NN NN O
population NN NN O
of NN NN O
Japanese NN NN O
patients NN NN O
with NN NN O
XLDCM NN NN B-SpecificDisease
. NN NN O

. NN NN O

9620771 NN NN O
Severe NN NN O
early-onset NN NN O
obesity NN NN B-SpecificDisease
, NN NN O
adrenal NN NN B-DiseaseClass
insufficiency NN NN I-DiseaseClass
and NN NN O
red NN NN O
hair NN NN O
pigmentation NN NN O
caused NN NN O
by NN NN O
POMC NN NN O
mutations NN NN O
in NN NN O
humans NN NN O
. NN NN O

Sequential NN NN O
cleavage NN NN O
of NN NN O
the NN NN O
precursor NN NN O
protein NN NN O
pre-pro-opiomelanocortin NN NN O
( NN NN O
POMC NN NN O
) NN NN O
generates NN NN O
the NN NN O
melanocortin NN NN O
peptides NN NN O
adrenocorticotrophin NN NN O
( NN NN O
ACTH NN NN O
) NN NN O
, NN NN O
melanocyte-stimulating NN NN O
hormones NN NN O
( NN NN O
MSH NN NN O
) NN NN O
alpha NN NN O
, NN NN O
beta NN NN O
and NN NN O
gamma NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
opioid-receptor NN NN O
ligand NN NN O
beta-endorphin NN NN O
. NN NN O

While NN NN O
a NN NN O
few NN NN O
cases NN NN O
of NN NN O
isolated NN NN O
ACTH NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
have NN NN O
been NN NN O
reported NN NN O
( NN NN O
OMIM NN NN O
201400 NN NN O
) NN NN O
, NN NN O
an NN NN O
inherited NN NN O
POMC NN NN O
defect NN NN O
has NN NN O
not NN NN O
been NN NN O
described NN NN O
so NN NN O
far NN NN O
. NN NN O

Recent NN NN O
studies NN NN O
in NN NN O
animal NN NN O
models NN NN O
elucidated NN NN O
a NN NN O
central NN NN O
role NN NN O
of NN NN O
alpha-MSH NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
food NN NN O
intake NN NN O
by NN NN O
activation NN NN O
of NN NN O
the NN NN O
brain NN NN O
melanocortin-4-receptor NN NN O
( NN NN O
MC4-R NN NN O
; NN NN O
refs NN NN O
3-5 NN NN O
) NN NN O
and NN NN O
the NN NN O
linkage NN NN O
of NN NN O
human NN NN O
obesity NN NN B-SpecificDisease
to NN NN O
chromosome NN NN O
2 NN NN O
in NN NN O
close NN NN O
proximity NN NN O
to NN NN O
the NN NN O
POMC NN NN O
locus NN NN O
, NN NN O
led NN NN O
to NN NN O
the NN NN O
proposal NN NN O
of NN NN O
an NN NN O
association NN NN O
of NN NN O
POMC NN NN O
with NN NN O
human NN NN O
obesity NN NN B-SpecificDisease
. NN NN O

The NN NN O
dual NN NN O
role NN NN O
of NN NN O
alpha-MSH NN NN O
in NN NN O
regulating NN NN O
food NN NN O
intake NN NN O
and NN NN O
influencing NN NN O
hair NN NN O
pigmentation NN NN O
predicts NN NN O
that NN NN O
the NN NN O
phenotype NN NN O
associated NN NN O
with NN NN O
a NN NN O
defect NN NN O
in NN NN O
POMC NN NN O
function NN NN O
would NN NN O
include NN NN O
obesity NN NN B-SpecificDisease
, NN NN O
alteration NN NN O
in NN NN O
pigmentation NN NN O
and NN NN O
ACTH NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

The NN NN O
observation NN NN O
of NN NN O
these NN NN O
symptoms NN NN O
in NN NN O
two NN NN O
probands NN NN O
prompted NN NN O
us NN NN O
to NN NN O
search NN NN O
for NN NN O
mutations NN NN O
within NN NN O
their NN NN O
POMC NN NN O
genes NN NN O
. NN NN O

Patient NN NN O
1 NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
a NN NN O
compound NN NN O
heterozygote NN NN O
for NN NN O
two NN NN O
mutations NN NN O
in NN NN O
exon NN NN O
3 NN NN O
( NN NN O
G7013T NN NN O
, NN NN O
C7133delta NN NN O
) NN NN O
which NN NN O
interfere NN NN O
with NN NN O
appropriate NN NN O
synthesis NN NN O
of NN NN O
ACTH NN NN O
and NN NN O
alpha-MSH NN NN O
. NN NN O

Patient NN NN O
2 NN NN O
was NN NN O
homozygous NN NN O
for NN NN O
a NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
2 NN NN O
( NN NN O
C3804A NN NN O
) NN NN O
which NN NN O
abolishes NN NN O
POMC NN NN O
translation NN NN O
. NN NN O

These NN NN O
findings NN NN O
represent NN NN O
the NN NN O
first NN NN O
examples NN NN O
of NN NN O
a NN NN O
genetic NN NN B-DiseaseClass
defect NN NN I-DiseaseClass
within NN NN O
the NN NN O
POMC NN NN O
gene NN NN O
and NN NN O
define NN NN O
a NN NN O
new NN NN O
monogenic NN NN B-DiseaseClass
endocrine NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
resulting NN NN O
in NN NN O
early-onset NN NN O
obesity NN NN B-SpecificDisease
, NN NN O
adrenal NN NN B-DiseaseClass
insufficiency NN NN I-DiseaseClass
and NN NN O
red NN NN O
hair NN NN O
pigmentation NN NN O
. NN NN O

. NN NN O

9634518 NN NN O
A NN NN O
European NN NN O
multicenter NN NN O
study NN NN O
of NN NN O
phenylalanine NN NN B-SpecificDisease
hydroxylase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
: NN NN O
classification NN NN O
of NN NN O
105 NN NN O
mutations NN NN O
and NN NN O
a NN NN O
general NN NN O
system NN NN O
for NN NN O
genotype-based NN NN O
prediction NN NN O
of NN NN O
metabolic NN NN O
phenotype NN NN O
. NN NN O

Phenylketonuria NN NN B-SpecificDisease
( NN NN O
PKU NN NN B-SpecificDisease
) NN NN O
and NN NN O
mild NN NN B-SpecificDisease
hyperphenylalaninemia NN NN I-SpecificDisease
( NN NN O
MHP NN NN B-SpecificDisease
) NN NN O
are NN NN O
allelic NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
( NN NN O
PAH NN NN O
) NN NN O
. NN NN O

Previous NN NN O
studies NN NN O
have NN NN O
suggested NN NN O
that NN NN O
the NN NN O
highly NN NN O
variable NN NN O
metabolic NN NN O
phenotypes NN NN O
of NN NN O
PAH NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
correlate NN NN O
with NN NN O
PAH NN NN O
genotypes NN NN O
. NN NN O

We NN NN O
identified NN NN O
both NN NN O
causative NN NN O
mutations NN NN O
in NN NN O
686 NN NN O
patients NN NN O
from NN NN O
seven NN NN O
European NN NN O
centers NN NN O
. NN NN O

On NN NN O
the NN NN O
basis NN NN O
of NN NN O
the NN NN O
phenotypic NN NN O
characteristics NN NN O
of NN NN O
297 NN NN O
functionally NN NN O
hemizygous NN NN O
patients NN NN O
, NN NN O
105 NN NN O
of NN NN O
the NN NN O
mutations NN NN O
were NN NN O
assigned NN NN O
to NN NN O
one NN NN O
of NN NN O
four NN NN O
arbitrary NN NN O
phenotype NN NN O
categories NN NN O
. NN NN O

We NN NN O
proposed NN NN O
and NN NN O
tested NN NN O
a NN NN O
simple NN NN O
model NN NN O
for NN NN O
correlation NN NN O
between NN NN O
genotype NN NN O
and NN NN O
phenotypic NN NN O
outcome NN NN O
. NN NN O

The NN NN O
observed NN NN O
phenotype NN NN O
matched NN NN O
the NN NN O
predicted NN NN O
phenotype NN NN O
in NN NN O
79 NN NN O
% NN NN O
of NN NN O
the NN NN O
cases NN NN O
, NN NN O
and NN NN O
in NN NN O
only NN NN O
5 NN NN O
of NN NN O
184 NN NN O
patients NN NN O
was NN NN O
the NN NN O
observed NN NN O
phenotype NN NN O
more NN NN O
than NN NN O
one NN NN O
category NN NN O
away NN NN O
from NN NN O
that NN NN O
expected NN NN O
. NN NN O

Among NN NN O
the NN NN O
seven NN NN O
contributing NN NN O
centers NN NN O
, NN NN O
the NN NN O
proportion NN NN O
of NN NN O
patients NN NN O
for NN NN O
whom NN NN O
the NN NN O
observed NN NN O
phenotype NN NN O
did NN NN O
not NN NN O
match NN NN O
the NN NN O
predicted NN NN O
phenotype NN NN O
was NN NN O
4 NN NN O
% NN NN O
-23 NN NN O
% NN NN O
( NN NN O
P NN NN O
. NN NN O

0001 NN NN O
) NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
differences NN NN O
in NN NN O
methods NN NN O
used NN NN O
for NN NN O
mutation NN NN O
detection NN NN O
or NN NN O
phenotype NN NN O
classification NN NN O
may NN NN O
account NN NN O
for NN NN O
a NN NN O
considerable NN NN O
proportion NN NN O
of NN NN O
genotype-phenotype NN NN O
inconsistencies NN NN O
. NN NN O

Our NN NN O
data NN NN O
indicate NN NN O
that NN NN O
the NN NN O
PAH-mutation NN NN O
genotype NN NN O
is NN NN O
the NN NN O
main NN NN O
determinant NN NN O
of NN NN O
metabolic NN NN O
phenotype NN NN O
in NN NN O
most NN NN O
patients NN NN O
with NN NN O
PAH NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
the NN NN O
classification NN NN O
of NN NN O
105 NN NN O
PAH NN NN O
mutations NN NN O
may NN NN O
allow NN NN O
the NN NN O
prediction NN NN O
of NN NN O
the NN NN O
biochemical NN NN O
phenotype NN NN O
in NN NN O
10 NN NN O
, NN NN O
000 NN NN O
genotypes NN NN O
, NN NN O
which NN NN O
may NN NN O
be NN NN O
useful NN NN O
for NN NN O
the NN NN O
management NN NN O
of NN NN O
hyperphenylalaninemia NN NN B-SpecificDisease
in NN NN O
newborns NN NN O
. NN NN O

9668171 NN NN O
Somatic NN NN O
instability NN NN O
of NN NN O
the NN NN O
CTG NN NN O
repeat NN NN O
in NN NN O
mice NN NN O
transgenic NN NN O
for NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
region NN NN O
is NN NN O
age NN NN O
dependent NN NN O
but NN NN O
not NN NN O
correlated NN NN O
to NN NN O
the NN NN O
relative NN NN O
intertissue NN NN O
transcription NN NN O
levels NN NN O
and NN NN O
proliferative NN NN O
capacities NN NN O
. NN NN O

A NN NN O
( NN NN O
CTG NN NN O
) NN NN O
nexpansion NN NN O
in NN NN O
the NN NN O
3-untranslated NN NN O
region NN NN O
( NN NN O
UTR NN NN O
) NN NN O
of NN NN O
the NN NN O
DM NN NN O
protein NN NN O
kinase NN NN O
gene NN NN O
( NN NN O
DMPK NN NN O
) NN NN O
is NN NN O
responsible NN NN O
for NN NN O
causing NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
. NN NN O

Major NN NN O
instability NN NN O
, NN NN O
with NN NN O
very NN NN O
large NN NN O
expansions NN NN O
between NN NN O
generations NN NN O
and NN NN O
high NN NN O
levels NN NN O
of NN NN O
somatic NN NN O
mosaicism NN NN O
, NN NN O
is NN NN O
observed NN NN O
in NN NN O
patients NN NN O
. NN NN O

There NN NN O
is NN NN O
a NN NN O
good NN NN O
correlation NN NN O
between NN NN O
repeat NN NN O
size NN NN O
( NN NN O
at NN NN O
least NN NN O
in NN NN O
leucocytes NN NN O
) NN NN O
, NN NN O
clinical NN NN O
severity NN NN O
and NN NN O
age NN NN O
of NN NN O
onset NN NN O
. NN NN O

The NN NN O
trinucleotide NN NN O
repeat NN NN O
instability NN NN O
mechanisms NN NN O
involved NN NN O
in NN NN O
DM NN NN B-SpecificDisease
and NN NN O
other NN NN O
human NN NN O
genetic NN NN B-DiseaseClass
diseases NN NN I-DiseaseClass
are NN NN O
unknown NN NN O
. NN NN O

We NN NN O
studied NN NN O
somatic NN NN O
instability NN NN O
by NN NN O
measuring NN NN O
the NN NN O
CTG NN NN O
repeat NN NN O
length NN NN O
at NN NN O
several NN NN O
ages NN NN O
in NN NN O
various NN NN O
tissues NN NN O
of NN NN O
transgenic NN NN O
mice NN NN O
carrying NN NN O
a NN NN O
( NN NN O
CTG NN NN O
) NN NN O
55expansion NN NN O
surrounded NN NN O
by NN NN O
45 NN NN O
kb NN NN O
of NN NN O
the NN NN O
human NN NN O
DM NN NN B-Modifier
region NN NN O
, NN NN O
using NN NN O
small-pool NN NN O
PCR NN NN O
. NN NN O

These NN NN O
mice NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
reproduce NN NN O
the NN NN O
intergenerational NN NN O
and NN NN O
somatic NN NN O
instability NN NN O
of NN NN O
the NN NN O
55 NN NN O
CTG NN NN O
repeat NN NN O
suggesting NN NN O
that NN NN O
surrounding NN NN O
sequences NN NN O
and NN NN O
the NN NN O
chromatin NN NN O
environment NN NN O
are NN NN O
involved NN NN O
in NN NN O
instability NN NN O
mechanisms NN NN O
. NN NN O

As NN NN O
observed NN NN O
in NN NN O
some NN NN O
of NN NN O
the NN NN O
tissues NN NN O
of NN NN O
DM NN NN B-Modifier
patients NN NN O
, NN NN O
there NN NN O
is NN NN O
a NN NN O
tendency NN NN O
for NN NN O
repeat NN NN O
length NN NN O
and NN NN O
somatic NN NN O
mosaicism NN NN O
to NN NN O
increase NN NN O
with NN NN O
the NN NN O
age NN NN O
of NN NN O
the NN NN O
mouse NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
we NN NN O
observed NN NN O
no NN NN O
correlation NN NN O
between NN NN O
the NN NN O
somatic NN NN O
mutation NN NN O
rate NN NN O
and NN NN O
tissue NN NN O
proliferation NN NN O
capacity NN NN O
. NN NN O

The NN NN O
somatic NN NN O
mutation NN NN O
rates NN NN O
in NN NN O
different NN NN O
tissues NN NN O
were NN NN O
also NN NN O
not NN NN O
correlated NN NN O
to NN NN O
the NN NN O
relative NN NN O
inter-tissue NN NN O
difference NN NN O
in NN NN O
transcriptional NN NN O
levels NN NN O
of NN NN O
the NN NN O
three NN NN O
genes NN NN O
( NN NN O
DMAHP NN NN O
, NN NN O
DMPK NN NN O
and NN NN O
59 NN NN O
) NN NN O
surrounding NN NN O
the NN NN O
repeat NN NN O
. NN NN O

. NN NN O

9671401 NN NN O
A NN NN O
novel NN NN O
missense NN NN O
mutation NN NN O
in NN NN O
patients NN NN O
from NN NN O
a NN NN O
retinoblastoma NN NN B-Modifier
pedigree NN NN O
showing NN NN O
only NN NN O
mild NN NN O
expression NN NN O
of NN NN O
the NN NN O
tumor NN NN B-Modifier
phenotype NN NN O
. NN NN O

We NN NN O
have NN NN O
used NN NN O
single NN NN O
strand NN NN O
conformation NN NN O
polymorphism NN NN O
analysis NN NN O
to NN NN O
study NN NN O
the NN NN O
27 NN NN O
exons NN NN O
of NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
in NN NN O
individuals NN NN O
from NN NN O
a NN NN O
family NN NN O
showing NN NN O
mild NN NN O
expression NN NN O
of NN NN O
the NN NN O
retinoblastoma NN NN B-Modifier
phenotype NN NN O
. NN NN O

In NN NN O
this NN NN O
family NN NN O
affected NN NN O
individuals NN NN O
developed NN NN O
unilateral NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
and NN NN O
, NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
linkage NN NN O
analysis NN NN O
, NN NN O
unaffected NN NN O
mutation NN NN O
carriers NN NN O
were NN NN O
also NN NN O
identified NN NN O
within NN NN O
the NN NN O
pedigree NN NN O
. NN NN O

A NN NN O
single NN NN O
band NN NN O
shift NN NN O
using NN NN O
SSCP NN NN O
was NN NN O
identified NN NN O
in NN NN O
exon NN NN O
21 NN NN O
which NN NN O
resulted NN NN O
in NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
converting NN NN O
a NN NN O
cys NN NN O
-- NN NN O
arg NN NN O
at NN NN O
nucleotide NN NN O
position NN NN O
28 NN NN O
in NN NN O
the NN NN O
exon NN NN O
. NN NN O

The NN NN O
mutation NN NN O
destroyed NN NN O
an NN NN O
NdeI NN NN O
restriction NN NN O
enzyme NN NN O
site NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
all NN NN O
family NN NN O
members NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
missense NN NN O
mutation NN NN O
co-segregated NN NN O
with NN NN O
patients NN NN O
with NN NN O
tumors NN NN B-DiseaseClass
or NN NN O
who NN NN O
, NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
linkage NN NN O
analysis NN NN O
had NN NN O
been NN NN O
predicted NN NN O
to NN NN O
carry NN NN O
the NN NN O
predisposing NN NN O
mutation NN NN O
. NN NN O

These NN NN O
observations NN NN O
point NN NN O
to NN NN O
another NN NN O
region NN NN O
of NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
where NN NN O
mutations NN NN O
only NN NN O
modify NN NN O
the NN NN O
function NN NN O
of NN NN O
the NN NN O
gene NN NN O
and NN NN O
raise NN NN O
important NN NN O
questions NN NN O
for NN NN O
genetic NN NN O
counseling NN NN O
in NN NN O
families NN NN O
with NN NN O
these NN NN O
distinctive NN NN O
phenotypes NN NN O
. NN NN O

. NN NN O

9674903 NN NN O
Maternal NN NN B-DiseaseClass
disomy NN NN I-DiseaseClass
and NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
consistent NN NN O
with NN NN O
gamete NN NN O
complementation NN NN O
in NN NN O
a NN NN O
case NN NN O
of NN NN O
familial NN NN O
translocation NN NN O
( NN NN O
3 NN NN O
; NN NN O
15 NN NN O
) NN NN O
( NN NN O
p25 NN NN O
; NN NN O
q11.2 NN NN O
) NN NN O
. NN NN O

Maternal NN NN B-SpecificDisease
uniparental NN NN I-SpecificDisease
disomy NN NN I-SpecificDisease
( NN NN I-SpecificDisease
UPD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
for NN NN I-SpecificDisease
chromosome NN NN I-SpecificDisease
15 NN NN I-SpecificDisease
is NN NN O
responsible NN NN O
for NN NN O
an NN NN O
estimated NN NN O
30 NN NN O
% NN NN O
of NN NN O
cases NN NN O
of NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
. NN NN O

We NN NN O
report NN NN O
on NN NN O
an NN NN O
unusual NN NN O
case NN NN O
of NN NN O
maternal NN NN B-SpecificDisease
disomy NN NN I-SpecificDisease
15 NN NN I-SpecificDisease
in NN NN O
PWS NN NN B-SpecificDisease
that NN NN O
is NN NN O
most NN NN O
consistent NN NN O
with NN NN O
adjacent-1 NN NN O
segregation NN NN O
of NN NN O
a NN NN O
paternal NN NN O
t NN NN O
( NN NN O
3 NN NN O
; NN NN O
15 NN NN O
) NN NN O
( NN NN O
p25 NN NN O
; NN NN O
q11 NN NN O
. NN NN O

2 NN NN O
) NN NN O
with NN NN O
simultaneous NN NN O
maternal NN NN O
meiotic NN NN O
nondisjunction NN NN O
for NN NN O
chromosome NN NN O
15 NN NN O
. NN NN O

The NN NN O
patient NN NN O
( NN NN O
J NN NN O
. NN NN O

B NN NN O
. NN NN O
) NN NN O

, NN NN O
a NN NN O
17-year-old NN NN O
white NN NN O
male NN NN O
with NN NN O
PWS NN NN B-SpecificDisease
, NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
47 NN NN O
chromosomes NN NN O
with NN NN O
a NN NN O
supernumerary NN NN O
, NN NN O
paternal NN NN O
der NN NN O
( NN NN O
15 NN NN O
) NN NN O
consisting NN NN O
of NN NN O
the NN NN O
short NN NN O
arm NN NN O
and NN NN O
the NN NN O
proximal NN NN O
long NN NN O
arm NN NN O
of NN NN O
chromosome NN NN O
15 NN NN O
, NN NN O
and NN NN O
distal NN NN O
chromosome NN NN O
arm NN NN O
3p NN NN O
. NN NN O

The NN NN O
t NN NN O
( NN NN O
3 NN NN O
; NN NN O
15 NN NN O
) NN NN O
was NN NN O
present NN NN O
in NN NN O
the NN NN O
balanced NN NN O
state NN NN O
in NN NN O
the NN NN O
patients NN NN O
father NN NN O
and NN NN O
a NN NN O
sister NN NN O
. NN NN O

Fluorescent NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
analysis NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
PWS NN NN B-Modifier
critical NN NN O
region NN NN O
resided NN NN O
on NN NN O
the NN NN O
derivative NN NN O
chromosome NN NN O
3 NN NN O
and NN NN O
that NN NN O
there NN NN O
was NN NN O
no NN NN O
deletion NN NN O
of NN NN O
the NN NN O
PWS NN NN B-Modifier
region NN NN O
on NN NN O
the NN NN O
normal NN NN O
pair NN NN O
of NN NN O
15s NN NN O
present NN NN O
in NN NN O
J NN NN O
. NN NN O

B NN NN O
. NN NN O

Methylation NN NN O
analysis NN NN O
at NN NN O
exon NN NN O
alpha NN NN O
of NN NN O
the NN NN O
small NN NN O
nuclear NN NN O
ribonucleoprotein-associated NN NN O
polypeptide NN NN O
N NN NN O
( NN NN O
SNRPN NN NN O
) NN NN O
gene NN NN O
showed NN NN O
a NN NN O
pattern NN NN O
characteristic NN NN O
of NN NN O
only NN NN O
the NN NN O
maternal NN NN O
chromosome NN NN O
15 NN NN O
in NN NN O
J NN NN O
. NN NN O

B NN NN O
. NN NN O

Maternal NN NN B-DiseaseClass
disomy NN NN I-DiseaseClass
was NN NN O
confirmed NN NN O
by NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
analysis NN NN O
of NN NN O
microsatellite NN NN O
repeats NN NN O
at NN NN O
the NN NN O
gamma-aminobutyric NN NN O
acid NN NN O
receptor NN NN O
beta3 NN NN O
subunit NN NN O
( NN NN O
GABRB3 NN NN O
) NN NN O
locus NN NN O
. NN NN O

A NN NN O
niece NN NN O
( NN NN O
B NN NN O
. NN NN O

B NN NN O
. NN NN O
) NN NN O

with NN NN O
45 NN NN O
chromosomes NN NN O
and NN NN O
the NN NN O
derivative NN NN O
3 NN NN O
but NN NN O
without NN NN O
the NN NN O
der NN NN O
( NN NN O
15 NN NN O
) NN NN O
demonstrated NN NN O
a NN NN O
phenotype NN NN O
consistent NN NN O
with NN NN O
that NN NN O
reported NN NN O
for NN NN O
haploinsufficiency NN NN O
of NN NN O
distal NN NN O
3 NN NN O
p NN NN O
. NN NN O

Uniparental NN NN B-DiseaseClass
disomy NN NN I-DiseaseClass
associated NN NN O
with NN NN O
unbalanced NN NN O
segregation NN NN O
of NN NN O
non-Robertsonian NN NN O
translocations NN NN O
has NN NN O
been NN NN O
reported NN NN O
previously NN NN O
but NN NN O
has NN NN O
not NN NN O
, NN NN O
to NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
been NN NN O
observed NN NN O
in NN NN O
a NN NN O
case NN NN O
of NN NN O
PWS NN NN B-SpecificDisease
. NN NN O

Furthermore NN NN O
, NN NN O
our NN NN O
findings NN NN O
are NN NN O
best NN NN O
interpreted NN NN O
as NN NN O
true NN NN O
gamete NN NN O
complementation NN NN O
resulting NN NN O
in NN NN O
maternal NN NN B-SpecificDisease
UPD NN NN I-SpecificDisease
15 NN NN I-SpecificDisease
and NN NN O
PWS NN NN B-SpecificDisease

9674906 NN NN O
Schwartz-Jampel NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
type NN NN I-SpecificDisease
2 NN NN I-SpecificDisease
and NN NN O
Stuve-Wiedemann NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
: NN NN O
a NN NN O
case NN NN O
for NN NN O
`` NN NN O
lumping NN NN O
'' NN NN O
. NN NN O

Recent NN NN O
studies NN NN O
demonstrated NN NN O
the NN NN O
existence NN NN O
of NN NN O
a NN NN O
genetically NN NN O
distinct NN NN O
, NN NN O
usually NN NN O
lethal NN NN O
form NN NN O
of NN NN O
the NN NN O
Schwartz-Jampel NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
SJS NN NN B-SpecificDisease
) NN NN O
of NN NN O
myotonia NN NN B-SpecificDisease
and NN NN O
skeletal NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
, NN NN O
which NN NN O
we NN NN O
called NN NN O
SJS NN NN B-SpecificDisease
type NN NN I-SpecificDisease
2 NN NN I-SpecificDisease
. NN NN O

This NN NN O
disorder NN NN O
is NN NN O
reminiscent NN NN O
of NN NN O
another NN NN O
rare NN NN O
condition NN NN O
, NN NN O
the NN NN O
Stuve-Wiedemann NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
SWS NN NN B-SpecificDisease
) NN NN O
, NN NN O
which NN NN O
comprises NN NN O
campomelia NN NN B-SpecificDisease
at NN NN O
birth NN NN O
with NN NN O
skeletal NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
, NN NN O
contractures NN NN B-SpecificDisease
, NN NN O
and NN NN O
early NN NN B-SpecificDisease
death NN NN I-SpecificDisease
. NN NN O

To NN NN O
test NN NN O
for NN NN O
possible NN NN O
nosologic NN NN O
identity NN NN O
between NN NN O
these NN NN O
disorders NN NN O
, NN NN O
we NN NN O
reviewed NN NN O
the NN NN O
literature NN NN O
and NN NN O
obtained NN NN O
a NN NN O
follow-up NN NN O
of NN NN O
the NN NN O
only NN NN O
two NN NN O
surviving NN NN O
patients NN NN O
, NN NN O
one NN NN O
with NN NN O
SJS NN NN B-SpecificDisease
type NN NN I-SpecificDisease
2 NN NN I-SpecificDisease
at NN NN O
age NN NN O
10 NN NN O
years NN NN O
and NN NN O
another NN NN O
with NN NN O
SWS NN NN B-SpecificDisease
at NN NN O
age NN NN O
7 NN NN O
years NN NN O
. NN NN O

Patients NN NN O
reported NN NN O
as NN NN O
having NN NN O
either NN NN O
neonatal NN NN O
SJS NN NN B-SpecificDisease
or NN NN O
SWS NN NN B-SpecificDisease
presented NN NN O
a NN NN O
combination NN NN O
of NN NN O
a NN NN O
severe NN NN O
, NN NN O
prenatal-onset NN NN O
neuromuscular NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
( NN NN O
with NN NN O
congenital NN NN B-SpecificDisease
joint NN NN I-SpecificDisease
contractures NN NN I-SpecificDisease
, NN NN O
respiratory NN NN O
and NN NN O
feeding NN NN O
difficulties NN NN O
, NN NN O
tendency NN NN O
to NN NN O
hyperthermia NN NN B-SpecificDisease
, NN NN O
and NN NN O
frequent NN NN O
death NN NN O
in NN NN O
infancy NN NN O
) NN NN O
with NN NN O
a NN NN O
distinct NN NN O
campomelic-metaphyseal NN NN B-SpecificDisease
skeletal NN NN I-SpecificDisease
dysplasia NN NN I-SpecificDisease
. NN NN O

The NN NN O
similarity NN NN O
of NN NN O
the NN NN O
clinical NN NN O
and NN NN O
radiographic NN NN O
findings NN NN O
is NN NN O
so NN NN O
extensive NN NN O
that NN NN O
these NN NN O
disorders NN NN O
appear NN NN O
to NN NN O
be NN NN O
a NN NN O
single NN NN O
entity NN NN O
. NN NN O

The NN NN O
follow-up NN NN O
observation NN NN O
of NN NN O
an NN NN O
identical NN NN O
and NN NN O
unique NN NN O
pattern NN NN O
of NN NN O
progressive NN NN O
bone NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
in NN NN O
the NN NN O
two NN NN O
patients NN NN O
( NN NN O
one NN NN O
with NN NN O
SJS NN NN B-SpecificDisease
type NN NN I-SpecificDisease
2 NN NN I-SpecificDisease
, NN NN O
one NN NN O
with NN NN O
SWS NN NN B-SpecificDisease
) NN NN O
surviving NN NN O
beyond NN NN O
infancy NN NN O
adds NN NN O
to NN NN O
the NN NN O
evidence NN NN O
in NN NN O
favor NN NN O
of NN NN O
identity NN NN O
. NN NN O

The NN NN O
hypothesis NN NN O
that NN NN O
SWS NN NN B-SpecificDisease
and NN NN O
SJS NN NN B-SpecificDisease
type NN NN I-SpecificDisease
2 NN NN I-SpecificDisease
are NN NN O
the NN NN O
same NN NN O
disorder NN NN O
should NN NN O
be NN NN O
testable NN NN O
by NN NN O
molecular NN NN O
methods NN NN O
. NN NN O

. NN NN O

9689113 NN NN O
A NN NN O
mouse NN NN O
model NN NN O
of NN NN O
severe NN NN O
von NN NN B-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
: NN NN O
defects NN NN O
in NN NN O
hemostasis NN NN O
and NN NN O
thrombosis NN NN B-SpecificDisease
. NN NN O

von NN NN B-SpecificDisease
Willebrand NN NN I-SpecificDisease
factor NN NN I-SpecificDisease
( NN NN I-SpecificDisease
vWf NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
causes NN NN O
severe NN NN O
von NN NN B-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
in NN NN O
humans NN NN O
. NN NN O

We NN NN O
generated NN NN O
a NN NN O
mouse NN NN O
model NN NN O
for NN NN O
this NN NN O
disease NN NN O
by NN NN O
using NN NN O
gene NN NN O
targeting NN NN O
. NN NN O

vWf-deficient NN NN B-Modifier
mice NN NN O
appeared NN NN O
normal NN NN O
at NN NN O
birth NN NN O
; NN NN O
they NN NN O
were NN NN O
viable NN NN O
and NN NN O
fertile NN NN O
. NN NN O

Neither NN NN O
vWf NN NN O
nor NN NN O
vWf NN NN O
propolypeptide NN NN O
( NN NN O
von NN NN B-Modifier
Willebrand NN NN I-Modifier
antigen NN NN O
II NN NN O
) NN NN O
were NN NN O
detectable NN NN O
in NN NN O
plasma NN NN O
, NN NN O
platelets NN NN O
, NN NN O
or NN NN O
endothelial NN NN O
cells NN NN O
of NN NN O
the NN NN O
homozygous NN NN O
mutant NN NN O
mice NN NN O
. NN NN O

The NN NN O
mutant NN NN O
mice NN NN O
exhibited NN NN O
defects NN NN O
in NN NN O
hemostasis NN NN O
with NN NN O
a NN NN O
highly NN NN O
prolonged NN NN O
bleeding NN NN O
time NN NN O
and NN NN O
spontaneous NN NN O
bleeding NN NN O
events NN NN O
in NN NN O
approximately NN NN O
10 NN NN O
% NN NN O
of NN NN O
neonates NN NN O
. NN NN O

As NN NN O
in NN NN O
the NN NN O
human NN NN O
disease NN NN O
, NN NN O
the NN NN O
factor NN NN O
VIII NN NN O
level NN NN O
in NN NN O
these NN NN O
mice NN NN O
was NN NN O
reduced NN NN O
strongly NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
the NN NN O
lack NN NN O
of NN NN O
protection NN NN O
provided NN NN O
by NN NN O
vWf NN NN O
. NN NN O

Defective NN NN O
thrombosis NN NN B-SpecificDisease
in NN NN O
mutant NN NN O
mice NN NN O
was NN NN O
also NN NN O
evident NN NN O
in NN NN O
an NN NN O
in NN NN O
vivo NN NN O
model NN NN O
of NN NN O
vascular NN NN B-SpecificDisease
injury NN NN I-SpecificDisease
. NN NN O

In NN NN O
this NN NN O
model NN NN O
, NN NN O
the NN NN O
exteriorized NN NN O
mesentery NN NN O
was NN NN O
superfused NN NN O
with NN NN O
ferric NN NN O
chloride NN NN O
and NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
fluorescently NN NN O
labeled NN NN O
platelets NN NN O
was NN NN O
observed NN NN O
by NN NN O
intravital NN NN O
microscopy NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
these NN NN O
mice NN NN O
very NN NN O
closely NN NN O
mimic NN NN O
severe NN NN O
human NN NN O
von NN NN B-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
and NN NN O
will NN NN O
be NN NN O
very NN NN O
useful NN NN O
for NN NN O
investigating NN NN O
the NN NN O
role NN NN O
of NN NN O
vWf NN NN O
in NN NN O
normal NN NN O
physiology NN NN O
and NN NN O
in NN NN O
disease NN NN O
models NN NN O
. NN NN O

. NN NN O

9700175 NN NN O
Oral NN NN O
contraceptives NN NN O
and NN NN O
the NN NN O
risk NN NN O
of NN NN O
hereditary NN NN B-SpecificDisease
ovarian NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Hereditary NN NN B-Modifier
Ovarian NN NN I-Modifier
Cancer NN NN I-Modifier
Clinical NN NN O
Study NN NN O
Group NN NN O
. NN NN O

BACKGROUND NN NN O
Women NN NN O
with NN NN O
mutations NN NN O
in NN NN O
either NN NN O
the NN NN O
BRCA1 NN NN O
or NN NN O
the NN NN O
BRCA2 NN NN O
gene NN NN O
have NN NN O
a NN NN O
high NN NN O
lifetime NN NN O
risk NN NN O
of NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Oral NN NN O
contraceptives NN NN O
protect NN NN O
against NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
in NN NN O
general NN NN O
, NN NN O
but NN NN O
it NN NN O
is NN NN O
not NN NN O
known NN NN O
whether NN NN O
they NN NN O
also NN NN O
protect NN NN O
against NN NN O
hereditary NN NN B-SpecificDisease
forms NN NN I-SpecificDisease
of NN NN I-SpecificDisease
ovarian NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

METHODS NN NN O
We NN NN O
enrolled NN NN O
207 NN NN O
women NN NN O
with NN NN O
hereditary NN NN B-SpecificDisease
ovarian NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
161 NN NN O
of NN NN O
their NN NN O
sisters NN NN O
as NN NN O
controls NN NN O
in NN NN O
a NN NN O
case-control NN NN O
study NN NN O
. NN NN O

All NN NN O
the NN NN O
patients NN NN O
carried NN NN O
a NN NN O
pathogenic NN NN O
mutation NN NN O
in NN NN O
either NN NN O
BRCA1 NN NN O
( NN NN O
179 NN NN O
women NN NN O
) NN NN O
or NN NN O
BRCA2 NN NN O
( NN NN O
28 NN NN O
women NN NN O
) NN NN O
. NN NN O

The NN NN O
control NN NN O
women NN NN O
were NN NN O
enrolled NN NN O
regardless NN NN O
of NN NN O
whether NN NN O
or NN NN O
not NN NN O
they NN NN O
had NN NN O
either NN NN O
mutation NN NN O
. NN NN O

Lifetime NN NN O
histories NN NN O
of NN NN O
oral-contraceptive NN NN O
use NN NN O
were NN NN O
obtained NN NN O
by NN NN O
interview NN NN O
or NN NN O
by NN NN O
written NN NN O
questionnaire NN NN O
and NN NN O
were NN NN O
compared NN NN O
between NN NN O
patients NN NN O
and NN NN O
control NN NN O
women NN NN O
, NN NN O
after NN NN O
adjustment NN NN O
for NN NN O
year NN NN O
of NN NN O
birth NN NN O
and NN NN O
parity NN NN O
. NN NN O

RESULTS NN NN O
The NN NN O
adjusted NN NN O
odds NN NN O
ratio NN NN O
for NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
associated NN NN O
with NN NN O
any NN NN O
past NN NN O
use NN NN O
of NN NN O
oral NN NN O
contraceptives NN NN O
was NN NN O
0 NN NN O
. NN NN O

5 NN NN O
( NN NN O
95 NN NN O
percent NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
0 NN NN O
. NN NN O

3 NN NN O
to NN NN O
0 NN NN O
. NN NN O

8 NN NN O
) NN NN O
. NN NN O

The NN NN O
risk NN NN O
decreased NN NN O
with NN NN O
increasing NN NN O
duration NN NN O
of NN NN O
use NN NN O
( NN NN O
P NN NN O
for NN NN O
trend NN NN O
, NN NN O
0 NN NN O
. NN NN O

001 NN NN O
) NN NN O
; NN NN O
use NN NN O
for NN NN O
six NN NN O
or NN NN O
more NN NN O
years NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
60 NN NN O
percent NN NN O
reduction NN NN O
in NN NN O
risk NN NN O
. NN NN O

Oral-contraceptive NN NN O
use NN NN O
protected NN NN O
against NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
both NN NN O
for NN NN O
carriers NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
mutation NN NN O
( NN NN O
odds NN NN O
ratio NN NN O
, NN NN O
0 NN NN O
. NN NN O

5 NN NN O
; NN NN O
95 NN NN O
percent NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
0 NN NN O
. NN NN O

3 NN NN O
to NN NN O
0 NN NN O
. NN NN O

9 NN NN O
) NN NN O
and NN NN O
for NN NN O
carriers NN NN O
of NN NN O
the NN NN O
BRCA2 NN NN O
mutation NN NN O
( NN NN O
odds NN NN O
ratio NN NN O
, NN NN O
0 NN NN O
. NN NN O

4 NN NN O
; NN NN O
95 NN NN O
percent NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
0 NN NN O
. NN NN O

2 NN NN O
to NN NN O
1 NN NN O
. NN NN O

1 NN NN O
) NN NN O
. NN NN O

CONCLUSIONS NN NN O
Oral-contraceptive NN NN O
use NN NN O
may NN NN O
reduce NN NN O
the NN NN O
risk NN NN O
of NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
in NN NN O
women NN NN O
with NN NN O
pathogenic NN NN O
mutations NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
or NN NN O
BRCA2 NN NN O
gene NN NN O

9702690 NN NN O
A NN NN O
Japanese NN NN O
family NN NN O
with NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
with NN NN O
a NN NN O
codon NN NN O
291 NN NN O
deletion NN NN O
: NN NN O
a NN NN O
clinical NN NN O
, NN NN O
biochemical NN NN O
, NN NN O
pathological NN NN O
, NN NN O
and NN NN O
genetic NN NN O
report NN NN O
. NN NN O

We NN NN O
report NN NN O
a NN NN O
Japanese NN NN O
family NN NN O
with NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
with NN NN O
a NN NN O
three NN NN O
base NN NN O
pair NN NN O
deletion NN NN O
( NN NN O
delGAG NN NN O
291 NN NN O
) NN NN O
in NN NN O
the NN NN O
ALD NN NN B-Modifier
gene NN NN O
. NN NN O

A NN NN O
variety NN NN O
of NN NN O
phenotypes NN NN O
were NN NN O
observed NN NN O
within NN NN O
this NN NN O
family NN NN O
. NN NN O

While NN NN O
the NN NN O
proband NN NN O
( NN NN O
patient NN NN O
1 NN NN O
) NN NN O
was NN NN O
classified NN NN O
as NN NN O
having NN NN O
a NN NN O
rare NN NN O
intermediate NN NN O
type NN NN O
of NN NN O
adult NN NN O
cerebral NN NN O
and NN NN O
cerebello-brain NN NN O
stem NN NN O
forms NN NN O
, NN NN O
his NN NN O
younger NN NN O
brother NN NN O
( NN NN O
patient NN NN O
2 NN NN O
) NN NN O
and NN NN O
nephew NN NN O
( NN NN O
patient NN NN O
3 NN NN O
) NN NN O
had NN NN O
a NN NN O
childhood NN NN O
ALD NN NN B-Modifier
type NN NN O
. NN NN O

Another NN NN O
nephew NN NN O
( NN NN O
patient NN NN O
4 NN NN O
) NN NN O
of NN NN O
patient NN NN O
1 NN NN O
was NN NN O
classified NN NN O
as NN NN O
having NN NN O
an NN NN O
adolescent NN NN O
form NN NN O
. NN NN O

The NN NN O
tau NN NN O
level NN NN O
in NN NN O
the NN NN O
cerebrospinal NN NN O
fluid NN NN O
( NN NN O
CSF NN NN O
) NN NN O
in NN NN O
patient NN NN O
1 NN NN O
was NN NN O
as NN NN O
high NN NN O
as NN NN O
that NN NN O
of NN NN O
patients NN NN O
with NN NN O
Alzheimers NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
AD NN NN B-SpecificDisease
) NN NN O
. NN NN O

His NN NN O
brain NN NN O
magnetic NN NN O
resonance NN NN O
image NN NN O
( NN NN O
MRI NN NN O
) NN NN O
showed NN NN O
abnormalities NN NN B-DiseaseClass
in NN NN I-DiseaseClass
the NN NN I-DiseaseClass
bilateral NN NN I-DiseaseClass
cerebellar NN NN I-DiseaseClass
hemispheres NN NN I-DiseaseClass
and NN NN O
brain NN NN O
stem NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
cerebral NN NN O
white NN NN O
matter NN NN O
, NN NN O
where NN NN O
marked NN NN O
reductions NN NN O
of NN NN O
the NN NN O
cerebral NN NN O
blood NN NN O
flow NN NN O
and NN NN O
oxygen NN NN O
metabolism NN NN O
were NN NN O
clearly NN NN O
demonstrated NN NN O
by NN NN O
positron NN NN O
emission NN NN O
tomography NN NN O
( NN NN O
PET NN NN O
) NN NN O
. NN NN O

In NN NN O
patients NN NN O
2 NN NN O
and NN NN O
3 NN NN O
, NN NN O
the NN NN O
autopsy NN NN O
findings NN NN O
showed NN NN O
massive NN NN O
demyelination NN NN B-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
cerebral NN NN I-DiseaseClass
white NN NN I-DiseaseClass
matter NN NN I-DiseaseClass
with NN NN O
sparing NN NN O
of NN NN O
the NN NN O
U-fibers NN NN O
, NN NN O
compatible NN NN O
with NN NN O
the NN NN O
findings NN NN O
of NN NN O
childhood NN NN O
ALD NN NN B-SpecificDisease
. NN NN O

Oleic NN NN O
and NN NN O
erucic NN NN O
acids NN NN O
( NN NN O
Lorenzos NN NN O
Oil NN NN O
) NN NN O
were NN NN O
administered NN NN O
to NN NN O
patients NN NN O
1 NN NN O
and NN NN O
4 NN NN O
, NN NN O
but NN NN O
sufficient NN NN O
effectiveness NN NN O
was NN NN O
not NN NN O
obtained NN NN O
. NN NN O

The NN NN O
findings NN NN O
in NN NN O
this NN NN O
family NN NN O
suggest NN NN O
that NN NN O
delGAG291 NN NN O
is NN NN O
part NN NN O
of NN NN O
the NN NN O
cause NN NN O
of NN NN O
Japanese NN NN O
ALD NN NN B-SpecificDisease
with NN NN O
phenotypic NN NN O
variations NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
although NN NN O
the NN NN O
scale NN NN O
of NN NN O
the NN NN O
study NN NN O
is NN NN O
limited NN NN O
, NN NN O
there NN NN O
is NN NN O
a NN NN O
possibility NN NN O
that NN NN O
PET NN NN O
can NN NN O
detect NN NN O
an NN NN O
insidious NN NN B-DiseaseClass
lesion NN NN I-DiseaseClass
which NN NN O
is NN NN O
undetectable NN NN O
by NN NN O
computed NN NN O
tomogram NN NN O
( NN NN O
CT NN NN O
) NN NN O
or NN NN O
MRI NN NN O
analysis NN NN O
, NN NN O
and NN NN O
that NN NN O
the NN NN O
higher NN NN O
level NN NN O
of NN NN O
tau NN NN O
reflects NN NN O
the NN NN O
process NN NN O
of NN NN O
neuronal NN NN B-DiseaseClass
degeneration NN NN I-DiseaseClass
in NN NN O
ALD NN NN B-SpecificDisease
. NN NN O

Lorenzos NN NN O
Oil NN NN O
should NN NN O
be NN NN O
given NN NN O
in NN NN O
the NN NN O
early NN NN O
stage NN NN O
. NN NN O

. NN NN O

9703418 NN NN O
Nonsense NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
4 NN NN O
of NN NN O
human NN NN O
complement NN NN O
C9 NN NN O
gene NN NN O
is NN NN O
the NN NN O
major NN NN O
cause NN NN O
of NN NN O
Japanese NN NN O
complement NN NN B-SpecificDisease
C9 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
ninth NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
human NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
( NN NN O
C9 NN NN O
) NN NN O
is NN NN O
the NN NN O
most NN NN O
common NN NN O
complement NN NN B-DiseaseClass
deficiency NN NN I-DiseaseClass
in NN NN O
Japan NN NN O
but NN NN O
is NN NN O
rare NN NN O
in NN NN O
other NN NN O
countries NN NN O
. NN NN O

We NN NN O
studied NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
C9 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
four NN NN O
Japanese NN NN O
C9-deficient NN NN B-Modifier
patients NN NN O
who NN NN O
had NN NN O
suffered NN NN O
from NN NN O
meningococcal NN NN B-SpecificDisease
meningitis NN NN I-SpecificDisease
. NN NN O

Direct NN NN O
sequencing NN NN O
of NN NN O
amplified NN NN O
C9 NN NN O
cDNA NN NN O
and NN NN O
DNA NN NN O
revealed NN NN O
a NN NN O
nonsense NN NN O
substitution NN NN O
( NN NN O
CGA NN NN O
-- NN NN O
TGA NN NN O
) NN NN O
at NN NN O
codon NN NN O
95 NN NN O
in NN NN O
exon NN NN O
4 NN NN O
in NN NN O
the NN NN O
four NN NN O
C9-deficient NN NN B-Modifier
individuals NN NN O
. NN NN O

An NN NN O
allele-specific NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
system NN NN O
designed NN NN O
to NN NN O
detect NN NN O
exclusively NN NN O
only NN NN O
one NN NN O
of NN NN O
the NN NN O
normal NN NN O
and NN NN O
mutant NN NN O
alleles NN NN O
indicated NN NN O
that NN NN O
all NN NN O
the NN NN O
four NN NN O
patients NN NN O
were NN NN O
homozygous NN NN O
for NN NN O
the NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
4 NN NN O
and NN NN O
that NN NN O
the NN NN O
parents NN NN O
of NN NN O
patient NN NN O
2 NN NN O
were NN NN O
heterozygous NN NN O
. NN NN O

The NN NN O
common NN NN O
mutation NN NN O
at NN NN O
codon NN NN O
95 NN NN O
in NN NN O
exon NN NN O
4 NN NN O
might NN NN O
be NN NN O
responsible NN NN O
for NN NN O
most NN NN O
Japanese NN NN O
C9 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

. NN NN O

9703501 NN NN O
BRCA1 NN NN O
required NN NN O
for NN NN O
transcription-coupled NN NN O
repair NN NN O
of NN NN O
oxidative NN NN O
DNA NN NN O
damage NN NN O
. NN NN O

The NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
susceptibility NN NN O
gene NN NN O
BRCA1 NN NN O
encodes NN NN O
a NN NN O
zinc NN NN O
finger NN NN O
protein NN NN O
of NN NN O
unknown NN NN O
function NN NN O
. NN NN O

Association NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
protein NN NN O
with NN NN O
the NN NN O
DNA NN NN O
repair NN NN O
protein NN NN O
Rad51 NN NN O
and NN NN O
changes NN NN O
in NN NN O
the NN NN O
phosphorylation NN NN O
and NN NN O
cellular NN NN O
localization NN NN O
of NN NN O
the NN NN O
protein NN NN O
after NN NN O
exposure NN NN O
to NN NN O
DNA-damaging NN NN O
agents NN NN O
are NN NN O
consistent NN NN O
with NN NN O
a NN NN O
role NN NN O
for NN NN O
BRCA1 NN NN O
in NN NN O
DNA NN NN O
repair NN NN O
. NN NN O

Here NN NN O
, NN NN O
it NN NN O
is NN NN O
shown NN NN O
that NN NN O
mouse NN NN O
embryonic NN NN O
stem NN NN O
cells NN NN O
deficient NN NN B-Modifier
in NN NN I-Modifier
BRCA1 NN NN I-Modifier
are NN NN O
defective NN NN O
in NN NN O
the NN NN O
ability NN NN O
to NN NN O
carry NN NN O
out NN NN O
transcription-coupled NN NN O
repair NN NN O
of NN NN O
oxidative NN NN O
DNA NN NN O
damage NN NN O
, NN NN O
and NN NN O
are NN NN O
hypersensitive NN NN O
to NN NN O
ionizing NN NN O
radiation NN NN O
and NN NN O
hydrogen NN NN O
peroxide NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
BRCA1 NN NN O
participates NN NN O
, NN NN O
directly NN NN O
or NN NN O
indirectly NN NN O
, NN NN O
in NN NN O
transcription-coupled NN NN O
repair NN NN O
of NN NN O
oxidative NN NN O
DNA NN NN O
damage NN NN O
. NN NN O

. NN NN O

9705283 NN NN O
Truncation NN NN O
mutations NN NN O
in NN NN O
the NN NN O
transactivation NN NN O
region NN NN O
of NN NN O
PAX6 NN NN O
result NN NN O
in NN NN O
dominant-negative NN NN O
mutants NN NN O
. NN NN O

PAX6 NN NN O
is NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
with NN NN O
two NN NN O
DNA-binding NN NN O
domains NN NN O
( NN NN O
paired NN NN O
box NN NN O
and NN NN O
homeobox NN NN O
) NN NN O
and NN NN O
a NN NN O
proline-serine-threonine NN NN O
( NN NN O
PST NN NN O
) NN NN O
-rich NN NN O
transactivation NN NN O
domain NN NN O
. NN NN O

PAX6 NN NN O
regulates NN NN O
eye NN NN O
development NN NN O
in NN NN O
animals NN NN O
ranging NN NN O
from NN NN O
jellyfish NN NN O
to NN NN O
Drosophila NN NN O
to NN NN O
humans NN NN O
. NN NN O

Heterozygous NN NN O
mutations NN NN O
in NN NN O
the NN NN O
human NN NN O
PAX6 NN NN O
gene NN NN O
result NN NN O
in NN NN O
various NN NN O
phenotypes NN NN O
, NN NN O
including NN NN O
aniridia NN NN B-SpecificDisease
, NN NN O
Peters NN NN B-SpecificDisease
anomaly NN NN I-SpecificDisease
, NN NN O
autosomal NN NN B-SpecificDisease
dominant NN NN I-SpecificDisease
keratitis NN NN I-SpecificDisease
, NN NN O
and NN NN O
familial NN NN B-SpecificDisease
foveal NN NN I-SpecificDisease
dysplasia NN NN I-SpecificDisease
. NN NN O

It NN NN O
is NN NN O
believed NN NN O
that NN NN O
the NN NN O
mutated NN NN O
allele NN NN O
of NN NN O
PAX6 NN NN O
produces NN NN O
an NN NN O
inactive NN NN O
protein NN NN O
and NN NN O
aniridia NN NN B-SpecificDisease
is NN NN O
caused NN NN O
due NN NN O
to NN NN O
genetic NN NN O
haploinsufficiency NN NN O
. NN NN O

However NN NN O
, NN NN O
several NN NN O
truncation NN NN O
mutations NN NN O
have NN NN O
been NN NN O
found NN NN O
to NN NN O
occur NN NN O
in NN NN O
the NN NN O
C-terminal NN NN O
half NN NN O
of NN NN O
PAX6 NN NN O
in NN NN O
patients NN NN O
with NN NN O
Aniridia NN NN B-SpecificDisease
resulting NN NN O
in NN NN O
mutant NN NN O
proteins NN NN O
that NN NN O
retain NN NN O
the NN NN O
DNA-binding NN NN O
domains NN NN O
but NN NN O
have NN NN O
lost NN NN O
most NN NN O
of NN NN O
the NN NN O
transactivation NN NN O
domain NN NN O
. NN NN O

It NN NN O
is NN NN O
not NN NN O
clear NN NN O
whether NN NN O
such NN NN O
mutants NN NN O
really NN NN O
behave NN NN O
as NN NN O
loss-of-function NN NN O
mutants NN NN O
as NN NN O
predicted NN NN O
by NN NN O
haploinsufficiency NN NN O
. NN NN O

Contrary NN NN O
to NN NN O
this NN NN O
theory NN NN O
, NN NN O
our NN NN O
data NN NN O
showed NN NN O
that NN NN O
these NN NN O
mutants NN NN O
are NN NN O
dominant-negative NN NN O
in NN NN O
transient NN NN O
transfection NN NN O
assays NN NN O
when NN NN O
they NN NN O
are NN NN O
coexpressed NN NN O
with NN NN O
wild-type NN NN O
PAX6 NN NN O
. NN NN O

We NN NN O
found NN NN O
that NN NN O
the NN NN O
dominant-negative NN NN O
effects NN NN O
result NN NN O
from NN NN O
the NN NN O
enhanced NN NN O
DNA NN NN O
binding NN NN O
ability NN NN O
of NN NN O
these NN NN O
mutants NN NN O
. NN NN O

Kinetic NN NN O
studies NN NN O
of NN NN O
binding NN NN O
and NN NN O
dissociation NN NN O
revealed NN NN O
that NN NN O
various NN NN O
truncation NN NN O
mutants NN NN O
have NN NN O
3-5-fold NN NN O
higher NN NN O
affinity NN NN O
to NN NN O
various NN NN O
DNA-binding NN NN O
sites NN NN O
when NN NN O
compared NN NN O
with NN NN O
the NN NN O
wild-type NN NN O
PAX6 NN NN O
. NN NN O

These NN NN O
results NN NN O
provide NN NN O
a NN NN O
new NN NN O
insight NN NN O
into NN NN O
the NN NN O
role NN NN O
of NN NN O
mutant NN NN O
PAX6 NN NN O
in NN NN O
causing NN NN O
aniridia NN NN B-SpecificDisease
. NN NN O

. NN NN O

9709714 NN NN O
Reversal NN NN O
of NN NN O
severe NN NN O
hypertrophic NN NN B-SpecificDisease
cardiomyopathy NN NN I-SpecificDisease
and NN NN O
excellent NN NN O
neuropsychologic NN NN O
outcome NN NN O
in NN NN O
very-long-chain NN NN B-SpecificDisease
acyl-coenzyme NN NN I-SpecificDisease
A NN NN I-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Very-long-chain NN NN B-SpecificDisease
acyl-coenzyme NN NN I-SpecificDisease
A NN NN I-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
VLCAD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
a NN NN O
disorder NN NN O
of NN NN O
fatty NN NN O
acid NN NN O
beta NN NN O
oxidation NN NN O
that NN NN O
reportedly NN NN O
has NN NN O
high NN NN O
rates NN NN O
of NN NN O
morbidity NN NN O
and NN NN O
mortality NN NN O
. NN NN O

We NN NN O
describe NN NN O
the NN NN O
outcome NN NN O
of NN NN O
a NN NN O
5-year-old NN NN O
girl NN NN O
with NN NN O
VLCAD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
who NN NN O
was NN NN O
first NN NN O
seen NN NN O
at NN NN O
5 NN NN O
months NN NN O
of NN NN O
age NN NN O
with NN NN O
severe NN NN O
hypertrophic NN NN B-SpecificDisease
cardiomyopathy NN NN I-SpecificDisease
, NN NN O
hepatomegaly NN NN B-SpecificDisease
, NN NN O
encephalopathy NN NN B-DiseaseClass
, NN NN O
and NN NN O
hypotonia NN NN B-SpecificDisease
. NN NN O

Biochemical NN NN O
studies NN NN O
indicated NN NN O
VLCAD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
caused NN NN O
by NN NN O
a NN NN O
stable NN NN O
yet NN NN O
inactive NN NN O
enzyme NN NN O
. NN NN O

Molecular NN NN O
genetic NN NN O
analysis NN NN O
of NN NN O
her NN NN O
VLCAD NN NN O
gene NN NN O
revealed NN NN O
a NN NN O
T1372C NN NN O
( NN NN O
F458L NN NN O
) NN NN O
missense NN NN O
mutation NN NN O
and NN NN O
a NN NN O
1668 NN NN O
ACAG NN NN O
1669 NN NN O
splice NN NN O
site NN NN O
mutation NN NN O
. NN NN O

After NN NN O
initial NN NN O
treatment NN NN O
with NN NN O
intravenous NN NN O
glucose NN NN O
and NN NN O
carnitine NN NN O
, NN NN O
the NN NN O
patient NN NN O
has NN NN O
thrived NN NN O
on NN NN O
a NN NN O
low-fat NN NN O
diet NN NN O
supplemented NN NN O
with NN NN O
medium-chain NN NN O
triglyceride NN NN O
oil NN NN O
and NN NN O
carnitine NN NN O
and NN NN O
avoidance NN NN O
of NN NN O
fasting NN NN O
. NN NN O

Her NN NN O
ventricular NN NN O
hypertrophy NN NN O
resolved NN NN O
significantly NN NN O
over NN NN O
1 NN NN O
year NN NN O
, NN NN O
and NN NN O
cognitively NN NN O
, NN NN O
she NN NN O
is NN NN O
in NN NN O
the NN NN O
superior NN NN O
range NN NN O
for NN NN O
age NN NN O
. NN NN O

Clinical NN NN O
recognition NN NN O
of NN NN O
VLCAD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
important NN NN O
because NN NN O
it NN NN O
is NN NN O
one NN NN O
of NN NN O
the NN NN O
few NN NN O
directly NN NN O
treatable NN NN O
causes NN NN O
of NN NN O
cardiomyopathy NN NN B-DiseaseClass
in NN NN O
children NN NN O
. NN NN O

. NN NN O

9714764 NN NN O
Cloning NN NN O
of NN NN O
a NN NN O
novel NN NN O
member NN NN O
of NN NN O
the NN NN O
low-density NN NN O
lipoprotein NN NN O
receptor NN NN O
family NN NN O
. NN NN O

A NN NN O
gene NN NN O
encoding NN NN O
a NN NN O
novel NN NN O
transmembrane NN NN O
protein NN NN O
was NN NN O
identified NN NN O
by NN NN O
DNA NN NN O
sequence NN NN O
analysis NN NN O
within NN NN O
the NN NN O
insulin-dependent NN NN B-Modifier
diabetes NN NN I-Modifier
mellitus NN NN I-Modifier
( NN NN O
IDDM NN NN B-Modifier
) NN NN O
locus NN NN O
IDDM4 NN NN O
on NN NN O
chromosome NN NN O
11q13 NN NN O
. NN NN O

Based NN NN O
on NN NN O
its NN NN O
chromosomal NN NN O
position NN NN O
, NN NN O
this NN NN O
gene NN NN O
is NN NN O
a NN NN O
candidate NN NN O
for NN NN O
conferring NN NN O
susceptibility NN NN O
to NN NN O
diabetes NN NN B-DiseaseClass
. NN NN O

The NN NN O
gene NN NN O
, NN NN O
termed NN NN O
low-density NN NN O
lipoprotein NN NN O
receptor NN NN O
related NN NN O
protein NN NN O
5 NN NN O
( NN NN O
LRP5 NN NN O
) NN NN O
, NN NN O
encodes NN NN O
a NN NN O
protein NN NN O
of NN NN O
1615 NN NN O
amino NN NN O
acids NN NN O
that NN NN O
contains NN NN O
conserved NN NN O
modules NN NN O
which NN NN O
are NN NN O
characteristic NN NN O
of NN NN O
the NN NN O
low-density NN NN O
lipoprotein NN NN O
( NN NN O
LDL NN NN O
) NN NN O
receptor NN NN O
family NN NN O
. NN NN O

These NN NN O
modules NN NN O
include NN NN O
a NN NN O
putative NN NN O
signal NN NN O
peptide NN NN O
for NN NN O
protein NN NN O
export NN NN O
, NN NN O
four NN NN O
epidermal NN NN O
growth NN NN O
factor NN NN O
( NN NN O
EGF NN NN O
) NN NN O
repeats NN NN O
with NN NN O
associated NN NN O
spacer NN NN O
domains NN NN O
, NN NN O
three NN NN O
LDL-receptor NN NN O
( NN NN O
LDLR NN NN O
) NN NN O
repeats NN NN O
, NN NN O
a NN NN O
single NN NN O
transmembrane NN NN O
spanning NN NN O
domain NN NN O
, NN NN O
and NN NN O
a NN NN O
cytoplasmic NN NN O
domain NN NN O
. NN NN O

The NN NN O
encoded NN NN O
protein NN NN O
has NN NN O
a NN NN O
unique NN NN O
organization NN NN O
of NN NN O
EGF NN NN O
and NN NN O
LDLR NN NN O
repeats NN NN O
; NN NN O
therefore NN NN O
, NN NN O
LRP5 NN NN O
likely NN NN O
represents NN NN O
a NN NN O
new NN NN O
category NN NN O
of NN NN O
the NN NN O
LDLR NN NN O
family NN NN O
. NN NN O

Both NN NN O
human NN NN O
and NN NN O
mouse NN NN O
LRP5 NN NN O
cDNAs NN NN O
have NN NN O
been NN NN O
isolated NN NN O
and NN NN O
the NN NN O
encoded NN NN O
mature NN NN O
proteins NN NN O
are NN NN O
95 NN NN O
% NN NN O
identical NN NN O
, NN NN O
indicating NN NN O
a NN NN O
high NN NN O
degree NN NN O
of NN NN O
evolutionary NN NN O
conservation NN NN O
. NN NN O

. NN NN O

9724771 NN NN O
The NN NN O
APC NN NN B-Modifier
variants NN NN O
I1307K NN NN O
and NN NN O
E1317Q NN NN O
are NN NN O
associated NN NN O
with NN NN O
colorectal NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
, NN NN O
but NN NN O
not NN NN O
always NN NN O
with NN NN O
a NN NN O
family NN NN O
history NN NN O
. NN NN O

Classical NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
( NN NN O
FAP NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
high-penetrance NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
that NN NN O
predisposes NN NN O
to NN NN O
hundreds NN NN O
or NN NN O
thousands NN NN O
of NN NN O
colorectal NN NN B-CompositeMention
adenomas NN NN I-CompositeMention
and NN NN I-CompositeMention
carcinoma NN NN I-CompositeMention
and NN NN O
that NN NN O
results NN NN O
from NN NN O
truncating NN NN O
mutations NN NN O
in NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
. NN NN O

A NN NN O
variant NN NN O
of NN NN O
FAP NN NN B-SpecificDisease
is NN NN O
attenuated NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
, NN NN O
which NN NN O
results NN NN O
from NN NN O
germ-line NN NN O
mutations NN NN O
in NN NN O
the NN NN O
5 NN NN O
and NN NN O
3 NN NN O
regions NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
. NN NN O

Attenuated NN NN B-Modifier
adenomatous NN NN I-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
patients NN NN O
have NN NN O
`` NN NN O
multiple NN NN O
`` NN NN O
colorectal NN NN B-SpecificDisease
adenomas NN NN I-SpecificDisease
( NN NN O
typically NN NN O
fewer NN NN O
than NN NN O
100 NN NN O
) NN NN O
without NN NN O
the NN NN O
florid NN NN O
phenotype NN NN O
of NN NN O
classical NN NN O
FAP NN NN B-SpecificDisease
. NN NN O

Another NN NN O
group NN NN O
of NN NN O
patients NN NN O
with NN NN O
multiple NN NN O
adenomas NN NN B-DiseaseClass
has NN NN O
no NN NN O
mutations NN NN O
in NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
, NN NN O
and NN NN O
their NN NN O
phenotype NN NN O
probably NN NN O
results NN NN O
from NN NN O
variation NN NN O
at NN NN O
a NN NN O
locus NN NN O
, NN NN O
or NN NN O
loci NN NN O
, NN NN O
elsewhere NN NN O
in NN NN O
the NN NN O
genome NN NN O
. NN NN O

Recently NN NN O
, NN NN O
however NN NN O
, NN NN O
a NN NN O
missense NN NN O
variant NN NN O
of NN NN O
APC NN NN B-SpecificDisease
( NN NN O
I1307K NN NN O
) NN NN O
was NN NN O
described NN NN O
that NN NN O
confers NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
colorectal NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
, NN NN O
including NN NN O
multiple NN NN O
adenomas NN NN B-DiseaseClass
, NN NN O
in NN NN O
Ashkenazim NN NN O
. NN NN O

We NN NN O
have NN NN O
studied NN NN O
a NN NN O
set NN NN O
of NN NN O
164 NN NN O
patients NN NN O
with NN NN O
multiple NN NN O
colorectal NN NN B-CompositeMention
adenomas NN NN I-CompositeMention
and NN NN I-CompositeMention
/ NN NN I-CompositeMention
or NN NN I-CompositeMention
carcinoma NN NN I-CompositeMention
and NN NN O
analyzed NN NN O
codons NN NN O
1263-1377 NN NN O
( NN NN O
exon NN NN O
15G NN NN O
) NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
for NN NN O
germ-line NN NN O
variants NN NN O
. NN NN O

Three NN NN O
patients NN NN O
with NN NN O
the NN NN O
I1307K NN NN O
allele NN NN O
were NN NN O
detected NN NN O
, NN NN O
each NN NN O
of NN NN O
Ashkenazi NN NN O
descent NN NN O
. NN NN O

Four NN NN O
patients NN NN O
had NN NN O
a NN NN O
germ-line NN NN O
E1317Q NN NN O
missense NN NN O
variant NN NN O
of NN NN O
APC NN NN O
that NN NN O
was NN NN O
not NN NN O
present NN NN O
in NN NN O
controls NN NN O
; NN NN O
one NN NN O
of NN NN O
these NN NN O
individuals NN NN O
had NN NN O
an NN NN O
unusually NN NN O
large NN NN O
number NN NN O
of NN NN O
metaplastic NN NN B-SpecificDisease
polyps NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
colorectum NN NN I-SpecificDisease
. NN NN O

There NN NN O
is NN NN O
increasing NN NN O
evidence NN NN O
that NN NN O
there NN NN O
exist NN NN O
germ-line NN NN O
variants NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
that NN NN O
predispose NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
multiple NN NN O
colorectal NN NN B-CompositeMention
adenomas NN NN I-CompositeMention
and NN NN I-CompositeMention
carcinoma NN NN I-CompositeMention
, NN NN O
but NN NN O
without NN NN O
the NN NN O
florid NN NN O
phenotype NN NN O
of NN NN O
classical NN NN O
FAP NN NN B-SpecificDisease
, NN NN O
and NN NN O
possibly NN NN O
with NN NN O
importance NN NN O
for NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
risk NN NN O
in NN NN O
the NN NN O
general NN NN O
population NN NN O
. NN NN O

. NN NN O

9729124 NN NN O
Genomic NN NN O
structure NN NN O
of NN NN O
the NN NN O
human NN NN O
congenital NN NN B-Modifier
chloride NN NN I-Modifier
diarrhea NN NN I-Modifier
( NN NN O
CLD NN NN B-Modifier
) NN NN O
gene NN NN O
. NN NN O

Congenital NN NN B-SpecificDisease
chloride NN NN I-SpecificDisease
diarrhea NN NN I-SpecificDisease
( NN NN O
CLD NN NN B-SpecificDisease
) NN NN O
is NN NN O
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
a NN NN O
gene NN NN O
which NN NN O
encodes NN NN O
an NN NN O
intestinal NN NN O
anion NN NN O
transporter NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
the NN NN O
complete NN NN O
genomic NN NN O
organization NN NN O
of NN NN O
the NN NN O
human NN NN O
CLD NN NN B-Modifier
gene NN NN O
which NN NN O
spans NN NN O
approximately NN NN O
39kb NN NN O
, NN NN O
and NN NN O
comprises NN NN O
21 NN NN O
exons NN NN O
. NN NN O

All NN NN O
exon NN NN O
/ NN NN O
intron NN NN O
boundaries NN NN O
conform NN NN O
to NN NN O
the NN NN O
GT NN NN O
/ NN NN O
AG NN NN O
rule NN NN O
. NN NN O

An NN NN O
analysis NN NN O
of NN NN O
the NN NN O
putative NN NN O
promoter NN NN O
region NN NN O
sequence NN NN O
shows NN NN O
a NN NN O
putative NN NN O
TATA NN NN O
box NN NN O
and NN NN O
predicts NN NN O
multiple NN NN O
transcription NN NN O
factor NN NN O
binding NN NN O
sites NN NN O
. NN NN O

The NN NN O
genomic NN NN O
structure NN NN O
was NN NN O
determined NN NN O
using NN NN O
DNA NN NN O
from NN NN O
several NN NN O
sources NN NN O
including NN NN O
multiple NN NN O
large-insert NN NN O
libaries NN NN O
and NN NN O
genomic NN NN O
DNA NN NN O
from NN NN O
Finnish NN NN O
CLD NN NN B-Modifier
patients NN NN O
and NN NN O
controls NN NN O
. NN NN O

Exon-specific NN NN O
primers NN NN O
developed NN NN O
in NN NN O
this NN NN O
study NN NN O
will NN NN O
facilitate NN NN O
mutation NN NN O
screening NN NN O
studies NN NN O
of NN NN O
patients NN NN O
with NN NN O
the NN NN O
disease NN NN O
. NN NN O

Genomic NN NN O
sequencing NN NN O
of NN NN O
a NN NN O
BAC NN NN O
clone NN NN O
H_RG364P16 NN NN O
revealed NN NN O
the NN NN O
presence NN NN O
of NN NN O
another NN NN O
, NN NN O
highly NN NN O
homologous NN NN O
gene NN NN O
3 NN NN O
of NN NN O
the NN NN O
CLD NN NN B-Modifier
gene NN NN O
, NN NN O
with NN NN O
a NN NN O
similar NN NN O
genomic NN NN O
structure NN NN O
, NN NN O
recently NN NN O
identified NN NN O
as NN NN O
the NN NN O
Pendred NN NN B-Modifier
syndrome NN NN I-Modifier
gene NN NN O
( NN NN O
PDS NN NN B-SpecificDisease
) NN NN O
. NN NN O

. NN NN O

9731533 NN NN O
The NN NN O
APCI1307K NN NN O
allele NN NN O
and NN NN O
cancer NN NN B-Modifier
risk NN NN O
in NN NN O
a NN NN O
community-based NN NN O
study NN NN O
of NN NN O
Ashkenazi NN NN O
Jews NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
APC NN NN O
are NN NN O
classically NN NN O
associated NN NN O
with NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
( NN NN O
FAP NN NN B-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
highly NN NN O
penetrant NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
multiple NN NN O
intestinal NN NN O
polyps NN NN B-DiseaseClass
and NN NN O
, NN NN O
without NN NN O
surgical NN NN O
intervention NN NN O
, NN NN O
the NN NN O
development NN NN O
of NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
( NN NN O
CRC NN NN B-SpecificDisease
) NN NN O
. NN NN O

APC NN NN B-SpecificDisease
is NN NN O
a NN NN O
tumour-suppressor NN NN O
gene NN NN O
, NN NN O
and NN NN O
somatic NN NN O
loss NN NN O
occurs NN NN O
in NN NN O
tumours NN NN B-DiseaseClass
. NN NN O

The NN NN O
germline NN NN O
T-to-A NN NN O
transversion NN NN O
responsible NN NN O
for NN NN O
the NN NN O
APC NN NN O
I1307K NN NN O
allele NN NN O
converts NN NN O
the NN NN O
wild-type NN NN O
sequence NN NN O
to NN NN O
a NN NN O
homopolymer NN NN O
tract NN NN O
( NN NN O
A8 NN NN O
) NN NN O
that NN NN O
is NN NN O
genetically NN NN O
unstable NN NN O
and NN NN O
prone NN NN O
to NN NN O
somatic NN NN O
mutation NN NN O
. NN NN O

The NN NN O
I1307K NN NN O
allele NN NN O
was NN NN O
found NN NN O
in NN NN O
6 NN NN O
. NN NN O

1 NN NN O
% NN NN O
of NN NN O
unselected NN NN O
Ashkenazi NN NN O
Jews NN NN O
and NN NN O
higher NN NN O
proportions NN NN O
of NN NN O
Ashkenazim NN NN O
with NN NN O
family NN NN O
or NN NN O
personal NN NN O
histories NN NN O
of NN NN O
CRC NN NN B-SpecificDisease
( NN NN O
ref NN NN O
. NN NN O

2 NN NN O
) NN NN O
. NN NN O

To NN NN O
evaluate NN NN O
the NN NN O
role NN NN O
of NN NN O
I1307K NN NN O
in NN NN O
cancer NN NN B-DiseaseClass
, NN NN O
we NN NN O
genotyped NN NN O
5 NN NN O
, NN NN O
081 NN NN O
Ashkenazi NN NN O
volunteers NN NN O
in NN NN O
a NN NN O
community NN NN O
survey NN NN O
. NN NN O

Risk NN NN O
of NN NN O
developing NN NN O
colorectal NN NN B-CompositeMention
, NN NN I-CompositeMention
breast NN NN I-CompositeMention
and NN NN I-CompositeMention
other NN NN I-CompositeMention
cancers NN NN I-CompositeMention
were NN NN O
compared NN NN O
between NN NN O
genotyped NN NN O
I1307K NN NN O
carriers NN NN O
and NN NN O
non-carriers NN NN O
and NN NN O
their NN NN O
first-degree NN NN O
relatives NN NN O
. NN NN O

9733027 NN NN O
Sperm NN NN O
DNA NN NN O
analysis NN NN O
in NN NN O
a NN NN O
Friedreich NN NN B-Modifier
ataxia NN NN I-Modifier
premutation NN NN O
carrier NN NN O
suggests NN NN O
both NN NN O
meiotic NN NN O
and NN NN O
mitotic NN NN O
expansion NN NN O
in NN NN O
the NN NN O
FRDA NN NN B-Modifier
gene NN NN O
. NN NN O

Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
is NN NN O
usually NN NN O
caused NN NN O
by NN NN O
an NN NN O
expansion NN NN O
of NN NN O
a NN NN O
GAA NN NN O
trinucleotide NN NN O
repeat NN NN O
in NN NN O
intron NN NN O
1 NN NN O
of NN NN O
the NN NN O
FRDA NN NN B-Modifier
gene NN NN O
. NN NN O

Occasionally NN NN O
, NN NN O
a NN NN O
fully NN NN O
expanded NN NN O
allele NN NN O
has NN NN O
been NN NN O
found NN NN O
to NN NN O
arise NN NN O
from NN NN O
a NN NN O
premutation NN NN O
of NN NN O
100 NN NN O
or NN NN O
less NN NN O
triplet NN NN O
repeats NN NN O
. NN NN O

We NN NN O
have NN NN O
examined NN NN O
the NN NN O
sperm NN NN O
DNA NN NN O
of NN NN O
a NN NN O
premutation NN NN O
carrier NN NN O
. NN NN O

This NN NN O
mans NN NN O
leucocyte NN NN O
DNA NN NN O
showed NN NN O
one NN NN O
normal NN NN O
allele NN NN O
and NN NN O
one NN NN O
allele NN NN O
of NN NN O
approximately NN NN O
100 NN NN O
repeats NN NN O
. NN NN O

His NN NN O
sperm NN NN O
showed NN NN O
an NN NN O
expanded NN NN O
allele NN NN O
in NN NN O
a NN NN O
tight NN NN O
range NN NN O
centering NN NN O
on NN NN O
a NN NN O
size NN NN O
of NN NN O
approximately NN NN O
320 NN NN O
trinucleotide NN NN O
repeats NN NN O
. NN NN O

His NN NN O
affected NN NN O
son NN NN O
has NN NN O
repeat NN NN O
sizes NN NN O
of NN NN O
1040 NN NN O
and NN NN O
540 NN NN O
. NN NN O

These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
expansion NN NN O
occurs NN NN O
in NN NN O
two NN NN O
stages NN NN O
, NN NN O
the NN NN O
first NN NN O
during NN NN O
meiosis NN NN O
followed NN NN O
by NN NN O
a NN NN O
second NN NN O
mitotic NN NN O
expansion NN NN O
. NN NN O

We NN NN O
also NN NN O
show NN NN O
that NN NN O
in NN NN O
all NN NN O
informative NN NN O
carrier NN NN O
father NN NN O
to NN NN O
affected NN NN O
child NN NN O
transmissions NN NN O
, NN NN O
with NN NN O
the NN NN O
notable NN NN O
exception NN NN O
of NN NN O
the NN NN O
premutation NN NN O
carrier NN NN O
, NN NN O
the NN NN O
expansion NN NN O
size NN NN O
decreases NN NN O
. NN NN O

. NN NN O

9744473 NN NN O
The NN NN O
R496H NN NN O
mutation NN NN O
of NN NN O
arylsulfatase NN NN O
A NN NN O
does NN NN O
not NN NN O
cause NN NN O
metachromatic NN NN B-SpecificDisease
leukodystrophy NN NN I-SpecificDisease
. NN NN O

Deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
arylsulfatase NN NN I-SpecificDisease
A NN NN I-SpecificDisease
( NN NN O
ARSA NN NN O
) NN NN O
enzyme NN NN O
activity NN NN O
causes NN NN O
metachromatic NN NN B-SpecificDisease
leukodystrophy NN NN I-SpecificDisease
( NN NN O
MLD NN NN B-SpecificDisease
) NN NN O
. NN NN O

A NN NN O
number NN NN O
of NN NN O
ARSA NN NN O
gene NN NN O
mutations NN NN O
responsible NN NN O
for NN NN O
MLD NN NN B-SpecificDisease
have NN NN O
been NN NN O
identified NN NN O
. NN NN O

Recently NN NN O
, NN NN O
the NN NN O
R496H NN NN O
mutation NN NN O
of NN NN O
ARSA NN NN O
was NN NN O
proposed NN NN O
to NN NN O
be NN NN O
a NN NN O
cause NN NN O
of NN NN O
MLD NN NN B-SpecificDisease
( NN NN O
Draghia NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
1997 NN NN O
) NN NN O
. NN NN O

We NN NN O
have NN NN O
investigated NN NN O
the NN NN O
R496H NN NN O
mutation NN NN O
and NN NN O
found NN NN O
this NN NN O
mutation NN NN O
at NN NN O
a NN NN O
relatively NN NN O
high NN NN O
frequency NN NN O
in NN NN O
an NN NN O
African NN NN O
American NN NN O
population NN NN O
( NN NN O
f NN NN O
= NN NN O
0 NN NN O
. NN NN O

09 NN NN O
, NN NN O
n NN NN O
= NN NN O
61 NN NN O
subjects NN NN O
) NN NN O
. NN NN O

The NN NN O
ARSA NN NN O
enzyme NN NN O
activity NN NN O
in NN NN O
subjects NN NN O
with NN NN O
and NN NN O
without NN NN O
the NN NN O
R496H NN NN O
mutation NN NN O
was NN NN O
determined NN NN O
and NN NN O
found NN NN O
to NN NN O
be NN NN O
normal NN NN O
. NN NN O

It NN NN O
is NN NN O
therefore NN NN O
concluded NN NN O
that NN NN O
the NN NN O
R496H NN NN O
mutation NN NN O
of NN NN O
ARSA NN NN O
does NN NN O
not NN NN O
negatively NN NN O
influence NN NN O
the NN NN O
activity NN NN O
of NN NN O
ARSA NN NN O
and NN NN O
is NN NN O
not NN NN O
a NN NN O
cause NN NN O
of NN NN O
MLD NN NN B-SpecificDisease

9770531 NN NN O
Down-regulation NN NN O
of NN NN O
transmembrane NN NN O
carbonic NN NN O
anhydrases NN NN O
in NN NN O
renal NN NN B-Modifier
cell NN NN I-Modifier
carcinoma NN NN I-Modifier
cell NN NN O
lines NN NN O
by NN NN O
wild-type NN NN O
von NN NN B-Modifier
Hippel-Lindau NN NN I-Modifier
transgenes NN NN O
. NN NN O

To NN NN O
discover NN NN O
genes NN NN O
involved NN NN O
in NN NN O
von NN NN B-Modifier
Hippel-Lindau NN NN I-Modifier
( NN NN O
VHL NN NN B-Modifier
) NN NN O
-mediated NN NN O
carcinogenesis NN NN O
, NN NN O
we NN NN O
used NN NN O
renal NN NN B-Modifier
cell NN NN I-Modifier
carcinoma NN NN I-Modifier
cell NN NN O
lines NN NN O
stably NN NN O
transfected NN NN O
with NN NN O
wild-type NN NN O
VHL-expressing NN NN O
transgenes NN NN O
. NN NN O

Large-scale NN NN O
RNA NN NN O
differential NN NN O
display NN NN O
technology NN NN O
applied NN NN O
to NN NN O
these NN NN O
cell NN NN O
lines NN NN O
identified NN NN O
several NN NN O
differentially NN NN O
expressed NN NN O
genes NN NN O
, NN NN O
including NN NN O
an NN NN O
alpha NN NN O
carbonic NN NN O
anhydrase NN NN O
gene NN NN O
, NN NN O
termed NN NN O
CA12 NN NN O
. NN NN O

The NN NN O
deduced NN NN O
protein NN NN O
sequence NN NN O
was NN NN O
classified NN NN O
as NN NN O
a NN NN O
one-pass NN NN O
transmembrane NN NN O
CA NN NN O
possessing NN NN O
an NN NN O
apparently NN NN O
intact NN NN O
catalytic NN NN O
domain NN NN O
in NN NN O
the NN NN O
extracellular NN NN O
CA NN NN O
module NN NN O
. NN NN O

Reintroduced NN NN O
wild-type NN NN O
VHL NN NN B-SpecificDisease
strongly NN NN O
inhibited NN NN O
the NN NN O
overexpression NN NN O
of NN NN O
the NN NN O
CA12 NN NN O
gene NN NN O
in NN NN O
the NN NN O
parental NN NN O
renal NN NN B-Modifier
cell NN NN I-Modifier
carcinoma NN NN I-Modifier
cell NN NN O
lines NN NN O
. NN NN O

Similar NN NN O
results NN NN O
were NN NN O
obtained NN NN O
with NN NN O
CA9 NN NN O
, NN NN O
encoding NN NN O
another NN NN O
transmembrane NN NN O
CA NN NN O
with NN NN O
an NN NN O
intact NN NN O
catalytic NN NN O
domain NN NN O
. NN NN O

Although NN NN O
both NN NN O
domains NN NN O
of NN NN O
the NN NN O
VHL NN NN B-Modifier
protein NN NN O
contribute NN NN O
to NN NN O
regulation NN NN O
of NN NN O
CA12 NN NN O
expression NN NN O
, NN NN O
the NN NN O
elongin NN NN O
binding NN NN O
domain NN NN O
alone NN NN O
could NN NN O
effectively NN NN O
regulate NN NN O
CA9 NN NN O
expression NN NN O
. NN NN O

We NN NN O
mapped NN NN O
CA12 NN NN O
and NN NN O
CA9 NN NN O
loci NN NN O
to NN NN O
chromosome NN NN O
bands NN NN O
15q22 NN NN O
and NN NN O
17q21 NN NN O
. NN NN O

2 NN NN O
respectively NN NN O
, NN NN O
regions NN NN O
prone NN NN O
to NN NN O
amplification NN NN O
in NN NN O
some NN NN O
human NN NN O
cancers NN NN B-DiseaseClass
. NN NN O

Additional NN NN O
experiments NN NN O
are NN NN O
needed NN NN O
to NN NN O
define NN NN O
the NN NN O
role NN NN O
of NN NN O
CA NN NN O
IX NN NN O
and NN NN O
CA NN NN O
XII NN NN O
enzymes NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
pH NN NN O
in NN NN O
the NN NN O
extracellular NN NN O
microenvironment NN NN O
and NN NN O
its NN NN O
potential NN NN O
impact NN NN O
on NN NN O
cancer NN NN B-Modifier
cell NN NN O
growth NN NN O
. NN NN O

9771706 NN NN O
A NN NN O
gene NN NN O
encoding NN NN O
a NN NN O
transmembrane NN NN O
protein NN NN O
is NN NN O
mutated NN NN O
in NN NN O
patients NN NN O
with NN NN O
diabetes NN NN B-SpecificDisease
mellitus NN NN I-SpecificDisease
and NN NN O
optic NN NN B-SpecificDisease
atrophy NN NN I-SpecificDisease
( NN NN O
Wolfram NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
) NN NN O
. NN NN O

Wolfram NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
WFS NN NN B-SpecificDisease
; NN NN O
OMIM NN NN O
222300 NN NN O
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
neurodegenerative NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
defined NN NN O
by NN NN O
young-onset NN NN O
non-immune NN NN O
insulin-dependent NN NN B-SpecificDisease
diabetes NN NN I-SpecificDisease
mellitus NN NN I-SpecificDisease
and NN NN O
progressive NN NN O
optic NN NN B-SpecificDisease
atrophy NN NN I-SpecificDisease
. NN NN O

Linkage NN NN O
to NN NN O
markers NN NN O
on NN NN O
chromosome NN NN O
4p NN NN O
was NN NN O
confirmed NN NN O
in NN NN O
five NN NN O
families NN NN O
. NN NN O

On NN NN O
the NN NN O
basis NN NN O
of NN NN O
meiotic NN NN O
recombinants NN NN O
and NN NN O
disease-associated NN NN O
haplotypes NN NN O
, NN NN O
the NN NN O
WFS NN NN B-Modifier
gene NN NN O
was NN NN O
localized NN NN O
to NN NN O
a NN NN O
BAC NN NN O
/ NN NN O
P1 NN NN O
contig NN NN O
of NN NN O
less NN NN O
than NN NN O
250 NN NN O
kb NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
a NN NN O
novel NN NN O
gene NN NN O
( NN NN O
WFS1 NN NN O
) NN NN O
encoding NN NN O
a NN NN O
putative NN NN O
transmembrane NN NN O
protein NN NN O
were NN NN O
found NN NN O
in NN NN O
all NN NN O
affected NN NN O
individuals NN NN O
in NN NN O
six NN NN O
WFS NN NN B-Modifier
families NN NN O
, NN NN O
and NN NN O
these NN NN O
mutations NN NN O
were NN NN O
associated NN NN O
with NN NN O
the NN NN O
disease NN NN O
phenotype NN NN O
. NN NN O

WFS1 NN NN O
appears NN NN O
to NN NN O
function NN NN O
in NN NN O
survival NN NN O
of NN NN O
islet NN NN O
beta-cells NN NN O
and NN NN O
neurons NN NN O
. NN NN O

. NN NN O

9774970 NN NN O
Stable NN NN O
interaction NN NN O
between NN NN O
the NN NN O
products NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
genes NN NN O
in NN NN O
mitotic NN NN O
and NN NN O
meiotic NN NN O
cells NN NN O
. NN NN O

BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
account NN NN O
for NN NN O
most NN NN O
cases NN NN O
of NN NN O
familial NN NN O
, NN NN O
early NN NN O
onset NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
/ NN NN I-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
and NN NN O
encode NN NN O
products NN NN O
that NN NN O
each NN NN O
interact NN NN O
with NN NN O
hRAD51 NN NN O
. NN NN O

Results NN NN O
presented NN NN O
here NN NN O
show NN NN O
that NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
coexist NN NN O
in NN NN O
a NN NN O
biochemical NN NN O
complex NN NN O
and NN NN O
colocalize NN NN O
in NN NN O
subnuclear NN NN O
foci NN NN O
in NN NN O
somatic NN NN O
cells NN NN O
and NN NN O
on NN NN O
the NN NN O
axial NN NN O
elements NN NN O
of NN NN O
developing NN NN O
synaptonemal NN NN O
complexes NN NN O
. NN NN O

Like NN NN O
BRCA1 NN NN O
and NN NN O
RAD51 NN NN O
, NN NN O
BRCA2 NN NN O
relocates NN NN O
to NN NN O
PCNA NN NN O
+ NN NN O
replication NN NN O
sites NN NN O
following NN NN O
exposure NN NN O
of NN NN O
S NN NN O
phase NN NN O
cells NN NN O
to NN NN O
hydroxyurea NN NN O
or NN NN O
UV NN NN O
irradiation NN NN O
. NN NN O

Thus NN NN O
, NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
participate NN NN O
, NN NN O
together NN NN O
, NN NN O
in NN NN O
a NN NN O
pathway NN NN O
( NN NN O
s NN NN O
) NN NN O
associated NN NN O
with NN NN O
the NN NN O
activation NN NN O
of NN NN O
double-strand NN NN O
break NN NN O
repair NN NN O
and NN NN O
/ NN NN O
or NN NN O
homologous NN NN O
recombination NN NN O
. NN NN O

Dysfunction NN NN O
of NN NN O
this NN NN O
pathway NN NN O
may NN NN O
be NN NN O
a NN NN O
general NN NN O
phenomenon NN NN O
in NN NN O
the NN NN O
majority NN NN O
of NN NN O
cases NN NN O
of NN NN O
hereditary NN NN B-CompositeMention
breast NN NN I-CompositeMention
and NN NN I-CompositeMention
/ NN NN I-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

. NN NN O

9790667 NN NN O
A NN NN O
novel NN NN O
Arg362Ser NN NN O
mutation NN NN O
in NN NN O
the NN NN O
sterol NN NN O
27-hydroxylase NN NN O
gene NN NN O
( NN NN O
CYP27 NN NN O
) NN NN O
: NN NN O
its NN NN O
effects NN NN O
on NN NN O
pre-mRNA NN NN O
splicing NN NN O
and NN NN O
enzyme NN NN O
activity NN NN O
. NN NN O

A NN NN O
novel NN NN O
C NN NN O
to NN NN O
A NN NN O
mutation NN NN O
in NN NN O
the NN NN O
sterol NN NN O
27-hydroxylase NN NN O
gene NN NN O
( NN NN O
CYP27 NN NN O
) NN NN O
was NN NN O
identified NN NN O
by NN NN O
sequencing NN NN O
amplified NN NN O
CYP27 NN NN O
gene NN NN O
products NN NN O
from NN NN O
a NN NN O
patient NN NN O
with NN NN O
cerebrotendinous NN NN B-SpecificDisease
xanthomatosis NN NN I-SpecificDisease
( NN NN O
CTX NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
mutation NN NN O
changed NN NN O
the NN NN O
adrenodoxin NN NN O
cofactor NN NN O
binding NN NN O
residue NN NN O
362Arg NN NN O
to NN NN O
362Ser NN NN O
( NN NN O
CGT NN NN O
362Arg NN NN O
to NN NN O
AGT NN NN O
362Ser NN NN O
) NN NN O
, NN NN O
and NN NN O
was NN NN O
responsible NN NN O
for NN NN O
deficiency NN NN O
in NN NN O
the NN NN O
sterol NN NN O
27-hydroxylase NN NN O
activity NN NN O
, NN NN O
as NN NN O
confirmed NN NN O
by NN NN O
expression NN NN O
of NN NN O
mutant NN NN O
cDNA NN NN O
into NN NN O
COS-1 NN NN O
cells NN NN O
. NN NN O

Quantitative NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
the NN NN O
expression NN NN O
of NN NN O
CYP27 NN NN O
gene NN NN O
mRNA NN NN O
in NN NN O
the NN NN O
patient NN NN O
represented NN NN O
52 NN NN O
. NN NN O

5 NN NN O
% NN NN O
of NN NN O
the NN NN O
normal NN NN O
level NN NN O
. NN NN O

As NN NN O
the NN NN O
mutation NN NN O
occurred NN NN O
at NN NN O
the NN NN O
penultimate NN NN O
nucleotide NN NN O
of NN NN O
exon NN NN O
6 NN NN O
( NN NN O
-2 NN NN O
position NN NN O
of NN NN O
exon NN NN O
6-intron NN NN O
6 NN NN O
splice NN NN O
site NN NN O
) NN NN O
of NN NN O
the NN NN O
gene NN NN O
, NN NN O
we NN NN O
hypothesized NN NN O
that NN NN O
the NN NN O
mutation NN NN O
may NN NN O
partially NN NN O
affect NN NN O
the NN NN O
normal NN NN O
splicing NN NN O
efficiency NN NN O
in NN NN O
exon NN NN O
6 NN NN O
and NN NN O
cause NN NN O
alternative NN NN O
splicing NN NN O
elsewhere NN NN O
, NN NN O
which NN NN O
resulted NN NN O
in NN NN O
decreased NN NN O
transcript NN NN O
in NN NN O
the NN NN O
patient NN NN O
. NN NN O

Transfection NN NN O
of NN NN O
constructed NN NN O
minigenes NN NN O
, NN NN O
with NN NN O
or NN NN O
without NN NN O
the NN NN O
mutation NN NN O
, NN NN O
into NN NN O
COS-1 NN NN O
cells NN NN O
confirmed NN NN O
that NN NN O
the NN NN O
mutant NN NN O
minigene NN NN O
was NN NN O
responsible NN NN O
for NN NN O
a NN NN O
mRNA NN NN O
species NN NN O
alternatively NN NN O
spliced NN NN O
at NN NN O
an NN NN O
activated NN NN O
cryptic NN NN O
5 NN NN O
splice NN NN O
site NN NN O
88 NN NN O
bp NN NN O
upstream NN NN O
from NN NN O
the NN NN O
3 NN NN O
end NN NN O
of NN NN O
exon NN NN O
6 NN NN O
. NN NN O

Our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
the NN NN O
C NN NN O
to NN NN O
A NN NN O
mutation NN NN O
at NN NN O
the NN NN O
penultimate NN NN O
nucleotide NN NN O
of NN NN O
exon NN NN O
6 NN NN O
of NN NN O
the NN NN O
CYP27 NN NN O
gene NN NN O
not NN NN O
only NN NN O
causes NN NN O
the NN NN O
deficiency NN NN B-SpecificDisease
in NN NN I-SpecificDisease
the NN NN I-SpecificDisease
sterol NN NN I-SpecificDisease
27-hydroxylase NN NN I-SpecificDisease
activity NN NN I-SpecificDisease
, NN NN O
but NN NN O
also NN NN O
partially NN NN O
leads NN NN O
to NN NN O
alternative NN NN O
pre-mRNA NN NN O
splicing NN NN O
of NN NN O
the NN NN O
gene NN NN O
. NN NN O

To NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
report NN NN O
regarding NN NN O
effects NN NN O
on NN NN O
pre-mRNA NN NN O
splicing NN NN O
of NN NN O
a NN NN O
mutation NN NN O
at NN NN O
the NN NN O
-2 NN NN O
position NN NN O
of NN NN O
a NN NN O
5 NN NN O
splice NN NN O
site NN NN O
. NN NN O

9792409 NN NN O
ATM NN NN O
germline NN NN O
mutations NN NN O
in NN NN O
classical NN NN O
ataxia-telangiectasia NN NN B-Modifier
patients NN NN O
in NN NN O
the NN NN O
Dutch NN NN O
population NN NN O
. NN NN O

Germline NN NN O
mutations NN NN O
in NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
are NN NN O
responsible NN NN O
for NN NN O
the NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
ataxia-telangiectasia NN NN B-SpecificDisease
( NN NN O
A-T NN NN B-SpecificDisease
) NN NN O
. NN NN O

In NN NN O
our NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
determined NN NN O
the NN NN O
ATM NN NN O
mutation NN NN O
spectrum NN NN O
in NN NN O
19 NN NN O
classical NN NN O
A-T NN NN B-Modifier
patients NN NN O
, NN NN O
including NN NN O
some NN NN O
immigrant NN NN O
populations NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
12 NN NN O
of NN NN O
Dutch NN NN O
ethnic NN NN O
origin NN NN O
. NN NN O

Both NN NN O
the NN NN O
protein NN NN O
truncation NN NN O
test NN NN O
( NN NN O
PTT NN NN O
) NN NN O
and NN NN O
the NN NN O
restriction NN NN O
endonuclease NN NN O
fingerprinting NN NN O
( NN NN O
REF NN NN O
) NN NN O
method NN NN O
were NN NN O
used NN NN O
and NN NN O
compared NN NN O
for NN NN O
their NN NN O
detection NN NN O
efficiency NN NN O
, NN NN O
identifying NN NN O
76 NN NN O
% NN NN O
and NN NN O
60 NN NN O
% NN NN O
of NN NN O
the NN NN O
mutations NN NN O
, NN NN O
respectively NN NN O
. NN NN O

Most NN NN O
patients NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
compound NN NN O
heterozygote NN NN O
. NN NN O

Seventeen NN NN O
mutations NN NN O
were NN NN O
distinct NN NN O
, NN NN O
of NN NN O
which NN NN O
10 NN NN O
were NN NN O
not NN NN O
reported NN NN O
previously NN NN O
. NN NN O

Mutations NN NN O
are NN NN O
small NN NN O
deletions NN NN O
or NN NN O
point NN NN O
mutations NN NN O
frequently NN NN O
affecting NN NN O
splice NN NN O
sites NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
a NN NN O
16 NN NN O
. NN NN O

7-kb NN NN O
genomic NN NN O
deletion NN NN O
of NN NN O
the NN NN O
3 NN NN O
end NN NN O
of NN NN O
the NN NN O
gene NN NN O
, NN NN O
most NN NN O
likely NN NN O
a NN NN O
result NN NN O
of NN NN O
recombination NN NN O
between NN NN O
two NN NN O
LINE NN NN O
elements NN NN O
, NN NN O
was NN NN O
identified NN NN O
. NN NN O

The NN NN O
most NN NN O
frequently NN NN O
found NN NN O
mutation NN NN O
, NN NN O
identified NN NN O
in NN NN O
three NN NN O
unrelated NN NN O
Turkish NN NN O
A-T NN NN B-Modifier
individuals NN NN O
, NN NN O
was NN NN O
previously NN NN O
described NN NN O
to NN NN O
be NN NN O
a NN NN O
Turkish NN NN O
A-T NN NN B-Modifier
founder NN NN O
mutation NN NN O
. NN NN O

The NN NN O
presence NN NN O
of NN NN O
a NN NN O
founder NN NN O
mutation NN NN O
among NN NN O
relatively NN NN O
small NN NN O
ethnic NN NN O
population NN NN O
groups NN NN O
in NN NN O
Western NN NN O
Europe NN NN O
could NN NN O
indicate NN NN O
a NN NN O
high NN NN O
carrier NN NN O
frequency NN NN O
in NN NN O
such NN NN O
communities NN NN O
. NN NN O

In NN NN O
patients NN NN O
of NN NN O
Dutch NN NN O
ethnic NN NN O
origin NN NN O
, NN NN O
however NN NN O
, NN NN O
no NN NN O
significant NN NN O
founder NN NN O
effect NN NN O
could NN NN O
be NN NN O
identified NN NN O
. NN NN O

The NN NN O
observed NN NN O
genetic NN NN O
heterogeneity NN NN O
including NN NN O
the NN NN O
relative NN NN O
high NN NN O
percentage NN NN O
of NN NN O
splice-site NN NN O
mutations NN NN O
had NN NN O
no NN NN O
reflection NN NN O
on NN NN O
the NN NN O
phenotype NN NN O
. NN NN O

All NN NN O
patients NN NN O
manifested NN NN O
classical NN NN O
A-T NN NN B-SpecificDisease
and NN NN O
increased NN NN O
cellular NN NN O
radioresistant NN NN O
DNA NN NN O
synthesis NN NN O
. NN NN O

9792860 NN NN O
Determination NN NN O
of NN NN O
the NN NN O
genomic NN NN O
structure NN NN O
of NN NN O
the NN NN O
COL4A4 NN NN O
gene NN NN O
and NN NN O
of NN NN O
novel NN NN O
mutations NN NN O
causing NN NN O
autosomal NN NN B-SpecificDisease
recessive NN NN I-SpecificDisease
Alport NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Autosomal NN NN B-SpecificDisease
recessive NN NN I-SpecificDisease
Alport NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
a NN NN O
progressive NN NN O
hematuric NN NN B-SpecificDisease
glomerulonephritis NN NN I-SpecificDisease
characterized NN NN O
by NN NN O
glomerular NN NN B-DiseaseClass
basement NN NN I-DiseaseClass
membrane NN NN I-DiseaseClass
abnormalities NN NN I-DiseaseClass
and NN NN O
associated NN NN O
with NN NN O
mutations NN NN O
in NN NN O
either NN NN O
the NN NN O
COL4A3 NN NN O
or NN NN O
the NN NN O
COL4A4 NN NN O
gene NN NN O
, NN NN O
which NN NN O
encode NN NN O
the NN NN O
alpha3 NN NN O
and NN NN O
alpha4 NN NN O
type NN NN O
IV NN NN O
collagen NN NN O
chains NN NN O
, NN NN O
respectively NN NN O
. NN NN O

To NN NN O
date NN NN O
, NN NN O
mutation NN NN O
screening NN NN O
in NN NN O
the NN NN O
two NN NN O
genes NN NN O
has NN NN O
been NN NN O
hampered NN NN O
by NN NN O
the NN NN O
lack NN NN O
of NN NN O
genomic NN NN O
structure NN NN O
information NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
the NN NN O
complete NN NN O
characterization NN NN O
of NN NN O
the NN NN O
48 NN NN O
exons NN NN O
of NN NN O
the NN NN O
COL4A4 NN NN O
gene NN NN O
, NN NN O
a NN NN O
comprehensive NN NN O
gene NN NN O
screen NN NN O
, NN NN O
and NN NN O
the NN NN O
subsequent NN NN O
detection NN NN O
of NN NN O
10 NN NN O
novel NN NN O
mutations NN NN O
in NN NN O
eight NN NN O
patients NN NN O
diagnosed NN NN O
with NN NN O
autosomal NN NN B-SpecificDisease
recessive NN NN I-SpecificDisease
Alport NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Furthermore NN NN O
, NN NN O
we NN NN O
identified NN NN O
a NN NN O
glycine NN NN O
to NN NN O
alanine NN NN O
substitution NN NN O
in NN NN O
the NN NN O
collagenous NN NN O
domain NN NN O
that NN NN O
is NN NN O
apparently NN NN O
silent NN NN O
in NN NN O
the NN NN O
heterozygous NN NN O
carriers NN NN O
, NN NN O
in NN NN O
11 NN NN O
. NN NN O

5 NN NN O
% NN NN O
of NN NN O
all NN NN O
control NN NN O
individuals NN NN O
, NN NN O
and NN NN O
in NN NN O
one NN NN O
control NN NN O
individual NN NN O
homozygous NN NN O
for NN NN O
this NN NN O
glycine NN NN O
substitution NN NN O
. NN NN O

There NN NN O
has NN NN O
been NN NN O
no NN NN O
previous NN NN O
finding NN NN O
of NN NN O
a NN NN O
glycine NN NN O
substitution NN NN O
that NN NN O
is NN NN O
not NN NN O
associated NN NN O
with NN NN O
any NN NN O
obvious NN NN O
phenotype NN NN O
in NN NN O
homozygous NN NN O
individuals NN NN O
. NN NN O

9792861 NN NN O
Founder NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
mutations NN NN O
in NN NN O
French NN NN O
Canadian NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
families NN NN O
. NN NN O

We NN NN O
have NN NN O
identified NN NN O
four NN NN O
mutations NN NN O
in NN NN O
each NN NN O
of NN NN O
the NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
-susceptibility NN NN O
genes NN NN O
, NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
, NN NN O
in NN NN O
French NN NN O
Canadian NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
and NN NN O
breast NN NN B-Modifier
/ NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
families NN NN O
from NN NN O
Quebec NN NN O
. NN NN O

To NN NN O
identify NN NN O
founder NN NN O
effects NN NN O
, NN NN O
we NN NN O
examined NN NN O
independently NN NN O
ascertained NN NN O
French NN NN O
Canadian NN NN O
cancer NN NN B-Modifier
families NN NN O
for NN NN O
the NN NN O
distribution NN NN O
of NN NN O
these NN NN O
eight NN NN O
mutations NN NN O
. NN NN O

Mutations NN NN O
were NN NN O
found NN NN O
in NN NN O
41 NN NN O
of NN NN O
97 NN NN O
families NN NN O
. NN NN O

Six NN NN O
of NN NN O
eight NN NN O
mutations NN NN O
were NN NN O
observed NN NN O
at NN NN O
least NN NN O
twice NN NN O
. NN NN O

The NN NN O
BRCA1 NN NN O
C4446T NN NN O
mutation NN NN O
was NN NN O
the NN NN O
most NN NN O
common NN NN O
mutation NN NN O
found NN NN O
, NN NN O
followed NN NN O
by NN NN O
the NN NN O
BRCA2 NN NN O
8765delAG NN NN O
mutation NN NN O
. NN NN O

Together NN NN O
, NN NN O
these NN NN O
mutations NN NN O
were NN NN O
found NN NN O
in NN NN O
28 NN NN O
of NN NN O
41 NN NN O
families NN NN O
identified NN NN O
to NN NN O
have NN NN O
a NN NN O
mutation NN NN O
. NN NN O

The NN NN O
odds NN NN O
of NN NN O
detection NN NN O
of NN NN O
any NN NN O
of NN NN O
the NN NN O
four NN NN O
BRCA1 NN NN O
mutations NN NN O
was NN NN O
18 NN NN O
. NN NN O

7x NN NN O
greater NN NN O
if NN NN O
one NN NN O
or NN NN O
more NN NN O
cases NN NN O
of NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
were NN NN O
also NN NN O
present NN NN O
in NN NN O
the NN NN O
family NN NN O
. NN NN O

The NN NN O
odds NN NN O
of NN NN O
detection NN NN O
of NN NN O
any NN NN O
of NN NN O
the NN NN O
four NN NN O
BRCA2 NN NN O
mutations NN NN O
was NN NN O
5 NN NN O
. NN NN O

3x NN NN O
greater NN NN O
if NN NN O
there NN NN O
were NN NN O
at NN NN O
least NN NN O
five NN NN O
cases NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
in NN NN O
the NN NN O
family NN NN O
. NN NN O

Interestingly NN NN O
, NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
case NN NN O
36 NN NN O
years NN NN O
of NN NN O
age NN NN O
was NN NN O
strongly NN NN O
predictive NN NN O
of NN NN O
the NN NN O
presence NN NN O
of NN NN O
any NN NN O
of NN NN O
the NN NN O
eight NN NN O
mutations NN NN O
screened NN NN O
. NN NN O

Carriers NN NN O
of NN NN O
the NN NN O
same NN NN O
mutation NN NN O
, NN NN O
from NN NN O
different NN NN O
families NN NN O
, NN NN O
shared NN NN O
similar NN NN O
haplotypes NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
mutant NN NN O
alleles NN NN O
were NN NN O
likely NN NN O
to NN NN O
be NN NN O
identical NN NN O
by NN NN O
descent NN NN O
for NN NN O
a NN NN O
mutation NN NN O
in NN NN O
the NN NN O
founder NN NN O
population NN NN O
. NN NN O

The NN NN O
identification NN NN O
of NN NN O
common NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
mutations NN NN O
will NN NN O
facilitate NN NN O
carrier NN NN O
detection NN NN O
in NN NN O
French NN NN O
Canadian NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
and NN NN O
breast NN NN B-Modifier
/ NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
families NN NN O
. NN NN O

9800909 NN NN O
Are NN NN O
Dp71 NN NN O
and NN NN O
Dp140 NN NN O
brain NN NN O
dystrophin NN NN O
isoforms NN NN O
related NN NN O
to NN NN O
cognitive NN NN B-DiseaseClass
impairment NN NN I-DiseaseClass
in NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
? NN NN O

Molecular NN NN O
study NN NN O
and NN NN O
neuropsychological NN NN O
analysis NN NN O
were NN NN O
performed NN NN O
concurrently NN NN O
on NN NN O
49 NN NN O
patients NN NN O
with NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
in NN NN O
order NN NN O
to NN NN O
find NN NN O
a NN NN O
molecular NN NN O
explanation NN NN O
for NN NN O
the NN NN O
cognitive NN NN B-DiseaseClass
impairment NN NN I-DiseaseClass
observed NN NN O
in NN NN O
most NN NN O
DMD NN NN B-Modifier
patients NN NN O
. NN NN O

Complete NN NN O
analysis NN NN O
of NN NN O
the NN NN O
dystrophin NN NN O
gene NN NN O
was NN NN O
performed NN NN O
to NN NN O
define NN NN O
the NN NN O
localization NN NN O
of NN NN O
deletions NN NN O
and NN NN O
duplications NN NN O
in NN NN O
relation NN NN O
to NN NN O
the NN NN O
different NN NN O
DMD NN NN B-Modifier
promoters NN NN O
. NN NN O

Qualitative NN NN O
analysis NN NN O
of NN NN O
the NN NN O
Dp71 NN NN O
transcript NN NN O
and NN NN O
testing NN NN O
for NN NN O
the NN NN O
specific NN NN O
first NN NN O
exon NN NN O
of NN NN O
Dp140 NN NN O
were NN NN O
also NN NN O
carried NN NN O
out NN NN O
. NN NN O

Neuropsychological NN NN O
analysis NN NN O
assessed NN NN O
verbal NN NN O
and NN NN O
visuospatial NN NN O
intelligence NN NN O
, NN NN O
verbal NN NN O
memory NN NN O
, NN NN O
and NN NN O
reading NN NN O
skills NN NN O
. NN NN O

Comparison NN NN O
of NN NN O
molecular NN NN O
and NN NN O
psychometric NN NN O
findings NN NN O
demonstrated NN NN O
that NN NN O
deletions NN NN O
and NN NN O
duplications NN NN O
that NN NN O
were NN NN O
localized NN NN O
in NN NN O
the NN NN O
distal NN NN O
part NN NN O
of NN NN O
the NN NN O
gene NN NN O
seemed NN NN O
to NN NN O
be NN NN O
preferentially NN NN O
associated NN NN O
with NN NN O
cognitive NN NN B-DiseaseClass
impairment NN NN I-DiseaseClass
. NN NN O

Two NN NN O
altered NN NN O
Dp71 NN NN O
transcripts NN NN O
and NN NN O
two NN NN O
deleted NN NN O
Dp140 NN NN O
DNA NN NN O
sequences NN NN O
were NN NN O
found NN NN O
in NN NN O
four NN NN O
patients NN NN O
with NN NN O
severe NN NN O
cerebral NN NN B-DiseaseClass
dysfunction NN NN I-DiseaseClass
. NN NN O

These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
some NN NN O
sequences NN NN O
located NN NN O
in NN NN O
the NN NN O
distal NN NN O
part NN NN O
of NN NN O
the NN NN O
gene NN NN O
and NN NN O
, NN NN O
in NN NN O
particular NN NN O
, NN NN O
some NN NN O
DMD NN NN B-Modifier
isoforms NN NN O
expressed NN NN O
in NN NN O
the NN NN O
brain NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
the NN NN O
cognitive NN NN B-DiseaseClass
impairment NN NN I-DiseaseClass
associated NN NN O
with NN NN O
DMD NN NN B-SpecificDisease
. NN NN O

. NN NN O

9831355 NN NN O
I1307K NN NN O
APC NN NN O
and NN NN O
hMLH1 NN NN O
mutations NN NN O
in NN NN O
a NN NN O
non-Jewish NN NN O
family NN NN O
with NN NN O
hereditary NN NN B-SpecificDisease
non-polyposis NN NN I-SpecificDisease
colorectal NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

We NN NN O
describe NN NN O
a NN NN O
French NN NN O
Canadian NN NN O
hereditary NN NN B-Modifier
non-polyposis NN NN I-Modifier
colorectal NN NN I-Modifier
cancer NN NN I-Modifier
( NN NN O
HNPCC NN NN B-Modifier
) NN NN O
kindred NN NN O
which NN NN O
carries NN NN O
a NN NN O
novel NN NN O
truncating NN NN O
mutation NN NN O
in NN NN O
hMLH1 NN NN O
. NN NN O

Interestingly NN NN O
, NN NN O
the NN NN O
I1307K NN NN O
APC NN NN O
polymorphism NN NN O
, NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
is NN NN O
also NN NN O
present NN NN O
in NN NN O
this NN NN O
family NN NN O
. NN NN O

The NN NN O
I1307K NN NN O
polymorphism NN NN O
has NN NN O
previously NN NN O
only NN NN O
been NN NN O
identified NN NN O
in NN NN O
individuals NN NN O
of NN NN O
self-reported NN NN O
Ashkenazi NN NN O
Jewish NN NN O
origins NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
in NN NN O
this NN NN O
family NN NN O
, NN NN O
there NN NN O
appears NN NN O
to NN NN O
be NN NN O
no NN NN O
relationship NN NN O
between NN NN O
the NN NN O
I1307K NN NN O
polymorphism NN NN O
and NN NN O
the NN NN O
presence NN NN O
or NN NN O
absence NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
. NN NN O

. NN NN O

9843038 NN NN O
Identification NN NN O
of NN NN O
a NN NN O
novel NN NN O
mutation NN NN O
of NN NN O
the NN NN O
CPO NN NN O
gene NN NN O
in NN NN O
a NN NN O
Japanese NN NN O
hereditary NN NN B-Modifier
coproporphyria NN NN I-Modifier
family NN NN O
. NN NN O

Hereditary NN NN B-SpecificDisease
coproporphyria NN NN I-SpecificDisease
( NN NN O
HCP NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
a NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
coproporphyrinogen NN NN I-SpecificDisease
oxidase NN NN I-SpecificDisease
( NN NN O
CPO NN NN O
) NN NN O
caused NN NN O
by NN NN O
a NN NN O
mutation NN NN O
in NN NN O
the NN NN O
CPO NN NN O
gene NN NN O
. NN NN O

Only NN NN O
11 NN NN O
mutations NN NN O
of NN NN O
the NN NN O
gene NN NN O
have NN NN O
been NN NN O
reported NN NN O
in NN NN O
HCP NN NN B-Modifier
patients NN NN O
. NN NN O

We NN NN O
report NN NN O
another NN NN O
mutation NN NN O
in NN NN O
a NN NN O
Japanese NN NN O
family NN NN O
. NN NN O

Polymerase NN NN O
chain NN NN O
reaction-single NN NN O
strand NN NN O
conformational NN NN O
polymorphism NN NN O
and NN NN O
direct NN NN O
sequence NN NN O
analyses NN NN O
demonstrated NN NN O
a NN NN O
C NN NN O
to NN NN O
T NN NN O
substitution NN NN O
in NN NN O
exon NN NN O
1 NN NN O
of NN NN O
the NN NN O
CPO NN NN O
gene NN NN O
at NN NN O
nucleotide NN NN O
position NN NN O
85 NN NN O
, NN NN O
which NN NN O
lies NN NN O
in NN NN O
the NN NN O
putative NN NN O
presequence NN NN O
for NN NN O
targeting NN NN O
to NN NN O
mitochondria NN NN O
. NN NN O

This NN NN O
mutation NN NN O
changes NN NN O
the NN NN O
codon NN NN O
for NN NN O
glutamine NN NN O
to NN NN O
a NN NN O
termination NN NN O
codon NN NN O
at NN NN O
amino NN NN O
acid NN NN O
position NN NN O
29 NN NN O
. NN NN O

MaeI NN NN O
restriction NN NN O
analysis NN NN O
showed NN NN O
two NN NN O
other NN NN O
carriers NN NN O
in NN NN O
the NN NN O
family NN NN O
. NN NN O

The NN NN O
C-T NN NN O
mutation NN NN O
is NN NN O
located NN NN O
within NN NN O
a NN NN O
recently NN NN O
proposed NN NN O
putative NN NN O
alternative NN NN O
translation NN NN O
initiation NN NN O
codon NN NN O
( NN NN O
TIC-1 NN NN O
) NN NN O
, NN NN O
supporting NN NN O
that NN NN O
TIC-1 NN NN O
is NN NN O
the NN NN O
real NN NN O
TIC NN NN O
rather NN NN O
than NN NN O
TIC-2 NN NN O
. NN NN O

. NN NN O

9848786 NN NN O
Human NN NN B-SpecificDisease
complement NN NN I-SpecificDisease
factor NN NN I-SpecificDisease
H NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
associated NN NN O
with NN NN O
hemolytic NN NN B-SpecificDisease
uremic NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

This NN NN O
study NN NN O
reports NN NN O
on NN NN O
six NN NN O
cases NN NN O
of NN NN O
deficiency NN NN B-SpecificDisease
in NN NN I-SpecificDisease
the NN NN I-SpecificDisease
human NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
regulatory NN NN I-SpecificDisease
protein NN NN I-SpecificDisease
Factor NN NN I-SpecificDisease
H NN NN I-SpecificDisease
( NN NN O
FH NN NN O
) NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
an NN NN O
acute NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Five NN NN O
of NN NN O
the NN NN O
cases NN NN O
were NN NN O
observed NN NN O
in NN NN O
children NN NN O
presenting NN NN O
with NN NN O
idiopathic NN NN O
hemolytic NN NN B-SpecificDisease
uremic NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
HUS NN NN B-SpecificDisease
) NN NN O
. NN NN O

Two NN NN O
of NN NN O
the NN NN O
children NN NN O
exhibited NN NN O
a NN NN O
homozygous NN NN O
deficiency NN NN O
characterized NN NN O
by NN NN O
the NN NN O
absence NN NN O
of NN NN O
the NN NN O
150-kD NN NN O
form NN NN O
of NN NN O
Factor NN NN O
H NN NN O
and NN NN O
the NN NN O
presence NN NN O
, NN NN O
upon NN NN O
immunoblotting NN NN O
, NN NN O
of NN NN O
the NN NN O
42-kD NN NN O
Factor NN NN O
H-like NN NN O
protein NN NN O
1 NN NN O
( NN NN O
FHL-1 NN NN O
) NN NN O
and NN NN O
other NN NN O
FH-related NN NN O
protein NN NN O
( NN NN O
FHR NN NN O
) NN NN O
bands NN NN O
. NN NN O

Southern NN NN O
blot NN NN O
and NN NN O
PCR NN NN O
analysis NN NN O
of NN NN O
DNA NN NN O
of NN NN O
one NN NN O
patient NN NN O
with NN NN O
homozygous NN NN O
deficiency NN NN O
ruled NN NN O
out NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
large NN NN O
deletion NN NN O
of NN NN O
the NN NN O
FH NN NN O
gene NN NN O
as NN NN O
the NN NN O
underlying NN NN O
defect NN NN O
for NN NN O
the NN NN O
deficiency NN NN O
. NN NN O

The NN NN O
other NN NN O
four NN NN O
children NN NN O
presented NN NN O
with NN NN O
heterozygous NN NN O
deficiency NN NN O
and NN NN O
exhibited NN NN O
a NN NN O
normal NN NN O
immunoblotting NN NN O
pattern NN NN O
of NN NN O
proteins NN NN O
of NN NN O
the NN NN O
FH NN NN O
family NN NN O
. NN NN O

Factor NN NN B-SpecificDisease
H NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
the NN NN O
only NN NN O
complement NN NN B-DiseaseClass
deficiency NN NN I-DiseaseClass
associated NN NN O
with NN NN O
HUS NN NN B-SpecificDisease
. NN NN O

These NN NN O
observations NN NN O
suggest NN NN O
a NN NN O
role NN NN O
for NN NN O
FH NN NN O
and NN NN O
/ NN NN O
or NN NN O
FH NN NN O
receptors NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
idiopathic NN NN O
HUS NN NN B-SpecificDisease
. NN NN O

. NN NN O

9852676 NN NN O
Further NN NN O
evidence NN NN O
for NN NN O
a NN NN O
major NN NN O
ancient NN NN O
mutation NN NN O
underlying NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
from NN NN O
linkage NN NN O
disequilibrium NN NN O
studies NN NN O
in NN NN O
the NN NN O
Japanese NN NN O
population NN NN O
. NN NN O

The NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
( NN NN O
DM NN NN B-Modifier
) NN NN O
mutation NN NN O
is NN NN O
an NN NN O
unstable NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
repeat NN NN O
, NN NN O
present NN NN O
at NN NN O
a NN NN O
copy NN NN O
number NN NN O
of NN NN O
5-37 NN NN O
repeats NN NN O
on NN NN O
normal NN NN O
chromosomes NN NN O
but NN NN O
amplified NN NN O
to NN NN O
50-3000 NN NN O
copies NN NN O
on NN NN O
DM NN NN B-Modifier
chromosomes NN NN O
. NN NN O

Previous NN NN O
findings NN NN O
in NN NN O
Caucasian NN NN O
populations NN NN O
of NN NN O
a NN NN O
DM NN NN B-Modifier
founder NN NN O
chromosome NN NN O
raise NN NN O
a NN NN O
question NN NN O
about NN NN O
the NN NN O
molecular NN NN O
events NN NN O
involved NN NN O
in NN NN O
the NN NN O
expansion NN NN O
mutation NN NN O
. NN NN O

To NN NN O
investigate NN NN O
whether NN NN O
a NN NN O
founder NN NN O
chromosome NN NN O
for NN NN O
the NN NN O
DM NN NN B-Modifier
mutation NN NN O
exists NN NN O
in NN NN O
the NN NN O
Japanese NN NN O
population NN NN O
, NN NN O
we NN NN O
genotyped NN NN O
families NN NN O
using NN NN O
polymorphic NN NN O
markers NN NN O
near NN NN O
the NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
repeat NN NN O
region NN NN O
and NN NN O
constructed NN NN O
haplotypes NN NN O
. NN NN O

Six NN NN O
different NN NN O
haplotypes NN NN O
were NN NN O
found NN NN O
and NN NN O
DM NN NN B-Modifier
alleles NN NN O
were NN NN O
always NN NN O
haplotype NN NN O
A NN NN O
. NN NN O

To NN NN O
find NN NN O
an NN NN O
origin NN NN O
of NN NN O
the NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
repeat NN NN O
mutation NN NN O
and NN NN O
to NN NN O
investigate NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
the NN NN O
expansion NN NN O
mutation NN NN O
in NN NN O
the NN NN O
Japanese NN NN O
population NN NN O
we NN NN O
have NN NN O
studied NN NN O
90 NN NN O
Japanese NN NN O
DM NN NN B-Modifier
families NN NN O
comprising NN NN O
190 NN NN O
affected NN NN O
and NN NN O
130 NN NN O
unaffected NN NN O
members NN NN O
. NN NN O

The NN NN O
results NN NN O
suggest NN NN O
that NN NN O
a NN NN O
few NN NN O
common NN NN O
ancestral NN NN O
mutations NN NN O
in NN NN O
both NN NN O
Caucasian NN NN O
and NN NN O
Japanese NN NN O
populations NN NN O
have NN NN O
originated NN NN O
by NN NN O
expansion NN NN O
of NN NN O
an NN NN O
ancestral NN NN O
n NN NN O
= NN NN O
5 NN NN O
repeat NN NN O
to NN NN O
n NN NN O
= NN NN O
19-37 NN NN O
copies NN NN O
. NN NN O

These NN NN O
data NN NN O
support NN NN O
multistep NN NN O
models NN NN O
of NN NN O
triplet NN NN O
repeat NN NN O
expansion NN NN O
that NN NN O
have NN NN O
been NN NN O
proposed NN NN O
for NN NN O
both NN NN O
DM NN NN B-SpecificDisease
and NN NN O
Friedreichs NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
. NN NN O

. NN NN O

9856498 NN NN O
The NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
C6 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
the NN NN O
western NN NN O
Cape NN NN O
, NN NN O
South NN NN O
Africa NN NN O
. NN NN O

Deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
sixth NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
human NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
( NN NN O
C6 NN NN O
) NN NN O
has NN NN O
been NN NN O
reported NN NN O
in NN NN O
a NN NN O
number NN NN O
of NN NN O
families NN NN O
from NN NN O
the NN NN O
western NN NN O
Cape NN NN O
, NN NN O
South NN NN O
Africa NN NN O
. NN NN O

Meningococcal NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
is NN NN O
endemic NN NN O
in NN NN O
the NN NN O
Cape NN NN O
and NN NN O
almost NN NN O
all NN NN O
pedigrees NN NN O
of NN NN O
total NN NN O
C6 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
( NN NN O
C6Q0 NN NN O
) NN NN O
have NN NN O
been NN NN O
ascertained NN NN O
because NN NN O
of NN NN O
recurrent NN NN O
disease NN NN O
. NN NN O

We NN NN O
have NN NN O
sequenced NN NN O
the NN NN O
expressed NN NN O
exons NN NN O
of NN NN O
the NN NN O
C6 NN NN O
gene NN NN O
from NN NN O
selected NN NN O
cases NN NN O
and NN NN O
have NN NN O
found NN NN O
three NN NN O
molecular NN NN O
defects NN NN O
leading NN NN O
to NN NN O
total NN NN O
deficiency NN NN O
879delG NN NN O
, NN NN O
which NN NN O
is NN NN O
the NN NN O
common NN NN O
defect NN NN O
in NN NN O
the NN NN O
Cape NN NN O
and NN NN O
hitherto NN NN O
unreported NN NN O
, NN NN O
and NN NN O
1195delC NN NN O
and NN NN O
1936delG NN NN O
, NN NN O
which NN NN O
have NN NN O
been NN NN O
previously NN NN O
reported NN NN O
in NN NN O
African-Americans NN NN O
. NN NN O

We NN NN O
also NN NN O
show NN NN O
that NN NN O
the NN NN O
879delG NN NN O
and NN NN O
1195delC NN NN O
defects NN NN O
are NN NN O
associated NN NN O
with NN NN O
characteristic NN NN O
C6 NN NN O
/ NN NN O
C7 NN NN O
region NN NN O
DNA NN NN O
marker NN NN O
haplotypes NN NN O
, NN NN O
although NN NN O
small NN NN O
variations NN NN O
were NN NN O
observed NN NN O
. NN NN O

The NN NN O
1936delG NN NN O
defect NN NN O
was NN NN O
observed NN NN O
only NN NN O
once NN NN O
in NN NN O
the NN NN O
Cape NN NN O
, NN NN O
but NN NN O
its NN NN O
associated NN NN O
haplotype NN NN O
could NN NN O
be NN NN O
deduced NN NN O
. NN NN O

The NN NN O
data NN NN O
from NN NN O
the NN NN O
haplotypes NN NN O
indicate NN NN O
that NN NN O
these NN NN O
three NN NN O
molecular NN NN O
defects NN NN O
account NN NN O
for NN NN O
the NN NN O
defects NN NN O
in NN NN O
all NN NN O
the NN NN O
38 NN NN O
unrelated NN NN O
C6Q0 NN NN O
individuals NN NN O
we NN NN O
have NN NN O
studied NN NN O
from NN NN O
the NN NN O
Cape NN NN O
. NN NN O

We NN NN O
have NN NN O
also NN NN O
observed NN NN O
the NN NN O
879delG NN NN O
defect NN NN O
in NN NN O
two NN NN O
Dutch NN NN O
C6-deficient NN NN B-Modifier
kindreds NN NN O
, NN NN O
but NN NN O
the NN NN O
879delG NN NN O
defect NN NN O
in NN NN O
the NN NN O
Cape NN NN O
probably NN NN O
did NN NN O
not NN NN O
come NN NN O
from NN NN O
The NN NN O
Netherlands NN NN O
. NN NN O

. NN NN O

9856499 NN NN O
Complement NN NN B-SpecificDisease
C7 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
: NN NN O
seven NN NN O
further NN NN O
molecular NN NN O
defects NN NN O
and NN NN O
their NN NN O
associated NN NN O
marker NN NN O
haplotypes NN NN O
. NN NN O

Seven NN NN O
further NN NN O
molecular NN NN O
bases NN NN O
of NN NN O
C7 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
are NN NN O
described NN NN O
. NN NN O

All NN NN O
these NN NN O
new NN NN O
molecular NN NN O
defects NN NN O
involve NN NN O
single-nucleotide NN NN O
events NN NN O
, NN NN O
deletions NN NN O
and NN NN O
substitutions NN NN O
, NN NN O
some NN NN O
of NN NN O
which NN NN O
alter NN NN O
splice NN NN O
sites NN NN O
, NN NN O
and NN NN O
others NN NN O
codons NN NN O
. NN NN O

They NN NN O
are NN NN O
distributed NN NN O
along NN NN O
the NN NN O
C7 NN NN O
gene NN NN O
, NN NN O
but NN NN O
predominantly NN NN O
towards NN NN O
the NN NN O
3 NN NN O
end NN NN O
. NN NN O

All NN NN O
were NN NN O
found NN NN O
in NN NN O
compound NN NN O
heterozygous NN NN O
individuals NN NN O
. NN NN O

The NN NN O
C6 NN NN O
/ NN NN O
C7 NN NN O
marker NN NN O
haplotypes NN NN O
associated NN NN O
with NN NN O
most NN NN O
C7 NN NN B-SpecificDisease
defects NN NN I-SpecificDisease
are NN NN O
tabulated NN NN O
. NN NN O

. NN NN O

9861003 NN NN O
A NN NN O
genome-wide NN NN O
search NN NN O
for NN NN O
chromosomal NN NN O
loci NN NN O
linked NN NN O
to NN NN O
mental NN NN O
health NN NN O
wellness NN NN O
in NN NN O
relatives NN NN O
at NN NN O
high NN NN O
risk NN NN O
for NN NN O
bipolar NN NN B-SpecificDisease
affective NN NN I-SpecificDisease
disorder NN NN I-SpecificDisease
among NN NN O
the NN NN O
Old NN NN O
Order NN NN O
Amish NN NN O
. NN NN O

Bipolar NN NN B-SpecificDisease
affective NN NN I-SpecificDisease
disorder NN NN I-SpecificDisease
( NN NN O
BPAD NN NN B-SpecificDisease
; NN NN O
manic-depressive NN NN B-SpecificDisease
illness NN NN I-SpecificDisease
) NN NN O
is NN NN O
characterized NN NN O
by NN NN O
episodes NN NN O
of NN NN O
mania NN NN B-SpecificDisease
and NN NN O
/ NN NN O
or NN NN O
hypomania NN NN B-SpecificDisease
interspersed NN NN O
with NN NN O
periods NN NN O
of NN NN O
depression NN NN B-SpecificDisease
. NN NN O

Compelling NN NN O
evidence NN NN O
supports NN NN O
a NN NN O
significant NN NN O
genetic NN NN O
component NN NN O
in NN NN O
the NN NN O
susceptibility NN NN O
to NN NN O
develop NN NN O
BPAD NN NN B-SpecificDisease
. NN NN O

To NN NN O
date NN NN O
, NN NN O
however NN NN O
, NN NN O
linkage NN NN O
studies NN NN O
have NN NN O
attempted NN NN O
only NN NN O
to NN NN O
identify NN NN O
chromosomal NN NN O
loci NN NN O
that NN NN O
cause NN NN O
or NN NN O
increase NN NN O
the NN NN O
risk NN NN O
of NN NN O
developing NN NN O
BPAD NN NN B-SpecificDisease
. NN NN O

To NN NN O
determine NN NN O
whether NN NN O
there NN NN O
could NN NN O
be NN NN O
protective NN NN O
alleles NN NN O
that NN NN O
prevent NN NN O
or NN NN O
reduce NN NN O
the NN NN O
risk NN NN O
of NN NN O
developing NN NN O
BPAD NN NN B-SpecificDisease
, NN NN O
similar NN NN O
to NN NN O
what NN NN O
is NN NN O
observed NN NN O
in NN NN O
other NN NN O
genetic NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
, NN NN O
we NN NN O
used NN NN O
mental NN NN O
health NN NN O
wellness NN NN O
( NN NN O
absence NN NN O
of NN NN O
any NN NN O
psychiatric NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
) NN NN O
as NN NN O
the NN NN O
phenotype NN NN O
in NN NN O
our NN NN O
genome-wide NN NN O
linkage NN NN O
scan NN NN O
of NN NN O
several NN NN O
large NN NN O
multigeneration NN NN O
Old NN NN O
Order NN NN O
Amish NN NN O
pedigrees NN NN O
exhibiting NN NN O
an NN NN O
extremely NN NN O
high NN NN O
incidence NN NN O
of NN NN O
BPAD NN NN B-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
found NN NN O
strong NN NN O
evidence NN NN O
for NN NN O
a NN NN O
locus NN NN O
on NN NN O
chromosome NN NN O
4p NN NN O
at NN NN O
D4S2949 NN NN O
( NN NN O
maximum NN NN O
GENEHUNTER-PLUS NN NN O
nonparametric NN NN O
linkage NN NN O
score NN NN O
= NN NN O
4 NN NN O
. NN NN O

05 NN NN O
, NN NN O
P NN NN O
= NN NN O
5 NN NN O
. NN NN O

22 NN NN O
x NN NN O
10 NN NN O
( NN NN O
-4 NN NN O
) NN NN O
; NN NN O
SIBPAL NN NN O
Pempirical NN NN O
value NN NN O
3 NN NN O
x NN NN O
10 NN NN O
( NN NN O
-5 NN NN O
) NN NN O
) NN NN O
and NN NN O
suggestive NN NN O
evidence NN NN O
for NN NN O
a NN NN O
locus NN NN O
on NN NN O
chromosome NN NN O
4q NN NN O
at NN NN O
D4S397 NN NN O
( NN NN O
maximum NN NN O
GENEHUNTER-PLUS NN NN O
nonparametric NN NN O
linkage NN NN O
score NN NN O
= NN NN O
3 NN NN O
. NN NN O

29 NN NN O
, NN NN O
P NN NN O
= NN NN O
2 NN NN O
. NN NN O

57 NN NN O
x NN NN O
10 NN NN O
( NN NN O
-3 NN NN O
) NN NN O
; NN NN O
SIBPAL NN NN O
Pempirical NN NN O
value NN NN O
1 NN NN O
x NN NN O
10 NN NN O
( NN NN O
-3 NN NN O
) NN NN O
) NN NN O
that NN NN O
are NN NN O
linked NN NN O
to NN NN O
mental NN NN O
health NN NN O
wellness NN NN O
. NN NN O

These NN NN O
findings NN NN O
are NN NN O
consistent NN NN O
with NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
certain NN NN O
alleles NN NN O
could NN NN O
prevent NN NN O
or NN NN O
modify NN NN O
the NN NN O
clinical NN NN O
manifestations NN NN O
of NN NN O
BPAD NN NN B-SpecificDisease
and NN NN O
perhaps NN NN O
other NN NN O
related NN NN O
affective NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
. NN NN O

9863607 NN NN O
Segregation NN NN O
distortion NN NN O
in NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
which NN NN O
, NN NN O
in NN NN O
the NN NN O
typical NN NN O
pedigree NN NN O
, NN NN O
shows NN NN O
a NN NN O
three NN NN O
generation NN NN O
anticipation NN NN O
cascade NN NN O
. NN NN O

This NN NN O
results NN NN O
in NN NN O
infertility NN NN B-SpecificDisease
and NN NN O
congenital NN NN B-SpecificDisease
myotonic NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
CDM NN NN B-SpecificDisease
) NN NN O
with NN NN O
the NN NN O
disappearance NN NN O
of NN NN O
DM NN NN B-SpecificDisease
in NN NN O
that NN NN O
pedigree NN NN O
. NN NN O

The NN NN O
concept NN NN O
of NN NN O
segregation NN NN O
distortion NN NN O
, NN NN O
where NN NN O
there NN NN O
is NN NN O
preferential NN NN O
transmission NN NN O
of NN NN O
the NN NN O
larger NN NN O
allele NN NN O
at NN NN O
the NN NN O
DM NN NN B-Modifier
locus NN NN O
, NN NN O
has NN NN O
been NN NN O
put NN NN O
forward NN NN O
to NN NN O
explain NN NN O
partially NN NN O
the NN NN O
maintenance NN NN O
of NN NN O
DM NN NN B-SpecificDisease
in NN NN O
the NN NN O
population NN NN O
. NN NN O

In NN NN O
a NN NN O
survey NN NN O
of NN NN O
DM NN NN B-SpecificDisease
in NN NN O
Northern NN NN O
Ireland NN NN O
, NN NN O
59 NN NN O
pedigrees NN NN O
were NN NN O
ascertained NN NN O
. NN NN O

Sibships NN NN O
where NN NN O
the NN NN O
status NN NN O
of NN NN O
all NN NN O
the NN NN O
members NN NN O
had NN NN O
been NN NN O
identified NN NN O
were NN NN O
examined NN NN O
to NN NN O
determine NN NN O
the NN NN O
transmission NN NN O
of NN NN O
the NN NN O
DM NN NN B-Modifier
expansion NN NN O
from NN NN O
affected NN NN O
parents NN NN O
to NN NN O
their NN NN O
offspring NN NN O
. NN NN O

Where NN NN O
the NN NN O
transmitting NN NN O
parent NN NN O
was NN NN O
male NN NN O
, NN NN O
58 NN NN O
. NN NN O

3 NN NN O
% NN NN O
of NN NN O
the NN NN O
offspring NN NN O
were NN NN O
affected NN NN O
, NN NN O
and NN NN O
in NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
female NN NN O
transmitting NN NN O
parent NN NN O
, NN NN O
68 NN NN O
. NN NN O

7 NN NN O
% NN NN O
were NN NN O
affected NN NN O
. NN NN O

Studies NN NN O
on NN NN O
meiotic NN NN O
drive NN NN O
in NN NN O
DM NN NN B-SpecificDisease
have NN NN O
shown NN NN O
increased NN NN O
transmission NN NN O
of NN NN O
the NN NN O
larger NN NN O
allele NN NN O
at NN NN O
the NN NN O
DM NN NN B-Modifier
locus NN NN O
in NN NN O
non-DM NN NN O
heterozygotes NN NN O
for NN NN O
CTGn NN NN O
. NN NN O

This NN NN O
study NN NN O
provides NN NN O
further NN NN O
evidence NN NN O
that NN NN O
the NN NN O
DM NN NN B-Modifier
expansion NN NN O
tends NN NN O
to NN NN O
be NN NN O
transmitted NN NN O
preferentially NN NN O
. NN NN O

9867744 NN NN O
Diagnosis NN NN O
of NN NN O
hemochromatosis NN NN B-SpecificDisease
. NN NN O

If NN NN O
untreated NN NN O
, NN NN O
hemochromatosis NN NN B-SpecificDisease
can NN NN O
cause NN NN O
serious NN NN O
illness NN NN O
and NN NN O
early NN NN B-SpecificDisease
death NN NN I-SpecificDisease
, NN NN O
but NN NN O
the NN NN O
disease NN NN O
is NN NN O
still NN NN O
substantially NN NN O
under-diagnosed NN NN O
. NN NN O

The NN NN O
cornerstone NN NN O
of NN NN O
screening NN NN O
and NN NN O
case NN NN O
detection NN NN O
is NN NN O
the NN NN O
measurement NN NN O
of NN NN O
serum NN NN O
transferrin NN NN O
saturation NN NN O
and NN NN O
the NN NN O
serum NN NN O
ferritin NN NN O
level NN NN O
. NN NN O

Once NN NN O
the NN NN O
diagnosis NN NN O
is NN NN O
suspected NN NN O
, NN NN O
physicians NN NN O
must NN NN O
use NN NN O
serum NN NN O
ferritin NN NN O
levels NN NN O
and NN NN O
hepatic NN NN O
iron NN NN O
stores NN NN O
on NN NN O
liver NN NN O
biopsy NN NN O
specimens NN NN O
to NN NN O
assess NN NN O
patients NN NN O
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
iron NN NN B-SpecificDisease
overload NN NN I-SpecificDisease
. NN NN O

Liver NN NN O
biopsy NN NN O
is NN NN O
also NN NN O
used NN NN O
to NN NN O
establish NN NN O
the NN NN O
presence NN NN O
or NN NN O
absence NN NN O
of NN NN O
cirrhosis NN NN B-SpecificDisease
, NN NN O
which NN NN O
can NN NN O
affect NN NN O
prognosis NN NN O
and NN NN O
management NN NN O
. NN NN O

A NN NN O
DNA-based NN NN O
test NN NN O
for NN NN O
the NN NN O
HFE NN NN O
gene NN NN O
is NN NN O
commercially NN NN O
available NN NN O
, NN NN O
but NN NN O
its NN NN O
place NN NN O
in NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
hemochromatosis NN NN B-SpecificDisease
is NN NN O
still NN NN O
being NN NN O
evaluated NN NN O
. NN NN O

Currently NN NN O
, NN NN O
the NN NN O
most NN NN O
useful NN NN O
role NN NN O
for NN NN O
this NN NN O
test NN NN O
is NN NN O
in NN NN O
the NN NN O
detection NN NN O
of NN NN O
hemochromatosis NN NN B-SpecificDisease
in NN NN O
the NN NN O
family NN NN O
members NN NN O
of NN NN O
patients NN NN O
with NN NN O
a NN NN O
proven NN NN O
case NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

It NN NN O
is NN NN O
crucial NN NN O
to NN NN O
diagnose NN NN O
hemochromatosis NN NN B-SpecificDisease
before NN NN O
hepatic NN NN B-SpecificDisease
cirrhosis NN NN I-SpecificDisease
develops NN NN O
because NN NN O
phlebotomy NN NN O
therapy NN NN O
can NN NN O
avert NN NN O
serious NN NN O
chronic NN NN O
disease NN NN O
and NN NN O
can NN NN O
even NN NN O
lead NN NN O
to NN NN O
normal NN NN O
life NN NN O
expectancy NN NN O
. NN NN O

. NN NN O

9869602 NN NN O
Prevalence NN NN O
of NN NN O
the NN NN O
I1307K NN NN O
APC NN NN B-Modifier
gene NN NN O
variant NN NN O
in NN NN O
Israeli NN NN O
Jews NN NN O
of NN NN O
differing NN NN O
ethnic NN NN O
origin NN NN O
and NN NN O
risk NN NN O
for NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

BACKGROUND NN NN O
& NN NN O
AIMS NN NN O
Israeli NN NN O
Jews NN NN O
of NN NN O
European NN NN O
birth NN NN O
, NN NN O
i NN NN O
. NN NN O

e NN NN O
. NN NN O

, NN NN O
Ashkenazim NN NN O
, NN NN O
have NN NN O
the NN NN O
highest NN NN O
colorectal NN NN B-Modifier
cancer NN NN I-Modifier
incidence NN NN O
of NN NN O
any NN NN O
Israeli NN NN O
ethnic NN NN O
group NN NN O
. NN NN O

The NN NN O
I1307K NN NN O
APC NN NN B-Modifier
gene NN NN O
variant NN NN O
was NN NN O
found NN NN O
in NN NN O
6 NN NN O
. NN NN O

1 NN NN O
% NN NN O
of NN NN O
American NN NN O
Jews NN NN O
, NN NN O
28 NN NN O
% NN NN O
of NN NN O
their NN NN O
familial NN NN O
colorectal NN NN B-Modifier
cancer NN NN I-Modifier
cases NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
non-Jews NN NN O
. NN NN O

We NN NN O
assessed NN NN O
the NN NN O
I1307K NN NN O
prevalence NN NN O
in NN NN O
Israeli NN NN O
Jews NN NN O
of NN NN O
differing NN NN O
ethnic NN NN O
origin NN NN O
and NN NN O
risk NN NN O
for NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

METHODS NN NN O
DNA NN NN O
samples NN NN O
from NN NN O
500 NN NN O
unrelated NN NN O
Jews NN NN O
of NN NN O
European NN NN O
or NN NN O
non-European NN NN O
origin NN NN O
, NN NN O
with NN NN O
or NN NN O
without NN NN O
a NN NN O
personal NN NN O
and NN NN O
/ NN NN O
or NN NN O
family NN NN O
history NN NN O
of NN NN O
neoplasia NN NN B-DiseaseClass
, NN NN O
were NN NN O
examined NN NN O
for NN NN O
the NN NN O
I1307K NN NN O
variant NN NN O
by NN NN O
the NN NN O
allele-specific NN NN O
oligonucleotide NN NN O
( NN NN O
ASO NN NN O
) NN NN O
method NN NN O
. NN NN O

RESULTS NN NN O
In NN NN O
persons NN NN O
at NN NN O
average NN NN O
risk NN NN O
for NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
I1307K NN NN O
was NN NN O
found NN NN O
in NN NN O
5 NN NN O
. NN NN O

0 NN NN O
% NN NN O
of NN NN O
120 NN NN O
European NN NN O
and NN NN O
1 NN NN O
. NN NN O

6 NN NN O
% NN NN O
of NN NN O
188 NN NN O
non-European NN NN O
Jews NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O

08 NN NN O
) NN NN O
. NN NN O

It NN NN O
occurred NN NN O
in NN NN O
15 NN NN O
. NN NN O

4 NN NN O
% NN NN O
of NN NN O
52 NN NN O
Ashkenazi NN NN O
Israelis NN NN O
with NN NN O
familial NN NN O
cancer NN NN B-DiseaseClass
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O

02 NN NN O
) NN NN O
and NN NN O
was NN NN O
not NN NN O
detected NN NN O
in NN NN O
51 NN NN O
non-European NN NN O
Jews NN NN O
at NN NN O
increased NN NN O
cancer NN NN B-Modifier
risk NN NN O
. NN NN O

Colorectal NN NN B-SpecificDisease
neoplasia NN NN I-SpecificDisease
occurred NN NN O
personally NN NN O
or NN NN O
in NN NN O
the NN NN O
families NN NN O
of NN NN O
13 NN NN O
of NN NN O
20 NN NN O
Ashkenazi NN NN O
I1307K NN NN O
carriers NN NN O
, NN NN O
8 NN NN O
of NN NN O
whom NN NN O
also NN NN O
had NN NN O
a NN NN O
personal NN NN O
or NN NN O
family NN NN O
history NN NN O
of NN NN O
noncolonic NN NN O
neoplasia NN NN B-DiseaseClass
. NN NN O

CONCLUSIONS NN NN O
The NN NN O
I1307K NN NN O
APC NN NN O
variant NN NN O
may NN NN O
represent NN NN O
a NN NN O
susceptibility NN NN O
gene NN NN O
for NN NN O
colorectal NN NN B-CompositeMention
, NN NN I-CompositeMention
or NN NN I-CompositeMention
other NN NN I-CompositeMention
, NN NN I-CompositeMention
cancers NN NN I-CompositeMention
in NN NN O
Ashkenazi NN NN O
Jews NN NN O
, NN NN O
and NN NN O
partially NN NN O
explains NN NN O
the NN NN O
higher NN NN O
incidence NN NN O
of NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
in NN NN O
European NN NN O
Israelis NN NN O
. NN NN O

9888388 NN NN O
Systematic NN NN O
analysis NN NN O
of NN NN O
coproporphyrinogen NN NN O
oxidase NN NN O
gene NN NN O
defects NN NN O
in NN NN O
hereditary NN NN B-SpecificDisease
coproporphyria NN NN I-SpecificDisease
and NN NN O
mutation NN NN O
update NN NN O
. NN NN O

Hereditary NN NN B-SpecificDisease
coproporphyria NN NN I-SpecificDisease
( NN NN O
HC NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
acute NN NN O
hepatic NN NN B-SpecificDisease
porphyria NN NN I-SpecificDisease
with NN NN O
autosomal NN NN O
dominant NN NN O
inheritance NN NN O
caused NN NN O
by NN NN O
deficient NN NN B-SpecificDisease
activity NN NN I-SpecificDisease
of NN NN I-SpecificDisease
coproporphyrinogen NN NN I-SpecificDisease
III NN NN I-SpecificDisease
oxidase NN NN I-SpecificDisease
( NN NN O
CPO NN NN O
) NN NN O
. NN NN O

Clinical NN NN O
manifestations NN NN O
of NN NN O
the NN NN O
disease NN NN O
are NN NN O
characterized NN NN O
by NN NN O
acute NN NN O
attacks NN NN O
of NN NN O
neurological NN NN B-DiseaseClass
dysfunction NN NN I-DiseaseClass
often NN NN O
precipitated NN NN O
by NN NN O
drugs NN NN O
, NN NN O
fasting NN NN O
, NN NN O
cyclical NN NN O
hormonal NN NN O
changes NN NN O
, NN NN O
or NN NN O
infectious NN NN B-DiseaseClass
diseases NN NN I-DiseaseClass
. NN NN O

Skin NN NN O
photosensitivity NN NN O
may NN NN O
also NN NN O
be NN NN O
present NN NN O
. NN NN O

The NN NN O
seven NN NN O
exons NN NN O
, NN NN O
the NN NN O
exon NN NN O
/ NN NN O
intron NN NN O
boundaries NN NN O
and NN NN O
part NN NN O
of NN NN O
3 NN NN O
noncoding NN NN O
sequence NN NN O
of NN NN O
the NN NN O
CPO NN NN O
gene NN NN O
were NN NN O
systematically NN NN O
analyzed NN NN O
by NN NN O
an NN NN O
exon-by-exon NN NN O
denaturing NN NN O
gradient NN NN O
gel NN NN O
electrophoresis NN NN O
( NN NN O
DGGE NN NN O
) NN NN O
strategy NN NN O
followed NN NN O
by NN NN O
direct NN NN O
sequencing NN NN O
in NN NN O
seven NN NN O
unrelated NN NN O
heterozygous NN NN O
HC NN NN B-Modifier
patients NN NN O
from NN NN O
France NN NN O
, NN NN O
Holland NN NN O
, NN NN O
and NN NN O
Czech NN NN O
Republic NN NN O
. NN NN O

Seven NN NN O
novel NN NN O
mutations NN NN O
and NN NN O
two NN NN O
new NN NN O
polymorphisms NN NN O
were NN NN O
detected NN NN O
. NN NN O

Among NN NN O
these NN NN O
mutations NN NN O
two NN NN O
are NN NN O
missense NN NN O
( NN NN O
G197W NN NN O
, NN NN O
W427R NN NN O
) NN NN O
, NN NN O
two NN NN O
are NN NN O
nonsense NN NN O
( NN NN O
Q306X NN NN O
, NN NN O
Q385X NN NN O
) NN NN O
, NN NN O
two NN NN O
are NN NN O
small NN NN O
deletions NN NN O
( NN NN O
662de14bp NN NN O
; NN NN O
1168del3bp NN NN O
removing NN NN O
a NN NN O
glycine NN NN O
at NN NN O
position NN NN O
390 NN NN O
) NN NN O
, NN NN O
and NN NN O
one NN NN O
is NN NN O
a NN NN O
splicing NN NN O
mutation NN NN O
( NN NN O
IVS1-15c NN NN O
-- NN NN O
g NN NN O
) NN NN O
which NN NN O
creates NN NN O
a NN NN O
new NN NN O
acceptor NN NN O
splice NN NN O
site NN NN O
. NN NN O

The NN NN O
pathological NN NN O
significance NN NN O
of NN NN O
the NN NN O
point NN NN O
mutations NN NN O
G197W NN NN O
, NN NN O
W427R NN NN O
, NN NN O
and NN NN O
the NN NN O
in-frame NN NN O
deletion NN NN O
390delGly NN NN O
were NN NN O
assessed NN NN O
by NN NN O
their NN NN O
respective NN NN O
expression NN NN O
in NN NN O
a NN NN O
prokaryotic NN NN O
system NN NN O
using NN NN O
site-directed NN NN O
mutagenesis NN NN O
. NN NN O

These NN NN O
mutations NN NN O
resulted NN NN O
in NN NN O
the NN NN O
absence NN NN O
or NN NN O
a NN NN O
dramatic NN NN O
decrease NN NN O
of NN NN O
CPO NN NN O
activity NN NN O
. NN NN O

The NN NN O
two NN NN O
polymorphisms NN NN O
were NN NN O
localized NN NN O
in NN NN O
noncoding NN NN O
part NN NN O
of NN NN O
the NN NN O
gene NN NN O
1 NN NN O
) NN NN O
a NN NN O
C NN NN O
/ NN NN O
G NN NN O
polymorphism NN NN O
in NN NN O
the NN NN O
promotor NN NN O
region NN NN O
, NN NN O
142 NN NN O
bp NN NN O
upstream NN NN O
from NN NN O
the NN NN O
transcriptional NN NN O
initiation NN NN O
site NN NN O
( NN NN O
-142C NN NN O
/ NN NN O
G NN NN O
) NN NN O
, NN NN O
and NN NN O
2 NN NN O
) NN NN O
a NN NN O
6 NN NN O
bp NN NN O
deletion NN NN O
polymorphism NN NN O
in NN NN O
the NN NN O
3 NN NN O
noncoding NN NN O
part NN NN O
of NN NN O
the NN NN O
CPO NN NN O
gene NN NN O
, NN NN O
574 NN NN O
bp NN NN O
downstream NN NN O
of NN NN O
the NN NN O
last NN NN O
base NN NN O
of NN NN O
the NN NN O
normal NN NN O
termination NN NN O
codon NN NN O
( NN NN O
+ NN NN O
574 NN NN O
delATTCTT NN NN O
) NN NN O
. NN NN O

Five NN NN O
intragenic NN NN O
dimorphisms NN NN O
are NN NN O
now NN NN O
well NN NN O
characterized NN NN O
and NN NN O
the NN NN O
high NN NN O
degree NN NN O
of NN NN O
allelic NN NN O
heterogeneity NN NN O
in NN NN O
HC NN NN B-SpecificDisease
is NN NN O
demonstrated NN NN O
with NN NN O
seven NN NN O
new NN NN O
different NN NN O
mutations NN NN O
making NN NN O
a NN NN O
total NN NN O
of NN NN O
nineteen NN NN O
CPO NN NN O
gene NN NN B-DiseaseClass
defects NN NN I-DiseaseClass
reported NN NN O
so NN NN O
far NN NN O
. NN NN O

. NN NN O

9888390 NN NN O
Coincidence NN NN O
of NN NN O
two NN NN O
novel NN NN O
arylsulfatase NN NN O
A NN NN O
alleles NN NN O
and NN NN O
mutation NN NN O
459+1G NN NN O
A NN NN O
within NN NN O
a NN NN O
family NN NN O
with NN NN O
metachromatic NN NN B-SpecificDisease
leukodystrophy NN NN I-SpecificDisease
: NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
phenotypic NN NN O
heterogeneity NN NN O
. NN NN O

In NN NN O
a NN NN O
family NN NN O
with NN NN O
three NN NN O
siblings NN NN O
, NN NN O
one NN NN O
developed NN NN O
classical NN NN O
late NN NN O
infantile NN NN O
metachromatic NN NN B-SpecificDisease
leukodystrophy NN NN I-SpecificDisease
( NN NN O
MLD NN NN B-SpecificDisease
) NN NN O
, NN NN O
fatal NN NN O
at NN NN O
age NN NN O
5 NN NN O
years NN NN O
, NN NN O
with NN NN O
deficient NN NN O
arylsulfatase NN NN O
A NN NN O
( NN NN O
ARSA NN NN O
) NN NN O
activity NN NN O
and NN NN O
increased NN NN O
galactosylsulfatide NN NN O
( NN NN O
GS NN NN O
) NN NN O
excretion NN NN O
. NN NN O

The NN NN O
two NN NN O
other NN NN O
siblings NN NN O
, NN NN O
apparently NN NN O
healthy NN NN O
at NN NN O
12 NN NN O
( NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
) NN NN O
and NN NN O
15 NN NN O
years NN NN O
, NN NN O
respectively NN NN O
, NN NN O
and NN NN O
their NN NN O
father NN NN O
, NN NN O
apparently NN NN O
healthy NN NN O
as NN NN O
well NN NN O
, NN NN O
presented NN NN O
ARSA NN NN O
and NN NN O
GS NN NN O
values NN NN O
within NN NN O
the NN NN O
range NN NN O
of NN NN O
MLD NN NN B-Modifier
patients NN NN O
. NN NN O

Mutation NN NN O
screening NN NN O
and NN NN O
sequence NN NN O
analysis NN NN O
disclosed NN NN O
the NN NN O
involvement NN NN O
of NN NN O
three NN NN O
different NN NN O
ARSA NN NN O
mutations NN NN O
being NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
intrafamilial NN NN O
phenotypic NN NN O
heterogeneity NN NN O
. NN NN O

The NN NN O
late NN NN O
infantile NN NN O
patient NN NN O
inherited NN NN O
from NN NN O
his NN NN O
mother NN NN O
the NN NN O
frequent NN NN O
0-type NN NN O
mutation NN NN O
459 NN NN O
+ NN NN O
1G NN NN O
A NN NN O
, NN NN O
and NN NN O
from NN NN O
his NN NN O
father NN NN O
a NN NN O
novel NN NN O
, NN NN O
single NN NN O
basepair NN NN O
microdeletion NN NN O
of NN NN O
guanine NN NN O
at NN NN O
nucleotide NN NN O
7 NN NN O
in NN NN O
exon NN NN O
1 NN NN O
( NN NN O
7delG NN NN O
) NN NN O
. NN NN O

The NN NN O
two NN NN O
clinically NN NN O
unaffected NN NN O
siblings NN NN O
carried NN NN O
the NN NN O
maternal NN NN O
mutation NN NN O
459 NN NN O
+ NN NN O
1G NN NN O
A NN NN O
and NN NN O
, NN NN O
on NN NN O
their NN NN O
paternal NN NN O
allele NN NN O
, NN NN O
a NN NN O
novel NN NN O
cytosine NN NN O
to NN NN O
thymidine NN NN O
transition NN NN O
at NN NN O
nucleotide NN NN O
2435 NN NN O
in NN NN O
exon NN NN O
8 NN NN O
, NN NN O
resulting NN NN O
in NN NN O
substitution NN NN O
of NN NN O
alanine NN NN O
464 NN NN O
by NN NN O
valine NN NN O
( NN NN O
A464V NN NN O
) NN NN O
. NN NN O

The NN NN O
fathers NN NN O
genotype NN NN O
thus NN NN O
was NN NN O
7delG NN NN O
/ NN NN O
A464V NN NN O
. NN NN O

Mutation NN NN O
A464V NN NN O
was NN NN O
not NN NN O
found NN NN O
in NN NN O
18 NN NN O
unrelated NN NN O
MLD NN NN B-Modifier
patients NN NN O
and NN NN O
50 NN NN O
controls NN NN O
. NN NN O

A464V NN NN O
, NN NN O
although NN NN O
clearly NN NN O
modifying NN NN O
ARSA NN NN O
and NN NN O
GS NN NN O
levels NN NN O
, NN NN O
apparently NN NN O
bears NN NN O
little NN NN O
significance NN NN O
for NN NN O
clinical NN NN O
manifestation NN NN O
of NN NN O
MLD NN NN B-SpecificDisease
, NN NN O
mimicking NN NN O
the NN NN O
frequent NN NN O
ARSA NN NN O
pseudodeficiency NN NN O
allele NN NN O
. NN NN O

Our NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
in NN NN O
certain NN NN O
genetic NN NN O
conditions NN NN O
MLD NN NN B-Modifier
-like NN NN O
ARSA NN NN O
and NN NN O
GS NN NN O
values NN NN O
need NN NN O
not NN NN O
be NN NN O
paralleled NN NN O
by NN NN O
clinical NN NN O
disease NN NN O
, NN NN O
a NN NN O
finding NN NN O
with NN NN O
serious NN NN O
diagnostic NN NN O
and NN NN O
prognostic NN NN O
implications NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
further NN NN O
ARSA NN NN O
alleles NN NN O
functionally NN NN O
similar NN NN O
to NN NN O
A464V NN NN O
might NN NN O
exist NN NN O
which NN NN O
, NN NN O
together NN NN O
with NN NN O
0-type NN NN O
mutations NN NN O
, NN NN O
may NN NN O
cause NN NN O
pathological NN NN O
ARSA NN NN O
and NN NN O
GS NN NN O
levels NN NN O
, NN NN O
but NN NN O
not NN NN O
clinical NN NN O
outbreak NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

. NN NN O

9927033 NN NN O
Human NN NN O
MLH1 NN NN O
deficiency NN NN O
predisposes NN NN O
to NN NN O
hematological NN NN B-DiseaseClass
malignancy NN NN I-DiseaseClass
and NN NN O
neurofibromatosis NN NN B-SpecificDisease
type NN NN I-SpecificDisease
1 NN NN I-SpecificDisease
. NN NN O

Heterozygous NN NN O
germ-line NN NN O
mutations NN NN O
in NN NN O
the NN NN O
DNA NN NN O
mismatch NN NN O
repair NN NN O
genes NN NN O
lead NN NN O
to NN NN O
hereditary NN NN B-SpecificDisease
nonpolyposis NN NN I-SpecificDisease
colorectal NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

The NN NN O
disease NN NN O
susceptibility NN NN O
of NN NN O
individuals NN NN O
who NN NN O
constitutionally NN NN O
lack NN NN O
both NN NN O
wild-type NN NN O
alleles NN NN O
is NN NN O
unknown NN NN O
. NN NN O

We NN NN O
have NN NN O
identified NN NN O
three NN NN O
offspring NN NN O
in NN NN O
a NN NN O
hereditary NN NN B-Modifier
nonpolyposis NN NN I-Modifier
colorectal NN NN I-Modifier
cancer NN NN I-Modifier
family NN NN O
who NN NN O
developed NN NN O
hematological NN NN B-DiseaseClass
malignancy NN NN I-DiseaseClass
at NN NN O
a NN NN O
very NN NN O
early NN NN O
age NN NN O
, NN NN O
and NN NN O
at NN NN O
least NN NN O
two NN NN O
of NN NN O
them NN NN O
displayed NN NN O
signs NN NN O
of NN NN O
neurofibromatosis NN NN B-SpecificDisease
type NN NN I-SpecificDisease
1 NN NN I-SpecificDisease
( NN NN O
NF1 NN NN B-SpecificDisease
) NN NN O
. NN NN O

DNA NN NN O
sequence NN NN O
analysis NN NN O
and NN NN O
allele-specific NN NN O
amplification NN NN O
in NN NN O
two NN NN O
siblings NN NN O
revealed NN NN O
a NN NN O
homozygous NN NN O
MLH1 NN NN O
mutation NN NN O
( NN NN O
C676T NN NN O
-- NN NN O
Arg226Stop NN NN O
) NN NN O
. NN NN O

Thus NN NN O
, NN NN O
a NN NN O
homozygous NN NN O
germ-line NN NN O
MLH1 NN NN O
mutation NN NN O
and NN NN O
consequent NN NN O
mismatch NN NN O
repair NN NN O
deficiency NN NN O
results NN NN O
in NN NN O
a NN NN O
mutator NN NN O
phenotype NN NN O
characterized NN NN O
by NN NN O
leukemia NN NN B-DiseaseClass
and NN NN O
/ NN NN O
or NN NN O
lymphoma NN NN B-DiseaseClass
associated NN NN O
with NN NN O
neurofibromatosis NN NN B-SpecificDisease
type NN NN I-SpecificDisease
1 NN NN I-SpecificDisease
. NN NN O

. NN NN O

9931324 NN NN O
Missense NN NN O
mutations NN NN O
in NN NN O
the NN NN O
most NN NN O
ancient NN NN O
residues NN NN O
of NN NN O
the NN NN O
PAX6 NN NN O
paired NN NN O
domain NN NN O
underlie NN NN O
a NN NN O
spectrum NN NN O
of NN NN O
human NN NN O
congenital NN NN B-DiseaseClass
eye NN NN I-DiseaseClass
malformations NN NN I-DiseaseClass
. NN NN O

Mutations NN NN O
of NN NN O
the NN NN O
human NN NN O
PAX6 NN NN O
gene NN NN O
underlie NN NN O
aniridia NN NN B-SpecificDisease
( NN NN O
congenital NN NN B-SpecificDisease
absence NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
iris NN NN I-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
rare NN NN O
dominant NN NN O
malformation NN NN B-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
eye NN NN I-DiseaseClass
. NN NN O

The NN NN O
spectrum NN NN O
of NN NN O
PAX6 NN NN O
mutations NN NN O
in NN NN O
aniridia NN NN B-Modifier
patients NN NN O
is NN NN O
highly NN NN O
biased NN NN O
, NN NN O
with NN NN O
92 NN NN O
% NN NN O
of NN NN O
all NN NN O
reported NN NN O
mutations NN NN O
leading NN NN O
to NN NN O
premature NN NN O
truncation NN NN O
of NN NN O
the NN NN O
protein NN NN O
( NN NN O
nonsense NN NN O
, NN NN O
splicing NN NN O
, NN NN O
insertions NN NN O
and NN NN O
deletions NN NN O
) NN NN O
and NN NN O
just NN NN O
2 NN NN O
% NN NN O
leading NN NN O
to NN NN O
substitution NN NN O
of NN NN O
one NN NN O
amino NN NN O
acid NN NN O
by NN NN O
another NN NN O
( NN NN O
missense NN NN O
) NN NN O
. NN NN O

The NN NN O
extraordinary NN NN O
conservation NN NN O
of NN NN O
the NN NN O
PAX6 NN NN O
protein NN NN O
at NN NN O
the NN NN O
amino NN NN O
acid NN NN O
level NN NN O
amongst NN NN O
vertebrates NN NN O
predicts NN NN O
that NN NN O
pathological NN NN O
missense NN NN O
mutations NN NN O
should NN NN O
in NN NN O
fact NN NN O
be NN NN O
common NN NN O
even NN NN O
though NN NN O
they NN NN O
are NN NN O
hardly NN NN O
ever NN NN O
seen NN NN O
in NN NN O
aniridia NN NN B-Modifier
patients NN NN O
. NN NN O

This NN NN O
indicates NN NN O
that NN NN O
there NN NN O
is NN NN O
a NN NN O
heavy NN NN O
ascertainment NN NN O
bias NN NN O
in NN NN O
the NN NN O
selection NN NN O
of NN NN O
patients NN NN O
for NN NN O
PAX6 NN NN O
mutation NN NN O
analysis NN NN O
and NN NN O
that NN NN O
the NN NN O
missing NN NN O
PAX6 NN NN O
missense NN NN O
mutations NN NN O
frequently NN NN O
may NN NN O
underlie NN NN O
phenotypes NN NN O
distinct NN NN O
from NN NN O
textbook NN NN O
aniridia NN NN B-SpecificDisease
. NN NN O

Here NN NN O
we NN NN O
present NN NN O
four NN NN O
novel NN NN O
PAX6 NN NN O
missense NN NN O
mutations NN NN O
, NN NN O
two NN NN O
in NN NN O
association NN NN O
with NN NN O
atypical NN NN O
phenotypes NN NN O
ectopia NN NN B-SpecificDisease
pupillae NN NN I-SpecificDisease
( NN NN O
displaced NN NN B-SpecificDisease
pupils NN NN I-SpecificDisease
) NN NN O
and NN NN O
congenital NN NN B-SpecificDisease
nystagmus NN NN I-SpecificDisease
( NN NN O
searching NN NN B-SpecificDisease
gaze NN NN I-SpecificDisease
) NN NN O
, NN NN O
and NN NN O
two NN NN O
in NN NN O
association NN NN O
with NN NN O
more NN NN O
recognizable NN NN O
aniridia NN NN B-Modifier
phenotypes NN NN O
. NN NN O

Strikingly NN NN O
, NN NN O
all NN NN O
four NN NN O
mutations NN NN O
are NN NN O
located NN NN O
within NN NN O
the NN NN O
PAX6 NN NN O
paired NN NN O
domain NN NN O
and NN NN O
affect NN NN O
amino NN NN O
acids NN NN O
which NN NN O
are NN NN O
highly NN NN O
conserved NN NN O
in NN NN O
all NN NN O
known NN NN O
paired NN NN O
domain NN NN O
proteins NN NN O
. NN NN O

Our NN NN O
results NN NN O
support NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
the NN NN O
under-representation NN NN O
of NN NN O
missense NN NN O
mutations NN NN O
is NN NN O
caused NN NN O
by NN NN O
ascertainment NN NN O
bias NN NN O
and NN NN O
suggest NN NN O
that NN NN O
a NN NN O
substantial NN NN O
burden NN NN O
of NN NN O
PAX6 NN NN B-DiseaseClass
-related NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
remains NN NN O
to NN NN O
be NN NN O
uncovered NN NN O
. NN NN O

. NN NN O

993342 NN NN O
The NN NN O
chromosomal NN NN O
order NN NN O
of NN NN O
genes NN NN O
controlling NN NN O
the NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
, NN NN O
properdin NN NN O
factor NN NN O
B NN NN O
, NN NN O
and NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
second NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
. NN NN O

The NN NN O
relationship NN NN O
of NN NN O
the NN NN O
genes NN NN O
coding NN NN O
for NN NN O
HLA NN NN O
to NN NN O
those NN NN O
coding NN NN O
for NN NN O
properdin NN NN O
Factor NN NN O
B NN NN O
allotypes NN NN O
and NN NN O
for NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
second NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
( NN NN O
C2 NN NN O
) NN NN O
was NN NN O
studied NN NN O
in NN NN O
families NN NN O
of NN NN O
patients NN NN O
with NN NN O
connective NN NN O
tissue NN NN O
disorders NN NN O
. NN NN O

Patients NN NN O
were NN NN O
selected NN NN O
because NN NN O
they NN NN O
were NN NN O
heterozygous NN NN O
or NN NN O
homozygous NN NN O
for NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

12 NN NN O
families NN NN O
with NN NN O
15 NN NN O
matings NN NN O
informative NN NN O
for NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
were NN NN O
found NN NN O
. NN NN O

Of NN NN O
57 NN NN O
informative NN NN O
meioses NN NN O
, NN NN O
two NN NN O
crossovers NN NN O
were NN NN O
noted NN NN O
between NN NN O
the NN NN O
C2 NN NN B-Modifier
deficiency NN NN I-Modifier
gene NN NN O
and NN NN O
the NN NN O
HLA-B NN NN O
gene NN NN O
, NN NN O
with NN NN O
a NN NN O
recombinant NN NN O
fraction NN NN O
of NN NN O
0 NN NN O
. NN NN O

035 NN NN O
. NN NN O

A NN NN O
lod NN NN O
score NN NN O
of NN NN O
13 NN NN O
was NN NN O
calculated NN NN O
for NN NN O
linkage NN NN O
between NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
HLA-B NN NN O
at NN NN O
a NN NN O
maximum NN NN O
likelihood NN NN O
value NN NN O
of NN NN O
the NN NN O
recombinant NN NN O
fraction NN NN O
of NN NN O
0 NN NN O
. NN NN O

04 NN NN O
. NN NN O

18 NN NN O
families NN NN O
with NN NN O
21 NN NN O
informative NN NN O
matings NN NN O
for NN NN O
both NN NN O
properdin NN NN O
Factor NN NN O
B NN NN O
allotype NN NN O
and NN NN O
HLA-B NN NN O
were NN NN O
found NN NN O
. NN NN O

Of NN NN O
72 NN NN O
informative NN NN O
meioses NN NN O
, NN NN O
three NN NN O
recombinants NN NN O
were NN NN O
found NN NN O
, NN NN O
giving NN NN O
a NN NN O
recombinant NN NN O
fraction NN NN O
of NN NN O
0 NN NN O
. NN NN O

042 NN NN O
. NN NN O

A NN NN O
lod NN NN O
score NN NN O
of NN NN O
16 NN NN O
between NN NN O
HLA-B NN NN O
and NN NN O
Factor NN NN O
B NN NN O
allotypes NN NN O
was NN NN O
calculated NN NN O
at NN NN O
a NN NN O
maximum NN NN O
likelihood NN NN O
value NN NN O
of NN NN O
the NN NN O
recombinant NN NN O
fraction NN NN O
of NN NN O
0 NN NN O
. NN NN O

04 NN NN O
. NN NN O

A NN NN O
crossover NN NN O
was NN NN O
shown NN NN O
to NN NN O
have NN NN O
occurred NN NN O
between NN NN O
genes NN NN O
for NN NN O
Factor NN NN O
B NN NN O
and NN NN O
HLA-D NN NN O
, NN NN O
in NN NN O
which NN NN O
HLA-D NN NN O
segregared NN NN O
with NN NN O
HLA-A NN NN O
and NN NN O
B NN NN O
. NN NN O

These NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
the NN NN O
genes NN NN O
for NN NN O
Factor NN NN O
B NN NN O
and NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
are NN NN O
located NN NN O
outside NN NN O
those NN NN O
for NN NN O
HLA NN NN O
, NN NN O
that NN NN O
the NN NN O
order NN NN O
of NN NN O
genese NN NN O
is NN NN O
HLA-A NN NN O
, NN NN O
-B NN NN O
, NN NN O
-D NN NN O
, NN NN O
Factor NN NN O
B NN NN O
allotype NN NN O
, NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
that NN NN O
the NN NN O
genes NN NN O
coding NN NN O
for NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
Factor NN NN O
B NN NN O
allotypes NN NN O
are NN NN O
approximately NN NN O
3 NN NN O
-- NN NN O
5 NN NN O
centimorgans NN NN O
from NN NN O
the NN NN O
HLA-A NN NN O
and NN NN O
HLA-B NN NN O
loci NN NN O
, NN NN O
and NN NN O
that NN NN O
the NN NN O
apparent NN NN O
lack NN NN O
of NN NN O
recombinants NN NN O
between NN NN O
the NN NN O
Factor NN NN O
B NN NN O
gene NN NN O
and NN NN O
C2 NN NN B-Modifier
deficiency NN NN I-Modifier
gene NN NN O
suggests NN NN O
that NN NN O
these NN NN O
two NN NN O
genes NN NN O
lie NN NN O
in NN NN O
close NN NN O
proximity NN NN O
to NN NN O
one NN NN O
another NN NN O
. NN NN O

9949197 NN NN O
Distribution NN NN O
of NN NN O
emerin NN NN O
and NN NN O
lamins NN NN O
in NN NN O
the NN NN O
heart NN NN O
and NN NN O
implications NN NN O
for NN NN O
Emery-Dreifuss NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

Emerin NN NN O
is NN NN O
a NN NN O
nuclear NN NN O
membrane NN NN O
protein NN NN O
which NN NN O
is NN NN O
missing NN NN O
or NN NN O
defective NN NN O
in NN NN O
Emery-Dreifuss NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
EDMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

It NN NN O
is NN NN O
one NN NN O
member NN NN O
of NN NN O
a NN NN O
family NN NN O
of NN NN O
lamina-associated NN NN O
proteins NN NN O
which NN NN O
includes NN NN O
LAP1 NN NN O
, NN NN O
LAP2 NN NN O
and NN NN O
lamin NN NN O
B NN NN O
receptor NN NN O
( NN NN O
LBR NN NN O
) NN NN O
. NN NN O

A NN NN O
panel NN NN O
of NN NN O
16 NN NN O
monoclonal NN NN O
antibodies NN NN O
( NN NN O
mAbs NN NN O
) NN NN O
has NN NN O
been NN NN O
mapped NN NN O
to NN NN O
six NN NN O
specific NN NN O
sites NN NN O
throughout NN NN O
the NN NN O
emerin NN NN O
molecule NN NN O
using NN NN O
phage-displayed NN NN O
peptide NN NN O
libraries NN NN O
and NN NN O
has NN NN O
been NN NN O
used NN NN O
to NN NN O
localize NN NN O
emerin NN NN O
in NN NN O
human NN NN O
and NN NN O
rabbit NN NN O
heart NN NN O
. NN NN O

Several NN NN O
mAbs NN NN O
against NN NN O
different NN NN O
emerin NN NN O
epitopes NN NN O
did NN NN O
not NN NN O
recognize NN NN O
intercalated NN NN O
discs NN NN O
in NN NN O
the NN NN O
heart NN NN O
, NN NN O
though NN NN O
they NN NN O
recognized NN NN O
cardiomyocyte NN NN O
nuclei NN NN O
strongly NN NN O
, NN NN O
both NN NN O
at NN NN O
the NN NN O
rim NN NN O
and NN NN O
in NN NN O
intranuclear NN NN O
spots NN NN O
or NN NN O
channels NN NN O
. NN NN O

A NN NN O
polyclonal NN NN O
rabbit NN NN O
antiserum NN NN O
against NN NN O
emerin NN NN O
did NN NN O
recognize NN NN O
both NN NN O
nuclear NN NN O
membrane NN NN O
and NN NN O
intercalated NN NN O
discs NN NN O
but NN NN O
, NN NN O
after NN NN O
affinity NN NN O
purification NN NN O
against NN NN O
a NN NN O
pure-emerin NN NN O
band NN NN O
on NN NN O
a NN NN O
western NN NN O
blot NN NN O
, NN NN O
it NN NN O
stained NN NN O
only NN NN O
the NN NN O
nuclear NN NN O
membrane NN NN O
. NN NN O

These NN NN O
results NN NN O
would NN NN O
not NN NN O
be NN NN O
expected NN NN O
if NN NN O
immunostaining NN NN O
at NN NN O
intercalated NN NN O
discs NN NN O
were NN NN O
due NN NN O
to NN NN O
a NN NN O
product NN NN O
of NN NN O
the NN NN O
emerin NN NN O
gene NN NN O
and NN NN O
, NN NN O
therefore NN NN O
, NN NN O
cast NN NN O
some NN NN O
doubt NN NN O
upon NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
cardiac NN NN B-DiseaseClass
defects NN NN I-DiseaseClass
in NN NN O
EDMD NN NN B-SpecificDisease
are NN NN O
caused NN NN O
by NN NN O
absence NN NN O
of NN NN O
emerin NN NN O
from NN NN O
intercalated NN NN O
discs NN NN O
. NN NN O

Although NN NN O
emerin NN NN O
was NN NN O
abundant NN NN O
in NN NN O
the NN NN O
membranes NN NN O
of NN NN O
cardiomyocyte NN NN O
nuclei NN NN O
, NN NN O
it NN NN O
was NN NN O
absent NN NN O
from NN NN O
many NN NN O
non-myocyte NN NN O
cells NN NN O
in NN NN O
the NN NN O
heart NN NN O
. NN NN O

This NN NN O
distribution NN NN O
of NN NN O
emerin NN NN O
was NN NN O
similar NN NN O
to NN NN O
that NN NN O
of NN NN O
lamin NN NN O
A NN NN O
, NN NN O
a NN NN O
candidate NN NN O
gene NN NN O
for NN NN O
an NN NN O
autosomal NN NN O
form NN NN O
of NN NN O
EDMD NN NN B-SpecificDisease
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
lamin NN NN O
B1 NN NN O
was NN NN O
absent NN NN O
from NN NN O
cardiomyocyte NN NN O
nuclei NN NN O
, NN NN O
showing NN NN O
that NN NN O
lamin NN NN O
B1 NN NN O
is NN NN O
not NN NN O
essential NN NN O
for NN NN O
localization NN NN O
of NN NN O
emerin NN NN O
to NN NN O
the NN NN O
nuclear NN NN O
lamina NN NN O
. NN NN O

Lamin NN NN O
B1 NN NN O
is NN NN O
also NN NN O
almost NN NN O
completely NN NN O
absent NN NN O
from NN NN O
skeletal NN NN O
muscle NN NN O
nuclei NN NN O
. NN NN O

In NN NN O
EDMD NN NN B-SpecificDisease
, NN NN O
the NN NN O
additional NN NN O
absence NN NN O
of NN NN O
lamin NN NN O
B1 NN NN O
from NN NN O
heart NN NN O
and NN NN O
skeletal NN NN O
muscle NN NN O
nuclei NN NN O
which NN NN O
already NN NN O
lack NN NN O
emerin NN NN O
may NN NN O
offer NN NN O
an NN NN O
alternative NN NN O
explanation NN NN O
of NN NN O
why NN NN O
these NN NN O
tissues NN NN O
are NN NN O
particularly NN NN O
affected NN NN O
. NN NN O

. NN NN O

9949209 NN NN O
Genetic NN NN O
mapping NN NN O
of NN NN O
the NN NN O
copper NN NN B-Modifier
toxicosis NN NN I-Modifier
locus NN NN O
in NN NN O
Bedlington NN NN O
terriers NN NN O
to NN NN O
dog NN NN O
chromosome NN NN O
10 NN NN O
, NN NN O
in NN NN O
a NN NN O
region NN NN O
syntenic NN NN O
to NN NN O
human NN NN O
chromosome NN NN O
region NN NN O
2p13-p16 NN NN O
. NN NN O

Abnormal NN NN O
hepatic NN NN B-SpecificDisease
copper NN NN I-SpecificDisease
accumulation NN NN I-SpecificDisease
is NN NN O
recognized NN NN O
as NN NN O
an NN NN O
inherited NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
in NN NN O
man NN NN O
, NN NN O
mouse NN NN O
, NN NN O
rat NN NN O
and NN NN O
dog NN NN O
. NN NN O

The NN NN O
major NN NN O
cause NN NN O
of NN NN O
hepatic NN NN B-SpecificDisease
copper NN NN I-SpecificDisease
accumulation NN NN I-SpecificDisease
in NN NN O
man NN NN O
is NN NN O
a NN NN O
dysfunctional NN NN O
ATP7B NN NN O
gene NN NN O
, NN NN O
causing NN NN O
Wilson NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
WD NN NN B-SpecificDisease
) NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
ATP7B NN NN O
genes NN NN O
have NN NN O
also NN NN O
been NN NN O
demonstrated NN NN O
in NN NN O
mouse NN NN O
and NN NN O
rat NN NN O
. NN NN O

The NN NN O
ATP7B NN NN O
gene NN NN O
has NN NN O
been NN NN O
excluded NN NN O
in NN NN O
the NN NN O
much NN NN O
rarer NN NN O
human NN NN O
copper NN NN B-SpecificDisease
overload NN NN I-SpecificDisease
disease NN NN O
non-Indian NN NN B-SpecificDisease
childhood NN NN I-SpecificDisease
cirrhosis NN NN I-SpecificDisease
, NN NN O
indicating NN NN O
genetic NN NN O
heterogeneity NN NN O
. NN NN O

By NN NN O
investigating NN NN O
the NN NN O
common NN NN O
autosomal NN NN O
recessive NN NN O
copper NN NN B-SpecificDisease
toxicosis NN NN I-SpecificDisease
( NN NN O
CT NN NN B-SpecificDisease
) NN NN O
in NN NN O
Bedlington NN NN O
terriers NN NN O
, NN NN O
we NN NN O
have NN NN O
identified NN NN O
a NN NN O
new NN NN O
locus NN NN O
involved NN NN O
in NN NN O
progressive NN NN O
liver NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
. NN NN O

We NN NN O
examined NN NN O
whether NN NN O
the NN NN O
WD NN NN B-Modifier
gene NN NN O
ATP7B NN NN O
was NN NN O
also NN NN O
causative NN NN O
for NN NN O
CT NN NN B-SpecificDisease
by NN NN O
investigating NN NN O
the NN NN O
chromosomal NN NN O
co-localization NN NN O
of NN NN O
ATP7B NN NN O
and NN NN O
C04107 NN NN O
, NN NN O
using NN NN O
fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
( NN NN O
FISH NN NN O
) NN NN O
. NN NN O

C04107 NN NN O
is NN NN O
an NN NN O
anonymous NN NN O
microsatellite NN NN O
marker NN NN O
closely NN NN O
linked NN NN O
to NN NN O
CT NN NN B-SpecificDisease
. NN NN O

However NN NN O
, NN NN O
BAC NN NN O
clones NN NN O
containing NN NN O
ATP7B NN NN O
and NN NN O
C04107 NN NN O
mapped NN NN O
to NN NN O
the NN NN O
canine NN NN O
chromosome NN NN O
regions NN NN O
CFA22q11 NN NN O
and NN NN O
CFA10q26 NN NN O
, NN NN O
respectively NN NN O
, NN NN O
demonstrating NN NN O
that NN NN O
WD NN NN B-SpecificDisease
can NN NN O
not NN NN O
be NN NN O
homologous NN NN O
to NN NN O
CT NN NN B-SpecificDisease
. NN NN O

The NN NN O
copper NN NN O
transport NN NN O
genes NN NN O
CTR1 NN NN O
and NN NN O
CTR2 NN NN O
were NN NN O
also NN NN O
excluded NN NN O
as NN NN O
candidate NN NN O
genes NN NN O
for NN NN O
CT NN NN B-SpecificDisease
since NN NN O
they NN NN O
both NN NN O
mapped NN NN O
to NN NN O
canine NN NN O
chromosome NN NN O
region NN NN O
CFA11q22 NN NN O
. NN NN O

2-22 NN NN O
. NN NN O

5 NN NN O
. NN NN O

A NN NN O
transcribed NN NN O
sequence NN NN O
identified NN NN O
from NN NN O
the NN NN O
C04107-containing NN NN O
BAC NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
homologous NN NN O
to NN NN O
a NN NN O
gene NN NN O
expressed NN NN O
from NN NN O
human NN NN O
chromosome NN NN O
2p13-p16 NN NN O
, NN NN O
a NN NN O
region NN NN O
devoid NN NN O
of NN NN O
any NN NN O
positional NN NN O
candidate NN NN O
genes NN NN O
. NN NN O

9950360 NN NN O
Molecular NN NN O
analysis NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
in NN NN O
205 NN NN O
families NN NN O
: NN NN O
extended NN NN O
genotype-phenotype NN NN O
correlations NN NN O
in NN NN O
FAP NN NN B-SpecificDisease
and NN NN O
evidence NN NN O
for NN NN O
the NN NN O
role NN NN O
of NN NN O
APC NN NN B-Modifier
amino NN NN O
acid NN NN O
changes NN NN O
in NN NN O
colorectal NN NN B-Modifier
cancer NN NN I-Modifier
predisposition NN NN O
. NN NN O

BACKGROUND NN NN O
/ NN NN O
AIMS NN NN O
The NN NN O
development NN NN O
of NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
a NN NN O
variable NN NN O
range NN NN O
of NN NN O
extracolonic NN NN O
manifestations NN NN O
in NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
( NN NN O
FAP NN NN B-SpecificDisease
) NN NN O
is NN NN O
the NN NN O
result NN NN O
of NN NN O
the NN NN O
dominant NN NN O
inheritance NN NN O
of NN NN O
adenomatous NN NN B-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
( NN NN O
APC NN NN B-Modifier
) NN NN O
gene NN NN O
mutations NN NN O
. NN NN O

In NN NN O
this NN NN O
study NN NN O
, NN NN O
direct NN NN O
mutation NN NN O
analysis NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
was NN NN O
performed NN NN O
to NN NN O
determine NN NN O
genotype-phenotype NN NN O
correlations NN NN O
for NN NN O
nine NN NN O
extracolonic NN NN O
manifestations NN NN O
and NN NN O
to NN NN O
investigate NN NN O
the NN NN O
incidence NN NN O
of NN NN O
APC NN NN B-Modifier
mutations NN NN O
in NN NN O
non-FAP NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

METHODS NN NN O
The NN NN O
APC NN NN B-Modifier
gene NN NN O
was NN NN O
analysed NN NN O
in NN NN O
190 NN NN O
unrelated NN NN O
FAP NN NN B-Modifier
and NN NN O
15 NN NN O
non-FAP NN NN O
colorectal NN NN B-Modifier
cancer NN NN I-Modifier
patients NN NN O
using NN NN O
denaturing NN NN O
gradient NN NN O
gel NN NN O
electrophoresis NN NN O
, NN NN O
the NN NN O
protein NN NN O
truncation NN NN O
test NN NN O
, NN NN O
and NN NN O
direct NN NN O
sequencing NN NN O
. NN NN O

RESULTS NN NN O
Chain NN NN O
terminating NN NN O
signals NN NN O
were NN NN O
only NN NN O
identified NN NN O
in NN NN O
patients NN NN O
belonging NN NN O
to NN NN O
the NN NN O
FAP NN NN B-Modifier
group NN NN O
( NN NN O
105 NN NN O
patients NN NN O
) NN NN O
. NN NN O

Amino NN NN O
acid NN NN O
changes NN NN O
were NN NN O
identified NN NN O
in NN NN O
four NN NN O
patients NN NN O
, NN NN O
three NN NN O
of NN NN O
whom NN NN O
belonged NN NN O
to NN NN O
the NN NN O
non-FAP NN NN O
group NN NN O
of NN NN O
colorectal NN NN B-Modifier
cancer NN NN I-Modifier
patients NN NN O
. NN NN O

Genotype-phenotype NN NN O
correlations NN NN O
identified NN NN O
significant NN NN O
differences NN NN O
in NN NN O
the NN NN O
nature NN NN O
of NN NN O
certain NN NN O
extracolonic NN NN O
manifestations NN NN O
in NN NN O
FAP NN NN B-Modifier
patients NN NN O
belonging NN NN O
to NN NN O
three NN NN O
mutation NN NN O
subgroups NN NN O
. NN NN O

CONCLUSIONS NN NN O
Extended NN NN O
genotype-phenotype NN NN O
correlations NN NN O
made NN NN O
in NN NN O
this NN NN O
study NN NN O
may NN NN O
have NN NN O
the NN NN O
potential NN NN O
to NN NN O
determine NN NN O
the NN NN O
most NN NN O
appropriate NN NN O
surveillance NN NN O
and NN NN O
prophylactic NN NN O
treatment NN NN O
regimens NN NN O
for NN NN O
those NN NN O
patients NN NN O
with NN NN O
mutations NN NN O
associated NN NN O
with NN NN O
life NN NN O
threatening NN NN O
conditions NN NN O
. NN NN O

This NN NN O
study NN NN O
also NN NN O
provided NN NN O
evidence NN NN O
for NN NN O
the NN NN O
pathological NN NN O
nature NN NN O
of NN NN O
amino NN NN O
acid NN NN O
changes NN NN O
in NN NN O
APC NN NN O
associated NN NN O
with NN NN O
both NN NN O
FAP NN NN B-Modifier
and NN NN O
non-FAP NN NN O
colorectal NN NN B-Modifier
cancer NN NN I-Modifier
patients NN NN O
. NN NN O

. NN NN O

9973276 NN NN O
Inherited NN NN B-SpecificDisease
colorectal NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
and NN NN O
cancer NN NN B-Modifier
risk NN NN O
of NN NN O
the NN NN O
APC NN NN O
I1307K NN NN O
polymorphism NN NN O
. NN NN O

Germ-line NN NN O
and NN NN O
somatic NN NN O
truncating NN NN O
mutations NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
are NN NN O
thought NN NN O
to NN NN O
initiate NN NN O
colorectal NN NN B-Modifier
tumor NN NN I-Modifier
formation NN NN O
in NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
sporadic NN NN O
colorectal NN NN O
carcinogenesis NN NN O
, NN NN O
respectively NN NN O
. NN NN O

Recently NN NN O
, NN NN O
an NN NN O
isoleucine NN NN O
-- NN NN O
lysine NN NN O
polymorphism NN NN O
at NN NN O
codon NN NN O
1307 NN NN O
( NN NN O
I1307K NN NN O
) NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
has NN NN O
been NN NN O
identified NN NN O
in NN NN O
6 NN NN O
% NN NN O
-7 NN NN O
% NN NN O
of NN NN O
the NN NN O
Ashkenazi NN NN O
Jewish NN NN O
population NN NN O
. NN NN O

To NN NN O
assess NN NN O
the NN NN O
risk NN NN O
of NN NN O
this NN NN O
common NN NN O
APC NN NN B-Modifier
allelic NN NN O
variant NN NN O
in NN NN O
colorectal NN NN O
carcinogenesis NN NN O
, NN NN O
we NN NN O
have NN NN O
analyzed NN NN O
a NN NN O
large NN NN O
cohort NN NN O
of NN NN O
unselected NN NN O
Ashkenazi NN NN O
Jewish NN NN O
subjects NN NN O
with NN NN O
adenomatous NN NN B-SpecificDisease
polyps NN NN I-SpecificDisease
and NN NN O
. NN NN O

or NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN I-SpecificDisease
for NN NN O
the NN NN O
APC NN NN O
I1307K NN NN O
polymorphism NN NN O
. NN NN O

The NN NN O
APC NN NN O
I1307K NN NN O
allele NN NN O
was NN NN O
identified NN NN O
in NN NN O
48 NN NN O
( NN NN O
10 NN NN O
. NN NN O

1 NN NN O
% NN NN O
) NN NN O
of NN NN O
476 NN NN O
patients NN NN O
. NN NN O

Compared NN NN O
with NN NN O
the NN NN O
frequency NN NN O
in NN NN O
two NN NN O
separate NN NN O
population NN NN O
control NN NN O
groups NN NN O
, NN NN O
the NN NN O
APC NN NN O
I1307K NN NN O
allele NN NN O
is NN NN O
associated NN NN O
with NN NN O
an NN NN O
estimated NN NN O
relative NN NN O
risk NN NN O
of NN NN O
1 NN NN O
. NN NN O

5-1 NN NN O
. NN NN O

7 NN NN O
for NN NN O
colorectal NN NN B-SpecificDisease
neoplasia NN NN I-SpecificDisease
( NN NN O
both NN NN O
P NN NN O
= NN NN O
. NN NN O

01 NN NN O
) NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
compared NN NN O
with NN NN O
noncarriers NN NN O
, NN NN O
APC NN NN O
I1307K NN NN O
carriers NN NN O
had NN NN O
increased NN NN O
numbers NN NN O
of NN NN O
adenomas NN NN B-DiseaseClass
and NN NN O
colorectal NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
per NN NN O
patient NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O

03 NN NN O
) NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
a NN NN O
younger NN NN O
age NN NN O
at NN NN O
diagnosis NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
APC NN NN O
I1307K NN NN O
variant NN NN O
leads NN NN O
to NN NN O
increased NN NN O
adenoma NN NN B-Modifier
formation NN NN O
and NN NN O
directly NN NN O
contributes NN NN O
to NN NN O
3 NN NN O
% NN NN O
-4 NN NN O
% NN NN O
of NN NN O
all NN NN O
Ashkenazi NN NN O
Jewish NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

The NN NN O
estimated NN NN O
relative NN NN O
risk NN NN O
for NN NN O
carriers NN NN O
may NN NN O
justify NN NN O
specific NN NN O
clinical NN NN O
screening NN NN O
for NN NN O
the NN NN O
360 NN NN O
, NN NN O
000 NN NN O
Americans NN NN O
expected NN NN O
to NN NN O
harbor NN NN O
this NN NN O
allele NN NN O
, NN NN O
and NN NN O
genetic NN NN O
testing NN NN O
in NN NN O
the NN NN O
setting NN NN O
of NN NN O
long-term-outcome NN NN O
studies NN NN O
may NN NN O
impact NN NN O
significantly NN NN O
on NN NN O
colorectal NN NN B-Modifier
cancer NN NN I-Modifier
prevention NN NN O
in NN NN O
this NN NN O
population NN NN O
. NN NN O

9988281 NN NN O
Localization NN NN O
of NN NN O
human NN NN O
BRCA1 NN NN O
and NN NN O
its NN NN O
loss NN NN O
in NN NN O
high-grade NN NN O
, NN NN O
non-inherited NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
. NN NN O

Although NN NN O
the NN NN O
link NN NN O
between NN NN O
the NN NN O
BRCA1 NN NN O
tumour NN NN B-Modifier
-suppressor NN NN O
gene NN NN O
and NN NN O
hereditary NN NN B-CompositeMention
breast NN NN I-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
is NN NN O
established NN NN O
, NN NN O
the NN NN O
role NN NN O
, NN NN O
if NN NN O
any NN NN O
, NN NN O
of NN NN O
BRCA1 NN NN O
in NN NN O
non-familial NN NN B-DiseaseClass
cancers NN NN I-DiseaseClass
is NN NN O
unclear NN NN O
. NN NN O

BRCA1 NN NN O
mutations NN NN O
are NN NN O
rare NN NN O
in NN NN O
sporadic NN NN B-DiseaseClass
cancers NN NN I-DiseaseClass
, NN NN O
but NN NN O
loss NN NN O
of NN NN O
BRCA1 NN NN O
resulting NN NN O
from NN NN O
reduced NN NN O
expression NN NN O
or NN NN O
incorrect NN NN O
subcellular NN NN O
localization NN NN O
is NN NN O
postulated NN NN O
to NN NN O
be NN NN O
important NN NN O
in NN NN O
non-familial NN NN B-CompositeMention
breast NN NN I-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancers NN NN I-CompositeMention
. NN NN O

Epigenetic NN NN O
loss NN NN O
, NN NN O
however NN NN O
, NN NN O
has NN NN O
not NN NN O
received NN NN O
general NN NN O
acceptance NN NN O
due NN NN O
to NN NN O
controversy NN NN O
regarding NN NN O
the NN NN O
subcellular NN NN O
localization NN NN O
of NN NN O
BRCA1 NN NN O
proteins NN NN O
, NN NN O
reports NN NN O
of NN NN O
which NN NN O
have NN NN O
ranged NN NN O
from NN NN O
exclusively NN NN O
nuclear NN NN O
, NN NN O
to NN NN O
conditionally NN NN O
nuclear NN NN O
, NN NN O
to NN NN O
the NN NN O
ER NN NN O
/ NN NN O
golgi NN NN O
, NN NN O
to NN NN O
cytoplasmic NN NN O
invaginations NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
. NN NN O

In NN NN O
an NN NN O
attempt NN NN O
to NN NN O
resolve NN NN O
this NN NN O
issue NN NN O
, NN NN O
we NN NN O
have NN NN O
comprehensively NN NN O
characterized NN NN O
19 NN NN O
anti-BRCA1 NN NN O
antibodies NN NN O
. NN NN O

These NN NN O
reagents NN NN O
detect NN NN O
a NN NN O
220-kD NN NN O
protein NN NN O
localized NN NN O
in NN NN O
discrete NN NN O
nuclear NN NN O
foci NN NN O
in NN NN O
all NN NN O
epithelial NN NN O
cell NN NN O
lines NN NN O
, NN NN O
including NN NN O
those NN NN O
derived NN NN O
from NN NN O
breast NN NN B-SpecificDisease
malignancies NN NN I-SpecificDisease
. NN NN O

Immunohistochemical NN NN O
staining NN NN O
of NN NN O
human NN NN O
breast NN NN O
specimens NN NN O
also NN NN O
revealed NN NN O
BRCA1 NN NN O
nuclear NN NN O
foci NN NN O
in NN NN O
benign NN NN O
breast NN NN O
, NN NN O
invasive NN NN B-DiseaseClass
lobular NN NN I-DiseaseClass
cancers NN NN I-DiseaseClass
and NN NN O
low-grade NN NN B-SpecificDisease
ductal NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
. NN NN O

Conversely NN NN O
, NN NN O
BRCA1 NN NN O
expression NN NN O
was NN NN O
reduced NN NN O
or NN NN O
undetectable NN NN O
in NN NN O
the NN NN O
majority NN NN O
of NN NN O
high-grade NN NN O
, NN NN O
ductal NN NN B-SpecificDisease
carcinomas NN NN I-SpecificDisease
, NN NN O
suggesting NN NN O
that NN NN O
absence NN NN O
of NN NN O
BRCA1 NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
a NN NN O
significant NN NN O
percentage NN NN O
of NN NN O
sporadic NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancers NN NN I-SpecificDisease
. NN NN O

. NN NN O

